

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Sr VP for Administration</u></b>				
<b><u>Capital Project Management</u></b>				
<b>Denny, Warren E</b>	3048104739	\$80,000.	\$0.	\$80,000.
KY Transportation Cabinet University of Kentucky Bicycle Plan Transportation Implementation Project				
<b>Capital Project Management</b>	<b>Totals:</b>	<b>\$80,000.</b>	<b>\$0.</b>	<b>\$80,000.</b>
	<b>Sr VP for Administration Totals:</b>	<b>\$80,000.</b>	<b>\$0.</b>	<b>\$80,000.</b>
<b><u>Research</u></b>				
<b><u>VP for Research</u></b>				
<b>Staben, Charles A</b>	3048103738	\$2,000,000.	\$0.	\$2,000,000.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				
<b>Staben, Charles A</b>	3048104378	\$80,040.	\$0.	\$80,040.
Southeastern Universities Research Association Inc SURA Bioenergy Fellow Agreement				
<b>VP for Research</b>	<b>Totals:</b>	<b>\$2,080,040.</b>	<b>\$0.</b>	<b>\$2,080,040.</b>
<b><u>Sr Assoc VP Research &amp; Econ Dev</u></b>				
<b>Harvey, Dean E</b>	3048103778	\$165,700.	\$0.	\$165,700.
Economic Development Administration University of Kentucky Technology Development Center				
<b>Sr Assoc VP Research &amp; Econ Dev</b>	<b>Totals:</b>	<b>\$165,700.</b>	<b>\$0.</b>	<b>\$165,700.</b>
<b><u>KY Geological Survey</u></b>				
<b>Anderson, Warren H</b>	3048104745	\$72,914.	\$0.	\$72,914.
Perry County Coal Corp Evaluation of Carbon Sequestration and CO2 EOR Potential, Perry County, KY				
<b>Dinger, James S</b>	3048103760	\$94,100.	\$0.	\$94,100.
Tunnel Management Inc Hydrogeochemistry of Tunnel Roadbed Subsidence				
<b>Dinger, James S</b>	3048104098	\$50,000.	\$0.	\$50,000.
KY Infrastructure Authority Development of Community Water Sources				
<b>Dinger, James S</b>	3048104687	\$48,169.	\$0.	\$48,169.
KY Department of Environmental Protection Nutrient Analysis of Mountain Bioregion Streams in Eastern Kentucky				
<b>Eble, Cortland F</b>	3048104704	\$12,500.	\$0.	\$12,500.
KY Office of Energy Policy Kentucky Coal and Shale Analyses in Support of Southeast Regional Carbon Sequestration Partnership (SECARB) Phase II Project 10				
<b>Gooding, Patrick J</b>		\$10,000.	\$0.	\$10,000.
US Geological Survey Inventory of Oil and Gas Records at the KGS and Investigation of Digital Photographic Methods for Cores and Well Cuttings				
<b>Gooding, Patrick J</b>	3048103513	\$5,000.	\$0.	\$5,000.
US Geological Survey Inventory of Current Collection Resources and Data Preservation at the Kentucky Geological Survey				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>KY Geological Survey</u></b>				
<b>Greb, Stephen F</b>	3046917300	\$0.	\$15,000.	\$15,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
<b>Greb, Stephen F</b>	3046917300	\$0.	\$5,000.	\$5,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
<b>Greb, Stephen F</b>	3046917300	\$0.	\$60,000.	\$60,000.
US Geological Survey Kentucky Coal Data for the National Coal Resource Data System				
<b>Greb, Stephen F</b>	3046957200	\$0.	\$9,926.	\$9,926.
Virginia Polytechnic Institute and State University Southeast Kentucky: Coals as CO2 Sequestration Reservoirs (part of Southeast Regional Carbon Sequestration Partnership Phase 2 Project)				
<b>Greb, Stephen F</b>	3046961500	\$0.	\$120,546.	\$120,546.
Battelle Memorial Institute Kentucky Part of Phase 2 of the Midwest Regional Carbon Sequestration Partnership (MRCSP)				
<b>Harris, David C</b>	3046862700	\$0.	\$53,000.	\$53,000.
University of Illinois A Systems Approach to Identifying Exploration and Development Opportunities in the Illinois Basin: Digital Portfolio of Plays in Underexplored Lower Paleozoic Rocks				
<b>Harris, David C</b>	3048104211	\$5,000,000.	\$0.	\$5,000,000.
KY Office of Energy Policy Research into Enhanced Oil and Gas Recovery Carbon Dioxide (HB1)				
<b>Hickman, John B</b>	3048103523	\$202,606.	\$0.	\$202,606.
Multiple Industry Sponsors Rough Creek Graben Deep Gas Consortium				
<b>Hickman, John B</b>	3048103523	\$0.	\$19,734.	\$19,734.
Multiple Industry Sponsors Rough Creek Graben Deep Gas Consortium				
<b>Hickman, John B</b>	3048103523	\$0.	\$25,000.	\$25,000.
Multiple Industry Sponsors Rough Creek Graben Deep Gas Consortium				
<b>Lynch, Michael J</b>		\$15,000.	\$0.	\$15,000.
KY Board of Registration for Professional Geologists Communications Specialist Liaison for the Kentucky Board of Registration for Professional Geologists				
<b>Nuttall, Brandon C</b>		\$52,221.	\$0.	\$52,221.
IHS Energy Group Enhancement of the PI/Dwights (IHS Energy) Oil Production Data for Kentucky				
<b>Nuttall, Brandon C</b>	3046954900	\$0.	\$175,582.	\$175,582.
Illinois State Geological Survey Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Research</b>				
<b><u>KY Geological Survey</u></b>				
<b>Nuttall, Brandon C</b>	3046954900	\$0.	\$123,314.	\$123,314.
Illinois State Geological Survey Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II				
<b>Parris, Thomas M</b>	3048102147	\$163,446.	\$0.	\$163,446.
KY Office of Energy Policy Evaluation of Geologic CO2 Sequestration Potential and CO2 Enhanced Oil Recovery in Kentucky				
<b>Wang, Zhenming N</b>	3048091700	\$0.	\$36,001.	\$36,001.
US Geological Survey Operation of the Mid-American Integrated Seismic Network-UKY				
<b>Weisenfluh, Gerald A</b>	3048019600	\$0.	\$125,000.	\$125,000.
KY Transportation Cabinet Integrating Geotechnical Drill Hole Data with Geologic Information				
<b>Weisenfluh, Gerald A</b>	3048023300	\$0.	\$50,000.	\$50,000.
KY Transportation Cabinet Geotechnical Guide to Cored Rock in Kentucky SPR 07-338				
<b>KY Geological Survey</b>	<b>Totals:</b>	<b>\$5,725,956.</b>	<b>\$818,103.</b>	<b>\$6,544,059.</b>
<b><u>Appalachian Center</u></b>				
<b>Knight, Evelyn A</b>		\$25,000.	\$0.	\$25,000.
KY Department for Public Health UK Diabetes Evaluation				
<b>Knight, Evelyn A</b>	3048104459	\$10,000.	\$0.	\$10,000.
Shelley and Donald Rubin Foundation Mapping a Mountain Path: Digitize Manipur				
<b>Zeidler, Kimberly J</b>	3048083800	\$0.	\$17,000.	\$17,000.
KY Council on Postsecondary Education Making Nonlinear Algebra Accessible				
<b>Zeidler, Kimberly J</b>	3048104496	\$190,000.	\$0.	\$190,000.
KY Department of Education University of Kentucky Science Alliance				
<b>Appalachian Center</b>	<b>Totals:</b>	<b>\$225,000.</b>	<b>\$17,000.</b>	<b>\$242,000.</b>
<b><u>Interdisc Human Development Institute</u></b>				
<b>Compton, Jonathan F</b>	3048103635	\$0.	\$44,846.	\$44,846.
KY Health Services Cabinet FY 08/Dept of Aging/RWJ Grant				
<b>Compton, Jonathan F</b>	3048103635	\$13,622.	\$0.	\$13,622.
KY Health Services Cabinet FY 08/Dept of Aging/RWJ Grant				
<b>Compton, Jonathan F</b>	3048103635	\$0.	\$26,495.	\$26,495.
KY Health Services Cabinet FY 08/Dept of Aging/RWJ Grant				
<b>Compton, Jonathan F</b>	3048104248	\$0.	\$2,700.	\$2,700.
KY Department of Education UK Post Secondary Transition State Improvement Grant				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Compton, Jonathan F</b>	3048104248	\$269,299.	\$0.	\$269,299.
KY Department of Education UK Post Secondary Transition State Improvement Grant				
<b>Fleming, Bernard P</b>	3046935400	\$0.	\$84,766.	\$84,766.
Department of Education Ky. Resident Training Program in Rehabilitation Technology				
<b>Hall, Meada G</b>	3048103642	\$81,784.	\$0.	\$81,784.
KY Department of Education UK Community Based Work Transition				
<b>Harrison, Elizabeth</b>	3048103796	\$98,142.	\$0.	\$98,142.
KY Department of Education ParaEducators of Kentucky				
<b>Harrison, Ron N</b>	3048002200	\$0.	\$153,352.	\$153,352.
KY Department of Vocational Rehabilitation KYBLN (Kentucky Business Leadership Network)				
<b>Kearns, Jacqueline</b>		\$39,996.	\$0.	\$39,996.
University of Minnesota Multi-State General Supervision Enhancement Grant Consortium				
<b>Kearns, Jacqueline</b>		\$166,916.	\$0.	\$166,916.
KY Department of Education Low Incidence Instructional Strategies				
<b>Kearns, Jacqueline</b>	3048104002	\$1,999,997.	\$0.	\$1,999,997.
Department of Education GSEG Consortia: Priority B, AA-AAS Validity Evaluation				
<b>Kearns, Jacqueline</b>	3048104002	\$0.	\$1,499,997.	\$1,499,997.
Department of Education GSEG Consortia: Priority B, AA-AAS Validity Evaluation				
<b>Kleinert, Harold L</b>	3048103512	\$490,000.	\$0.	\$490,000.
Administration for Children and Families University Center for Excellence				
<b>Kleinert, Harold L</b>	3048104005	\$194,174.	\$0.	\$194,174.
Association of Centers on Disabilities Brighter Tomorrows: Transforming Existing Down Syndrome Professional Education Tools for Broader Dissemination and Use				
<b>Lewis, Preston O</b>	3048103717	\$199,997.	\$0.	\$199,997.
Department of Education Supported Math Accessibility Reading Tool (SMART)				
<b>Rous, Beth</b>	3046683300	\$0.	\$2,200.	\$2,200.
Prichard Committee Early Childhood Parent Leadership Initiative				
<b>Rous, Beth</b>	3048011000	\$0.	\$-375,000.	\$-375,000.
KY Families and Children Cabinet Training Into Practice Project				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Rous, Beth</b>	3048014000	\$0.	\$42,650.	\$42,650.
KY Families and Children Cabinet Child Care CCR&R Services				
<b>Rous, Beth</b>	3048014000	\$0.	\$90,871.	\$90,871.
KY Families and Children Cabinet Child Care CCR&R Services				
<b>Rous, Beth</b>	3048023200	\$0.	\$129,570.	\$129,570.
KY Families and Children Cabinet Child Care Quality Services				
<b>Rous, Beth</b>	3048053500	\$0.	\$6,500.	\$6,500.
KY Health Services Cabinet KY Early Childhood Transition Project 2				
<b>Rous, Beth</b>	3048103231	\$195,001.	\$0.	\$195,001.
KY Department of Education Early Childhood Data Platform				
<b>Rous, Beth</b>	3048103505	\$150,059.	\$0.	\$150,059.
KY Department for Public Health 08 UK KY Early Childhood Data System-First Steps				
<b>Rous, Beth</b>	3048103505	\$0.	\$149,000.	\$149,000.
KY Department for Public Health 08 UK KY Early Childhood Data System-First Steps				
<b>Rous, Beth</b>	3048103506	\$58,014.	\$0.	\$58,014.
KY Department for Public Health CHFS/DPH 08 UK First Step Transition				
<b>Rous, Beth</b>	3048103795	\$86,451.	\$0.	\$86,451.
KY Department of Education Early Childhood Transition Project				
<b>Rous, Beth</b>	3048104003	\$375,000.	\$0.	\$375,000.
KY Families and Children Cabinet Training Into Practice Project '08				
<b>Rous, Beth</b>	3048104410	\$50,000.	\$0.	\$50,000.
University of North Carolina Early Childhood Personnel Center				
<b>Rous, Beth</b>	3048104455	\$12,017.	\$0.	\$12,017.
Eastern KY University UTC-Child Preparation Assessment				
<b>Sheppard-Jones, Kathleen A</b>	3048104095	\$90,153.	\$0.	\$90,153.
KY Department of Vocational Rehabilitation Vocational Rehab Miscellaneous Professional Services				
<b>Wickham, Donna R</b>	3046766800	\$0.	\$59,417.	\$59,417.
Pearson Educational Measurement ILSAA-Washington				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Interdisc Human Development Institute</u></b>				
<b>Wickham, Donna R</b>	3046846000	\$0.	\$340,000.	\$340,000.
Pearson Educational Measurement ILSSA NJ				
<b>Wickham, Donna R</b>	3048063700	\$0.	\$-188,500.	\$-188,500.
Pearson Educational Measurement Minnesota Alternate Assessment (MTAS)				
<b>Wickham, Donna R</b>	3048103658	\$388,771.	\$0.	\$388,771.
KY Department of Education KY Alternate Portfolio Program				
<b>Wickham, Donna R</b>	3048103658	\$0.	\$634,119.	\$634,119.
KY Department of Education KY Alternate Portfolio Program				
<b>Wickham, Donna R</b>	3048103797	\$346,135.	\$0.	\$346,135.
Pearson Educational Measurement ILSSA Puerto Rico				
<b>Wickham, Donna R</b>	3048103797	\$0.	\$123,174.	\$123,174.
Pearson Educational Measurement ILSSA Puerto Rico				
<b>Wickham, Donna R</b>	3048103885	\$299,272.	\$0.	\$299,272.
District of Columbia Public Schools DC Comprehensive Assessment System - Alternate Assessment				
<b>Interdisc Human Development Institute</b>	<b>Totals:</b>	<b>\$5,604,800.</b>	<b>\$2,826,157.</b>	<b>\$8,430,957.</b>
<b><u>Computational Sciences</u></b>				
<b>Connolly, John W</b>		\$92,197.	\$0.	\$92,197.
KY Council on Postsecondary Education State EPSCoR				
<b>Connolly, John W</b>	3046901800	\$0.	\$250,000.	\$250,000.
National Science Foundation Building Kentucky's New Economy with EPSCoR				
<b>Connolly, John W</b>	3048103751	\$57,302.	\$0.	\$57,302.
National Science Foundation EPSCoR Cyberinfrastructure Assessment Workshop				
<b>Kucera, Barbara A</b>	3046951400	\$0.	\$1,000,000.	\$1,000,000.
Department of Treasury Kentucky Center for Resilient Information Systems				
<b>Menon, Madhusudan K</b>	3046915000	\$0.	\$60,000.	\$60,000.
US Army Nanoelectronics of Carbon Nanotube Multi-Terminal Junctions				
<b>Menon, Madhusudan K</b>	3048104223	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Nanoelectronics of Two-and Three- Terminal Junctions of Graphene Ribbons				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Research</b>				
<b><u>Computational Sciences</u></b>				
<b>MENON, MADHU</b>	3046385700	\$0.	\$30,765.	\$30,765.
Department of Energy Magnetism in Low-Dimensional Carbon Materials				
<b>MENON, MADHU</b>	3046385700	\$0.	\$100,000.	\$100,000.
Department of Energy Magnetism in Low-Dimensional Carbon Materials				
<b>Computational Sciences</b>	<b>Totals:</b>	<b>\$169,499.</b>	<b>\$1,440,765.</b>	<b>\$1,610,264.</b>
<b><u>KY Water Resources Institute</u></b>				
<b>Ormsbee, Lindell E</b>	3046738000	\$0.	\$176,880.	\$176,880.
Department of Energy Kentucky Research Consortium for Energy and Environment				
<b>Ormsbee, Lindell E</b>	3046989200	\$0.	\$92,335.	\$92,335.
US Geological Survey State Water Research Institute Program				
<b>Ormsbee, Lindell E</b>	3048103410	\$349,983.	\$0.	\$349,983.
KY Health Services Cabinet UK Paducah Gaseous Diffusion Plant (AIP)				
<b>Ormsbee, Lindell E</b>	3048103410	\$0.	\$104,000.	\$104,000.
KY Health Services Cabinet UK Paducah Gaseous Diffusion Plant (AIP)				
<b>Ormsbee, Lindell E</b>	3048103521	\$94,201.	\$0.	\$94,201.
KY Department for Public Health 08 UK Maxey Flats				
<b>Ormsbee, Lindell E</b>	3048103521	\$0.	\$30,000.	\$30,000.
KY Department for Public Health 08 UK Maxey Flats				
<b>Ormsbee, Lindell E</b>	3048103772	\$81,000.	\$0.	\$81,000.
KY River Authority Watershed Management Service FY 07-08				
<b>KY Water Resources Institute</b>	<b>Totals:</b>	<b>\$525,184.</b>	<b>\$403,215.</b>	<b>\$928,399.</b>
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Andrews, Rodney</b>	3046944900	\$0.	\$108,795.	\$108,795.
Defence Science and Technology Laboratory United King Polyhedral Activated Carbon Composites				
<b>Andrews, Rodney</b>	3048059900	\$0.	\$15,000.	\$15,000.
Materials Sciences Corp DOD SBIR Phase II: High Strength Nanomaterials Fiber for Lightweight Composite Missile Cases				
<b>Andrews, Rodney</b>	3048059900	\$0.	\$69,077.	\$69,077.
Materials Sciences Corp DOD SBIR Phase II: High Strength Nanomaterials Fiber for Lightweight Composite Missile Cases				
<b>Andrews, Rodney</b>	3048059900	\$0.	\$68,703.	\$68,703.
Materials Sciences Corp DOD SBIR Phase II: High Strength Nanomaterials Fiber for Lightweight Composite Missile Cases				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Andrews, Rodney</b>	3048103217	\$25,000.	\$0.	\$25,000.
US Army Research Office				
Workshop on Porous Carbons: Adsorbents for CBRN Protection				
<b>Andrews, Rodney</b>	3048103650	\$10,000.	\$0.	\$10,000.
Materials Sciences Corp				
DOD SBIR Phase 1: Carbon Nanotube Composite Epoxy Resins for Improved Thermal Conductivity and Damage Resistance - Option 1				
<b>Andrews, Rodney</b>	3048103871	\$133,124.	\$0.	\$133,124.
KY Office of Energy Policy				
R&D Seed Grant: On-site Thermochemical Densification of Biomass				
<b>Andrews, Rodney</b>	3048103897	\$110,000.	\$0.	\$110,000.
KY Office of Energy Policy				
Consortium for Advanced Power Generation				
<b>Andrews, Rodney</b>	3048104066	\$235,669.	\$0.	\$235,669.
Evergreen Solar Inc				
Process Development of Pitch-Based Carbon Fiber Core / Evergreen Solar				
<b>Andrews, Rodney</b>	3048104369	\$100,000.	\$0.	\$100,000.
KY Office of Energy Policy				
Regional Energy Partnerships - Kentucky Regional Offices				
<b>Andrews, Rodney</b>	3048104464	\$20,155.	\$0.	\$20,155.
Materials Sciences Corp				
Carbon Nanofibers, Testing and Fabrication				
<b>Andrews, Rodney</b>	3048104562	\$150,000.	\$0.	\$150,000.
Materials Sciences Corp				
Multifunctional Polymer Composites SBIR Phase II				
<b>Andrews, Rodney</b>	3048104683	\$342,516.	\$0.	\$342,516.
KY Office of Energy Policy				
GOEP Matching: Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky CAER				
<b>Crocker, Mark</b>		\$92,400.	\$0.	\$92,400.
KY Office of Energy Policy				
GOEP R&D Seed Grant: Controlled Production of Microalgae in a Demonstration-Scale Photobioreactor				
<b>Crocker, Mark</b>	3046947300	\$0.	\$42,667.	\$42,667.
Department of Energy				
Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Crocker, Mark</b>	3046947300	\$0.	\$40,000.	\$40,000.
Department of Energy				
Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Crocker, Mark</b>	3046947300	\$0.	\$40,000.	\$40,000.
Department of Energy				
Investigation of Aging Mechanisms in Lean NOx Traps				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Research</u></b>				
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Crocker, Mark</b>	3046947300	\$0.	\$60,000.	\$60,000.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
<b>Davis, Burtron H</b>	3048083500	\$0.	\$434,607.	\$434,607.
National Aeronautics and Space Administration Basic Studies for the Production and Upgrading of Fischer-Tropsch Synthesis Products to Fuels				
<b>Davis, Burtron H</b>	3048103898	\$328,200.	\$0.	\$328,200.
KY Office of Energy Policy Catalysts Studies in Support of Commercial CTL Projects in Kentucky				
<b>Davis, Burtron H</b>	3048104038	\$55,104.	\$0.	\$55,104.
US Office of Naval Research Fischer-Tropsch Synthesis Using Carbon Dioxide as the Carbon Source				
<b>Davis, Burtron H</b>	3048104431	\$60,000.	\$0.	\$60,000.
US Office of Naval Research Fischer-Tropsch Synthesis Using Carbon Dioxide as the Carbon Source				
<b>Graham, Ursula M</b>	3048103641	\$93,899.	\$0.	\$93,899.
Toyota Motor Manufacturing USA Inc In-situ catalyst nanoparticle formation inside membrane material/membrane electrolyte assemblies (MEAs) for fuel cell applications - Phase II				
<b>Hiett, John K</b>	3048103224	\$204,839.	\$0.	\$204,839.
KY Department for Natural Resources Mine Mapping Program				
<b>Hower, James C</b>	3046657000	\$0.	\$10,000.	\$10,000.
West Virginia University Coal By-Products Recycling Consortium - Eastern Region Technical Director				
<b>Jacobs, Gary</b>	3048104042	\$103,170.	\$0.	\$103,170.
KY Office of Energy Policy R&D Seed Grant: Toward Understanding How Alkali Promoters Alleviate CO2 Production and enhance Cain Growth Probability Over Iron Fischer-Tropsch Synthesis Catalysts				
<b>Lipka, Steve</b>		\$1,172,280.	\$0.	\$1,172,280.
EON AG A Facile Method for Storing and Rapid Release of Renewable Energy to an Electrical Grid / EON Storage Devices				
<b>Lipka, Steve</b>	3048104401	\$128,597.	\$0.	\$128,597.
US Office of Naval Research High Energy Density Carbons for Electrochemical Capacitors				
<b>Liu, Kunlei</b>	3048103899	\$148,640.	\$0.	\$148,640.
KY Office of Energy Policy R&D Seed Grant: Development of Liquid Membrane for Solvent-Based Post-Combustion CO2 Scrubber				
<b>McAlister, Marybeth</b>	3048103753	\$15,000.	\$0.	\$15,000.
Department of Energy World of Coal Ash (WOCA) Conference				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Research</b>				
<b><u>Ctr for Applied Energy Research</u></b>				
<b>Meier, Mark S</b>	3048104725	\$35,244.	\$0.	\$35,244.
Siemens Power Co Conductive Polymer Materials Development Program				
<b>Taulbee, Darrell N</b>	3048104335	\$0.	\$815,765.	\$815,765.
National Institute for Hometown Security Reducing the Explosion Potential of Ammonium Nitrate Fertilizer				
<b>Taulbee, Darrell N</b>	3048104335	\$20,000.	\$0.	\$20,000.
National Institute for Hometown Security Reducing the Explosion Potential of Ammonium Nitrate Fertilizer				
<b>Taulbee, Darrell N</b>	3048104504	\$79,429.	\$0.	\$79,429.
KY Office of Energy Policy GOEP R&D Seed Grant: Demonstration of the Combustion Characteristics of Fuel Briquettes made from Fine Coal and Biomass				
<b>Ctr for Applied Energy Research</b>	<b>Totals:</b>	<b>\$3,663,266.</b>	<b>\$1,704,614.</b>	<b>\$5,367,880.</b>
<b><u>Div of Laboratory Animal Research</u></b>				
<b>Smiley, Jeffrey R</b>	3048104678	\$445,460.	\$0.	\$445,460.
National Center for Research Resources Enhancement of BBSRB Vivarium				
<b>Div of Laboratory Animal Research</b>	<b>Totals:</b>	<b>\$445,460.</b>	<b>\$0.</b>	<b>\$445,460.</b>
	<b>Research Totals:</b>	<b>\$18,604,905.</b>	<b>\$7,209,854.</b>	<b>\$25,814,759.</b>
<b><u>Dentistry</u></b>				
<b><u>Dentistry</u></b>				
<b>Ebersole, Jeffrey L</b>	3048033600	\$0.	\$8,790.	\$8,790.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Diseases: AEC				
<b>Raybould, Ted P</b>	3048104058	\$320,467.	\$0.	\$320,467.
Health Resources and Services Administration Residency Training in General and Pediatric Dentistry: Advocacy and Care Disparities				
<b>Dentistry</b>	<b>Totals:</b>	<b>\$320,467.</b>	<b>\$8,790.</b>	<b>\$329,257.</b>
<b><u>Dentistry Research &amp; Graduate Studies</u></b>				
<b>Ebersole, Jeffrey L</b>	3048067600	\$0.	\$5,766.	\$5,766.
University of Florida Oral Pathogens: Polymicrobial Virulence Interactions				
<b>Ebersole, Jeffrey L</b>	3048103780	\$0.	\$-225,650.	\$-225,650.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Diseases: AEC				
<b>Ebersole, Jeffrey L</b>	3048103780	\$0.	\$225,650.	\$225,650.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Diseases: AEC				
<b>Ebersole, Jeffrey L</b>	3048103780	\$2,134,817.	\$0.	\$2,134,817.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Diseases: AEC				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Dentistry</u></b>				
<b><u>Dentistry Research &amp; Graduate Studies</u></b>				
<b>Novak, Karen F</b>	3048104412	\$219,750.	\$0.	\$219,750.
National Institute of Dental Research Analyses of Host-Biofilm Interactions: A Novel Polymicrobial Model				
<b>Novak, Michael J</b>	3048104411	\$0.	\$45,739.	\$45,739.
University of Minnesota Effects of Periodontal Therapy on Preterm Birth				
<b>Novak, Michael J</b>	3048104411	\$182,961.	\$0.	\$182,961.
University of Minnesota Effects of Periodontal Therapy on Preterm Birth				
<b>Dentistry Research &amp; Graduate Studies</b>	<b>Totals:</b>	<b>\$2,537,528.</b>	<b>\$51,505.</b>	<b>\$2,589,033.</b>
<b><u>Oral Health Science</u></b>				
<b>Arevalo, Oscar</b>	3048103631	\$374,200.	\$0.	\$374,200.
KY Department for Public Health Support for Dental Public Health Activities				
<b>De Leeuw, Rinskje</b>	3046972300	\$0.	\$135,000.	\$135,000.
National Institute of Dental Research Central Pain Processing in Chronic Face Pain: fMRI Study				
<b>Raybould, Ted P</b>	3046894300	\$0.	\$2,530.	\$2,530.
Nova Pharmaceuticals A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Patients Undergoing Mandibular Dental Procedures				
<b>Oral Health Science</b>	<b>Totals:</b>	<b>\$374,200.</b>	<b>\$137,530.</b>	<b>\$511,730.</b>
<b><u>Oral Health Practice</u></b>				
<b>Miller, Craig S</b>	3048079800	\$0.	\$236,872.	\$236,872.
University of Texas at Austin Development of a Multianalyte Lab-on-a-Chip System for Saliva-Bases Diagnostics				
<b>Miller, Craig S</b>	3048103659	\$219,750.	\$0.	\$219,750.
National Institute of Dental Research Effects of ART on Oral Epithelial Cell Biology				
<b>Novak, Karen F</b>	3048104644	\$2,400.	\$0.	\$2,400.
American Association for Dental Research 2008 AADR Student Research Fellowship: Aaron Rose				
<b>Yepes, Juan F</b>	3048104388	\$2.	\$0.	\$2.
Amarillo Biosciences Inc Eval of Natural Human Interferon Alpha in the Treatment of Oral Warts in HIV				
<b>Oral Health Practice</b>	<b>Totals:</b>	<b>\$222,152.</b>	<b>\$236,872.</b>	<b>\$459,024.</b>
	<b>Dentistry Totals:</b>	<b>\$3,454,347.</b>	<b>\$434,697.</b>	<b>\$3,889,044.</b>
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Brown, Emma J</b>	3048104243	\$219,510.	\$0.	\$219,510.
Center for Disease Control and Prevention PS07-003 MARI: HIV Testing Factors Among Rural/Small City Black Men				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Chung, Misook L</b>	3048032000	\$0.	\$99,918.	\$99,918.
National Institute for Nursing Research Impact of Family Distress and Burden on Patients Outcomes in Heart Failure				
<b>Hahn, Ellen J</b>	3048103628	\$140,000.	\$0.	\$140,000.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				
<b>Hahn, Ellen J</b>	3048093000	\$0.	\$604,454.	\$604,454.
National Heart Lung and Blood Institute An Intervention for Promoting Smoke-free Policy in Rural Kentucky				
<b>Hahn, Ellen J</b>	3048103546	\$30,000.	\$0.	\$30,000.
KY Department for Public Health Indoor Radon Project				
<b>Hahn, Ellen J</b>	3048103628	\$0.	\$14,666.	\$14,666.
KY Health Services Cabinet Community Partnerships for Tobacco Cessation and Prevention				
<b>Hahn, Ellen J</b>	3048104094	\$50,000.	\$0.	\$50,000.
Foundation for a Healthy KY UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy				
<b>Hahn, Ellen J</b>	3048104354	\$50,000.	\$0.	\$50,000.
Robert Wood Johnson Foundation Northern Kentucky Clean Indoor Air Collaborative For Healthy Communities				
<b>Hahn, Ellen J</b>	3048104367	\$5,000.	\$0.	\$5,000.
American Nonsmokers Rights Foundation Rapid Response Assistance Agreement				
<b>Hardinpierce, M G</b>	3048104611	\$10,000.	\$0.	\$10,000.
American Association of Critical Care Nurses Inflammation, Cardiovascular Function and Weaning From Mechanical Ventilation				
<b>Hatcher, Jennifer</b>		\$135,058.	\$0.	\$135,058.
National Cancer Institute Promoting Mammography in African American Women Visiting the Emergency Department				
<b>Howard, Patricia B</b>		\$71,774.	\$0.	\$71,774.
Health Resources and Services Administration Advanced Education Nursing Traineeships				
<b>Howard, Patricia B</b>	3048103724	\$11,517.	\$0.	\$11,517.
Department for Mental Health Mental Retardation Service Kentucky Seclusion and Restraint Reduction				
<b>Kirschling, Jane</b>	3048104018	\$36,000.	\$0.	\$36,000.
Lexington Fayette County Health Department Harrison Elementary Clinic 2007-2008				
<b>Moser, Debra K</b>	3046791500	\$0.	\$-250,863.	\$-250,863.
National Institute for Nursing Research Biobehavioral Intervention in Heart Failure				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Moser, Debra K</b>	3046791500	\$0.	\$298,700.	\$298,700.
National Institute for Nursing Research Biobehavioral Intervention in Heart Failure				
<b>Moser, Debra K</b>	3046987000	\$0.	\$800.	\$800.
Patient Centered Education and Research Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF)				
<b>Moser, Debra K</b>	3046987000	\$0.	\$5,000.	\$5,000.
Patient Centered Education and Research Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF)				
<b>Moser, Debra K</b>	3046987000	\$0.	\$600.	\$600.
Patient Centered Education and Research Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF)				
<b>Moser, Debra K</b>	3048060900	\$0.	\$-14,621.	\$-14,621.
University of California San Francisco Improving Self Care Behaviors and Outcomes in Rural Patients with Heart Failure				
<b>Moser, Debra K</b>	3048104217	\$14,415.	\$0.	\$14,415.
Mayo Clinic Heart Failure in the Community				
<b>Moser, Debra K</b>	3048104228	\$292,423.	\$0.	\$292,423.
National Institute for Nursing Research Center for Biobehavioral Research in Self-Management of Cardiopulmonary Disease				
<b>Moser, Debra K</b>	3048104417	\$2.	\$0.	\$2.
University of California San Francisco Post Discharge Nausea and Vomiting: Incidence and Management Strategies				
<b>Moser, Debra K</b>	3048104714	\$74,350.	\$0.	\$74,350.
University of Arkansas Predicting CHD Events in Black and White Women				
<b>Reed, Deborah B</b>	3048104034	\$370,949.	\$0.	\$370,949.
National Institute of Occupational Safety and Health Refinement and Enhancement of Agricultural Safety Curricula for Children (REACCH)				
<b>Schreiber, Judith A</b>	3048103681	\$30,000.	\$0.	\$30,000.
American Cancer Society Optimism, Locus of Control, Spirituality, and Meaning in Life in Cancer Patients				
<b>Stanhope, Marcia K</b>	3048104607	\$0.	\$-30,529.	\$-30,529.
Lexington Fayette County Health Department Hope Center Health Care Clinic				
<b>Stanhope, Marcia K</b>	3048104607	\$144,414.	\$0.	\$144,414.
Lexington Fayette County Health Department Hope Center Health Care Clinic				
<b>Williams, Carolyn A</b>	3048104231	\$50,000.	\$0.	\$50,000.
American Academy of Nursing Distinguished Nurse Scholar in Residence Award				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Nursing</u></b>				
<b><u>Nursing</u></b>				
<b>Wu, Jia-Rong</b>	3048104602	\$10,000.	\$0.	\$10,000.
American Association of Critical Care Nurses Effect of a Theory-Based, Medication-taking Behavior Feedback Intervention on Medication Adherence and Outcomes in Patients with Heart Failure				
<b>Nursing</b>	<b>Totals:</b>	<b>\$1,745,412.</b>	<b>\$728,125.</b>	<b>\$2,473,537.</b>
	<b>Nursing Totals:</b>	<b>\$1,745,412.</b>	<b>\$728,125.</b>	<b>\$2,473,537.</b>
<b><u>Medicine</u></b>				
<b><u>General Clinical Research Center</u></b>				
<b>Perman, Jay A</b>	3046986000	\$0.	\$100,800.	\$100,800.
National Center for Research Resources General Clinical Research Center				
<b>Perman, Jay A</b>	3046986000	\$0.	\$16,569.	\$16,569.
National Center for Research Resources General Clinical Research Center				
<b>Perman, Jay A</b>	3046986000	\$0.	\$14,239.	\$14,239.
National Center for Research Resources General Clinical Research Center				
<b>General Clinical Research Center</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$131,608.</b>	<b>\$131,608.</b>
<b><u>Area Health Educ Ctr</u></b>				
<b>Norton, James C</b>	3048102111	\$25,000.	\$0.	\$25,000.
KY Health Services Cabinet AHEC Hispanic Health Education				
<b>Norton, James C</b>	3048103214	\$750,000.	\$0.	\$750,000.
KY Department for Public Health FY08 SAAA UK Area Health Education Centers				
<b>Norton, James C</b>	3048103214	\$0.	\$67,667.	\$67,667.
KY Department for Public Health FY08 SAAA UK Area Health Education Centers				
<b>Norton, James C</b>	3048103799	\$277,900.	\$0.	\$277,900.
University of Louisville Model State Supported AHEC project				
<b>Area Health Educ Ctr</b>	<b>Totals:</b>	<b>\$1,052,900.</b>	<b>\$67,667.</b>	<b>\$1,120,567.</b>
<b><u>Kentucky Telecare</u></b>				
<b>Sprang, Robert R</b>	3048103896	\$0.	\$88,518.	\$88,518.
University of Louisville Rural Health Bioterrorism and Emergency Preparedness				
<b>Sprang, Robert R</b>	3048103896	\$333,959.	\$0.	\$333,959.
University of Louisville Rural Health Bioterrorism and Emergency Preparedness				
<b>Kentucky Telecare</b>	<b>Totals:</b>	<b>\$333,959.</b>	<b>\$88,518.</b>	<b>\$422,477.</b>

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Spinal Cord &amp; Brain Injury Res Ctr</b>				
<b>Chen, Jinhui</b>	3046862800	\$0.	\$97,614.	\$97,614.
KY Spinal Cord and Head Injury Research Trust Wnt Singaling Pathway and Neural Stem Cell Fate Determination				
<b>Duale, Hanad</b>	3048104341	\$98,820.	\$0.	\$98,820.
Paralyzed Veterans of America Intraspinal Plasticity Contributing to Autonomic Dysreflexia Following SCI				
<b>Geddes, James W</b>	3046866800	\$0.	\$99,883.	\$99,883.
KY Spinal Cord and Head Injury Research Trust Timing and Duration of Calpain Inhibition Following SCI				
<b>Geddes, James W</b>	3048058100	\$0.	\$43,333.	\$43,333.
National Institute of Mental Health Mechanisms of Neurologic Disease Course				
<b>Geddes, James W</b>	3048103705	\$42,000.	\$0.	\$42,000.
American Heart Association Great Rivers Affiliate Fellowship for Naga: Role of cyclophilin D in the vulnerability of neuronal and synaptic mitochondria to undergo permeability transition.				
<b>Geddes, James W</b>	3048104347	\$99,089.	\$0.	\$99,089.
KY Spinal Cord and Head Injury Research Trust Inhibition of ERK 1/2 Signaling Following Spinal Cord Injury				
<b>Geddes, James W</b>	3048104350	\$99,971.	\$0.	\$99,971.
KY Spinal Cord and Head Injury Research Trust Implications of High Neuronal Cyclophilin D Levels for Spinal Cord Injury				
<b>Geddes, James W</b>	3048104731	\$50,000.	\$0.	\$50,000.
Paralysis Project of America Calpain Knockdown to minimize damage and deficits following SCI				
<b>Geddes, James W</b>	3048104737	\$895,644.	\$0.	\$895,644.
National Institute of Neurological Disorders & Stroke Calpain as a Therapeutic Target for TBI (P01)				
<b>Hall, Edward D</b>	3046888000	\$0.	\$563,593.	\$563,593.
National Institute of Neurological Disorders & Stroke UK Spinal Cord & Brain Injury Research Center Core Grant				
<b>Hall, Edward D</b>	3048081200	\$0.	\$99,706.	\$99,706.
KY Spinal Cord and Head Injury Research Trust Antioxidant/Calpain Inhibitor Combination Strategy in Acute SCI				
<b>Hall, Edward D</b>	3048103801	\$268,783.	\$0.	\$268,783.
National Institute on Drug Abuse Therapeutic Strategies for Neurodegeneration Training Grant				
<b>Lifshitz, Jonathan</b>	3048104351	\$99,994.	\$0.	\$99,994.
KY Spinal Cord and Head Injury Research Trust Somatosensory Circuit Disruption and Rehabilitation after Diffuse Brain Injury				
<b>Rabchevsky, Alexander G</b>	3046809800	\$0.	\$322,980.	\$322,980.
National Institute of Neurological Disorders & Stroke Role of the Intraspinal Plasticity in Automatic Dysreflexia				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Spinal Cord &amp; Brain Injury Res Ctr</u></b>				
<b>Saatman, Kathryn</b>	3048081300	\$0.	\$98,340.	\$98,340.
KY Spinal Cord and Head Injury Research Trust Calpatatin in brain contusion and axonal injury: a novel therapeutic approach				
<b>Saatman, Kathryn</b>	3048104348	\$98,855.	\$0.	\$98,855.
KY Spinal Cord and Head Injury Research Trust Neuroprotective Efficacy of Regionally Targeted IGF-1 Overexpression for Traumatic Brain Injury				
<b>Sullivan, Patrick G</b>	3046755000	\$0.	\$287,643.	\$287,643.
National Institute of Neurological Disorders & Stroke Mitochondrial Uncoupling as a Therapeutic Target in TBI				
<b>Sullivan, Patrick G</b>	3046755000	\$0.	-\$63,432.	-\$63,432.
National Institute of Neurological Disorders & Stroke Mitochondrial Uncoupling as a Therapeutic Target in TBI				
<b>Spinal Cord &amp; Brain Injury Res Ctr</b>	<b>Totals:</b>	<b>\$1,753,156.</b>	<b>\$1,549,660.</b>	<b>\$3,302,816.</b>
<b><u>Graduate Center for Toxicology</u></b>				
<b>Gu, Liya</b>	3046878300	\$0.	\$24,715.	\$24,715.
National Cancer Institute DNA Mismatch Repair Deficiency and Leukemia Relapse				
<b>Gu, Liya</b>	3046878300	\$0.	\$253,918.	\$253,918.
National Cancer Institute DNA Mismatch Repair Deficiency and Leukemia Relapse				
<b>Gu, Liya</b>	3046878300	\$0.	\$34,442.	\$34,442.
National Cancer Institute DNA Mismatch Repair Deficiency and Leukemia Relapse				
<b>Li, Guo-Min</b>	3046967200	\$0.	\$44,679.	\$44,679.
National Institute of General Medical Sciences Dissection and Reconstitution of Mismatch Repair				
<b>Li, Guo-Min</b>	3046967200	\$0.	\$202,747.	\$202,747.
National Institute of General Medical Sciences Dissection and Reconstitution of Mismatch Repair				
<b>Li, Guo-Min</b>	3046967200	\$0.	\$50,687.	\$50,687.
National Institute of General Medical Sciences Dissection and Reconstitution of Mismatch Repair				
<b>Li, Guo-Min</b>	3046998900	\$0.	\$227,246.	\$227,246.
National Cancer Institute Mechnism of PCNA-Dependant 5' -3' Mismatch Excisiion				
<b>ORREN, DAVID K</b>	3046815200	\$0.	\$229,054.	\$229,054.
National Cancer Institute Biochemical Basis of WRN and RecQ Helicase Function				
<b>ORREN, DAVID K</b>	3048104760	\$30,033.	\$0.	\$30,033.
University of Massachusetts Regulation WRN Deacetylation by SIRT1 After DNA Damage				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Graduate Center for Toxicology</u></b>				
<b>Shi, Xianglin</b>	3048083200	\$0.	\$55,670.	\$55,670.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
<b>Shi, Xianglin</b>	3048083200	\$0.	\$222,680.	\$222,680.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
<b>Shi, Xianglin</b>	3048089500	\$0.	\$287,295.	\$287,295.
National Institute of Environmental Health Sciences Apple Peel Extract Protects UV-induced Carcinogenesis				
<b>Shi, Xianglin</b>	3048104536	\$329,625.	\$0.	\$329,625.
National Institute of Environmental Health Sciences Reactive Oxygen Species in Ni(II) Carcinogenesis				
<b>SHI, XIANGLIN</b>	3048054000	\$0.	\$15,000.	\$15,000.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
<b>SHI, XIANGLIN</b>	3048054000	\$0.	\$45,449.	\$45,449.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
<b>SHI, XIANGLIN</b>	3048054000	\$0.	\$181,797.	\$181,797.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
<b>St Clair, Daret K</b>	3046863800	\$0.	\$98,655.	\$98,655.
University of Pennsylvania The Role of Radicals in Space Radiation-Induced Malignant Transformations				
<b>St Clair, Daret K</b>	3046887100	\$0.	\$236,145.	\$236,145.
National Cancer Institute Mechanism of MnSOD Expression in Normal and Tumor Cells				
<b>VORE, MARY</b>		\$155,162.	\$0.	\$155,162.
National Institute of Environmental Health Sciences Molecular Mechanisms of Toxicity Training Grant				
<b>VORE, MARY</b>	3046774300	\$0.	\$222,254.	\$222,254.
National Institute Diabetes & Digestive & Kidney Prolactin and Bile Secretory Function				
<b>VORE, MARY</b>	3048103538	\$0.	\$38,431.	\$38,431.
National Institute of Environmental Health Sciences Molecular Mechanisms of Toxicity Training Grant				
<b>VORE, MARY</b>	3048104322	\$269,560.	\$0.	\$269,560.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				
<b>VORE, MARY</b>	3048104322	\$0.	\$60,651.	\$60,651.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Graduate Center for Toxicology</u></b>				
<b>VORE, MARY</b>	3048104322	\$0.	\$332,672.	\$332,672.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				
<b>VORE, MARY</b>	3048104352	\$34,160.	\$0.	\$34,160.
National Institute of Environmental Health Sciences Summer Educational Experience for Research in Toxicology				
<b>VORE, MARY</b>	3048104387	\$120,000.	\$0.	\$120,000.
National Center for Research Resources Roche Real-Time Polymerase Chain Reaction Workflow System				
<b>Wang, Zhigang</b>	3048103777	\$72,043.	\$0.	\$72,043.
KY Lung Cancer Research Fund A Transgenic Mouse Model for Understanding Rev1 and Lung Cancer				
<b>Graduate Center for Toxicology</b>	<b>Totals:</b>	<b>\$1,010,583.</b>	<b>\$2,864,187.</b>	<b>\$3,874,770.</b>
<b><u>McDowell Cancer Network</u></b>				
<b>Armstrong, Debra K</b>	3048103716	\$28,144.	\$0.	\$28,144.
KY Department for Public Health Kentucky Cancer Program Demonstration Project				
<b>Armstrong, Debra K</b>	3048103827	\$10,000.	\$0.	\$10,000.
KY Department for Public Health Kentucky Breast Cancer Screening Awareness Campaign				
<b>Baron, Andre</b>	3048104074	\$0.	\$65,607.	\$65,607.
Vermillion Inc OvaRI Assay Performance Testing Clinical Trial Using Serum from Women with Documented Ovarian Tumors				
<b>Baron, Andre</b>	3048104074	\$2.	\$0.	\$2.
Vermillion Inc OvaRI Assay Performance Testing Clinical Trial Using Serum from Women with Documented Ovarian Tumors				
<b>Davidson, Jeffrey N</b>	3048104030	\$270,000.	\$0.	\$270,000.
American Cancer Society University of Kentucky Institutional Research Grant				
<b>D'Orazio, John A</b>	3048103524	\$30,000.	\$0.	\$30,000.
Wendy Will Case Cancer Research Fund Manipulation of Pigmentation and Cutaneous UV Response by Topical Forskolin				
<b>D'Orazio, John A</b>	3048103790	\$73,250.	\$0.	\$73,250.
National Cancer Institute Defining the role of MC1R in UV-induced oxidative damage and DNA repair				
<b>Durbin, Eric B</b>	3048103617	\$4,500.	\$0.	\$4,500.
KY Department for Public Health KCR Data Matching Project				
<b>Fleming, Steven T</b>		\$224,230.	\$0.	\$224,230.
Center for Disease Control and Prevention Breast and Prostate Cancer Patterns of Care in Kentucky				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>McDowell Cancer Network</u></b>				
<b>Means, Robert T</b>	3046572100	\$0.	\$248,542.	\$248,542.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				
<b>Means, Robert T</b>	3046572100	\$0.	\$11,292.	\$11,292.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				
<b>Means, Robert T</b>	3046572100	\$0.	\$6,667.	\$6,667.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				
<b>Schwarze, Steven</b>	3048104622	\$329,589.	\$0.	\$329,589.
US Army Medical Research and Materiel Command Activating Cell Death Ligand Signaling Through Proteasome Inhibition				
<b>SCHWARZE, STEVE R</b>	3048102802	\$80,000.	\$0.	\$80,000.
New York Academy of Medicine Endoplasmic Reticulum Stress Pathway Activation in Prostate Cancer				
<b>Summers, Kristie D</b>	3048104370	\$2,752.	\$0.	\$2,752.
MDS Pharma Services Oncore training				
<b>Tucker, Thomas C</b>	3046921300	\$0.	\$899,111.	\$899,111.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
<b>Tucker, Thomas C</b>	3046921300	\$0.	\$183,206.	\$183,206.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
<b>Tucker, Thomas C</b>	3048104064	\$1,135,056.	\$0.	\$1,135,056.
Center for Disease Control and Prevention National Program of Cancer Registries				
<b>Wyatt, Stephen W</b>	3046859900	\$0.	\$830,978.	\$830,978.
National Cancer Institute Cancer Information Services				
<b>McDowell Cancer Network</b>	<b>Totals:</b>	<b>\$2,187,523.</b>	<b>\$2,245,403.</b>	<b>\$4,432,926.</b>
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Danner, Deborah D</b>	3048104318	\$55,020.	\$0.	\$55,020.
KY Health Services Cabinet Kentucky Quality Alzheimer's Dementia Care Project				
<b>Jicha, Gregory A</b>	3048001100	\$0.	\$14,000.	\$14,000.
University of California San Diego Evaluation of the Safety, Tolerability and Impact on Biomarkers of Antioxidant Treatment of Mild to Moderate Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048001100	\$0.	\$6,050.	\$6,050.
University of California San Diego Evaluation of the Safety, Tolerability and Impact on Biomarkers of Antioxidant Treatment of Mild to Moderate Alzheimer's Disease				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$13,000.	\$13,000.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$20,513.	\$20,513.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$45,522.	\$45,522.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048089900	\$0.	\$7,000.	\$7,000.
University of California San Diego Effects of DHA in Slowing the Progression of Alzheimer's Disease				
<b>Jicha, Gregory A</b>	3048103730	\$56,998.	\$0.	\$56,998.
Alzheimers Association Telemedicine Assessment of Cognition in Rural Kentucky: the TACK Study				
<b>Jicha, Gregory A</b>	3048103788	\$0.	\$7,498.	\$7,498.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048103788	\$0.	\$3,563.	\$3,563.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048103788	\$0.	\$1,500.	\$1,500.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048103788	\$2.	\$0.	\$2.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
<b>Jicha, Gregory A</b>	3048104560	\$2.	\$0.	\$2.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
<b>Jicha, Gregory A</b>	3048104560	\$0.	\$14,436.	\$14,436.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
<b>KELLER, JEFFREY N</b>	3046977400	\$0.	\$-111,443.	\$-111,443.
National Institute of Neurological Disorders & Stroke Genetic Basis for Alpha-Synuclein Toxicity				
<b>KELLER, JEFFREY N</b>	3048103606	\$0.	\$-1,568.	\$-1,568.
National Institute on Aging Dietary Restriction, Aging, and the Proteasome				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>KELLER, JEFFREY N</b>	3048103606	\$0.	\$-214,135.	\$-214,135.
National Institute on Aging Dietary Restriction, Aging, and the Proteasome				
<b>KELLER, JEFFREY N</b>	3048103606	\$271,025.	\$0.	\$271,025.
National Institute on Aging Dietary Restriction, Aging, and the Proteasome				
<b>KELLER, JEFFREY N</b>	3048103734	\$300,325.	\$0.	\$300,325.
National Institute on Aging Dietary restriction and proteasome-mediated protein degradation in the aging CNS				
<b>KELLER, JEFFREY N</b>	3048103734	\$0.	\$-271,274.	\$-271,274.
National Institute on Aging Dietary restriction and proteasome-mediated protein degradation in the aging CNS				
<b>LeVine, Harry</b>	3048043600	\$0.	\$181,371.	\$181,371.
National Institute on Aging A Screen for Small Molecule Inhibitors of Soluble Abeta Oligomer Assembly				
<b>LeVine, Harry</b>	3048058200	\$0.	\$80,538.	\$80,538.
Alzheimers Association Chaperone-Mediated Protein Refolding Dysfunction in Alzheimer's Disease				
<b>LeVine, Harry</b>	3048104659	\$62,038.	\$0.	\$62,038.
Emory University Alzheimer's Disease: Modeling Pathologic Strain-like Variants of Multimeric a-Beta				
<b>Lovell, Mark</b>	3048102141	\$48,006.	\$0.	\$48,006.
Scout Diagnostics, LLC STTR: Development of a Diagnostic Test for Alzheimer's Disease				
<b>Markesbery, William</b>	3046518500	\$0.	\$457,063.	\$457,063.
National Institute on Aging Prevention of Alzheimer's Disease by Vitamin E and Selenium				
<b>Markesbery, William</b>	3046969700	\$0.	\$7,325.	\$7,325.
Oregon Health and Sciences University Genetic Associations with Alzheimer-Free Survival				
<b>Markesbery, William</b>	3046969700	\$0.	\$5,860.	\$5,860.
Oregon Health and Sciences University Genetic Associations with Alzheimer-Free Survival				
<b>Markesbery, William</b>	3048103211	\$0.	\$1,890.	\$1,890.
National Institute on Aging Alzheimer's Disease Core Center				
<b>Markesbery, William</b>	3048103211	\$1,234,437.	\$0.	\$1,234,437.
National Institute on Aging Alzheimer's Disease Core Center				
<b>Markesbery, William</b>	3048103211	\$0.	\$-1,890.	\$-1,890.
National Institute on Aging Alzheimer's Disease Core Center				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>Markesbery, William</b>	3048103699	\$0.	\$2,599.	\$2,599.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 9				
<b>Markesbery, William</b>	3048103699	\$28,900.	\$0.	\$28,900.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 9				
<b>Markesbery, William</b>	3048104432	\$0.	\$-13,176.	\$-13,176.
National Institute on Aging Beta Amyloid and Oxidative Stress in Alzheimer's Disease				
<b>Markesbery, William</b>	3048104432	\$1,807,137.	\$0.	\$1,807,137.
National Institute on Aging Beta Amyloid and Oxidative Stress in Alzheimer's Disease				
<b>Markesbery, William</b>	3048104499	\$1,304,793.	\$0.	\$1,304,793.
National Institute on Aging Prevention of Alzheimer's Disease by Vitamin E and Selenium				
<b>Nelson, Peter</b>	3046980700	\$0.	\$176,729.	\$176,729.
National Institute of Neurological Disorders & Stroke Alpha-Synuclein MRNA is a Putative MicroRNA Target				
<b>Norris, Christopher M</b>	3048043000	\$0.	\$257,206.	\$257,206.
National Institute on Aging Calcineurin and Inflammatory Signaling Processes in Aging and AD				
<b>NORRIS, CHRISTOPHER</b>	3046825900	\$0.	\$88,511.	\$88,511.
National Institute on Aging Calcineurin and Biobehavioral Markers of Brain Aging				
<b>Scheff, Stephen W</b>	3046689300	\$0.	\$338,003.	\$338,003.
National Institute on Aging Response of the Aging Nervous System to Trauma				
<b>Scheff, Stephen W</b>	3048028900	\$0.	\$2,198.	\$2,198.
University of Pittsburgh Neurobiology and Cognitive Impairment (subcontract with University of Pittsburgh)				
<b>Scheff, Stephen W</b>	3048049400	\$0.	\$263,479.	\$263,479.
National Institute on Aging Synaptic Change in Mild Cognitive Impairment				
<b>Schmitt, Frederick A</b>	3046567200	\$0.	\$2,325.	\$2,325.
University of California San Diego Assessment Measures for AD Primary Prevention Trials				
<b>Snowdon, David A</b>	3048089800	\$0.	\$17,066.	\$17,066.
University of Waterloo Vascular Risk Factors, Vascular Pathology and Alzheimer's Disease				
<b>TELLING, GLENN</b>		\$78,049.	\$0.	\$78,049.
Department of Agriculture Production of transgenic mice expressing either porcine or mutant bovine PrP				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Sanders-Brown Center on Aging</u></b>				
<b>TELLING, GLENN</b>	3046631200	\$0.	\$399,002.	\$399,002.
Colorado State University US Based Collaboration in Emerging Viral and Prion Diseases				
<b>TELLING, GLENN</b>	3046713900	\$0.	\$319,222.	\$319,222.
University of Wisconsin Genetic Susceptibility and Biological Characterization of Chronic Wasting Disease				
<b>TELLING, GLENN</b>	3046905000	\$0.	\$317,923.	\$317,923.
National Institute of Neurological Disorders & Stroke Transgenic Studies of Prion Disease in Cervids				
<b>TELLING, GLENN</b>	3046990000	\$0.	\$80,000.	\$80,000.
Department of Agriculture Transgenic Analysis of Chronic Wasting Disease Strains USDA, ARS PWA				
<b>TELLING, GLENN</b>	3046990000	\$0.	\$30,000.	\$30,000.
Department of Agriculture Transgenic Analysis of Chronic Wasting Disease Strains USDA, ARS PWA				
<b>Sanders-Brown Center on Aging</b>	<b>Totals:</b>	<b>\$5,246,732.</b>	<b>\$2,547,906.</b>	<b>\$7,794,638.</b>
<b><u>Mag Resonance Imag Sys Ctr</u></b>				
<b>Smith, Charles D</b>	3046940800	\$0.	\$40,565.	\$40,565.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$42,031.	\$42,031.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$32,891.	\$32,891.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3046940800	\$0.	\$38,501.	\$38,501.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
<b>Smith, Charles D</b>	3048044900	\$0.	\$285,904.	\$285,904.
National Institute on Aging Imaging Brain Function/Structure in Presymptomatic FTD				
<b>Smith, Charles D</b>	3048044900	\$0.	\$291,979.	\$291,979.
National Institute on Aging Imaging Brain Function/Structure in Presymptomatic FTD				
<b>Mag Resonance Imag Sys Ctr</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$731,871.</b>	<b>\$731,871.</b>
<b><u>Rural Ky Healthcare</u></b>				
<b>Allen, Larry</b>	3048103303	\$30,000.	\$0.	\$30,000.
KY Department for Public Health Rural Cooperative Agreement				
<b>Allen, Larry</b>	3048103309	\$148,500.	\$0.	\$148,500.
Health Resources and Services Administration State Offices of Rural Health Grant Program				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Rural Ky Healthcare</u></b>				
<b>Allen, Larry</b>	3048103752	\$339,910.	\$0.	\$339,910.
Health Resources and Services Administration SHIP Grant Program				
<b>Allen, Larry</b>	3048103837	\$270,000.	\$0.	\$270,000.
Health Resources and Services Administration Kentucky State Loan Repayment Program				
<b>Allen, Larry</b>	3048104026	\$500,000.	\$0.	\$500,000.
Health Resources and Services Administration Rural Hospital Flexibility Grant Program				
<b>Cole, Cynthia M</b>	3048104063	\$0.	\$361.	\$361.
Appalachian Regional Commission Expansion of the Community-based Research Education in Eastern Kentucky (CREEK) Program				
<b>Samuels, Michael E</b>	3048103220	\$91,213.	\$0.	\$91,213.
Foundation for a Healthy KY Health Equity Grant				
<b>Rural Ky Healthcare</b>	<b>Totals:</b>	<b>\$1,379,623.</b>	<b>\$361.</b>	<b>\$1,379,984.</b>
<b><u>Center on Drug and Alcohol Research</u></b>				
<b>Havens, Jennifer Rochussen</b>		\$488,124.	\$0.	\$488,124.
National Institute on Drug Abuse Social Networks and HIV Risk Among Rural Drug Users				
<b>Leukefeld, Carl G</b>		\$4,515,858.	\$0.	\$4,515,858.
KY Health Services Cabinet TAP and Substance Abuse & Intimate Partner Violence Project				
<b>Leukefeld, Carl G</b>	3046756600	\$0.	\$-31.	\$-31.
Purdue Pharma LP Prescription Drug Study				
<b>Leukefeld, Carl G</b>	3048051700	\$0.	\$432,734.	\$432,734.
National Institute on Drug Abuse Central States Criminal Justice Drug Abuse Center (CJ-DATS)				
<b>Leukefeld, Carl G</b>	3048075900	\$0.	\$110,844.	\$110,844.
University of Arkansas Rural Stimulant Use & Mental Health: Services and Outcomes				
<b>Leukefeld, Carl G</b>	3048103300	\$0.	\$940,925.	\$940,925.
KY Health Services Cabinet TAP and Substance Abuse & Intimate Partner Violence Project				
<b>Leukefeld, Carl G</b>	3048103300	\$0.	\$-8.	\$-8.
KY Health Services Cabinet TAP and Substance Abuse & Intimate Partner Violence Project				
<b>Tindall, Michele Staton</b>	3046928800	\$0.	\$80,000.	\$80,000.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Center on Drug and Alcohol Research</u></b>				
<b>Tindall, Michele Staton</b>	3048103747	\$135,140.	\$0.	\$135,140.
KY Department of Corrections Treatment outcome study for prison-based substance abuse treatment program 07-08 (CJ-KTOS)				
<b>Walker, James R</b>	3048103425	\$1,316,276.	\$0.	\$1,316,276.
Department for Mental Health Mental Retardation Service Follow-up Study/Outcome Project (TAAA)				
<b>Walker, James R</b>	3048104610	\$109,715.	\$0.	\$109,715.
Eastern KY University UTC Division of Child Care - STARS Project				
<b>Walker, James R</b>	3048104615	\$60,000.	\$0.	\$60,000.
KY River Community Care Inc Program Evaluation, Clinical Training, and Consultative Services for KRCC Staff				
<b>Walsh, Sharon L</b>	3046966600	\$0.	\$491,594.	\$491,594.
National Institute on Drug Abuse Licit & Illicit Opioids: Comparative Studies in Humans				
<b>Walsh, Sharon L</b>	3046998700	\$0.	\$20,278.	\$20,278.
US Worldmeds LLC A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification				
<b>Walsh, Sharon L</b>	3046998700	\$0.	\$28,969.	\$28,969.
US Worldmeds LLC A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification				
<b>Walsh, Sharon L</b>	3046998700	\$0.	\$8,032.	\$8,032.
US Worldmeds LLC A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification				
<b>Walsh, Sharon L</b>	3046998700	\$0.	\$25,778.	\$25,778.
US Worldmeds LLC A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification				
<b>Walsh, Sharon L</b>	3046998700	\$0.	\$37,019.	\$37,019.
US Worldmeds LLC A Phase III, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification				
<b>Walsh, Sharon L</b>	3048048600	\$0.	\$615,232.	\$615,232.
National Institute on Drug Abuse Evaluation of Novel Treatments for Stimulant Dependence				
<b>Walsh, Sharon L</b>	3048092200	\$0.	\$355,629.	\$355,629.
National Institute on Drug Abuse Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Center on Drug and Alcohol Research</u></b>				
<b>Wong, Conrad J</b>	3048103671	\$177,980.	\$0.	\$177,980.
National Cancer Institute Internet Based Voucher Reinforcement for Smoking Cessation				
<b>Center on Drug and Alcohol Research</b>	<b>Totals:</b>	<b>\$6,803,093.</b>	<b>\$3,146,995.</b>	<b>\$9,950,088.</b>
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>BING, GUOYING</b>	3048104483	\$51,000.	\$0.	\$51,000.
P2D Inc TNF-alpha inhibitors protect against MPTP-induced Parkinson's disease				
<b>Bradley, Luke H.</b>	3048104226	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Neuronal protein recognition, specificity, and design				
<b>BRUCE-KELLER, ANNADORA</b>	3046800500	\$0.	-\$249,610.	-\$249,610.
National Institute of Neurological Disorders & Stroke Tat, NADPH Oxidase, and HIV-Dementia				
<b>BRUCE-KELLER, ANNADORA</b>	3048103708	\$64,831.	\$0.	\$64,831.
Virginia Commonwealth University Opiate Drug Abuse and CNS Vulnerability to HIV: Project 3				
<b>BRUCE-KELLER, ANNADORA</b>	3048103714	\$26,282.	\$0.	\$26,282.
Virginia Commonwealth University Opiate Drug Abuse and CNS Vulnerability to HIV Core B-2				
<b>Cass, Wayne A</b>	3048103646	\$183,125.	\$0.	\$183,125.
National Institute on Drug Abuse Calcitriol and Methamphetamine Neurotoxicity				
<b>Cass, Wayne A</b>	3048104047	\$0.	\$160,234.	\$160,234.
National Institute of Neurological Disorders & Stroke Calcitriol-Induced Restoration of Dopamine in a Model of Parkinson's Disease				
<b>Cass, Wayne A</b>	3048104047	\$160,234.	\$0.	\$160,234.
National Institute of Neurological Disorders & Stroke Calcitriol-Induced Restoration of Dopamine in a Model of Parkinson's Disease				
<b>Duncan, Marilyn J</b>	3048103522	\$300,325.	\$0.	\$300,325.
National Institute on Aging Neural Mechanisms Resetting the Aged Circadian Pacemaker				
<b>Duncan, Marilyn J</b>	3048104274	\$323,903.	\$0.	\$323,903.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
<b>Gash, Don M</b>	3046674800	\$0.	\$73,650.	\$73,650.
National Institute on Aging Aging of Central Dopaminergic Systems in Primates				
<b>Gash, Don M</b>	3046674800	\$0.	\$54,296.	\$54,296.
National Institute on Aging Aging of Central Dopaminergic Systems in Primates				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>Gash, Don M</b>	3046956000	\$0.	\$26,884.	\$26,884.
Medtronics Inc New Neural Therapy Studies: 2005-1				
<b>Gash, Don M</b>	3046956000	\$0.	\$4,947.	\$4,947.
Medtronics Inc New Neural Therapy Studies: 2005-1				
<b>Gash, Don M</b>	3046956000	\$0.	\$3,331.	\$3,331.
Medtronics Inc New Neural Therapy Studies: 2005-1				
<b>Gash, Don M</b>	3048091000	\$0.	\$11,800.	\$11,800.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$17,609.	\$17,609.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$51,785.	\$51,785.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$2,198.	\$2,198.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$30,522.	\$30,522.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$6,453.	\$6,453.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$52,567.	\$52,567.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$63,546.	\$63,546.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$496,402.	\$496,402.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048091000	\$0.	\$3,736.	\$3,736.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
<b>Gash, Don M</b>	3048103727	\$75,757.	\$0.	\$75,757.
Johnson and Johnson Screening Dopaminergic Trophic Factors in Rat Model Systems				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>Gash, Don M</b>	3048104342	\$138,980.	\$0.	\$138,980.
Ethicon Inc Pilot Assessment of Treatments in a Rat Model of Parkinson's Disease				
<b>Gash, Don M</b>	3048104619	\$92,321.	\$0.	\$92,321.
National Institute on Aging The Molecular and Cellular Basis on Brain Aging				
<b>GERHARDT, GREG A.</b>	3046733200	\$0.	\$411,662.	\$411,662.
National Institute on Drug Abuse Neurochem Chip: Methodology to Study Untethered Rats				
<b>GERHARDT, GREG A.</b>	3046967500	\$0.	\$29,246.	\$29,246.
Medical University of South Carolina Dual Hit Hypothesis of Aging Related DA Dysfunction				
<b>GERHARDT, GREG A.</b>	3048078800	\$0.	\$85,331.	\$85,331.
Ohio State University High-Speed detection of Stimulant-induced Cortical ACh Release				
<b>GERHARDT, GREG A.</b>	3048103740	\$1,186,609.	\$0.	\$1,186,609.
National Institute of Neurological Disorders & Stroke Morris K. Udall Parkinson's Center of Excellence: Restoration of Dopaminergic Function in Parkinson's Disease				
<b>GERHARDT, GREG A.</b>	3048104332	\$0.	\$12,384.	\$12,384.
Pfizer Inc Pharmacological studies of metabotropic glutamate receptor agonists on glutamate neurotransmission in the prefrontal cortex of awake, behaving rats				
<b>GERHARDT, GREG A.</b>	3048104332	\$72,000.	\$0.	\$72,000.
Pfizer Inc Pharmacological studies of metabotropic glutamate receptor agonists on glutamate neurotransmission in the prefrontal cortex of awake, behaving rats				
<b>GERHARDT, GREG A.</b>	3048104463	\$187,520.	\$0.	\$187,520.
Pfizer Inc Glutamate release studies on alpha 2/delta compounds in vitro using glutamate sensitive electrodes				
<b>GERHARDT, GREG A.</b>	3048104626	\$80,751.	\$0.	\$80,751.
Pfizer Inc Effects of Pregabalin (PGB) on resting Glutamate Levels and Stress-Induced Glutamate levels in the Prefrontal Cortex (PFC) and Amygdala of Awake, Behaving Rats				
<b>Gold, Brian T</b>	3046981800	\$0.	\$71,126.	\$71,126.
National Institute on Deafness & Other Communications Neural Substrates of Component Lexical Semantic Processes				
<b>Gold, Brian T</b>	3046981800	\$0.	\$71,126.	\$71,126.
National Institute on Deafness & Other Communications Neural Substrates of Component Lexical Semantic Processes				
<b>Jennes, Lothar H</b>	3046887300	\$0.	\$279,068.	\$279,068.
National Institute on Aging Neuroendocrine Mechanisms of Reproductive Aging				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Anatomy &amp; Neurobiology</u></b>				
<b>Joseph, Jane E</b>		\$298,650.	\$0.	\$298,650.
National Institute of Child Health and Human Development Functional Neuroanatomy of Development Changes in Face Processing				
<b>Joseph, Jane E</b>	3048103754	\$0.	\$302,360.	\$302,360.
National Institute of Child Health and Human Development Functional Neuroanatomy of Development Changes in Face Processing				
<b>Joseph, Jane E</b>	3048103764	\$59,694.	\$0.	\$59,694.
Autism Speaks Exploring Functional Brain Connectivity for Visual Cognition in Autism Spectrum Disorder				
<b>Snow, Diane M</b>	3048104091	\$326,000.	\$0.	\$326,000.
National Institute of Neurological Disorders & Stroke Designer PGs for CNS Injury				
<b>Snow, Diane M</b>	3048104215	\$75,000.	\$0.	\$75,000.
Christopher Reeve Paralysis Foundation Designer PGs for Spinal Cord Injury				
<b>Snow, Diane M</b>	3048104215	\$0.	\$-1,000.	\$-1,000.
Christopher Reeve Paralysis Foundation Designer PGs for Spinal Cord Injury				
<b>Zhang, Zhiming</b>	3048083900	\$0.	\$10,194.	\$10,194.
University of Pittsburgh Exercise Effects on the Primate Nigrostriatal Pathway				
<b>Zhang, Zhiming</b>	3048092900	\$0.	\$256,375.	\$256,375.
National Institute of Neurological Disorders & Stroke Relationship between BOLD Effects and DA Degeneration				
<b>Zhang, Zhiming</b>	3048092900	\$0.	\$64,094.	\$64,094.
National Institute of Neurological Disorders & Stroke Relationship between BOLD Effects and DA Degeneration				
<b>Anatomy &amp; Neurobiology</b>	<b>Totals:</b>	<b>\$3,722,982.</b>	<b>\$2,402,316.</b>	<b>\$6,125,298.</b>
<b><u>Anesthesiology</u></b>				
<b>Atallah, Joseph</b>	3046969000	\$0.	\$-2.	\$-2.
GlaxoSmithKline A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily for 12 Weeks for the Treatment of Opioid Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain				
<b>Atallah, Joseph</b>	3046969100	\$0.	\$-2.	\$-2.
GlaxoSmithKline A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain				
<b>Holtman, Joseph R</b>	3048026600	\$0.	\$154,117.	\$154,117.
Yaupon Therapeutics Inc STTR: Norketamine for Treatment of Pain				
<b>Anesthesiology</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$154,113.</b>	<b>\$154,113.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Emergency Medicine</b>				
<b>Humphries, Roger L</b>	3048087100	\$0.	\$-2,000.	\$-2,000.
MedImmune Inc An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated Lower Respiratory TRact Infections (LRI) or Apnea in Infants in the Emergency Department				
<b>Humphries, Roger L</b>	3048100900	\$0.	\$76,338.	\$76,338.
National Institute of Neurological Disorders & Stroke UK NETT Clinical Site hub				
<b>Humphries, Roger L</b>	3048104000	\$2.	\$0.	\$2.
University of Michigan UK NETT Clinical Hub Site				
<b>Emergency Medicine</b>	<b>Totals:</b>	<b>\$2.</b>	<b>\$74,338.</b>	<b>\$74,340.</b>
<b>Behavioral Science</b>				
<b>Andrykowski, Michael A</b>	3046847000	\$0.	\$167,022.	\$167,022.
H Lee Moffitt Cancer Center and Research I Cognitive Behavioral Aspects of Cancer-Related Fatigue				
<b>Andrykowski, Michael A</b>	3048085100	\$0.	\$29,945.	\$29,945.
University of South Florida Apolipoprotein E Genotype and Cognitive Performance in Breast Cancer Survivors				
<b>Cole, Cynthia M</b>	3048021500	\$0.	\$10,000.	\$10,000.
People Encouraging People Inc Evaluation of the Lee County People Encouraging People (PEP) Coalition				
<b>Fernander, Anita</b>	3048104060	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Examination of the Breathe Free for Women Stop Smoking Program Among African American Women: A Pilot Study				
<b>Garrity, Thomas F</b>		\$249,680.	\$0.	\$249,680.
National Institute on Drug Abuse Research Training in Drug Abuse Behavior				
<b>Kelly, Thomas H</b>	3048103866	\$53,919.	\$0.	\$53,919.
National Institute on Drug Abuse Separate and Combined Effects of Progesterone and Triazolam in Healthy Women				
<b>Knudsen, Hannah K</b>	3048104242	\$54,980.	\$0.	\$54,980.
University of Georgia Service delivery and the structure of adolescent treatment programs, measure the use of evidence based treatment techniques, and model the associations between program quality, state-level policies, and organizational characteristics.				
<b>Knudsen, Hannah K</b>	3048104382	\$27,528.	\$0.	\$27,528.
University of Georgia CTN Membership and Adoption of Innovative TX Practices				
<b>Knudsen, Hannah K</b>	3048104713	\$264,872.	\$0.	\$264,872.
National Institute on Drug Abuse Smoking Cessation Practices in Community Tx Programs				
<b>Leukefeld, Carl G</b>	3048077800	\$0.	\$260,118.	\$260,118.
National Center for Research Resources TRY-IT Translating Reserach to Youth through Information Technology				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Behavioral Science</u></b>				
<b>Rush, Craig R</b>	3046925900	\$0.	\$306,293.	\$306,293.
National Institute on Drug Abuse Stimulant Abuse Pharmacotherapy: Novel Antipsychotics				
<b>Rush, Craig R</b>	3046956200	\$0.	\$347,271.	\$347,271.
National Institute on Drug Abuse Preventing Cocaine Relapse: Developing Pharmacotherapies				
<b>Rush, Craig R</b>	3048004600	\$0.	\$348,516.	\$348,516.
National Institute on Drug Abuse Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications				
<b>Schoenberg, Nancy E</b>	3046833900	\$0.	\$328,168.	\$328,168.
National Cancer Institute An Appalachian Cervical Cancer Prevention Project				
<b>Schoenberg, Nancy E</b>	3046833900	\$0.	\$48,294.	\$48,294.
National Cancer Institute An Appalachian Cervical Cancer Prevention Project				
<b>Schoenberg, Nancy E</b>	3048104728	\$197,775.	\$0.	\$197,775.
National Cancer Institute Increasing Colorectal Cancer Screening for Patients with Multiple Morbidities				
<b>Stoops, William W</b>	3048104631	\$183,125.	\$0.	\$183,125.
National Institute on Drug Abuse Human Lab Model of Behavioral/ Pharmacological Treatment for Cocaine Dependence				
<b>Studts, Jamie Lawrence</b>	3048104418	\$0.	\$702.	\$702.
National Cancer Institute Adjuvant Treatment Decision Making for Lung Cancer				
<b>Studts, Jamie Lawrence</b>	3048104418	\$71,529.	\$0.	\$71,529.
National Cancer Institute Adjuvant Treatment Decision Making for Lung Cancer				
<b>Wong, Conrad J</b>	3048103534	\$0.	\$-177,980.	\$-177,980.
National Cancer Institute Internet Based Voucher Reinforcement for Smoking Cessation				
<b>Wong, Conrad J</b>	3048103534	\$177,980.	\$0.	\$177,980.
National Cancer Institute Internet Based Voucher Reinforcement for Smoking Cessation				
<b>Behavioral Science</b>	<b>Totals:</b>	<b>\$1,425,474.</b>	<b>\$1,668,349.</b>	<b>\$3,093,823.</b>
<b><u>Graduate Center for Nutritional Sciences</u></b>				
<b>Cassis, Lisa A</b>	3048103693	\$0.	\$0.	\$0.
National Heart Lung and Blood Institute Angiotensin: A Link Between Obesity and Hypertension				
<b>Glauert, Howard P</b>	3048103660	\$73,250.	\$0.	\$73,250.
National Cancer Institute Prevention of Cigarette Smoke-Induced Lung Cancer by Dietary Selenium				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Graduate Center for Nutritional Sciences</u></b>				
<b>Glauert, Howard P</b>	3048103661	\$31,132.	\$0.	\$31,132.
University of Iowa Semi-Volatile PCB's: Sources, Exposures, Toxicities				
<b>Glauert, Howard P</b>	3048104630	\$30,718.	\$0.	\$30,718.
University of Iowa Semi-Volatile PCBs: Sources, Exposures, Toxicities				
<b>Mao, Catherine</b>	3048103674	\$0.	\$12,634.	\$12,634.
National Heart Lung and Blood Institute Role of WNT13 and WNT13-Signaling in Endothelial Cell Survival				
<b>Shao, Jianhua</b>	3048103673	\$0.	\$177,814.	\$177,814.
National Institute Diabetes & Digestive & Kidney Fetal Adiponectin Expression and Obesity of GDM Offspring				
<b>Shao, Jianhua</b>	3048103750	\$197,500.	\$0.	\$197,500.
American Diabetes Association Inc Transcriptional Regulation of Adiponectin Gene Expression				
<b>Shao, Jianhua</b>	3048103762	\$60,500.	\$0.	\$60,500.
American Heart Association Great Rivers Affiliate Obesity and Adiponectin Gene Expression				
<b>Shao, Jianhua</b>	3048104484	\$293,000.	\$0.	\$293,000.
National Institute Diabetes & Digestive & Kidney Adiponectin and Regulation of Triglyceride Metabolism				
<b>St Clair, Daret K</b>	3048103535	\$86,028.	\$0.	\$86,028.
National Institute Diabetes & Digestive & Kidney Training Program in Oxidative Stress and Nutrition				
<b>Van Der Westhuyzen, Deneys R</b>	3048103765	\$21,000.	\$0.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship/Shetty: PI3-Kinase (P13K) Regulation of SR-BI Distribution and Selective Lipid Uptakes in Hepatocytes				
<b>Wang, Shuxia</b>	3048103758	\$65,000.	\$0.	\$65,000.
American Heart Association Repression of Thrombospondin I and Thrombospondin I Dependent TGF-B Activation in Diabetic Nephropathy				
<b>Graduate Center for Nutritional Sciences</b>	<b>Totals:</b>	<b>\$858,128.</b>	<b>\$190,448.</b>	<b>\$1,048,576.</b>
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Andres, Douglas A</b>	3048003000	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship/Rudolph: The Role of Rit GTPase Signaling in Neurons				
<b>Andres, Douglas A</b>	3048104716	\$366,250.	\$0.	\$366,250.
National Institute of Neurological Disorders & Stroke Regulation of Neuronal Survival by the Rit GTPase				
<b>DUTCH, REBECCA</b>	3048102144	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Rachel Schowalter: Host Cell Surface Components Required for HMPV Fusion Protein Binding and Fusion				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>DUTCH, REBECCA</b>	3048103832	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases HMPV Fusion Protein-host Cell Interactions				
<b>Finlin, Brian S</b>	3046894600	\$0.	\$138,000.	\$138,000.
American Diabetes Association Inc Regulation of 1-Type Calcium Channels by the Rem2 GTPase in Pancreatic Bata Cells				
<b>Fried, Michael Gregory</b>	3046889200	\$0.	\$247,257.	\$247,257.
National Institute of General Medical Sciences Cooperative Interactions in DNA Repair				
<b>Fried, Michael Gregory</b>	3048096900	\$0.	\$27,951.	\$27,951.
Ohio State University Molecular Basis of Interchromosomal Gene Regulation				
<b>Hersh, Louis B</b>	3046854400	\$0.	\$44,971.	\$44,971.
National Institute of Neurological Disorders & Stroke Estrogen, Androgen, Neprilysin and Amyloid Peptides				
<b>Hersh, Louis B</b>	3046854400	\$0.	\$179,887.	\$179,887.
National Institute of Neurological Disorders & Stroke Estrogen, Androgen, Neprilysin and Amyloid Peptides				
<b>Hersh, Louis B</b>	3048090500	\$0.	\$287,499.	\$287,499.
National Institute on Drug Abuse Degradation of Opioid Peptides				
<b>Hersh, Louis B</b>	3048103514	\$124,002.	\$0.	\$124,002.
National Institute on Drug Abuse Training in Drug Abuse Related Research				
<b>Hersh, Louis B</b>	3048103768	\$1,990,154.	\$0.	\$1,990,154.
National Center for Research Resources Center of Biomedical Research Excellence in the Molecular Basis of Human Disease				
<b>Hersh, Louis B</b>	3048104542	\$50,000.	\$0.	\$50,000.
Institute of the Study of Aging Inc Neprilysin and Peripheral Clearance of Amyloid Peptides				
<b>Hersh, Louis B</b>	3048104635	\$44,286.	\$0.	\$44,286.
KY Science and Technology Co Inc COMM FUND: Development of an enzyme-based treatment for Alzheimer's Disease				
<b>MCCANN, RICHARD</b>	3048003500	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship/Singiser: Talin2 and Intercalated Disc Assembly in Cardiac Cells				
<b>MCCANN, RICHARD</b>	3048103414	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Steven Smith: The Role of Talin in Cell Adhesion and Migration, and How a C-terminal Modular element Affects its Function				
<b>Murphy, Michael Paul</b>	3048104202	\$288,422.	\$0.	\$288,422.
National Institute of Neurological Disorders & Stroke Cellular Nucleic Acid Binding Protein (CNBP) in Aging and Disease				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Murphy, Michael Paul</b>	3048104202	\$0.	\$288,422.	\$288,422.
National Institute of Neurological Disorders & Stroke Cellular Nucleic Acid Binding Protein (CNBP) in Aging and Disease				
<b>Murphy, Michael Paul</b>	3048104233	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Development of an Assay System for the Measurement of Beta-Secretase				
<b>Noonan, Daniel</b>	3046965000	\$0.	\$50,000.	\$50,000.
LAM Foundation Defining Mechanisms for Anomalous Expression of Estrogen Receptor in LAM				
<b>OZCAN, SABIRE</b>	3046861800	\$0.	\$269,538.	\$269,538.
National Institute Diabetes & Digestive & Kidney Histone Acetylation and Insulin Gene Expression				
<b>OZCAN, SABIRE</b>	3048003400	\$0.	\$43,000.	\$43,000.
American Heart Association Ohio Valley Affiliate Fellowship/Muniappan: Engineering of Liver to Produce Insulin for Diabetes Therapy				
<b>OZCAN, SABIRE</b>	3048103413	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Nathan Vanderford: Regulation of the Glucose-Dependent Expression of MafA in Pancreatic Beta Cells				
<b>OZCAN, SABIRE</b>	3048103415	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Megan Sampley: PDX-1 Regulates Insulin Biosynthesis by Interaction with Transcription and Translation				
<b>OZCAN, SABIRE</b>	3048103417	\$42,000.	\$0.	\$42,000.
American Heart Association Ohio Valley Affiliate Fellowship for Xiaoqing Tang: Role of MicroRNAs in Insulin Production and Secretion in Pancreatic Beta-Cells				
<b>OZCAN, SABIRE</b>	3048104414	\$172,500.	\$0.	\$172,500.
American Diabetes Association Inc Role of Histone Deacetylation and Protein Phosphatases in Insulin Gene Expression				
<b>Sarge, Kevin D</b>	3046712600	\$0.	\$270,256.	\$270,256.
National Institute of General Medical Sciences Regulation of HSF1 and HSF2 by SUMO-1 Modification				
<b>Sarge, Kevin D</b>	3048104720	\$54,842.	\$0.	\$54,842.
National Institute of Child Health and Human Development Fellowship/Donald Wilkerson: Heat Shock Factor Function in Spermatogenesis				
<b>Spielmann, H Peter</b>	3048104084	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Development of Anti-Prenylated Protein Therapies for Lung Cancer				
<b>Stamm, Stefan</b>		\$54,000.	\$0.	\$54,000.
Families of Spinal Muscular Atrophy Regulation of SMN2 Exon 7 through Protein Phosphatase 1				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Molecular &amp; Cellular Biochemistry</u></b>				
<b>Stamm, Stefan</b>	3048104302	\$25,729.	\$0.	\$25,729.
University of Massachusetts Tau Missplicing Caused by RNA Processing Proteins Located on th Chromosome 21NIH				
<b>Tang, Xiaoqing</b>	3048103834	\$99,335.	\$0.	\$99,335.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
<b>Vander Kooi, Craig William</b>	3048104715	\$62,500.	\$0.	\$62,500.
Leukemia and Lymphoma Society Structural Studies of Flt3 Activation and Inhibition in AML				
<b>Waechter, Charles J</b>	3046925500	\$0.	\$312,545.	\$312,545.
National Institute of General Medical Sciences Regulation of Protein N-Glycosylation in the CNS				
<b>Whiteheart, Sidney W</b>	3046836200	\$0.	\$269,839.	\$269,839.
National Institute of Neurological Disorders & Stroke Structure/Function of N-ethylmaleimide Sensitive Factor				
<b>Whiteheart, Sidney W</b>	3048003200	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship/Choi: The Role of ADP-ribosylation factor 6 (Arf6) in Platelet Activation				
<b>Whiteheart, Sidney W</b>	3048003300	\$0.	\$20,000.	\$20,000.
American Heart Association Fellowship/Ren: Regulation of Platelet Exocytosis by Munc 13-4.				
<b>Whiteheart, Sidney W</b>	3048104241	\$293,000.	\$0.	\$293,000.
National Heart Lung and Blood Institute Molecular Mechanisms of Platelet Exocytosis				
<b>Whiteheart, Sidney W</b>	3048104241	\$0.	\$293,000.	\$293,000.
National Heart Lung and Blood Institute Molecular Mechanisms of Platelet Exocytosis				
<b>Whiteheart, Sidney W</b>	3048104711	\$256,375.	\$0.	\$256,375.
National Heart Lung and Blood Institute The Platelet Secretory Machinery				
<b>Zhu, Haining</b>	3046809700	\$0.	\$253,760.	\$253,760.
National Institute of Neurological Disorders & Stroke Proteomic and Functional Studies of Mitochondria in ALS				
<b>Molecular &amp; Cellular Biochemistry</b>	<b>Totals:</b>	<b>\$4,354,606.</b>	<b>\$3,058,925.</b>	<b>\$7,413,531.</b>
<b><u>Internal Medicine</u></b>				
<b>Ain, Kenneth B</b>	3046976500	\$0.	\$35,000.	\$35,000.
Celgene Phase II Trail of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas				
<b>Ain, Kenneth B</b>	3046976500	\$0.	\$35,000.	\$35,000.
Celgene Phase II Trail of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Ain, Kenneth B</b>	3048093400	\$0.	\$2,945.	\$2,945.
AstraZeneca Pharmaceuticals				
An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
<b>Ain, Kenneth B</b>	3048093400	\$0.	\$8,165.	\$8,165.
AstraZeneca Pharmaceuticals				
An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
<b>Anderson, James W</b>	3046910300	\$0.	\$890.	\$890.
PPD Development				
A 12-Week, double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of APD356 in Obese Patients				
<b>Anderson, James W</b>	3046922500	\$0.	\$9,329.	\$9,329.
Orexigen Therapeutics Inc				
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Combination Therapy for Safety and Efficacy in Subjects with Uncomplicated Obesity				
<b>Anderson, James W</b>	3046922500	\$0.	\$8,828.	\$8,828.
Orexigen Therapeutics Inc				
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Combination Therapy for Safety and Efficacy in Subjects with Uncomplicated Obesity				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$100.	\$100.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$650.	\$650.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$500.	\$500.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$300.	\$300.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$100.	\$100.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$-139.	\$-139.
Southwest Oncology Group				
Southwest Oncology Group Studies				
<b>Arnold, Susanne M</b>	3046259800	\$0.	\$139.	\$139.
Southwest Oncology Group				
Southwest Oncology Group Studies				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Arnold, Susanne M</b>	3046646400	\$0.	\$1,950.	\$1,950.
GlaxoSmithKline A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer				
<b>Arnold, Susanne M</b>	3046828600	\$0.	\$8,500.	\$8,500.
Eli Lilly and Company A Randomized Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer				
<b>Arnold, Susanne M</b>	3046876300	\$0.	\$16,730.	\$16,730.
Wyeth Research A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Once Weekly				
<b>Arnold, Susanne M</b>	3046943800	\$0.	\$2,524.	\$2,524.
NeoRx Corporation A Randomized Phase II Study of Picoplatin or Topotecan Second-Line Therapy for Subjects with Resistant or Refractory Small Cell Lung Cancer				
<b>Arnold, Susanne M</b>	3046943800	\$0.	\$1,187.	\$1,187.
NeoRx Corporation A Randomized Phase II Study of Picoplatin or Topotecan Second-Line Therapy for Subjects with Resistant or Refractory Small Cell Lung Cancer				
<b>Arnold, Susanne M</b>	3046976200	\$0.	\$11,798.	\$11,798.
Eli Lilly and Company A Phase One Trial of Gemcitavine and Paclitaxel (GEMTAX) Plus Low Dose Radiation in Patients with Recurrent Head and Neck Cancer				
<b>Arnold, Susanne M</b>	3048062300	\$0.	\$-5,000.	\$-5,000.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin vs Etoposide and Carboplatin in Extensive-stage Small Cell Lung Cancer				
<b>Arnold, Susanne M</b>	3048065800	\$0.	\$96,390.	\$96,390.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
<b>Arnold, Susanne M</b>	3048076600	\$0.	\$4,068.	\$4,068.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
<b>Arnold, Susanne M</b>	3048076600	\$0.	\$8,148.	\$8,148.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
<b>Arnold, Susanne M</b>	3048103831	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Early detection of lung cancer in a high-risk population defined by pulmonary function testing, biomarker identification, and computerized tomography scanning				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Arnold, Susanne M</b>	3048104325	\$2.	\$0.	\$2.
AMGen				
A Randomized, Open Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First Line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer and Cross				
<b>Arnold, Susanne M</b>	3048104326	\$2.	\$0.	\$2.
AMGen				
A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
<b>Arsenescu, Razvan I</b>	3046961300	\$0.	\$96,039.	\$96,039.
Eli and Edythe Broad Foundation				
Adiponectin in Crohn's Disease. Phenotype-genotype Correlations and Implications in Management				
<b>Arsenescu, Razvan I</b>	3046964400	\$0.	\$2,407.	\$2,407.
Robarts Research Institute				
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3046964400	\$0.	\$8,354.	\$8,354.
Robarts Research Institute				
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3046964400	\$0.	\$1,336.	\$1,336.
Robarts Research Institute				
A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048061500	\$0.	\$12,669.	\$12,669.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048061500	\$0.	\$6,502.	\$6,502.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048061500	\$0.	\$1,770.	\$1,770.
Robarts Research Institute				
A Prospective, Open-Label Study to Evaluate the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048103221	\$0.	\$20,415.	\$20,415.
AstraZeneca Pharmaceuticals				
Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048103221	\$2.	\$0.	\$2.
AstraZeneca Pharmaceuticals				
Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048103221	\$0.	\$20,413.	\$20,413.
AstraZeneca Pharmaceuticals				
Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Arsenescu, Razvan I</b>	3048104014	\$2.	\$0.	\$2.
Alba Therapeutics Corp A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
<b>Arsenescu, Razvan I</b>	3048104014	\$0.	\$22,778.	\$22,778.
Alba Therapeutics Corp A Phase IIb, randomized, double-blind, placebo controlled, dose ranging multicenter study to determine the safety, tolerance, and efficacy of AT-001 in celiac disease subjects during a gluten challenge				
<b>Arsenescu, Razvan I</b>	3048104247	\$19,829.	\$0.	\$19,829.
KY Science and Technology Co Inc KSEF R&D Excellence: Drug Eluting Biodegradable Seton for Treatment of Perianal Fistulas in Crohn's Disease				
<b>Arsenescu, Razvan I</b>	3048104522	\$2.	\$0.	\$2.
Robarts Research Institute An observational prospective study to identify clinical, endoscopic and/or biological predictors that correlate with histopathologic findings in subjects with moderate to severe ulcerative colitis				
<b>Arsenescu, Razvan I</b>	3048104522	\$0.	\$5,833.	\$5,833.
Robarts Research Institute An observational prospective study to identify clinical, endoscopic and/or biological predictors that correlate with histopathologic findings in subjects with moderate to severe ulcerative colitis				
<b>Arsenescu, Razvan I</b>	3048104625	\$2.	\$0.	\$2.
Alba Therapeutics Corp A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001				
<b>Booth, David C</b>	3046763800	\$0.	\$5,457.	\$5,457.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
<b>Booth, David C</b>	3046763800	\$0.	\$857.	\$857.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
<b>Booth, David C</b>	3046763800	\$0.	\$1,662.	\$1,662.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
<b>Booth, David C</b>	3046763800	\$0.	\$1,196.	\$1,196.
ENCYSIVE LP admin by ResearchPoint A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension (STRIDE-III)				
<b>Booth, David C</b>	3048012300	\$0.	\$590.	\$590.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Booth, David C</b>	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$2,835.	\$2,835.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$5,040.	\$5,040.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$1,890.	\$1,890.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Booth, David C</b>	3048012300	\$0.	\$144.	\$144.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
<b>Brown, Randy A</b>	3046911100	\$0.	\$-2,532.	\$-2,532.
Bristol Myers Squibb Company A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib				
<b>Brown, Randy A</b>	3046911100	\$0.	\$3,148.	\$3,148.
Bristol Myers Squibb Company A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib				
<b>Brown, Randy A</b>	3046911200	\$0.	\$2,530.	\$2,530.
Bristol Myers Squibb Company A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolrant of Imatinib Mesylate				
<b>Brown, Randy A</b>	3046911900	\$0.	\$3,998.	\$3,998.
Bristol Myers Squibb Company A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate				
<b>Brown, Randy A</b>	3048072300	\$0.	\$-2,000.	\$-2,000.
Wyeth Pharmaceuticals Inc A Phase I-II Trial of Mylotarg Following High-Dose Therapy and Autologus Peripheral Blood Stem Cell (PBSC) Transplant for Patients with AML in CR				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Bruemmer, Dennis C</b>	3046985800	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute				
Role of the Nuclear Receptor Nor-1 in Atherosclerosis and Vascular Injury				
<b>Bruemmer, Dennis C</b>	3048103230	\$65,000.	\$0.	\$65,000.
American Heart Association				
Anti-Inflammatory and Antiproliferative Liver X Receptor Signaling Pathways in Cardiovascular Disease				
<b>Bruemmer, Dennis C</b>	3048103419	\$42,000.	\$0.	\$42,000.
American Heart Association Ohio Valley Affiliate				
Nomiya Post-Doc Fellowship: Osteopontin Regulates Macrophage Infiltration into Adipose Tissue Leading to Insulin Resistance				
<b>Bruemmer, Dennis C</b>	3048103420	\$42,000.	\$0.	\$42,000.
American Heart Association Ohio Valley Affiliate				
Gizard Post-Doc Fellowship: Role of Telomerase in Macrophage Inflammation and Atherosclerosis				
<b>Bruemmer, Dennis C</b>	3048104331	\$100,000.	\$0.	\$100,000.
American Diabetes Association Inc				
Regulation of Telomerase Activation in Diabetic Vascular Complications				
<b>Bryson, James S</b>	3048012700	\$0.	\$75,000.	\$75,000.
KY Lung Cancer Research Fund				
Allogeneic Cell Therapy of Lung Cancer				
<b>Callahan, Leigh Ann</b>	3048099900	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute				
Oxidant Mediated Diaphragm Dysfunction in Diabetes				
<b>Campbell, Charles L.</b>	3046979000	\$0.	\$2,600.	\$2,600.
Schering Plough Co				
IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
<b>Campbell, Charles L.</b>	3048104421	\$2.	\$0.	\$2.
Scios Inc				
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
<b>Campbell, Charles L.</b>	3048104421	\$0.	\$2,998.	\$2,998.
Scios Inc				
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)				
<b>Campbell, Charles L.</b>	3048104547	\$2.	\$0.	\$2.
Portola Pharmaceuticals Inc				
ERASE-MI: Early Rapid Reversal of Platelet Thrombosis with Intravenous PRT060128 before PCI to optimize Reperfusion in Acute MI				
<b>Caudill, Timothy S</b>	3046875600	\$0.	\$375.	\$375.
AstraZeneca Pharmaceuticals				
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Caudill, Timothy S</b>	3046875600	\$0.	\$550.	\$550.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein				
<b>Caudill, Timothy S</b>	3046875600	\$0.	\$475.	\$475.
AstraZeneca Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein				
<b>Caudill, Timothy S</b>	3048103687	\$98,550.	\$0.	\$98,550.
Health Resources and Services Administration Training in Primary Care Medicine & Dentistry				
<b>Chasen, Craig A</b>	3046783200	\$0.	\$165.	\$165.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
<b>Chasen, Craig A</b>	3046783200	\$0.	\$2,093.	\$2,093.
Novartis ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension):				
<b>Chen-Izu, Ye</b>	3048103817	\$47,127.	\$0.	\$47,127.
American Heart Association Ca <sup>2+</sup> and Calmodulin Signaling in the Cardiac Myocyte under Hypertensive Stress				
<b>Conigliaro, Joseph</b>	3046971000	\$0.	\$9,416.	\$9,416.
University of Pittsburgh Patient and Societal Utilities for Alcohol Problems				
<b>Conigliaro, Joseph</b>	3046971200	\$0.	\$21,975.	\$21,975.
University of Pittsburgh Improving Quality of Primary Care for Anxiety Disorders				
<b>Conigliaro, Joseph</b>	3048104609	\$83,767.	\$0.	\$83,767.
Yale University Alcohol Associated Outcomes Among HIV +/- Aging Veterans				
<b>Crofford, Leslie J</b>	3046874000	\$0.	\$55,654.	\$55,654.
National Institute Arthritis Musculoskeletal & Skin Microsomal Prostaglandin E Synthase in Rheumatoid Arthritis				
<b>Crofford, Leslie J</b>	3046874000	\$0.	\$309,698.	\$309,698.
National Institute Arthritis Musculoskeletal & Skin Microsomal Prostaglandin E Synthase in Rheumatoid Arthritis				
<b>Crofford, Leslie J</b>	3046988500	\$0.	\$9,220.	\$9,220.
University of Pittsburgh Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Crofford, Leslie J</b>	3046988500	\$0.	\$6,000.	\$6,000.
University of Pittsburgh Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and				
<b>Crofford, Leslie J</b>	3048000900	\$0.	\$2,077.	\$2,077.
Wyeth Research A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety and Tolerability Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048000900	\$0.	\$3,150.	\$3,150.
Wyeth Research A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety and Tolerability Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048000900	\$0.	\$6,210.	\$6,210.
Wyeth Research A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety and Tolerability Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048089400	\$0.	\$3,443.	\$3,443.
Johnson and Johnson A Randomized, Double-Blind, Active And Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 .				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$2,722.	\$2,722.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$1,266.	\$1,266.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$2,268.	\$2,268.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$10,397.	\$10,397.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$2,000.	\$2,000.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$3,226.	\$3,226.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Crofford, Leslie J</b>	3048103427	\$2.	\$0.	\$2.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103427	\$0.	\$3,148.	\$3,148.
Allergan Pharmaceuticals Inc A Multicenter, Multiple-Dose, Double Blind, Randomized Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of AGN 203818 in Female Patients with Fibromyalgia Syndrome				
<b>Crofford, Leslie J</b>	3048103683	\$67,704.	\$0.	\$67,704.
University of Cincinnati Development of a Fibromyalgia Responder Index				
<b>Daugherty, Alan</b>	3046864200	\$0.	\$4,047.	\$4,047.
University of Virginia Sphingolipids and Cardiovascular Disease Type I Diabetes				
<b>Daugherty, Alan</b>	3046928200	\$0.	\$349,222.	\$349,222.
Philip Morris Inc Role of Endothelial AT1a receptors on sidestream Cigarette Smoke Induced Atherosclerosis and Vascular				
<b>Daugherty, Alan</b>	3046989400	\$0.	\$1,604,445.	\$1,604,445.
National Heart Lung and Blood Institute Mechanisms of Abdominal Aortic Aneurysm Formation				
<b>Daugherty, Alan</b>	3048012400	\$0.	\$92,011.	\$92,011.
James Cook University Osteoprotegerin and osteopontin in aortic aneurysm				
<b>Daugherty, Alan</b>	3048016800	\$0.	\$21,000.	\$21,000.
American Heart Association A. Phillip Owens: My88 Deficiency, in Bone Marrow Derived Cells, Attenuates both AngII-Mediated Atherosclerosis and AAA				
<b>Daugherty, Alan</b>	3048104603	\$46,880.	\$0.	\$46,880.
University of Virginia G2A Receptor in Atherosclerosis				
<b>Daugherty, Alan</b>	3048104643	\$144,190.	\$0.	\$144,190.
Merck and Company Inc LKR55806 Merck Inhibitor Rabbit Model Study				
<b>Daugherty, Alan</b>	3048104738	\$55,000.	\$0.	\$55,000.
University of Virginia ABCG1 Function in Diabetes				
<b>De Villiers, Willem</b>	3046569500	\$0.	\$5,253.	\$5,253.
Centocor Inc A Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate and Efficacy of Infliximab in Patients with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3046569500	\$0.	\$3,968.	\$3,968.
Centocor Inc A Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate and Efficacy of Infliximab in Patients with Active Ulcerative Colitis				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3046677300	\$0.	\$600.	\$600.
Berlex Laboratories Inc				
Open-Label Trial of Leukine (sargramostim) a Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Active Crohn's Disease				
<b>De Villiers, Willem</b>	3046677300	\$0.	\$500.	\$500.
Berlex Laboratories Inc				
Open-Label Trial of Leukine (sargramostim) a Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Active Crohn's Disease				
<b>De Villiers, Willem</b>	3046730900	\$0.	\$500.	\$500.
Berlex Laboratories Inc				
Randomized Stratified Double Blind Placebo Controlled Phase 2 Study of the Steroid Sparing Properties of Sargramostim (LEUKINE) Therapy in Patients with Corticosteroid-Dependent Crohn's Disease				
<b>De Villiers, Willem</b>	3046802500	\$0.	\$500.	\$500.
Berlex Laboratories Inc				
Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine) in Patients with Active Crohn's Disease and Prior Treatment Response to Sargramostim				
<b>De Villiers, Willem</b>	3046802500	\$0.	\$16,500.	\$16,500.
Berlex Laboratories Inc				
Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine) in Patients with Active Crohn's Disease and Prior Treatment Response to Sargramostim				
<b>De Villiers, Willem</b>	3046828400	\$0.	\$600.	\$600.
Centocor Inc				
Remicade Safety Under Long Term Study in Ulcerative Colitis (RESULTS-UC)				
<b>De Villiers, Willem</b>	3046864500	\$0.	\$672.	\$672.
Abbott Laboratories				
Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
<b>De Villiers, Willem</b>	3046864500	\$0.	\$672.	\$672.
Abbott Laboratories				
Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
<b>De Villiers, Willem</b>	3046864500	\$0.	\$-1,280.	\$-1,280.
Abbott Laboratories				
Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
<b>De Villiers, Willem</b>	3046864500	\$0.	\$1,952.	\$1,952.
Abbott Laboratories				
Multi-Center Open Labeled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease				
<b>De Villiers, Willem</b>	3046978300	\$0.	\$7,455.	\$7,455.
PDL BioPharma Inc				
Visilizumab				
<b>De Villiers, Willem</b>	3046978300	\$0.	\$5,868.	\$5,868.
PDL BioPharma Inc				
Visilizumab				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3046979600	\$0.	\$2,722.	\$2,722.
PDL BioPharma Inc Visilizumab				
<b>De Villiers, Willem</b>	3048044100	\$0.	\$4,736.	\$4,736.
ChemoCentryx Inc A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn's Disease				
<b>De Villiers, Willem</b>	3048063500	\$0.	\$3,120.	\$3,120.
Abbott Laboratories A Multicenter, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab				
<b>De Villiers, Willem</b>	3048063500	\$0.	\$8,280.	\$8,280.
Abbott Laboratories A Multicenter, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab				
<b>De Villiers, Willem</b>	3048063500	\$0.	\$7,386.	\$7,386.
Abbott Laboratories A Multicenter, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab				
<b>De Villiers, Willem</b>	3048063500	\$0.	\$1,500.	\$1,500.
Abbott Laboratories A Multicenter, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab				
<b>De Villiers, Willem</b>	3048066700	\$0.	\$1,612.	\$1,612.
Procter & Gamble Company A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trail to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg Mesalamine Tablet) Versus Asacol 2.4 g/day (400 mg Mesalamine Tablet) for the Treatment of Moderately Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048066700	\$0.	\$150.	\$150.
Procter & Gamble Company A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trail to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg Mesalamine Tablet) Versus Asacol 2.4 g/day (400 mg Mesalamine Tablet) for the Treatment of Moderately Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048066700	\$0.	\$2,268.	\$2,268.
Procter & Gamble Company A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trail to Assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg Mesalamine Tablet) Versus Asacol 2.4 g/day (400 mg Mesalamine Tablet) for the Treatment of Moderately Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048073100	\$0.	\$13,500.	\$13,500.
Salix Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3g Bid vs. Mesalamine (5-ASA) As Asacol 0.8 G Tid ub Mildly to				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3048073100	\$0.	\$13,500.	\$13,500.
Salix Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Actively Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3g Bid vs. Mesalamine (5-ASA) As Asacol 0.8 G Tid ub Mildly to				
<b>De Villiers, Willem</b>	3048103698	\$0.	\$1,998.	\$1,998.
Kendle International Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy with Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering from Crohn's Disease				
<b>De Villiers, Willem</b>	3048103698	\$2.	\$0.	\$2.
Kendle International Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy with Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering from Crohn's Disease				
<b>De Villiers, Willem</b>	3048103701	\$2.	\$0.	\$2.
Quintiles Inc Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103701	\$0.	\$5,998.	\$5,998.
Quintiles Inc Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$2,801.	\$2,801.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$0.	\$2,998.	\$2,998.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103743	\$2.	\$0.	\$2.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$1,701.	\$1,701.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$2.	\$0.	\$2.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$3,227.	\$3,227.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$3,663.	\$3,663.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3048103744	\$0.	\$3,436.	\$3,436.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
<b>De Villiers, Willem</b>	3048103809	\$2.	\$0.	\$2.
Salix Pharmaceuticals Inc A Multicenter Open-Label Trial To Evaluate the Long-Term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients with Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048103815	\$0.	\$3,648.	\$3,648.
Axcan Pharma Inc MAX-002 vs. Canasa in...Mild to Moderate Ulcerative Proctitis				
<b>De Villiers, Willem</b>	3048103815	\$2.	\$0.	\$2.
Axcan Pharma Inc MAX-002 vs. Canasa in...Mild to Moderate Ulcerative Proctitis				
<b>De Villiers, Willem</b>	3048103879	\$2.	\$0.	\$2.
Duke University A Phase III, multi-center, placebo-controlled, randomized, double-blind retreatment study to evaluate the safety and efficacy of PROCHYMAL IV Infusion for the reinduction of remission in subjects experiencing...moderate to severe Crohn's				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$5,290.	\$5,290.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$1,998.	\$1,998.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$-2,000.	\$-2,000.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$0.	\$5,034.	\$5,034.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
<b>De Villiers, Willem</b>	3048104103	\$2.	\$0.	\$2.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>De Villiers, Willem</b>	3048104254	\$2.	\$0.	\$2.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048104254	\$0.	\$2,998.	\$2,998.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048104254	\$0.	\$3,990.	\$3,990.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048104255	\$2.	\$0.	\$2.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
<b>De Villiers, Willem</b>	3048104557	\$2.	\$0.	\$2.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
<b>De Villiers, Willem</b>	3048104557	\$0.	\$4,998.	\$4,998.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
<b>Desimone, Philip A</b>	3046744000	\$0.	\$4,500.	\$4,500.
Novartis A Randomized, Double-Blind, Placebo-Controlled, Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum Who are Receiving First-Line Chemotherapy with Oxaliplatin				
<b>Desimone, Philip A</b>	3046777200	\$0.	\$948.	\$948.
Hoffmann La Roche Inc A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion				
<b>Desimone, Philip A</b>	3046875500	\$0.	\$13,000.	\$13,000.
Bristol Myers Squibb Company 02-GI-68IS-BM Clinical Protocol CA225006: A Phase III Randomized, Open-Label Multicenter Study of Irinotecan and Celtuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive				
<b>Desimone, Philip A</b>	3046875500	\$0.	\$3,666.	\$3,666.
Bristol Myers Squibb Company 02-GI-68IS-BM Clinical Protocol CA225006: A Phase III Randomized, Open-Label Multicenter Study of Irinotecan and Celtuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive				
<b>Desimone, Philip A</b>	3046875500	\$0.	\$-13,000.	\$-13,000.
Bristol Myers Squibb Company 02-GI-68IS-BM Clinical Protocol CA225006: A Phase III Randomized, Open-Label Multicenter Study of Irinotecan and Celtuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Desimone, Philip A</b>	3048004400	\$0.	\$5,510.	\$5,510.
Roche Laboratories A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients				
<b>Desimone, Philip A</b>	3048004400	\$0.	\$5,583.	\$5,583.
Roche Laboratories A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients				
<b>Desimone, Philip A</b>	3048004400	\$0.	\$4,347.	\$4,347.
Roche Laboratories A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients				
<b>Desimone, Philip A</b>	3048057200	\$0.	\$-2,000.	\$-2,000.
ICON Clinical Research A Phase 2 Study of ARQ 501 in Combination wit Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma				
<b>Desimone, Philip A</b>	3048057200	\$0.	\$5,494.	\$5,494.
ICON Clinical Research A Phase 2 Study of ARQ 501 in Combination wit Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma				
<b>Dignan, Mark B</b>	3046909700	\$0.	\$485,955.	\$485,955.
National Cancer Institute Increasing Colorectal Cancer Screening in Rural Kentucky				
<b>Dignan, Mark B</b>	3048102100	\$0.	\$53,944.	\$53,944.
National Cancer Institute Appalachia Community Cancer Network				
<b>Dignan, Mark B</b>	3048102100	\$0.	\$84,696.	\$84,696.
National Cancer Institute Appalachia Community Cancer Network				
<b>Dignan, Mark B</b>	3048102100	\$0.	\$68,500.	\$68,500.
National Cancer Institute Appalachia Community Cancer Network				
<b>Dignan, Mark B</b>	3048103503	\$13,626.	\$0.	\$13,626.
Klein Buendel Inc Disseminating Go Sun Smart to an Outdoor Recreation Industry				
<b>Dignan, Mark B</b>	3048103537	\$0.	\$9,128.	\$9,128.
KY Health Services Cabinet State Nutrition and Physical Activity Programs to Prevent Obesity and Other Chronic Disease				
<b>Dignan, Mark B</b>	3048103537	\$0.	\$-9,128.	\$-9,128.
KY Health Services Cabinet State Nutrition and Physical Activity Programs to Prevent Obesity and Other Chronic Disease				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Dignan, Mark B</b>	3048103537	\$25,000.	\$0.	\$25,000.
KY Health Services Cabinet State Nutrition and Physical Activity Programs to Prevent Obesity and Other Chronic Disease				
<b>Dignan, Mark B</b>	3048103537	\$0.	\$33,000.	\$33,000.
KY Health Services Cabinet State Nutrition and Physical Activity Programs to Prevent Obesity and Other Chronic Disease				
<b>Dignan, Mark B</b>	3048103542	\$0.	\$431,195.	\$431,195.
National Cancer Institute Patient Navigation for Cervical Cancer in Appalachia				
<b>Dignan, Mark B</b>	3048103542	\$390,913.	\$0.	\$390,913.
National Cancer Institute Patient Navigation for Cervical Cancer in Appalachia				
<b>Dignan, Mark B</b>	3048103800	\$246,972.	\$0.	\$246,972.
National Cancer Institute Kentucky Cancer Prevention and Control Training Program				
<b>Dignan, Mark B</b>	3048103883	\$727,000.	\$0.	\$727,000.
Center for Disease Control and Prevention Kentucky Prevention Research Center				
<b>Dignan, Mark B</b>	3048103883	\$0.	\$186,927.	\$186,927.
Center for Disease Control and Prevention Kentucky Prevention Research Center				
<b>Dignan, Mark B</b>	3048104633	\$1,057,654.	\$0.	\$1,057,654.
National Cancer Institute Appalachia Community Cancer Network				
<b>Doherty, Dennis E</b>	3046623400	\$0.	\$661.	\$661.
Boehringer Ingelheim A Randomized Double-Blind, Placebo-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)				
<b>Doherty, Dennis E</b>	3046623400	\$0.	\$1,755.	\$1,755.
Boehringer Ingelheim A Randomized Double-Blind, Placebo-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$1,353.	\$1,353.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$1,355.	\$1,355.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$6,804.	\$6,804.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Ipiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$1,353.	\$1,353.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Ipiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$5,953.	\$5,953.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Ipiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$1,543.	\$1,543.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Ipiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048024400	\$0.	\$5,223.	\$5,223.
InterMune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Ipiopathic Pulmonary Fibrosis				
<b>Doherty, Dennis E</b>	3048103304	\$0.	\$5,411.	\$5,411.
GlaxoSmithKline Randomized, Double-Blinded, Parallel-Group 12-week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg BID in Subjects				
<b>Doherty, Dennis E</b>	3048103304	\$2.	\$0.	\$2.
GlaxoSmithKline Randomized, Double-Blinded, Parallel-Group 12-week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg BID in Subjects				
<b>Doherty, Dennis E</b>	3048103685	\$2.	\$0.	\$2.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
<b>Doherty, Dennis E</b>	3048103685	\$0.	\$9,998.	\$9,998.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
<b>Doherty, Dennis E</b>	3048104205	\$0.	\$8,148.	\$8,148.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				
<b>Doherty, Dennis E</b>	3048104205	\$2.	\$0.	\$2.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$500.	\$500.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$7,038.	\$7,038.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$0.	\$498.	\$498.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104260	\$2.	\$0.	\$2.
Novartis A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from				
<b>Doherty, Dennis E</b>	3048104526	\$0.	\$16,180.	\$16,180.
Merck and Company Inc A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group, Dose-Ranging Study to MK-0633 in Adult Patients with Chronic Asthma				
<b>Doherty, Dennis E</b>	3048104526	\$0.	\$9,450.	\$9,450.
Merck and Company Inc A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group, Dose-Ranging Study to MK-0633 in Adult Patients with Chronic Asthma				
<b>Doherty, Dennis E</b>	3048104526	\$2.	\$0.	\$2.
Merck and Company Inc A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group, Dose-Ranging Study to MK-0633 in Adult Patients with Chronic Asthma				
<b>Doherty, Dennis E</b>	466743	\$0.	\$-1,400.	\$-1,400.
GlaxoSmithKline A Randomized Double-Blind Placebo-Controlled Parrell-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination				
<b>Fleischman, Roger A</b>	3046806900	\$0.	\$1,000.	\$1,000.
Favrille Inc Favid-06: Phase III, Randomized, Double Blind Placebo-controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin's Lymphoma				
<b>Fleischman, Roger A</b>	3046885900	\$0.	\$1,000.	\$1,000.
Favrille Inc Favid-09: Favid-0:Phase II Trig of Favid (Patient Specific Idiotyp/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid 06				
<b>Fleischman, Roger A</b>	3046885900	\$0.	\$2,500.	\$2,500.
Favrille Inc Favid-09: Favid-0:Phase II Trig of Favid (Patient Specific Idiotyp/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid 06				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Fleischman, Roger A</b>	3046885900	\$0.	\$-1,000.	\$-1,000.
Favrille Inc				
Favid-09: Favid-0:Phase II Trig of Favid (Patient Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid 06				
<b>Fleischman, Roger A</b>	3046885900	\$0.	\$1,000.	\$1,000.
Favrille Inc				
Favid-09: Favid-0:Phase II Trig of Favid (Patient Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive Favid on Study Favid 06				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$200.	\$200.
Eli Lilly and Company				
PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$400.	\$400.
Eli Lilly and Company				
PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048095800	\$0.	\$7,000.	\$7,000.
Eli Lilly and Company				
PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
<b>Fleischman, Roger A</b>	3048103811	\$0.	\$6,632.	\$6,632.
Celgene				
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma				
<b>Fleischman, Roger A</b>	3048103811	\$2.	\$0.	\$2.
Celgene				
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma				
<b>Fleischman, Roger A</b>	3048104624	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc				
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22-Positive, Follicular B-Cell				
<b>Greenberg, Richard N</b>	3046488300	\$0.	\$5,068.	\$5,068.
Merck and Company Inc				
Protocol 008-01 Study to Evaluate the Safety, Tolerability & Immunogenicity of the HIV-1 Gag DNA Vaccine Formulated with PBS or with Aluminum Phosphate Followed by AD5 HIV-1 Gag Vaccine in a Prime Boost Regimen				
<b>Greenberg, Richard N</b>	3046518800	\$0.	\$3,780.	\$3,780.
Schering Plough Co				
01-BMT-133:Open-Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections				
<b>Greenberg, Richard N</b>	3046518800	\$0.	\$4,260.	\$4,260.
Schering Plough Co				
01-BMT-133:Open-Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$444.	\$444.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$1,776.	\$1,776.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$1,935.	\$1,935.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$1,524.	\$1,524.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046665500	\$0.	\$444.	\$444.
Boehringer Ingelheim Randomized,Open-Label,Comparative Safety and Efficacy Study of Tipranavir Boosted with Low-dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients (Resist 1:)				
<b>Greenberg, Richard N</b>	3046768600	\$0.	\$5,670.	\$5,670.
VaxGen Inc 03-BMT-150: A Phase 2 Multi Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers (VAX006)				
<b>Greenberg, Richard N</b>	3046827900	\$0.	\$300.	\$300.
GlaxoSmithKline A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) Plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) When Administered in Combination with ...				
<b>Greenberg, Richard N</b>	3046838600	\$0.	\$542,970.	\$542,970.
VaxGen Inc A Phase I/II Clinical Trial Evaluating the Safety and Immunogenicity of LC16m8, a Modified Vaccinia Vaccine, in Healthy Volunteers				
<b>Greenberg, Richard N</b>	3046865800	\$0.	\$687.	\$687.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
<b>Greenberg, Richard N</b>	3046877200	\$0.	\$1,557.	\$1,557.
GlaxoSmithKline A Phase IIIB/IV, Open-Label, Multi-Center Trial to Evaluate the Safety, Tolerability, and Efficacy of HIV-1 Infected Subjects Switching Their Current Protease-Inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3046918500	\$0.	\$27,463.	\$27,463.
Virxsys Corporation				
A Phase II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Repeated doses of Autologous T Cells Transduced with VRX496 in HIV-Positive Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$2,779.	\$2,779.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$4,487.	\$4,487.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$3,896.	\$3,896.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$1,135.	\$1,135.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$1,742.	\$1,742.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$2,338.	\$2,338.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$2,338.	\$2,338.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046946700	\$0.	\$768.	\$768.
GlaxoSmithKline				
96-week Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus Truvada Administered in Conjunction with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$2,066.	\$2,066.
PPD Development Inc				
An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$5,935.	\$5,935.
PPD Development Inc				
An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$2,583.	\$2,583.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046975000	\$0.	\$5,418.	\$5,418.
PPD Development Inc An Open-Label Trail with TMC125 in HIV-1 Infected Subjects, who were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trail and were Treated for at least 48 weeks				
<b>Greenberg, Richard N</b>	3046999700	\$0.	\$16,436.	\$16,436.
PPD Development Inc A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers				
<b>Greenberg, Richard N</b>	3046999700	\$0.	\$87,443.	\$87,443.
PPD Development Inc A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers				
<b>Greenberg, Richard N</b>	3046999700	\$0.	\$14,106.	\$14,106.
PPD Development Inc A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers				
<b>Greenberg, Richard N</b>	3048056200	\$0.	\$3,148.	\$3,148.
Schering Plough Co Victor E2 Clinical Trail				
<b>Greenberg, Richard N</b>	3048056300	\$0.	\$3,148.	\$3,148.
Schering Plough Co Victor E1 Clinical Trail				
<b>Greenberg, Richard N</b>	3048060300	\$0.	\$45,817.	\$45,817.
DP Clinical Inc Immunogenicity Study of a Three-Dose Subcutaneous BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults				
<b>Greenberg, Richard N</b>	3048060300	\$0.	\$5,001.	\$5,001.
DP Clinical Inc Immunogenicity Study of a Three-Dose Subcutaneous BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults				
<b>Greenberg, Richard N</b>	3048060300	\$0.	\$3,586.	\$3,586.
DP Clinical Inc Immunogenicity Study of a Three-Dose Subcutaneous BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults				
<b>Greenberg, Richard N</b>	3048061700	\$0.	\$2,527.	\$2,527.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				
<b>Greenberg, Richard N</b>	3048061700	\$0.	\$552.	\$552.
Tibotec Pharmaceuticals Ltd A Phase II randomized, double-blinded, placebo controlled trial to investigate the efficacy, tolerability and safety of TMC 125 as part of				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3048075800	\$0.	\$1,369.	\$1,369.
GlaxoSmithKline				
A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B5701) in subjects with and without Hypersensitivity to Abacavir				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,351.	\$1,351.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,498.	\$1,498.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$5,789.	\$5,789.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,090.	\$1,090.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$4,053.	\$4,053.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$7,517.	\$7,517.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$2.	\$0.	\$2.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$2,259.	\$2,259.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$2,583.	\$2,583.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103306	\$0.	\$2,418.	\$2,418.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose				
<b>Greenberg, Richard N</b>	3048103895	\$2.	\$0.	\$2.
University of Massachusetts				
A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium difficile Toxin A [GS-CDA1] and a Human Monoclonal Antibody to				
<b>Greenberg, Richard N</b>	3048104321	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
<b>Greenberg, Richard N</b>	3048104321	\$0.	\$7,974.	\$7,974.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
<b>Greenberg, Richard N</b>	3048104349	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
<b>Greenberg, Richard N</b>	3048104349	\$0.	\$5,731.	\$5,731.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
<b>Greenberg, Richard N</b>	3048104641	\$2.	\$0.	\$2.
Boehringer Ingelheim				
A randomized, double-blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE with Truvada				
<b>Griffith, Charles H</b>	3048103686	\$169,042.	\$0.	\$169,042.
Health Resources and Services Administration				
Faculty Development in Prime Care - Internal Medicine and Pediatrics				
<b>Guo, Zhenheng</b>	3048104531	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute				
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Gurley, John C</b>	3046640500	\$0.	\$1,285.	\$1,285.
Medtronics Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
<b>Gurley, John C</b>	3046640500	\$0.	\$150.	\$150.
Medtronics Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
<b>Gurley, John C</b>	3046857600	\$0.	\$6,717.	\$6,717.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
<b>Gurley, John C</b>	3046857600	\$0.	\$328.	\$328.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
<b>Gurley, John C</b>	3046857600	\$0.	\$16,594.	\$16,594.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
<b>Gurley, John C</b>	3048034600	\$0.	\$36,880.	\$36,880.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$39,103.	\$39,103.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$3,857.	\$3,857.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$11,557.	\$11,557.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$4,361.	\$4,361.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$29,704.	\$29,704.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$28,696.	\$28,696.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Internal Medicine</u></b>				
<b>Gurley, John C</b>	3048034600	\$0.	\$2,475.	\$2,475.
AGA Medical Co				
Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$950.	\$950.
AGA Medical Co				
Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Gurley, John C</b>	3048034600	\$0.	\$3,686.	\$3,686.
AGA Medical Co				
Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
<b>Hamdalla, Hussam Nader</b>	3048104582	\$2.	\$0.	\$2.
Momenta Pharmaceuticals Inc				
A Randomized, Multi-Center, Open-Label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
<b>Hirschowitz, Edward A</b>	3048029300	\$0.	\$74,414.	\$74,414.
KY Lung Cancer Research Fund				
Identification of Novel Lung Tumor Proteins Using Tumor-Infiltrating B Cells				
<b>Hirschowitz, Edward A</b>	3048100100	\$0.	\$256,375.	\$256,375.
National Cancer Institute				
Autoantibodies in NSCLC as Markers of Disease				
<b>Howard, Dianna S</b>	3046579600	\$0.	\$6,450.	\$6,450.
Wyeth Ayerst Research Inc				
Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care (01-BMT-135)				
<b>Howard, Dianna S</b>	3048037800	\$0.	\$3,982.	\$3,982.
Genzyme Corp				
06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
<b>Howard, Dianna S</b>	3048037800	\$0.	\$711.	\$711.
Genzyme Corp				
06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
<b>Howard, Dianna S</b>	3048037800	\$0.	\$4,693.	\$4,693.
Genzyme Corp				
06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$4,140.	\$4,140.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$23,484.	\$23,484.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$6,095.	\$6,095.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
<b>Howard, Dianna S</b>	3048103404	\$2.	\$0.	\$2.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$5,463.	\$5,463.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
<b>Howard, Dianna S</b>	3048103404	\$0.	\$19,917.	\$19,917.
ViroPharma Inc				
A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
<b>Howard, Dianna S</b>	3048104472	\$2.	\$0.	\$2.
Pfizer Inc				
A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis				
<b>Howard, Dianna S</b>	3048104581	\$2.	\$0.	\$2.
i3 Research				
A Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study				
<b>Karounos, Dennis G</b>	3046861000	\$0.	\$775.	\$775.
George Washington University				
Natural History of the Development of Type 1 Diabetes				
<b>Karounos, Dennis G</b>	3046861000	\$0.	\$820.	\$820.
George Washington University				
Natural History of the Development of Type 1 Diabetes				
<b>Karounos, Dennis G</b>	3046861000	\$0.	\$620.	\$620.
George Washington University				
Natural History of the Development of Type 1 Diabetes				
<b>Karounos, Dennis G</b>	3048103618	\$98,783.	\$0.	\$98,783.
American Diabetes Association Inc				
Mechanisms of preventing type 1 diabetes with inactive insulin				
<b>King, Victoria L</b>	3048104393	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute				
The role of Prostaglandin E2 in Angiotensin II-induced vascular disease				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$608.	\$608.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$770.	\$770.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$774.	\$774.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$13,398.	\$13,398.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$770.	\$770.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$608.	\$608.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046775800	\$0.	\$774.	\$774.
Schering Plough Co Comparison of PEG-Intron 1/5 mcg/kg/wk Plus REBETOL vs. PeG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1				
<b>Koch, Alvaro</b>	3046922600	\$0.	\$2,000.	\$2,000.
Covance A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients with Advanced Hepatocellular carcinoma				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$14,499.	\$14,499.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$5,534.	\$5,534.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$9,351.	\$9,351.
Sanofi Aventis US Inc				
Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048068400	\$0.	\$16,030.	\$16,030.
Sanofi Aventis US Inc				
Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048072900	\$0.	\$4,532.	\$4,532.
Sanofi Aventis US Inc				
Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048072900	\$0.	\$10,939.	\$10,939.
Sanofi Aventis US Inc				
Satavaptan Cirrhotic Ascites Treatment Study: A Double-Blind, Randomized, Parallel Group Comparison of Treatment with Satavaptan at 5 to 10 mg daily Versus Placebo on top of Conventional Treatment in Patients with Ascites due to Cirrhosis of the Liver				
<b>Koch, Alvaro</b>	3048104355	\$2.	\$0.	\$2.
Debiovision Inc				
The Early Use of Sanvar with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension				
<b>Koch, Alvaro</b>	3048104355	\$0.	\$8,818.	\$8,818.
Debiovision Inc				
The Early Use of Sanvar with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension				
<b>Koch, Alvaro</b>	3048104481	\$2.	\$0.	\$2.
GlaxoSmithKline				
Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
<b>Koch, Alvaro</b>	3048104482	\$2.	\$0.	\$2.
GlaxoSmithKline				
Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy				
<b>Malluche, Hartmut H</b>	3048103863	\$13,581.	\$0.	\$13,581.
Childrens Hospital of Philadelphia				
Changes in Skeletal Microarchitecture Following Renal Transplantation				
<b>Malluche, Hartmut H</b>	3048104380	\$100,000.	\$0.	\$100,000.
American Society of Nephrology				
Renal Osteodystrophy: A Fresh Approach				
<b>Mardini, Houssam Eddin</b>	3048103706	\$0.	\$1,375.	\$1,375.
PRS Clinical Inc				
Chemoprevention of Colorectal Adenomas				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Mardini, Houssam Eddin</b>	3048103706	\$0.	\$3,498.	\$3,498.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
<b>Mardini, Houssam Eddin</b>	3048103706	\$2.	\$0.	\$2.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
<b>Massarweh, Suleiman A.</b>	3048103858	\$0.	\$89,636.	\$89,636.
Bayer Pharmaceuticals A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (NEXAVAR) to Existing Endocrine Therapy in Patients with Advanced Breast Cancer				
<b>Massarweh, Suleiman A.</b>	3048103858	\$2.	\$0.	\$2.
Bayer Pharmaceuticals A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (NEXAVAR) to Existing Endocrine Therapy in Patients with Advanced Breast Cancer				
<b>Massarweh, Suleiman A.</b>	3048104253	\$2.	\$0.	\$2.
GlaxoSmithKline An Open-Label Multi-Centre Study of Lapatinib in Combination with Chemotherapy in Patients with ErB2 Overexpressing Breast Cancer After Transtuzumab Failure in the Neoadjuvant or Adjuvant Setting				
<b>Massarweh, Suleiman A.</b>	3048104541	\$0.	\$16,898.	\$16,898.
Novartis A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure				
<b>Massarweh, Suleiman A.</b>	3048104541	\$2.	\$0.	\$2.
Novartis A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure				
<b>Mawad, Hanna W</b>	3048104427	\$0.	\$3,165.	\$3,165.
Roche Laboratories A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis Patients who Self Inject or Receive In-Center Injections				
<b>Mawad, Hanna W</b>	3048104427	\$2.	\$0.	\$2.
Roche Laboratories A Two-Arm, Randomized, Open-Label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 versus Epoetin Alfa in Peritoneal Dialysis Patients who Self Inject or Receive In-Center Injections				
<b>McDonagh, Kevin T</b>	3046946800	\$0.	\$9,467.	\$9,467.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
<b>McDonagh, Kevin T</b>	3046952500	\$0.	\$4,800.	\$4,800.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>McDonagh, Kevin T</b>	3046952500	\$0.	\$1,411.	\$1,411.
Bristol Myers Squibb Company				
A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
<b>McDonagh, Kevin T</b>	3046952500	\$0.	\$668.	\$668.
Bristol Myers Squibb Company				
A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$1,429.	\$1,429.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$679.	\$679.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$4,514.	\$4,514.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$3,150.	\$3,150.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$511.	\$511.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$3,634.	\$3,634.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046959100	\$0.	\$1,831.	\$1,831.
Bristol Myers Squibb Company				
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
<b>McDonagh, Kevin T</b>	3046974200	\$0.	\$4,778.	\$4,778.
Novartis				
Effect of Gleevec on pharmacokinetics of acetaminophen/paracetamol in patients with CML				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$540.	\$540.
Cephalon Inc				
A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$153,400.	\$153,400.
Cephalon Inc				
A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$1,080.	\$1,080.
Cephalon Inc				
A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$-153,400.	\$-153,400.
Cephalon Inc				
A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048050100	\$0.	\$540.	\$540.
Cephalon Inc				
A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda )Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
<b>McDonagh, Kevin T</b>	3048103824	\$2.	\$0.	\$2.
Proteolix Inc				
An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
<b>McDonagh, Kevin T</b>	3048103826	\$2.	\$0.	\$2.
Proteolix Inc				
An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma				
<b>McDonagh, Kevin T</b>	3048104375	\$2.	\$0.	\$2.
Erimos Pharmaceuticals LLC				
Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients				
<b>Miller, Beth A</b>	3046829900	\$0.	\$2,149.	\$2,149.
Genentech Inc				
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$1,526.	\$1,526.
Genentech Inc				
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$2,429.	\$2,429.
Genentech Inc				
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$462.	\$462.
Genentech Inc				
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Beth A</b>	3046829900	\$0.	\$60.	\$60.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$3,192.	\$3,192.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$2,128.	\$2,128.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$462.	\$462.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046829900	\$0.	\$2,285.	\$2,285.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
<b>Miller, Beth A</b>	3046988300	\$0.	\$1,923.	\$1,923.
GlaxoSmithKline A Multicenter, Randomized, Double-Blind, TRiple-Dummy, Placebo-Controlled, Parallel Group, Four-Weeek Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects with				
<b>Miller, Beth A</b>	3046988300	\$0.	\$1,861.	\$1,861.
GlaxoSmithKline A Multicenter, Randomized, Double-Blind, TRiple-Dummy, Placebo-Controlled, Parallel Group, Four-Weeek Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects with				
<b>Miller, Beth A</b>	3046994700	\$0.	\$3,341.	\$3,341.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3046994700	\$0.	\$1,316.	\$1,316.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3046994700	\$0.	\$1,746.	\$1,746.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Beth A</b>	3046994700	\$0.	\$245.	\$245.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3046994700	\$0.	\$4,455.	\$4,455.
Novartis A 26 Week, Randomized, Double-Blind, Parallel-Group-Controlled, Multi-center Study To Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy In Patients With Persistent Allergic Asthma				
<b>Miller, Beth A</b>	3048041000	\$0.	\$245.	\$245.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$1,923.	\$1,923.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$3,128.	\$3,128.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$490.	\$490.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$200.	\$200.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048041000	\$0.	\$1,996.	\$1,996.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
<b>Miller, Beth A</b>	3048104584	\$2.	\$0.	\$2.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Beth A</b>	3048104584	\$0.	\$1,498.	\$1,498.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$0.	\$1,498.	\$1,498.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104585	\$2.	\$0.	\$2.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 250mcg Twice Daily				
<b>Miller, Beth A</b>	3048104586	\$2.	\$0.	\$2.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 500mcg Twice Daily				
<b>Miller, Beth A</b>	3048104586	\$0.	\$1,498.	\$1,498.
GlaxoSmithKline A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 500mcg Twice Daily				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$250.	\$250.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$5,115.	\$5,115.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$4,247.	\$4,247.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$1,891.	\$1,891.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$250.	\$250.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$5,244.	\$5,244.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$1,339.	\$1,339.
Eli Lilly and Company Hypopituitary Control and Complications Study				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Miller, Ralph E</b>	3046644900	\$0.	\$1,287.	\$1,287.
Eli Lilly and Company Hypopituitary Control and Complications Study				
<b>Mokashi, Vishwesh Prakash</b>	3048017800	\$0.	\$43,000.	\$43,000.
American Heart Association Vishwesh Mokashi: Low Density Lipoprotein Receptor-Related Protein Initiates Angiotnesin II-Induced Abdominal Aortic Aneurysms				
<b>Moliterno, David Jon</b>	3046826600	\$0.	\$3,125.	\$3,125.
Aventis Pharmaceuticals Products Inc An International Phase 2-3, Stratified, Randomized, Open-Label, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients...				
<b>Morehead, Richard S</b>	3046861300	\$0.	\$4,538.	\$4,538.
Ortho McNeil Pharmaceuticals Levofloxacin Pharmacinetics in the Severely Obese				
<b>Morris, Andrew</b>	3046978800	\$0.	\$218,633.	\$218,633.
National Institute of General Medical Sciences Lysophosphatidic Acid - Synthesis, Actions and Inactivation				
<b>Morris, Andrew</b>	3048104439	\$492,660.	\$0.	\$492,660.
National Center for Research Resources Thermo/Finnigan TSQ AM Triple Stage Quadrupole Mass Spectrometer				
<b>Mukherjee, Debabrata</b>	3046910200	\$0.	\$750.	\$750.
Sanofi Synthelabo Inc SHINE: A Randomized Dose Ranging Study of Hexadecasaccharide				
<b>Mukherjee, Debabrata</b>	3046910200	\$0.	\$630.	\$630.
Sanofi Synthelabo Inc SHINE: A Randomized Dose Ranging Study of Hexadecasaccharide				
<b>Mukherjee, Debabrata</b>	3046943700	\$0.	\$900.	\$900.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trail Costar Paclitaxeletuting Coronary Stent System				
<b>Mukherjee, Debabrata</b>	3046943700	\$0.	\$1,500.	\$1,500.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trail Costar Paclitaxeletuting Coronary Stent System				
<b>Mukherjee, Debabrata</b>	3046943700	\$0.	\$630.	\$630.
Conor Medsystems COSTAR II: Cobalt Chromium Stent with Antiproliferative for Restenosis II Trail Costar Paclitaxeletuting Coronary Stent System				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$1,250.	\$1,250.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$2,950.	\$2,950.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$2,075.	\$2,075.
Guidant CPI				
CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$2,090.	\$2,090.
Guidant CPI				
CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048061600	\$0.	\$2,825.	\$2,825.
Guidant CPI				
CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
<b>Mukherjee, Debabrata</b>	3048104415	\$2.	\$0.	\$2.
Schering Plough Co				
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
<b>Nickl, Nicholas J</b>	3046456500	\$0.	\$10,310.	\$10,310.
G D Searle & Co				
Prevention of Sporadic Colorectal Adenomas with Celecoxib				
<b>Nickl, Nicholas J</b>	3046728400	\$0.	\$500.	\$500.
Medtronic Inc				
An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
<b>Nickl, Nicholas J</b>	3046728400	\$0.	\$1,300.	\$1,300.
Medtronic Inc				
An Evaluation of the Medtronic Gatekeeper System in the Treatment of subjects with GERD				
<b>Nickl, Nicholas J</b>	3046781800	\$0.	\$464.	\$464.
Novartis				
A 6-week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, to Assess the Efficacy and Tegaserod (6mgBID) & Placebo in Female Patients with Dyspepsia				
<b>Nickl, Nicholas J</b>	3048104337	\$75,000.	\$0.	\$75,000.
Lexington Foundation				
Effectiveness of Recommendations for Esophageal Cancer Screening: A Population Community Based Study				
<b>Pena, Luis R</b>	3048103663	\$2.	\$0.	\$2.
Solvay Pharmaceuticals				
A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
<b>Reynolds, L Raymond</b>	3048027100	\$0.	\$323.	\$323.
Novo Nordisk Pharmaceuticals Inc				
Effect on Glycemic Control of Two Doses of Liraglutide versus Glimepiride in Type 2 Diabetes				
<b>Reynolds, L Raymond</b>	3048027100	\$0.	\$3,999.	\$3,999.
Novo Nordisk Pharmaceuticals Inc				
Effect on Glycemic Control of Two Doses of Liraglutide versus Glimepiride in Type 2 Diabetes				
<b>Reynolds, L Raymond</b>	3048027100	\$0.	\$2,096.	\$2,096.
Novo Nordisk Pharmaceuticals Inc				
Effect on Glycemic Control of Two Doses of Liraglutide versus Glimepiride in Type 2 Diabetes				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Rinehart, John J</b>	3046969600	\$0.	\$-2,000.	\$-2,000.
Pfizer Inc Phase II Study of the Anti-Angiogenesis Agent AG-013736 as Second-or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$5,000.	\$5,000.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$2,394.	\$2,394.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$19,109.	\$19,109.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$8,719.	\$8,719.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048082900	\$0.	\$41,136.	\$41,136.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
<b>Rinehart, John J</b>	3048096700	\$0.	\$8,476.	\$8,476.
Tapestry Pharmaceuticals Inc A Phase 2 Trail of TPI 287 in Patients with Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Taxane Regimen				
<b>Rinehart, John J</b>	3048103816	\$2.	\$0.	\$2.
Eli Lilly and Company A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Second-Line Treatment in Patients with Unresectable or Metastatic Melanoma				
<b>Rinehart, John J</b>	3048103857	\$0.	\$4,998.	\$4,998.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
<b>Rinehart, John J</b>	3048103857	\$2.	\$0.	\$2.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
<b>Rinehart, John J</b>	3048104413	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Randomized Trial of Temsilrolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitnib Therapy				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Rinehart, John J</b>	3048104488	\$2.	\$0.	\$2.
Schering Plough Co An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel				
<b>Rinehart, John J</b>	3048104494	\$2.	\$0.	\$2.
Avax Technologies Inc Comparison of M-Vax plus Lose Dose Interleukin-2 versus Placebo Vaccine plus Low Dose Interleukin-2 Patients with Stage IV Melanoma				
<b>Romond, Edward H</b>	3046177800	\$0.	\$2,450.	\$2,450.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$2,425.	\$2,425.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$3,800.	\$3,800.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$15,450.	\$15,450.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$10,050.	\$10,050.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$12,000.	\$12,000.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$4,675.	\$4,675.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$4,700.	\$4,700.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$19,600.	\$19,600.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$2,600.	\$2,600.
NSABP Foundation NSABP Master Agreement				
<b>Romond, Edward H</b>	3046177800	\$0.	\$15,175.	\$15,175.
NSABP Foundation NSABP Master Agreement				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Romond, Edward H</b>	3048040300	\$0.	\$11,029.	\$11,029.
Eli Lilly and Company A Randomized Phase II Trail of Paclitaxel and Bevacizumab versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer				
<b>Rowland, Randall</b>	3048103818	\$0.	\$265.	\$265.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$50.	\$50.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$2,040.	\$2,040.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$865.	\$865.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$0.	\$21,521.	\$21,521.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103818	\$2.	\$0.	\$2.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
<b>Rowland, Randall</b>	3048103819	\$0.	\$450.	\$450.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$150.	\$150.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$400.	\$400.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$0.	\$15,448.	\$15,448.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Rowland, Randall</b>	3048103819	\$2.	\$0.	\$2.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
<b>Sawaya, Boutzos P</b>	3048104256	\$19,250.	\$0.	\$19,250.
KY Science and Technology Co Inc KSEF R&D Excellence: Mass Spectral Analysis of Parathyroid Hormone Peptides from Plasma				
<b>Smyth, Susan</b>	3048060100	\$0.	\$393,639.	\$393,639.
National Heart Lung and Blood Institute Integrin Signaling in Vascular Cells				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Smyth, Susan</b>	3048060100	\$0.	\$401,673.	\$401,673.
National Heart Lung and Blood Institute Integrin Signaling in Vascular Cells				
<b>Smyth, Susan</b>	3048060200	\$0.	\$238,941.	\$238,941.
National Heart Lung and Blood Institute Lysolipid Signaling in Cardiovascular Disease				
<b>Smyth, Susan</b>	3048103401	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Cheng Pre-Doc Fellowship: Signaling of LPA Receptors 1 and 2 is Vital for Regulation of Pulmonary Vascular Tone				
<b>Smyth, Susan</b>	3048103403	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Federico Pre-Doc Fellowship: The Role of Pyk2 in Platelet-eukocyte Interactions and the Arterial Response to Injury				
<b>Smyth, Susan</b>	3048103652.	\$2,000.	\$0.	\$2,000.
American Heart Association Fellowship for Suganya Manivannan: Student Scholarship in Cardiovascular Disease & Stroke				
<b>Smyth, Susan</b>	3048103742	\$0.	\$275,848.	\$275,848.
University of North Carolina Adhesion and Migration in Inflammation				
<b>Smyth, Susan</b>	3048104747	\$117,284.	\$0.	\$117,284.
National Heart Lung and Blood Institute NRSA Training Grant: Clinical Scholars Training in Cardiovascular Science				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$600.	\$600.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$3,200.	\$3,200.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$4,650.	\$4,650.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$1,950.	\$1,950.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046837600	\$0.	\$200.	\$200.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$5,400.	\$5,400.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$3,400.	\$3,400.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$1,250.	\$1,250.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$1,100.	\$1,100.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$5,750.	\$5,750.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$5,850.	\$5,850.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3046979000	\$0.	\$3,000.	\$3,000.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
<b>Steinhubl, Steven R</b>	3048007800	\$0.	\$62,304.	\$62,304.
Regado Biosciences Inc A Phase 1b Evaluation of the REGI Anticoagulation System: A Product for the Controlled Regulation of Factor IXa				
<b>Steinhubl, Steven R</b>	3048010500	\$0.	\$28,673.	\$28,673.
Eli Lilly and Company A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel				
<b>Steinhubl, Steven R</b>	3048010500	\$0.	\$7,742.	\$7,742.
Eli Lilly and Company A Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Acute Coronary Syndrome Who Have Recently Undergone Percutaneous Coronary Intervention and Are Receiving Clopidogrel				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,600.	\$1,600.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,000.	\$1,000.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$4,302.	\$4,302.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$10,700.	\$10,700.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,890.	\$1,890.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,600.	\$1,600.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$3,500.	\$3,500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$1,890.	\$1,890.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048012900	\$0.	\$5,501.	\$5,501.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				
<b>Steinhubl, Steven R</b>	3048047000	\$0.	\$10,342.	\$10,342.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
<b>Steinhubl, Steven R</b>	3048047000	\$0.	\$1,351.	\$1,351.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
<b>Steinhubl, Steven R</b>	3048047000	\$0.	\$1,701.	\$1,701.
Bristol Myers Squibb Company APPRAISE-1: Apixaban for Prevention of Acute Ischemic Safety Events				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$6,563.	\$6,563.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$4,860.	\$4,860.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$6,420.	\$6,420.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$4,680.	\$4,680.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$3,585.	\$3,585.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Steinhubl, Steven R</b>	3048066800	\$0.	\$10,260.	\$10,260.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
<b>Steinhubl, Steven R</b>	3048103622	\$2.	\$0.	\$2.
AstraZeneca Pharmaceuticals Plato: A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes				
<b>Steinhubl, Steven R</b>	3048103622	\$0.	\$3,998.	\$3,998.
AstraZeneca Pharmaceuticals Plato: A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$2,600.	\$2,600.
Johnson and Johnson A Propeptive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$3,200.	\$3,200.
Johnson and Johnson A Propeptive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$2.	\$0.	\$2.
Johnson and Johnson A Propeptive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>Steinhubl, Steven R</b>	3048103787	\$0.	\$3,598.	\$3,598.
Johnson and Johnson A Propeptive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
<b>STROBEL, GUNNAR G.</b>	3046738800	\$0.	\$1,060.	\$1,060.
Medtronics Inc InSync ICD Post Market Registry				
<b>Supinski, Gerald</b>	3048092400	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute MAPK/PKR Modulation of Diaphragm Weakness				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Supinski, Gerald</b>	3048092400	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute MAPK/PKR Modulation of Diaphragm Weakness				
<b>Supinski, Gerald</b>	3048103003	\$0.	\$71,126.	\$71,126.
National Heart Lung and Blood Institute Caspase Mediated Diaphragmatic Dysfunction				
<b>Supinski, Gerald</b>	3048103003	\$0.	\$284,503.	\$284,503.
National Heart Lung and Blood Institute Caspase Mediated Diaphragmatic Dysfunction				
<b>Tannock, Lisa R</b>	3048087500	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Angiotensin Induced Proteoglycans in Atherosclerosis				
<b>Temprano, James</b>	3048104212	\$50,000.	\$0.	\$50,000.
Foundation of the American College of Allergy Asthma and Immunology Oral Contraceptives and Asthma Control				
<b>Thornton, Alice C</b>	3048013100	\$0.	\$25,000.	\$25,000.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Thornton, Alice C</b>	3048013100	\$0.	\$100,000.	\$100,000.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Thornton, Alice C</b>	3048013100	\$0.	\$-27.	\$-27.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Thornton, Alice C</b>	3048013100	\$0.	\$554,054.	\$554,054.
KY Health Services Cabinet Kentucky HIV/AIDS Care Coordinator Program				
<b>Thornton, Alice C</b>	3048103741	\$150,000.	\$0.	\$150,000.
Emory University Kentucky AIDS Educational Training Center				
<b>Thornton, Alice C</b>	3048104501	\$0.	\$198,550.	\$198,550.
Health Resources and Services Administration Ryan White Part C Outpatient Early Intervention Services				
<b>Thornton, Alice C</b>	3048104501	\$490,382.	\$0.	\$490,382.
Health Resources and Services Administration Ryan White Part C Outpatient Early Intervention Services				
<b>Van Der Westhuyzen, Deneys R</b>	3046952300	\$0.	\$309,348.	\$309,348.
National Heart Lung and Blood Institute SR-BI and SR-BII Recycling and Selective Lipid Uptake				
<b>Van Der Westhuyzen, Deneys R</b>	3048101200	\$0.	\$1,416,306.	\$1,416,306.
National Heart Lung and Blood Institute HDL Function and Metabolism During Inflammation Admin Core A				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Van Zant, Gary</b>	3046732700	\$0.	\$349,631.	\$349,631.
National Institute on Aging Species Comparison of Stem Cell Aging				
<b>Van Zant, Gary</b>	3046830100	\$0.	\$266,530.	\$266,530.
National Institute on Aging Aging Stem Cells and Their Microenvironment				
<b>Waid, Thomas</b>	3048103709	\$2.	\$0.	\$2.
Novartis A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients				
<b>Waid, Thomas</b>	3048103709	\$0.	\$2,445.	\$2,445.
Novartis A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients				
<b>Waid, Thomas</b>	3048103709	\$0.	\$5,606.	\$5,606.
Novartis A 4-Week, Multicenter, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of myfortic and MMF (Cellcept) When Administered in Combination with Calcineurin Inhibitors in Renal Transplant Recipients				
<b>Waid, Thomas</b>	3048104654	\$2.	\$0.	\$2.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
<b>Waterstrat, Amanda Jo</b>	3048090300	\$0.	\$30,824.	\$30,824.
National Institute on Aging Genetic Regulation of Hematopoietic Stem Cell Number				
<b>Winter, Trevor Anthony</b>	3048103667	\$0.	\$2,498.	\$2,498.
PPD Development Inc An Open-Label, Multi-Center Trial to Examine the Long Term Safety, Efficacy and Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease who have Failed Tapering of Corticosteroids				
<b>Winter, Trevor Anthony</b>	3048103667	\$2.	\$0.	\$2.
PPD Development Inc An Open-Label, Multi-Center Trial to Examine the Long Term Safety, Efficacy and Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease who have Failed Tapering of Corticosteroids				
<b>Winter, Trevor Anthony</b>	3048103672	\$0.	\$2,498.	\$2,498.
PPD Development Inc A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease				
<b>Winter, Trevor Anthony</b>	3048103672	\$2.	\$0.	\$2.
PPD Development Inc A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effect of Certolizumab Pegol in Patients with Moderate to Severe Crohn's Disease				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Internal Medicine</b>				
<b>Zgoda, Michael A</b>	3046843500	\$0.	\$4,020.	\$4,020.
Emphasys Medical Inc Endobronchial Valve for Emphsema Palliation Trial - VENT				
<b>Ziada, Khaled M</b>	3046900000	\$0.	\$12,023.	\$12,023.
Omnicare Clinical Research A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3046900000	\$0.	\$34,164.	\$34,164.
Omnicare Clinical Research A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3046900000	\$0.	\$33,084.	\$33,084.
Omnicare Clinical Research A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCl versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3046944600	\$0.	\$800.	\$800.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atheroclerosis Development involving Rimonabant				
<b>Ziada, Khaled M</b>	3046944600	\$0.	\$7,800.	\$7,800.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atheroclerosis Development involving Rimonabant				
<b>Ziada, Khaled M</b>	3046944600	\$0.	\$4,410.	\$4,410.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atheroclerosis Development involving Rimonabant				
<b>Ziada, Khaled M</b>	3046944600	\$0.	\$185.	\$185.
Sanofi Synthelabo Inc STRADIVARIUS - Strategy to Reduce Atheroclerosis Development involving Rimonabant				
<b>Ziada, Khaled M</b>	3048104460	\$0.	\$3,998.	\$3,998.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3048104460	\$2.	\$0.	\$2.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
<b>Ziada, Khaled M</b>	3048104589	\$2.	\$0.	\$2.
AstraZeneca Pharmaceuticals A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
<b>Internal Medicine</b>	<b>Totals:</b>	<b>\$5,969,914.</b>	<b>\$14,055,038.</b>	<b>\$20,024,952.</b>
<b>Microbiology, Immunology &amp; Molecular Gen</b>				
<b>Bondada, Subbarao</b>	3046740900	\$0.	\$1,185,331.	\$1,185,331.
National Cancer Institute Growth Regulation and Therapy of Leukemias and Lymphomas				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Microbiology, Immunology &amp; Molecular Gen</u></b>				
<b>Carlyon, Jason A</b>	3046844700	\$0.	\$100,757.	\$100,757.
National Institute Diabetes & Digestive & Kidney Inhibition of NADPH Oxidase by Anaplasma Phagocytophila				
<b>Carlyon, Jason A</b>	3048103643	\$366,250.	\$0.	\$366,250.
National Institute of Allergy and Infectious Diseases Characterization of Anaplasma Phagocytophilum Adhesins				
<b>Cohen, Donald A</b>	3048103719	\$2.	\$0.	\$2.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
<b>Cohen, Donald A</b>	3048103719	\$0.	\$99,998.	\$99,998.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
<b>Cohen, Donald A</b>	3048103719	\$0.	\$100,000.	\$100,000.
Danone Research Effect of the Consumption of a Fermented Dairy Product on Immune Parameters in Healthy Adults				
<b>Garvy, Beth A</b>	3048103511	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Lines Fellowship: Neonatal T cell responses to influenza virus				
<b>Garvy, Beth A</b>	3048104324	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute Role of B cells in host defense against Pneumocystis				
<b>Kaetzel, Charlotte S</b>	3048104092	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases Novel in Vivo Models for Cell-Type Specific MyD88 Signaling in the Intestine				
<b>LUO, GUANGXIANG</b>	3046650400	\$0.	\$43,044.	\$43,044.
National Institute of Allergy and Infectious Diseases Cis-acting RNA Elements in Hepatitis C Virus Replication				
<b>LUO, GUANGXIANG</b>	3048103820	\$183,125.	\$0.	\$183,125.
National Institute of Allergy and Infectious Diseases Hepatitis C Virus Infection and Lipoproteins				
<b>LUO, GUANGXIANG</b>	3048104384	\$219,750.	\$0.	\$219,750.
National Institute Diabetes & Digestive & Kidney Transgenic Mouse Models of hepatitis C Virus Replication				
<b>Marti, Francesc</b>	3048104425	\$0.	\$15,034.	\$15,034.
National Institute Arthritis Musculoskeletal & Skin Lck activity in autoimmune TSAD-deficient Mice				
<b>Marti, Francesc</b>	3048104425	\$70,223.	\$0.	\$70,223.
National Institute Arthritis Musculoskeletal & Skin Lck activity in autoimmune TSAD-deficient Mice				
<b>Perry, Robert D</b>	3046735700	\$0.	\$43,044.	\$43,044.
National Institute of Allergy and Infectious Diseases Characterization of the Hms Phenotype of Yersinia Pestis				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Microbiology, Immunology &amp; Molecular Gen</u></b>				
<b>Perry, Robert D</b>	3046756200	\$0.	\$27,275.	\$27,275.
Arizona State University Attenuated Live and Recombinant Yersinia pestis Vaccines				
<b>Perry, Robert D</b>	3046756200	\$0.	\$155,554.	\$155,554.
Arizona State University Attenuated Live and Recombinant Yersinia pestis Vaccines				
<b>Perry, Robert D</b>	3048104447	\$137,571.	\$0.	\$137,571.
Syntiron LLC STTR: Yersinia iron-regulated membrane proteins as vaccine candidates				
<b>Perry, Robert D</b>	3048104684	\$366,250.	\$0.	\$366,250.
National Institute of Allergy and Infectious Diseases Yersiniabactin and Plague Pathogenesis				
<b>SINAI, ANTHONY P</b>	3046975100	\$0.	\$313,985.	\$313,985.
National Institute of Allergy and Infectious Diseases Blockade of Host Apoptosis by Toxoplasma Gondii				
<b>Spear, Brett T</b>	3048104385	\$300,325.	\$0.	\$300,325.
National Institute Diabetes & Digestive & Kidney Albumin-AFP Gene Family Regulation in Fetal and Adult Liver				
<b>Spear, Brett T</b>	3048104650	\$69,869.	\$0.	\$69,869.
Innexus Biotechnology Inc IgG1 knock-in mouse				
<b>Stevenson, Brian</b>	3046689200	\$0.	\$55,342.	\$55,342.
National Institute of Allergy and Infectious Diseases Borrelia Burgdorferi LuxS-Mediated Quorum Sensing				
<b>Stevenson, Brian</b>	3046983300	\$0.	\$348,872.	\$348,872.
National Institute of Allergy and Infectious Diseases Analysis of Borrelia Burgdorferi Erp Proteins				
<b>Straley, Susan C</b>	3048103204	\$0.	\$483,485.	\$483,485.
National Institute of Allergy and Infectious Diseases YopM and Protective Innate Defenses Against Plague				
<b>Woodward, Jerold G</b>	3048104077	\$0.	\$39,989.	\$39,989.
University of North Carolina Nanoparticle HIC Protein Vaccines for Cellular Responses				
<b>Woodward, Jerold G</b>	3048104077	\$0.	\$104,040.	\$104,040.
University of North Carolina Nanoparticle HIC Protein Vaccines for Cellular Responses				
<b>Woodward, Jerold G</b>	3048104077	\$30,765.	\$0.	\$30,765.
University of North Carolina Nanoparticle HIC Protein Vaccines for Cellular Responses				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Microbiology, Immunology &amp; Molecular Gen</u></b>				
<b>Yannelli, John R</b>	3048104320	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Generation of Cytotoxic T Lymphocytes (CTL) Against the Cisplatin Resistant Phenotype Displayed by Non Small Cell Lung Cancer				
<b>Microbiology, Immunology &amp; Molecular Gen</b>	<b>Totals:</b>	<b>\$2,458,591.</b>	<b>\$3,115,750.</b>	<b>\$5,574,341.</b>
<b><u>Family Practice &amp; Community Medicine</u></b>				
<b>Dassow, Paul</b>	3048044400	\$0.	\$231,631.	\$231,631.
State of Oregon Department of Justice Maximizing the Impact of a Critical Skills Curriculum for Prescribers				
<b>Dassow, Paul</b>	3048103654	\$182,957.	\$0.	\$182,957.
Health Resources and Services Administration Residency Training in Primary Care				
<b>Joyce, Jennifer M</b>	3048103315	\$187,746.	\$0.	\$187,746.
Health Resources and Services Administration Project to Improve Professionalism Training and Evaluation and to Expand Rural Training at the University of KY				
<b>Killip, Shersten</b>	3048094600	\$99,938.	\$0.	\$99,938.
National Patient Safety Foundation Patient Safety in After Hours Telephone Medicine				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$63,770.	\$63,770.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$2,488.	\$2,488.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$34,366.	\$34,366.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$24,403.	\$24,403.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$34,514.	\$34,514.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$58,825.	\$58,825.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$24,210.	\$24,210.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$34,394.	\$34,394.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Family Practice &amp; Community Medicine</u></b>				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$41,132.	\$41,132.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$64,715.	\$64,715.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$30,183.	\$30,183.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$62,268.	\$62,268.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$36,910.	\$36,910.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$65,337.	\$65,337.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$64,950.	\$64,950.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$0.	\$64,853.	\$64,853.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Roeder, Phillip W</b>	3048103104	\$2.	\$0.	\$2.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
<b>Stanley, Michael W</b>	3048103731	\$81,000.	\$0.	\$81,000.
KY Governors Office for Local Development E-Prescribing Partnerships in Kentucky (ePPIK)				
<b>Stanley, Michael W</b>	3048104492	\$649,500.	\$0.	\$649,500.
Health Resources and Services Administration Health Center Cluster (DHHS BPHC HRSA Section 330 Community Health Center)				
<b>Family Practice &amp; Community Medicine</b>	<b>Totals:</b>	<b>\$1,201,143.</b>	<b>\$938,949.</b>	<b>\$2,140,092.</b>
<b><u>Obstetrics &amp; Gynecology</u></b>				
<b>Coker, Ann L</b>	3048104049	\$285,941.	\$0.	\$285,941.
Center for Disease Control and Prevention Using Batterer Psychological Profile for Prevention of Partner Abuse				
<b>Curry, Thomas E</b>	3048104377	\$0.	\$118,943.	\$118,943.
National Center for Research Resources Center of Biomedical Research Excellence in Women's Health (COBRE)				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Obstetrics &amp; Gynecology</u></b>				
<b>Curry, Thomas E</b>	3048104377	\$0.	\$-39,835.	\$-39,835.
National Center for Research Resources Center of Biomedical Research Excellence in Women's Health (COBRE)				
<b>Curry, Thomas E</b>	3048104377	\$2,039,670.	\$0.	\$2,039,670.
National Center for Research Resources Center of Biomedical Research Excellence in Women's Health (COBRE)				
<b>Ferguson, James E</b>	3048102149	\$0.	\$75,000.	\$75,000.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
<b>Ferguson, James E</b>	3048102149	\$0.	\$300.	\$300.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
<b>Ferguson, James E</b>	3048103789	\$500,000.	\$0.	\$500,000.
National Institute on Drug Abuse Building Interdisciplinary Research Careers in Women's Health in Kentucky				
<b>Hansen, Wendy</b>	3046761900	\$0.	\$1,398.	\$1,398.
Quintiles Inc A Phase III Randomized Double Blind Placebo Controlled Multicenter Study to Assess the Efficacy Safety and Tolerability of Prochieve 8% Progesterone Gel in Preventing Preterm Delivery in Pregnant Women at Increased Risk for Preterm Delivery				
<b>Hansen, Wendy</b>	3046761900	\$0.	\$283.	\$283.
Quintiles Inc A Phase III Randomized Double Blind Placebo Controlled Multicenter Study to Assess the Efficacy Safety and Tolerability of Prochieve 8% Progesterone Gel in Preventing Preterm Delivery in Pregnant Women at Increased Risk for Preterm Delivery				
<b>Muse, Kenneth N</b>	3046599500	\$0.	\$1,016.	\$1,016.
Procter & Gamble Company Protocol 2001133:..Study to Evaluate Efficacy and Safety of Transdermal Testosterone (300 ug/day) for 24 Weeks and Safety for a Further 28-Week Open-Label Period in Women with Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$2,492.	\$2,492.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$726.	\$726.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$1,024.	\$1,024.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Obstetrics &amp; Gynecology</u></b>				
<b>Muse, Kenneth N</b>	3046856500	\$0.	\$2,295.	\$2,295.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				
<b>Muse, Kenneth N</b>	3046872000	\$0.	\$30,033.	\$30,033.
Novo Nordisk Pharmaceuticals Inc A Twelve Month Double-Blind Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Trial to Investigate the Efficacy and Safety of Vagafem Low Dose(10pg17Beta-Estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms				
<b>Muse, Kenneth N</b>	3046880700	\$0.	\$-1,700.	\$-1,700.
Berlex Laboratories Inc A Multicenter, Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Study Comparing a 2.2mg 17 beta-estradiol/0.69 mg Levonorgestrel Combination Transdermal Patch with a Placebo Patch in Postmenopausal Women to Determine the Lowest Effective Dose				
<b>Muse, Kenneth N</b>	3046961700	\$0.	\$799.	\$799.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
<b>Muse, Kenneth N</b>	3046961700	\$0.	\$2,513.	\$2,513.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
<b>Muse, Kenneth N</b>	3046961700	\$0.	\$7,539.	\$7,539.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
<b>Muse, Kenneth N</b>	3046961700	\$0.	\$8,277.	\$8,277.
Wyeth Research Protocol Number 3115A1-304-WW: A Double Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene / Conjugated Estrogens Combinations for the Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in				
<b>Muse, Kenneth N</b>	3048067300	\$0.	\$6,302.	\$6,302.
AMGen A Ramdomized Study to Evaluate Safety and Efficacy of Transitioning Therapy from Alendronate to Denosumab (AMG 12) in postmenopausal women with low bone mineral density				
<b>Muse, Kenneth N</b>	3048078700	\$0.	\$485.	\$485.
Wyeth Pharmaceuticals Inc The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause				
<b>Muse, Kenneth N</b>	3048078700	\$0.	\$12,968.	\$12,968.
Wyeth Pharmaceuticals Inc The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Obstetrics &amp; Gynecology</b>				
<b>Muse, Kenneth N</b>	3048078700	\$0.	\$9,368.	\$9,368.
Wyeth Pharmaceuticals Inc The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause				
<b>Muse, Kenneth N</b>	3048103737	\$136,299.	\$0.	\$136,299.
East Virginia Medical School NICHD Funded multicenter, open-label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR).				
<b>Muse, Kenneth N</b>	3048104076	\$2.	\$0.	\$2.
Cumberland Pharmaceuticals Inc A Multicenter, double-blind, parallel, placebo-controlled trial of Amelior (ibuprofen) injection for treatment of pain in post-operative adult patients. Protocol CPI-CL-008B				
<b>Muse, Kenneth N</b>	3048104076	\$0.	\$1,998.	\$1,998.
Cumberland Pharmaceuticals Inc A Multicenter, double-blind, parallel, placebo-controlled trial of Amelior (ibuprofen) injection for treatment of pain in post-operative adult patients. Protocol CPI-CL-008B				
<b>Muse, Kenneth N</b>	3048104346	\$0.	\$3,247.	\$3,247.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104346	\$2.	\$0.	\$2.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
<b>Muse, Kenneth N</b>	3048104487	\$0.	\$5,801.	\$5,801.
Bayer Pharmaceuticals Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses of the ultra low dose levonorgestral contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age				
<b>Muse, Kenneth N</b>	3048104487	\$2.	\$0.	\$2.
Bayer Pharmaceuticals Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses of the ultra low dose levonorgestral contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age				
<b>Muse, Kenneth N</b>	3048104550	\$2.	\$0.	\$2.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Disorder in Surgically Menopausal Women(testW008)				
<b>Muse, Kenneth N</b>	3048104551	\$2.	\$0.	\$2.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
<b>Muse, Kenneth N</b>	465042	\$0.	\$1,140.	\$1,140.
Eli Lilly and Company Long Term Monitoring of Safety in Subjects Treated with Duloxetine for Stress Urinary Incontinence				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Obstetrics &amp; Gynecology</b>				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$242.	\$242.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$12,496.	\$12,496.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$10,120.	\$10,120.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$3,520.	\$3,520.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$15,224.	\$15,224.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046897300	\$0.	\$184.	\$184.
Gynecologic Oncology Group				
Gynecologic Oncology Group				
<b>Ueland, Frederick R</b>	3046903100	\$0.	\$500.	\$500.
Genentech Inc				
A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Partuzumab (rhuMAb 2C4) in Combination with Gencitabine				
<b>Ueland, Frederick R</b>	3046903100	\$0.	\$10.	\$10.
Genentech Inc				
A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Partuzumab (rhuMAb 2C4) in Combination with Gencitabine				
<b>Ueland, Frederick R</b>	3048098500	\$0.	\$3,616.	\$3,616.
PrecisionMed Inc				
Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
<b>Ueland, Frederick R</b>	3048098500	\$0.	\$3,616.	\$3,616.
PrecisionMed Inc				
Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
<b>Ueland, Frederick R</b>	3048098500	\$0.	\$5,166.	\$5,166.
PrecisionMed Inc				
Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
<b>Ueland, Frederick R</b>	3048098500	\$0.	\$10,332.	\$10,332.
PrecisionMed Inc				
Whole Blood Protocol for OvaRI Assay Clinical Trial in Women with Ovarian Tumors				
<b>Ueland, Frederick R</b>	3048098700	\$0.	\$353.	\$353.
PrecisionMed Inc				
CLD2: To Compare the Effect of Different Type BD Vacutainer TUNes on OvaRi Assay				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Obstetrics &amp; Gynecology</u></b>				
<b>Ueland, Frederick R</b>	3048103872	\$0.	\$7,156.	\$7,156.
Genentech Inc A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
<b>Ueland, Frederick R</b>	3048103872	\$2.	\$0.	\$2.
Genentech Inc A Phase II, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
<b>VanNagell, John R</b>	3048102400	\$775,000.	\$0.	\$775,000.
KY Council on Postsecondary Education Ovarian Cancer Screening in Kentucky				
<b>Obstetrics &amp; Gynecology</b>	<b>Totals:</b>	<b>\$3,736,922.</b>	<b>\$324,947.</b>	<b>\$4,061,869.</b>
<b><u>Pathology &amp; Lab Medicine</u></b>				
<b>Cibull, Michael L</b>	3048104478	\$21,763.	\$0.	\$21,763.
Gynecologic Oncology Group Ovarian Tissue Bank				
<b>Lutz, Charles</b>	3048057500	\$0.	\$58,323.	\$58,323.
National Institute on Aging Natural Killer Subset Senescence and Clonality in Aging				
<b>Lutz, Charles</b>	3048103791	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Differential Expression of NKG2D Ligands in Airway SCC				
<b>Oeltgen, Peter R</b>	3048104556	\$41,660.	\$0.	\$41,660.
KY Science and Technology Co Inc KSEF Commercialization: Use of Delta Specific Opioid Deltorpin-Dvariant for Treating Stroke				
<b>Pathology &amp; Lab Medicine</b>	<b>Totals:</b>	<b>\$207,509.</b>	<b>\$58,323.</b>	<b>\$265,832.</b>
<b><u>Pediatrics</u></b>				
<b>Anstead, Michael I</b>	3048103215	\$0.	\$7,679.	\$7,679.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseudomonas aeruginosa				
<b>Anstead, Michael I</b>	3048103215	\$0.	\$22,782.	\$22,782.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseudomonas aeruginosa				
<b>Anstead, Michael I</b>	3048103215	\$0.	\$9,787.	\$9,787.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culture Negative for Pseudomonas Aeruginosa				
<b>Anstead, Michael I</b>	3048104537	\$78,015.	\$0.	\$78,015.
Cystic Fibrosis Foundation Multi-Center, Multi-National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Pediatrics</u></b>				
<b>Anstead, Michael I</b>	3048104538	\$81,204.	\$0.	\$81,204.
Cystic Fibrosis Foundation Multi-Center, Multi-National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa				
<b>Bada, Henrietta S</b>	3048103620	\$384,350.	\$0.	\$384,350.
KY Health Services Cabinet Infant Intensive Care				
<b>Bada, Henrietta S</b>	3048103645	\$34,867.	\$0.	\$34,867.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
<b>Bada, Henrietta S</b>	3048103645	\$0.	\$9,100.	\$9,100.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
<b>Bada, Henrietta S</b>	3048104495	\$20,862.	\$0.	\$20,862.
University of Tennessee Maternal Lifestyle Study Phase 4				
<b>Bay, Carolyn A</b>	3048103408	\$188,400.	\$0.	\$188,400.
KY Health Services Cabinet Genetic Services				
<b>Bricker, J Timothy</b>	3048103544	\$288,601.	\$0.	\$288,601.
KY Health Services Cabinet Newborn Screening				
<b>Desai, Nirmala S</b>	3048103878	\$2.	\$0.	\$2.
Royal Womens Hospital Infant Cooling Evaluation (ICE) Trial				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$5,000.	\$5,000.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$31,200.	\$31,200.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$23,194.	\$23,194.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$495.	\$495.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$752.	\$752.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$-18,500.	\$-18,500.
National Childhood Cancer Foundation Children's Oncology Group				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$18,500.	\$18,500.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$37,350.	\$37,350.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Greenwood, Martha F</b>	3048102811	\$0.	\$7,500.	\$7,500.
National Childhood Cancer Foundation Children's Oncology Group				
<b>Grigsby, Donna J</b>	3048104623	\$20,000.	\$0.	\$20,000.
Reach out and Read Inc Reach Out and Read (ROAR)				
<b>Hayes, Don</b>	3048103855	\$0.	\$3,148.	\$3,148.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
<b>Hayes, Don</b>	3048103855	\$2.	\$0.	\$2.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
<b>Johnson, Catherine M</b>	3048104512	\$3,300.	\$0.	\$3,300.
Gilead Sciences Inc Pulmonary Arterial Hypertension and Support for Congenital Heart Disease				
<b>Kanga, Jamshed F</b>	3046872500	\$0.	\$3,286.	\$3,286.
Cystic Fibrosis Foundation The EPIC Clinical Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
<b>Kanga, Jamshed F</b>	3046874600	\$0.	\$3,400.	\$3,400.
Cystic Fibrosis Foundation The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF				
<b>Kanga, Jamshed F</b>	3048077300	\$0.	\$5,000.	\$5,000.
Axcan Pharma Inc A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase MT20 to Placebo for the Correction of Steatorrhea in Patients with Cystic Fibrosis				
<b>Kanga, Jamshed F</b>	3048077300	\$0.	\$5,650.	\$5,650.
Axcan Pharma Inc A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase MT20 to Placebo for the Correction of Steatorrhea in Patients with Cystic Fibrosis				
<b>Kanga, Jamshed F</b>	3048087000	\$0.	\$39,510.	\$39,510.
Inspire Pharmaceuticals A Multicenter, Double-Blind, Placebo Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Kanga, Jamshed F</b>	3048087000	\$0.	\$9,998.	\$9,998.
Inspire Pharmaceuticals A Multicenter, Double-Blind, Placebo Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease				
<b>Kanga, Jamshed F</b>	3048104068	\$105,290.	\$0.	\$105,290.
Cystic Fibrosis Foundation Cystic Fibrosis Center Program				
<b>Kanga, Jamshed F</b>	3048104070	\$64,800.	\$0.	\$64,800.
Cystic Fibrosis Foundation Cystic Fibrosis Research TDN Grant				
<b>Kanga, Jamshed F</b>	3048104392	\$2.	\$0.	\$2.
Genentech Inc A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects with Severe Lung Disease				
<b>Kanga, Jamshed F</b>	3048104457	\$2.	\$0.	\$2.
Altus Pharmaceuticals Inc. A Phase III Randomized Double-Blind Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency				
<b>Li, Xiangan</b>	3048104262	\$65,000.	\$0.	\$65,000.
American Heart Association Scavenger Receptor BI and Endothelial Nitric Oxide Synthase Work Cooperatively to Prevent Endothelial Cell Dysfunction				
<b>Lomenick, Jefferson</b>	3048015500	\$0.	\$3,600.	\$3,600.
AstraZeneca Pharmaceuticals An Open -Label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of FASLODEX (Fulvestrant) in Girls with Progressive Precocious Puberty Associated with McCune-Albright Syndrome				
<b>Lomenick, Jefferson</b>	3048015500	\$0.	\$3,000.	\$3,000.
AstraZeneca Pharmaceuticals An Open -Label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of FASLODEX (Fulvestrant) in Girls with Progressive Precocious Puberty Associated with McCune-Albright Syndrome				
<b>Moscow, Jeffrey</b>	3048103508	\$170,800.	\$0.	\$170,800.
KY Commission for Children with Special Health Comprehensive Diagnosis				
<b>Moscow, Jeffrey</b>	3048103509	\$2,000.	\$0.	\$2,000.
KY Commission for Children with Special Health Comprehensive Hemophilia Program				
<b>Moscow, Jeffrey</b>	3048104214	\$150,000.	\$0.	\$150,000.
Susan G Komen Breast Cancer Foundation Thiamine Starvation with Thiaminase I for Breast Cancer Therapy				
<b>Omar, Hatim</b>	3048103619	\$303,094.	\$0.	\$303,094.
KY Health Services Cabinet Young Parents Program				
<b>Pinkstaff, Thomas H</b>	3048104428	\$390,592.	\$0.	\$390,592.
KY Health Services Cabinet Foster Care Services				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$-2,500.	\$-2,500.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$800.	\$800.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$2,500.	\$2,500.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$1,473.	\$1,473.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048104276	\$0.	\$998.	\$998.
Covance Hemophilia and Thrombosis Research Registry				
<b>Radulescu, Vlad</b>	3048104276	\$2.	\$0.	\$2.
Covance Hemophilia and Thrombosis Research Registry				
<b>Reynolds, Eric W</b>	3048065500	\$0.	\$108,000.	\$108,000.
National Institute of Child Health and Human Develop Cervical (Neck) Auscultation and Development Outcomes				
<b>Shashidhar, Harohalli</b>	3048059500	\$0.	\$2,503.	\$2,503.
Wyeth Pharmaceuticals Inc A Multi-Center, Open -label Pharmacokintic, Pharmacodynamic, Clinical Synptoms, and Safety Study of Pantoprazole Delayed-Released Granules Administered as A Suspension in Neonates and Preterm Infants with a Clinical Diagnosis of Gatroesophageal Disease.				
<b>Shashidhar, Harohalli</b>	3048059500	\$0.	\$1,207.	\$1,207.
Wyeth Pharmaceuticals Inc A Multi-Center, Open -label Pharmacokintic, Pharmacodynamic, Clinical Synptoms, and Safety Study of Pantoprazole Delayed-Released Granules Administered as A Suspension in Neonates and Preterm Infants with a Clinical Diagnosis of Gatroesophageal Disease.				
<b>Shashidhar, Harohalli</b>	3048103767	\$2.	\$0.	\$2.
United Biosource Corp Psychometric Validation fo the Pediatric Gastroesophageal Reflux Disease Sympton and Quality of Life Questionnaire				
<b>Shashidhar, Harohalli</b>	3048103767	\$0.	\$3,183.	\$3,183.
United Biosource Corp Psychometric Validation fo the Pediatric Gastroesophageal Reflux Disease Sympton and Quality of Life Questionnaire				
<b>Smart, Eric J</b>	3046982800	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Saturated Fatty Acid and Cardiovascular Disease				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Pediatrics</b>				
<b>Smart, Eric J</b>	3048048400	\$0.	\$291,616.	\$291,616.
National Institute Diabetes & Digestive & Kidney Protective Effects of Stearic Acid on Gestational and Acquired Diabetes Mellitus				
<b>Soares, Neelkamal</b>	3048104618	\$7,841.	\$0.	\$7,841.
American Academy of Pediatrics TIDBIT Across Appalachian Kentucky				
<b>Vranicar, Mark</b>	3046986600	\$0.	\$1,095.	\$1,095.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
<b>Vranicar, Mark</b>	3046986600	\$0.	\$3,150.	\$3,150.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
<b>Vranicar, Mark</b>	3046986600	\$0.	\$1,390.	\$1,390.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
<b>Vranicar, Mark</b>	3046986600	\$0.	\$43.	\$43.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
<b>Vranicar, Mark</b>	3046986600	\$0.	\$38.	\$38.
Bristol Myers Squibb Company A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of Cardiolite Myocardial Perfusion Imaging in Pediatric Subjects with Kawaski Disease				
<b>Wong, Peter</b>	3048103501	\$35,000.	\$0.	\$35,000.
KY Health Services Cabinet Pediatric Immunizations				
<b>Wong, Peter</b>	3048103510	\$108,000.	\$0.	\$108,000.
KY Health Services Cabinet Regional Pediatric Services				
<b>Young, Thomas L</b>	3048103409	\$12,792.	\$0.	\$12,792.
KY Health Services Cabinet Obesity Prevention Project				
<b>Young, Thomas L</b>	3048103600	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department Arlington Elementary School Center				
<b>Young, Thomas L</b>	3048103601	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department Johnson Elementary School Center				
<b>Young, Thomas L</b>	3048103602	\$8,000.	\$0.	\$8,000.
Lexington Fayette County Health Department Tates Creek Elementary School Center				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Pediatrics</u></b>				
<b>Young, Thomas L</b>	3048103604	\$31,200.	\$0.	\$31,200.
Lexington Fayette County Health Department Harrison Elementary School Center				
<b>Pediatrics</b>	<b>Totals:</b>	<b>\$2,586,020.</b>	<b>\$1,002,556.</b>	<b>\$3,588,576.</b>
<b><u>Molecular &amp; Biomedical Pharmacology</u></b>				
<b>Kaetzl, David M</b>	3048058700	\$0.	\$204,613.	\$204,613.
National Cancer Institute Molecular Mechanisms of Metastasis Suppression by NM23				
<b>Landfield, Philip W</b>	3046818000	\$0.	\$109,875.	\$109,875.
National Institute on Aging Calcium Regulation in Brain Aging and Alzheimer's Disease - Core A				
<b>Landfield, Philip W</b>	3046818000	\$0.	\$1,464,164.	\$1,464,164.
National Institute on Aging Calcium Regulation in Brain Aging and Alzheimer's Disease - Core A				
<b>Plattner, Rina</b>	3048103607	\$0.	\$-270,399.	\$-270,399.
National Institute of Health ABI kinases in growth factor signaling, motility, and invasion.				
<b>Plattner, Rina</b>	3048103607	\$270,399.	\$0.	\$270,399.
National Institute of Health ABI kinases in growth factor signaling, motility, and invasion.				
<b>Plattner, Rina</b>	3048103677	\$270,399.	\$0.	\$270,399.
National Cancer Institute ABI kinases in growth factor signaling, motility, and invasion.				
<b>Post, Steven R</b>	3046748800	\$0.	\$52,440.	\$52,440.
National Heart Lung and Blood Institute Regulation of Ras Signaling by Rlf in Hypertrophy				
<b>Post, Steven R</b>	3046748800	\$0.	\$209,761.	\$209,761.
National Heart Lung and Blood Institute Regulation of Ras Signaling by Rlf in Hypertrophy				
<b>Post, Steven R</b>	3048003100	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship/Allen-Klee: Regulation of insulin signaling by Rlf				
<b>Post, Steven R</b>	3048103416	\$42,000.	\$0.	\$42,000.
American Heart Association Ohio Valley Affiliate Fellowship for Bradford Blunt: Cardioprotective Effects of the Ras Interacting Protein Rlf				
<b>Post, Steven R</b>	3048104646	\$355,369.	\$0.	\$355,369.
National Heart Lung and Blood Institute Function and Regulation of SR-A in Atherosclerosis				
<b>Swanson, Hollie</b>	3048042200	\$0.	\$265,954.	\$265,954.
National Institute of Environmental Health Sciences AHR-Protac, a Novel Aryl Hydrocarbon Receptor Antagonist				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Molecular &amp; Biomedical Pharmacology</u></b>				
<b>Swanson, Hollie</b>	3048053100	\$0.	\$70,853.	\$70,853.
National Cancer Institute Chemopreventive properties of aryl hydrocarbon receptor antagonists				
<b>Swanson, Hollie</b>	3048104579	\$43,736.	\$0.	\$43,736.
Naprogenix Novel estrogen receptor ligands from plant genomics				
<b>Thibault, Olivier</b>	3048091400	\$0.	\$152,543.	\$152,543.
National Institute on Aging Mechanisms and use of antidiabetic agents in brain aging and Alzheimer's Disease				
<b>Molecular &amp; Biomedical Pharmacology</b>	<b>Totals:</b>	<b>\$981,903.</b>	<b>\$2,280,804.</b>	<b>\$3,262,707.</b>
<b><u>Physiology</u></b>				
<b>Campbell, Kenneth S</b>	3048040900	\$0.	\$58,323.	\$58,323.
National Institute on Aging Myocardial Stiffness in Aging Associated Diastolic Heart Failure				
<b>Campbell, Kenneth S</b>	3048104301	\$65,000.	\$0.	\$65,000.
American Heart Association Cycling Cross-Bridges Augment Passive Stiffness Components During Diastole				
<b>Campbell, Kenneth S</b>	3048104476	\$45,000.	\$0.	\$45,000.
Western KY University Gender Differences in Response to Simulated Microgravity With and Without Countermeasure				
<b>Delisle, Brian P.</b>	3048104544	\$65,000.	\$0.	\$65,000.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
<b>Delisle, Brian P.</b>	3048104544	\$0.	\$-28,397.	\$-28,397.
American Heart Association Abnormal Protein Folding caused by KCNH2 Mutations with Long QT Syndrome				
<b>Delisle, Brian P.</b>	3048104549	\$293,000.	\$0.	\$293,000.
National Heart Lung and Blood Institute Delayed Rectifier K Channel Biogenesis is Unveiled in Models of Long QT Syndrome				
<b>Esser, Karyn A</b>	3048102201	\$0.	\$305,188.	\$305,188.
National Institute Arthritis Musculoskeletal & Skin Intracellular Signaling during Skeletal Muscle Hypertrophy				
<b>Esser, Karyn A</b>	3048104593	\$322,300.	\$0.	\$322,300.
National Institute Arthritis Musculoskeletal & Skin Circadian Rhythms and Skeletal Muscle				
<b>Estus, George Steven</b>	3048032100	\$0.	\$257,497.	\$257,497.
National Institute on Aging LDLR Genetics, Splicing and AD Risk				
<b>Frazier, Donald T</b>	3048103520	\$276,104.	\$0.	\$276,104.
National Institute of General Medical Sciences Interactive Learning Modules for Writing Grant Proposals				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physiology</b>				
<b>Frolenkov, Gregory I</b>	3048104227	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Imaging of surface nanostructures in a living cell				
<b>GONG, MING CUI</b>	3048032700	\$0.	\$320,066.	\$320,066.
National Heart Lung and Blood Institute Vascular Smooth Muscle Hyper-Contractility and Hypertension in Type-II-Diabetes				
<b>GONG, MING CUI</b>	3048104465	\$172,500.	\$0.	\$172,500.
American Diabetes Association Inc Vascular Smooth Muscle Hyperactivity and Type II Diabetes--Associated Hypertension				
<b>Gu, Qihai</b>	3046920900	\$0.	\$46,000.	\$46,000.
Parker B Francis Foundation Pulmonary Stresses in Small Cell Lung Cancer: Neurogenic Mechanisms				
<b>Gu, Qihai</b>	3048103823	\$39,872.	\$0.	\$39,872.
American Lung Association Protease-activated Receptor-2 and Pulmonary C-neuron Hypersensitivity				
<b>HIGH, KARIN N</b>	3048103002	\$0.	\$54,861.	\$54,861.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
<b>HIGH, KARIN N</b>	3048103002	\$0.	\$351,925.	\$351,925.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
<b>HIGH, KARIN N</b>	3048103002	\$0.	\$351,936.	\$351,936.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
<b>HIGH, KARIN N</b>	3048103002	\$0.	\$-12,351.	\$-12,351.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
<b>Jin, Ying</b>	3048104675	\$49,880.	\$0.	\$49,880.
Paralysis Project of America Directing Axon Regeneration after Spinal Cord Injury				
<b>Lee, Lu Yuan</b>	3046925700	\$0.	\$235,419.	\$235,419.
National Heart Lung and Blood Institute Chemosensitivity of Tachykinin-Containing Lung Afferents				
<b>Lee, Lu Yuan</b>	3048104001	\$293,000.	\$0.	\$293,000.
National Heart Lung and Blood Institute Pulmonary C-Neuron Hypersensitivity: Cellular Mechanisms				
<b>McCarthy, John J</b>	3048103202	\$0.	\$71,785.	\$71,785.
National Institute Arthritis Musculoskeletal & Skin Circadian Regulation of Myod 1 Transcription				
<b>McClintock, Timothy S</b>	3046977300	\$0.	\$306,963.	\$306,963.
National Institute on Deafness & Other Communications Genomics of Olfactory Regeneration				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physiology</b>				
<b>McClintock, Timothy S</b>	3048032400	\$0.	\$308,317.	\$308,317.
National Institute on Deafness & Other Communications Functional Domains and Expression of Olfactory Receptors				
<b>McClintock, Timothy S</b>	3048032400	\$0.	\$15,000.	\$15,000.
National Institute on Deafness & Other Communications Functional Domains and Expression of Olfactory Receptors				
<b>McMullen, Colleen A</b>	3048050500	\$0.	\$71,126.	\$71,126.
National Institute on Deafness & Other Communications Molecular Mechanisms of Aging in the Intrinsic Laryngeal Muscles				
<b>McMullen, Colleen A</b>	3048050500	\$0.	\$71,126.	\$71,126.
National Institute on Deafness & Other Communications Molecular Mechanisms of Aging in the Intrinsic Laryngeal Muscles				
<b>Nikolova-Karakashian, Mariana</b>		\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Rozenova Fellowship: The role of Acid Sphingomyelinase as a regulator of TNF-alpha levels in endotoxic shock model				
<b>Nikolova-Karakashian, Mariana</b>	3048091200	\$0.	\$294,319.	\$294,319.
National Institute on Aging Role of Neutral Spingomyelinase-2 in Aging				
<b>Randall, David C</b>	3046945800	\$0.	\$318,269.	\$318,269.
National Institute of Neurological Disorders & Stroke Sympathetic Function in Diabetes				
<b>Randall, David C</b>	3048104583	\$112,565.	\$0.	\$112,565.
National Heart Lung and Blood Institute Interdisiplinary Cardiovascular Training Program				
<b>Reid, Michael B</b>		\$42,000.	\$0.	\$42,000.
American Heart Association Ohio Valley Affiliate Fellowship: Leonardo Ferreira: Intracellular Signaling of Cytokine Stimulated Protein Degradation in Skeletal Muscle				
<b>Reid, Michael B</b>	3048019500	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Predoctoral Fellowship for Melissa Smith: Mechanical Signal Transduction in Glucose Transport of Skeletal Muscle				
<b>Reid, Michael B</b>	3048103873	\$329,625.	\$0.	\$329,625.
National Space Biomedical Research Institute Redox Modulation of Muscle Function in Microgravity				
<b>Reid, Michael B</b>	3048104540	\$74,416.	\$0.	\$74,416.
National Heart Lung and Blood Institute Research Training in Muscle Biology of Cardiopulmonary Disease				
<b>Satin, Jonathan</b>		\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Byse Fellowship: The L-Type Calcium Channel as a Signaling Molecule in Cardiac Development				
<b>Satin, Jonathan</b>	3048104754	\$366,250.	\$0.	\$366,250.
National Heart Lung and Blood Institute Mechanisms of Long-term Cardiac Ion Channel Regulation				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

	New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>			
<b>Physiology</b>			
<b>Smart, Eric J</b>	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Bradshaw: EG-VEGF Mediated Angiogenesis			
<b>Smith, Bret N.</b> 3048103100	\$0.	\$377.	\$377.
National Institute of Neurological Disorders & Stroke Cannabinoid modulation of epileptiform activity in mice.			
<b>Smith, Bret N.</b> 3048103200	\$0.	\$-6,216.	\$-6,216.
National Institute Diabetes & Digestive & Kidney Neural Circuitry in the Caudal Solitary Complex			
<b>Smith, Bret N.</b> 3048103200	\$0.	\$2,065.	\$2,065.
National Institute Diabetes & Digestive & Kidney Neural Circuitry in the Caudal Solitary Complex			
<b>Smith, Bret N.</b> 3048104403	\$20,000.	\$0.	\$20,000.
Epilepsy Foundation of America Fellowship / Hunt: Posttraumatic Epileptiform Activity Following Controlled Cortical Impact in Mice			
<b>SMITH, GEORGE M.</b>	\$31,042.	\$0.	\$31,042.
National Institute of Neurological Disorders & Stroke Trimby Fellowship: Specific targeting of a neuronal subset using a novel chimeric vector pseudotype			
<b>SMITH, GEORGE M.</b>	\$17,225.	\$0.	\$17,225.
National Institute of Neurological Disorders & Stroke NRSA Fellowship for Ziembra: Reconstruction of the nigrostriatal pathway			
<b>SMITH, GEORGE M.</b> 3046853900	\$0.	\$233,067.	\$233,067.
National Institute of Neurological Disorders & Stroke Axonal Growth and Guidance for Nervous System Repair			
<b>SMITH, GEORGE M.</b> 3048080400	\$0.	\$97,405.	\$97,405.
KY Spinal Cord and Head Injury Research Trust Engineering Chondroitinase AC for Expression Within the Injured Spinal Cord			
<b>Snyder, Carol T</b> 3048011900	\$0.	\$-4,800.	\$-4,800.
KY Council on Postsecondary Education Professional Education Preparation Program			
<b>Snyder, Carol T</b> 3048011900	\$0.	\$6,000.	\$6,000.
KY Council on Postsecondary Education Professional Education Preparation Program			
<b>Snyder, Carol T</b> 3048011900	\$0.	\$160,800.	\$160,800.
KY Council on Postsecondary Education Professional Education Preparation Program			
<b>Stepanyan, Ruben</b> 3048104444	\$20,000.	\$0.	\$20,000.
National Organization for Hearing Research Role of TRPA1 channel in noise and drug induced hearing loss			
<b>Stocker, Sean D</b>	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Carmichael Fellowship: The Role of Forebrain TRPV Channels in Salt-Sensitive Hypertension			

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Physiology</b>				
<b>Stocker, Sean D</b>	3048021800	\$0.	\$44,000.	\$44,000.
American Heart Association Ohio Valley Affiliate Fellowship/Adams: Modulation of Rostral Ventrolateral Medulla Neuronal Activity during Phase II of a Severe Hemorrhage				
<b>Stocker, Sean D</b>	3048069200	\$0.	\$-16,000.	\$-16,000.
Merck and Company Inc Role of Brain AT1 Receptors in Obesity-Hypertension				
<b>Stocker, Sean D</b>	3048103530	\$0.	\$-16,742.	\$-16,742.
American Heart Association Ohio Valley Affiliate Carmichael Fellowship: The Role of Forebrain TRPV Channels in Salt-Sensitive Hypertension				
<b>Stocker, Sean D</b>	3048104279	\$65,000.	\$0.	\$65,000.
American Heart Association Neural Mechanisms Mediating Decompensated Hemorrhage				
<b>Stocker, Sean D</b>	3048104468	\$362,553.	\$0.	\$362,553.
National Heart Lung and Blood Institute Central Nervous System Mechanisms of Obesity Hypertension				
<b>Wilson, Melinda E</b>	3046707600	\$0.	\$349,167.	\$349,167.
National Heart Lung and Blood Institute HIV Protease Inhibitors, Macrophage Function and Estrogen				
<b>Wilson, Melinda E</b>	3048018000	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Predoctoral Fellowship for Amanda Prewitt: Estrogen Receptor Alpha mRNA Regulation in the Mouse Cortex Prior to and Following a Stroke-Like Injury				
<b>Physiology</b>	<b>Totals:</b>	<b>\$3,166,332.</b>	<b>\$4,288,495.</b>	<b>\$7,454,827.</b>
<b>Psychiatry</b>				
<b>Brenzel, Allen J</b>	3048103713	\$335,245.	\$0.	\$335,245.
KY Health Services Cabinet Comprehensive Assessment and Training Services Project: Medicaid/Title V				
<b>Brenzel, Allen J</b>	3048103877	\$162,216.	\$0.	\$162,216.
Eastern KY University UTC-IV-E Training (4-51200) / Title IV-E Administrative				
<b>De Leon, Jose</b>	3048103703	\$95,130.	\$0.	\$95,130.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
<b>De Leon, Jose</b>	3048103703	\$0.	\$-20,669.	\$-20,669.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
<b>De Leon, Jose</b>	3048103703	\$0.	\$20,669.	\$20,669.
Genomas Inc SBIR: DNA Diagnostics for Minimizing Side-Effects of Psychotropics				
<b>Glaser, Paul E</b>	3046770900	\$0.	\$167,999.	\$167,999.
National Institute of Mental Health ADHD, Stimulants and D4 Knockout Mice				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Psychiatry</b>				
<b>Glaser, Paul E</b>	3046986400	\$0.	\$1,764.	\$1,764.
Eli Lilly and Company				
Study of Atomoxetine HC1 in Treatment of Adults with ADHD & Comorbid Social Anxiety				
<b>Glaser, Paul E</b>	3046986400	\$0.	\$9,050.	\$9,050.
Eli Lilly and Company				
Study of Atomoxetine HC1 in Treatment of Adults with ADHD & Comorbid Social Anxiety				
<b>Glaser, Paul E</b>	3046986400	\$0.	\$13,010.	\$13,010.
Eli Lilly and Company				
Study of Atomoxetine HC1 in Treatment of Adults with ADHD & Comorbid Social Anxiety				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$9,342.	\$9,342.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$25,005.	\$25,005.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$19,021.	\$19,021.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,447.	\$1,447.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$259.	\$259.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,998.	\$1,998.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$2.	\$0.	\$2.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$10,496.	\$10,496.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$17,615.	\$17,615.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Psychiatry</b>				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$4,356.	\$4,356.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$4,760.	\$4,760.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,986.	\$1,986.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,685.	\$1,685.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$596.	\$596.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$3,232.	\$3,232.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$300.	\$300.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$1,103.	\$1,103.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$9,560.	\$9,560.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Glaser, Paul E</b>	3048103808	\$0.	\$4,334.	\$4,334.
Eli Lilly and Company				
A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
<b>Kaak, Hans O</b>		\$10,000.	\$0.	\$10,000.
KY Department for Public Health				
UK CATS Project: Early Mental Health Training				
<b>Lofwall, Michelle Renee</b>	3048103695	\$0.	\$1,023.	\$1,023.
CRS Associates LLC				
Product Familiarity Interview: Post marketing Surveillance Project for Subutex and Suboxone				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Psychiatry</b>				
<b>Lofwall, Michelle Renee</b>	3048103695	\$2.	\$0.	\$2.
CRS Associates LLC Product Familiarity Interview: Post marketing Surveillance Project for Subutex and Suboxone				
<b>Martin, Catherine A</b>		\$147,309.	\$0.	\$147,309.
Yaupon Therapeutics Inc SBIR: Lobeline Clinical Study in ADHD				
<b>Martin, Catherine A</b>	3048100600	\$0.	\$179,463.	\$179,463.
National Institute on Drug Abuse Modafinil and smoking cessation				
<b>Psychiatry Totals:</b>		<b>\$749,904.</b>	<b>\$489,404.</b>	<b>\$1,239,308.</b>
<b>Surgery</b>				
<b>Bernard, Andrew C</b>	3046720500	\$0.	\$315.	\$315.
Eli Lilly and Company Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Early Stage Severe Sepsis. Eli Lilly. 6/10/02				
<b>Bernard, Andrew C</b>	3048103668	\$40,000.	\$0.	\$40,000.
East Foundation Transfusion and T-Cell Receptor Expression				
<b>Bernard, Andrew C</b>	3048104408	\$0.	\$13,562.	\$13,562.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
<b>Bernard, Andrew C</b>	3048104408	\$2.	\$0.	\$2.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
<b>Chang, Phillip K</b>	3048103314	\$0.	\$6,978.	\$6,978.
Ortho Biotech Inc A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (epotin alfa: PROCRI) on Functional Outcomes in Anemic, Critically Ill, Blunt Trauma Subjects				
<b>Chang, Phillip K</b>	3048104448	\$3,695.	\$0.	\$3,695.
Eisai Medical Research Inc ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$8,060.	\$8,060.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$7,000.	\$7,000.
Medicure Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$1,000.	\$1,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$8,000.	\$8,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$26,000.	\$26,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$7,000.	\$7,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048079900	\$0.	\$12,000.	\$12,000.
Medicare Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk coronary Artery Bypass Graft (CABG) Surgery				
<b>Ferraris, Victor</b>	3048103733	\$2.	\$0.	\$2.
Nektar Inc An Open Label, Multicenter Study of the Safety, Tolerability, and Tissue Concentration of Amikan Delivered via Pulmonary Drug Delivery System - Project Cancelled by Sponsor				
<b>Ferraris, Victor</b>	3048103733	\$0.	\$1,998.	\$1,998.
Nektar Inc An Open Label, Multicenter Study of the Safety, Tolerability, and Tissue Concentration of Amikan Delivered via Pulmonary Drug Delivery System - Project Cancelled by Sponsor				
<b>Gagliardi, Raymond</b>	3048104040	\$70,000.	\$0.	\$70,000.
United States Surgical Corp Tyco Healthcare Minimally Invasive Surgery Fellowship				
<b>Johnston, Thomas</b>	3046533700	\$0.	\$3,000.	\$3,000.
Fujisawa Pharmaceuticals A Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation Vs. Long Term Maintenance Corticosteroid Therapy with Prograf and CellCept in Primary Renal Transplant Recipients				
<b>Johnston, Thomas</b>	3046533700	\$0.	\$2,520.	\$2,520.
Fujisawa Pharmaceuticals A Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation Vs. Long Term Maintenance Corticosteroid Therapy with Prograf and CellCept in Primary Renal Transplant Recipients				
<b>Johnston, Thomas</b>	3046661300	\$0.	\$1,700.	\$1,700.
Wyeth Research A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Johnston, Thomas</b>	3046661300	\$0.	\$4,365.	\$4,365.
Wyeth Research				
A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus vs Continued use of Calcineurin inhibitors in Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046816700	\$0.	\$630.	\$630.
Wyeth Pharmaceuticals Inc				
A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046816700	\$0.	\$7,522.	\$7,522.
Wyeth Pharmaceuticals Inc				
A Randomized, Open-label Study to Compare the Safety and Efficacy of Two Different Rapamune Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients				
<b>Johnston, Thomas</b>	3046944500	\$0.	\$18,586.	\$18,586.
Novartis				
A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
<b>Johnston, Thomas</b>	3046944500	\$0.	\$17,896.	\$17,896.
Novartis				
A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
<b>Johnston, Thomas</b>	3046944500	\$0.	\$12,063.	\$12,063.
Novartis				
A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$514.	\$514.
Bristol Myers Squibb Company				
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$3,086.	\$3,086.
Bristol Myers Squibb Company				
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$2,520.	\$2,520.
Bristol Myers Squibb Company				
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$1,543.	\$1,543.
Bristol Myers Squibb Company				
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$4,148.	\$4,148.
Bristol Myers Squibb Company				
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Johnston, Thomas</b>	3048064300	\$0.	\$2,057.	\$2,057.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
<b>Johnston, Thomas</b>	3048104315	\$0.	\$2,998.	\$2,998.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
<b>Johnston, Thomas</b>	3048104315	\$2.	\$0.	\$2.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
<b>Johnston, Thomas</b>	3048104407	\$0.	\$16,337.	\$16,337.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
<b>Johnston, Thomas</b>	3048104407	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
<b>Johnston, Thomas</b>	3048104532	\$2.	\$0.	\$2.
Novartis A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation				
<b>Kearney, Paul A</b>	3046969400	\$0.	\$88,121.	\$88,121.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
<b>Kearney, Paul A</b>	3046969400	\$0.	\$13,855.	\$13,855.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
<b>Kearney, Paul A</b>	3046969400	\$0.	\$14,394.	\$14,394.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
<b>Kearney, Paul A</b>	3048103545	\$0.	\$8,308.	\$8,308.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylalntrexone (MOA-728) for the Treatment of Post-Operative Ileus				
<b>Kearney, Paul A</b>	3048103545	\$0.	\$15,937.	\$15,937.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylalntrexone (MOA-728) for the Treatment of Post-Operative Ileus				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Kearney, Paul A</b>	3048103545	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post-Operative Ileus				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$14,375.	\$14,375.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$-450.	\$-450.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$23,854.	\$23,854.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kearney, Paul A</b>	3048104280	\$0.	\$9,721.	\$9,721.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kearney, Paul A</b>	3048104280	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$35,727.	\$35,727.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$1,215.	\$1,215.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$7,359.	\$7,359.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$19,912.	\$19,912.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$6,883.	\$6,883.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$24,027.	\$24,027.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046633200	\$0.	\$100.	\$100.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
<b>Kenady, Daniel E</b>	3046837300	\$0.	\$3,604.	\$3,604.
IRx Therapeutics Inc A Phase I Safety and Tolerability Study of Peri-Lymphatically Ultralow Dose IRX-2 in Patients with Squamous Cell Carcinoma of the Head and Neck Who Have Failed Surgery And/Or Radiation Therapy				
<b>Kenady, Daniel E</b>	3046919900	\$0.	\$1,059.	\$1,059.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
<b>Kenady, Daniel E</b>	3046919900	\$0.	\$11,972.	\$11,972.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
<b>Kenady, Daniel E</b>	3046919900	\$0.	\$879.	\$879.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
<b>Kyprianou, Natasha</b>	3046776300	\$0.	\$226,443.	\$226,443.
National Cancer Institute Anoikis Effect by Quinazolines on Prostate Growth				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>McKeown, John W</b>	3046972800	\$0.	\$22,470.	\$22,470.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
<b>McKeown, John W</b>	3046972800	\$0.	\$3,373.	\$3,373.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
<b>Mullett, Timothy</b>	3046871800	\$0.	\$2,610.	\$2,610.
Enzon Inc Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Mullett, Timothy</b>	3046871800	\$0.	\$10,231.	\$10,231.
Enzon Inc Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Mullett, Timothy</b>	3046871800	\$0.	\$1,512.	\$1,512.
Enzon Inc Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Mullett, Timothy</b>	3048104442	\$0.	\$1,260.	\$1,260.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Mullett, Timothy</b>	3048104442	\$0.	\$392.	\$392.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Mullett, Timothy</b>	3048104442	\$2.	\$0.	\$2.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$24,528.	\$24,528.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$13,335.	\$13,335.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$8,315.	\$8,315.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3046639300	\$0.	\$8,318.	\$8,318.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$1,800.	\$1,800.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$18,205.	\$18,205.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Ranjan, Dinesh</b>	3048103804	\$0.	\$950.	\$950.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Ranjan, Dinesh</b>	3048103804	\$2.	\$0.	\$2.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
<b>Rinker, Brian</b>		\$37,540.	\$0.	\$37,540.
Genzyme Corp An Evalutaion of the Relative Adhesion Reduction Efficacy of ACI-Maix Collagen Membrane and TenoGlide Tendon Protector Sheet in a Flexor Tendon Repair Model: A Histological Study				
<b>Rinker, Brian</b>	3048103773	\$0.	\$6,329.	\$6,329.
Genzyme Corp An Evalutaion of the Relative Adhesion Reduction Efficacy of ACI-Maix Collagen Membrane and TenoGlide Tendon Protector Sheet in a Flexor Tendon Repair Model: A Histological Study				
<b>Rinker, Brian</b>	3048103773	\$0.	\$7,706.	\$7,706.
Genzyme Corp An Evalutaion of the Relative Adhesion Reduction Efficacy of ACI-Maix Collagen Membrane and TenoGlide Tendon Protector Sheet in a Flexor Tendon Repair Model: A Histological Study				
<b>Rowland, Randall</b>	3046497900	\$0.	\$630.	\$630.
Antigenics A Multi Center Randomized Phase III Study of Oncophage Versus Observation in Patients with High Risk of Recurrence				
<b>Rowland, Randall</b>	3046497900	\$0.	\$200.	\$200.
Antigenics A Multi Center Randomized Phase III Study of Oncophage Versus Observation in Patients with High Risk of Recurrence				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Rowland, Randall</b>	3048104263	\$0.	\$265.	\$265.
Abt Associates Clinical Trials Inc International Survival Follow-Up Registry of Patients previously Enrolled in the Renal Cell Carcinoma Evaluations of Adjuvant Oncophage Treatment in the Antigenics C-100-12 (part 1)				
<b>Rowland, Randall</b>	3048104263	\$0.	\$3,298.	\$3,298.
Abt Associates Clinical Trials Inc International Survival Follow-Up Registry of Patients previously Enrolled in the Renal Cell Carcinoma Evaluations of Adjuvant Oncophage Treatment in the Antigenics C-100-12 (part 1)				
<b>Rowland, Randall</b>	3048104263	\$2.	\$0.	\$2.
Abt Associates Clinical Trials Inc International Survival Follow-Up Registry of Patients previously Enrolled in the Renal Cell Carcinoma Evaluations of Adjuvant Oncophage Treatment in the Antigenics C-100-12 (part 1)				
<b>Saha, Sibü</b>	3048103829	\$0.	\$50.	\$50.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$-655.	\$-655.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$4,810.	\$4,810.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$1,072.	\$1,072.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$655.	\$655.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$0.	\$125.	\$125.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048103829	\$2.	\$0.	\$2.
CVRx Inc Rheos Pivotal Trial				
<b>Saha, Sibü</b>	3048104218	\$0.	\$5,355.	\$5,355.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
<b>Saha, Sibü</b>	3048104218	\$0.	\$25,008.	\$25,008.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
<b>Saha, Sibü</b>	3048104218	\$2.	\$0.	\$2.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Stewart, Daniel</b>	3046819700	\$0.	\$303.	\$303.
Eli Lilly and Company Potential Mitigation of Reperfusion Injury in Skeletal Muscle Using Xigris (Activated Protein C)				
<b>Strup, Stephen</b>	3046954800	\$0.	\$630.	\$630.
Antigenics A Multi-Center, Randomized Phase 3 Study of Adjuvant Oncophage vs. Observation in Patients with High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma				
<b>Tibbs, Phillip A</b>	3046722800	\$0.	\$3,849.	\$3,849.
DePuy Spine A Post-Approval Evaluation of the Lumbar I/F Cage with VSP Spine System for PLIF				
<b>Tibbs, Phillip A</b>	3046722800	\$0.	\$15,060.	\$15,060.
DePuy Spine A Post-Approval Evaluation of the Lumbar I/F Cage with VSP Spine System for PLIF				
<b>Tibbs, Phillip A</b>	3048082800	\$0.	\$73,156.	\$73,156.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
<b>Tibbs, Phillip A</b>	3048104419	\$2.	\$0.	\$2.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
<b>Tobrek, Michal</b>	3046920100	\$0.	\$212,091.	\$212,091.
Philip Morris Inc Nicotine-Mediated Neuroprotection in Spinal Cord Injury				
<b>Tobrek, Michal</b>	3046928600	\$0.	\$266,666.	\$266,666.
National Institute of Neurological Disorders & Stroke Tat-Mediated Brain Endothelial Cell Dysfunction				
<b>Tobrek, Michal</b>	3046939200	\$0.	\$277,817.	\$277,817.
National Institute of Mental Health Tat, Amyloid Beta and Brain Endothelial Barrier Function				
<b>Tobrek, Michal</b>	3048104102	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Nanoparticle-Induced Dysfunction of Brain Endothelial Cells and Disruption of the Blood-Brain Barrier				
<b>Waid, Thomas</b>	3046750500	\$0.	\$1,817.	\$1,817.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046750500	\$0.	\$-630.	\$-630.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				
<b>Waid, Thomas</b>	3046750500	\$0.	\$7,269.	\$7,269.
Roche Pharmaceutical Research Associates Inc An Open Label, Randomized, Multicenter Study To Evaluate The Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil and Sirolimus				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Waid, Thomas</b>	3046863600	\$0.	\$7,829.	\$7,829.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$630.	\$630.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$26,757.	\$26,757.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$5,795.	\$5,795.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$10,358.	\$10,358.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3046863600	\$0.	\$1,726.	\$1,726.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Comb				
<b>Waid, Thomas</b>	3048033900	\$0.	\$600.	\$600.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs. Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose				
<b>Waid, Thomas</b>	3048033900	\$0.	\$900.	\$900.
Roche Laboratories				
An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs. Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose				
<b>Waid, Thomas</b>	3048103550	\$0.	\$-5,606.	\$-5,606.
Astellas Pharma US Inc				
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Waid, Thomas</b>	3048103550	\$0.	\$5,606.	\$5,606.
Astellas Pharma US Inc				
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Surgery</b>				
<b>Waid, Thomas</b>	3048103550	\$0.	\$1,148.	\$1,148.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Waid, Thomas</b>	3048103550	\$0.	\$3,444.	\$3,444.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
<b>Wang, Dongfang</b>	3048104357	\$56,326.	\$0.	\$56,326.
S P Tech Inc TransAortic Valve Pump for Urgent Left Heart Support				
<b>Wang, Dongfang</b>	3048104405	\$50,000.	\$0.	\$50,000.
Avalon Laboratories LLC Smart Cannulae				
<b>Young, Alfred B</b>	3046744600	\$0.	\$2,211.	\$2,211.
IVAX Research Inc A Multicenter Phase II Study of TP-38 in those Patients with Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection				
<b>Young, Alfred B</b>	3046744600	\$0.	\$4,159.	\$4,159.
IVAX Research Inc A Multicenter Phase II Study of TP-38 in those Patients with Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection				
<b>Young, Alfred B</b>	3046775300	\$0.	\$58,200.	\$58,200.
Xenova A Phase III Multicenter Study of Intratumoral/Interstitial Therapy with TransMID Compared to Best Standard of Care in Patients with Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme				
<b>Young, Alfred B</b>	3048103840	\$2.	\$0.	\$2.
Virginia Commonwealth University A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury				
<b>Young, Alfred B</b>	3048104383	\$162,159.	\$0.	\$162,159.
National Institute of Neurological Disorders & Stroke CASTBI Trial Planning Grant: Cyclosporine in Traumatic Brain Injury				
<b>Yurek, David M</b>	3046851500	\$0.	\$244,461.	\$244,461.
National Institute of Neurological Disorders & Stroke Stem Cell Adaptability in Parkinson's Disease				
<b>Yurek, David M</b>	3046851500	\$0.	\$61,115.	\$61,115.
National Institute of Neurological Disorders & Stroke Stem Cell Adaptability in Parkinson's Disease				
<b>Zhao, Hong-Bo</b>	3046808200	\$0.	\$241,240.	\$241,240.
National Institute on Deafness & Other Communications Functional Analysis of Inner Ear Gap Junctions				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

	New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>			
<b>Surgery</b>			
<b>Zhao, Hong-Bo</b> 3046808200 National Institute on Deafness & Other Communications Functional Analysis of Inner Ear Gap Junctions	\$0.	\$244,418.	\$244,418.
<b>Zwischenberger, Joseph</b> 3048104027 Collagenex Pharmaceuticals Inc Modified Tetracycline Effect on Sepsis Induced Mortality	\$121,403.	\$0.	\$121,403.
<b>Zwischenberger, Joseph</b> 3048104319 Compact Membrane Systems Inc Enhanced Long-Term Care of Severe Respiratory Failure	\$223,609.	\$0.	\$223,609.
<b>Surgery Totals:</b>	<b>\$784,760.</b>	<b>\$2,666,059.</b>	<b>\$3,450,819.</b>
<b>Neurology</b>			
<b>Bensalem Owen, Meriem Katre nec</b> 3048058400 Ortho McNeil Pharmaceuticals A Double-Blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy	\$0.	\$2,618.	\$2,618.
<b>Bensalem Owen, Meriem Katre nec</b> 3048058400 Ortho McNeil Pharmaceuticals A Double-Blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy	\$0.	\$13,245.	\$13,245.
<b>Bensalem Owen, Meriem Katre nec</b> 3048058400 Ortho McNeil Pharmaceuticals A Double-Blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy	\$0.	\$178.	\$178.
<b>Bensalem Owen, Meriem Katre nec</b> 3048058400 Ortho McNeil Pharmaceuticals A Double-Blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects with Seizures Indicative of New Onset Epilepsy	\$0.	\$3,750.	\$3,750.
<b>Bensalem Owen, Meriem Katre nec</b> 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$156.	\$156.
<b>Bensalem Owen, Meriem Katre nec</b> 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$319.	\$319.
<b>Bensalem Owen, Meriem Katre nec</b> 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$15,395.	\$15,395.
<b>Bensalem Owen, Meriem Katre nec</b> 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$2.	\$0.	\$2.

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Berger, Joseph R</b>	3046728000	\$0.	\$600.	\$600.
Cleveland Clinic Foundation				
A Multicenter Randomized Blinded Parallel Group Study of AVONEX in Combination with Oral Methotrexate Intravenous Methylprednisolone or Both in Subjects with Relapsing Remitting Multiple Sclerosis Who Have Breakthrough Disease on Avonex Monotherapy				
<b>Berger, Joseph R</b>	3046765100	\$0.	\$4,665.	\$4,665.
Berlex Laboratories Inc				
International Randomized Multicenter Phase III Study in Patients with Relapsing Remitting Multiple Sclerosis Comparing Over a Treatment Period of 104 Weeks: BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose				
<b>Berger, Joseph R</b>	3046951500	\$0.	\$13,779.	\$13,779.
Berlex Laboratories Inc				
Subtle Abnormalities in Normal Appearing White Matter of Relapsing-Remitting MS Patients and the Responses to Interferon-Beta: A Pilot Study				
<b>Berger, Joseph R</b>	3048102204	\$0.	\$27,442.	\$27,442.
UCB Pharma				
Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
<b>Berger, Joseph R</b>	3048102204	\$0.	\$3,150.	\$3,150.
UCB Pharma				
Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
<b>Berger, Joseph R</b>	3048102204	\$0.	\$9,320.	\$9,320.
UCB Pharma				
Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
<b>Berger, Joseph R</b>	3048103649	\$0.	\$49,000.	\$49,000.
Pfizer Inc				
JCV Expression During Treatment with MS Disease Modifying Drugs				
<b>Berger, Joseph R</b>	3048103649	\$0.	\$48,998.	\$48,998.
Pfizer Inc				
JCV Expression During Treatment with MS Disease Modifying Drugs				
<b>Berger, Joseph R</b>	3048103649	\$2.	\$0.	\$2.
Pfizer Inc				
JCV Expression During Treatment with MS Disease Modifying Drugs				
<b>Berger, Joseph R</b>	3048104087	\$0.	\$3,685.	\$3,685.
PPD Development Inc				
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
<b>Berger, Joseph R</b>	3048104087	\$0.	\$7,626.	\$7,626.
PPD Development Inc				
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Berger, Joseph R</b>	3048104087	\$2.	\$0.	\$2.
PPD Development Inc				
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
<b>Cambi, Franca</b>	3048079000	\$0.	\$320,469.	\$320,469.
National Institute of Neurological Disorders & Stroke				
PLP Alternative Splicing and Oligodendrocyte Differentiation				
<b>Cambi, Franca</b>	3048104458	\$137,468.	\$0.	\$137,468.
National Institute of Neurological Disorders & Stroke				
Neuroprotection Exploratory Trials in PD (NET-PD)				
<b>Fakhoury, Toufic A</b>	3046747200	\$0.	\$904.	\$904.
Schwarz BioSciences Inc				
A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3046747200	\$0.	\$676.	\$676.
Schwarz BioSciences Inc				
A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3046747200	\$0.	\$904.	\$904.
Schwarz BioSciences Inc				
A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3046755700	\$0.	\$3,141.	\$3,141.
GlaxoSmithKline				
LAM40124 An Assesment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy				
<b>Fakhoury, Toufic A</b>	3046755700	\$0.	\$3,483.	\$3,483.
GlaxoSmithKline				
LAM40124 An Assesment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy				
<b>Fakhoury, Toufic A</b>	3046777300	\$0.	\$3,979.	\$3,979.
Scirex				
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400 and 600mg/day) as Adjunctive Therapy in Subjects with Partial Seizures with or without Secondary Generalization				
<b>Fakhoury, Toufic A</b>	3046843900	\$0.	\$16,234.	\$16,234.
Schwarz BioSciences Inc				
An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
<b>Fakhoury, Toufic A</b>	3046843900	\$0.	\$9,410.	\$9,410.
Schwarz BioSciences Inc				
An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Fakhoury, Toufic A</b>	3046870900	\$0.	\$800.	\$800.
GlaxoSmithKline A Multicenter, Double Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended Release Adjunctive Therapy in Subjects with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3046870900	\$0.	\$650.	\$650.
GlaxoSmithKline A Multicenter, Double Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended Release Adjunctive Therapy in Subjects with Partial Seizures				
<b>Fakhoury, Toufic A</b>	3046978500	\$0.	\$5,616.	\$5,616.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3046978500	\$0.	\$17,534.	\$17,534.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 MG/DAY) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048091100	\$0.	\$3,778.	\$3,778.
Johnson and Johnson A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by and Open-Label Extension Study				
<b>Fakhoury, Toufic A</b>	3048094100	\$0.	\$1,987.	\$1,987.
GlaxoSmithKline A Multi-Center, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048094100	\$0.	\$1,456.	\$1,456.
GlaxoSmithKline A Multi-Center, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048094100	\$0.	\$1,738.	\$1,738.
GlaxoSmithKline A Multi-Center, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048094100	\$0.	\$2,611.	\$2,611.
GlaxoSmithKline A Multi-Center, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048103108	\$0.	\$207.	\$207.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048103108	\$0.	\$18,666.	\$18,666.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Fakhoury, Toufic A</b>	3048103108	\$0.	\$13,639.	\$13,639.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
<b>Fakhoury, Toufic A</b>	3048103882	\$0.	\$3,148.	\$3,148.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103882	\$0.	\$14,352.	\$14,352.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103882	\$2.	\$0.	\$2.
UCB Pharma An International, Double-Blind, Parallel-Group, Placebo-Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (16 to 70 years old) with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103891	\$0.	\$10,626.	\$10,626.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048103891	\$2.	\$0.	\$2.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104048	\$0.	\$1,498.	\$1,498.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104048	\$2.	\$0.	\$2.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104396	\$2.	\$0.	\$2.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
<b>Fakhoury, Toufic A</b>	3048104533	\$0.	\$3,148.	\$3,148.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104533	\$0.	\$-10,626.	\$-10,626.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Fakhoury, Toufic A</b>	3048104533	\$0.	\$10,626.	\$10,626.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104533	\$2.	\$0.	\$2.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104574	\$0.	\$6,970.	\$6,970.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104574	\$2.	\$0.	\$2.
Ortho McNeil Pharmaceuticals A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures				
<b>Fakhoury, Toufic A</b>	3048104596	\$0.	\$3,148.	\$3,148.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
<b>Fakhoury, Toufic A</b>	3048104596	\$2.	\$0.	\$2.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$6,150.	\$6,150.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$1,060.	\$1,060.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048103412	\$0.	\$5,767.	\$5,767.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
<b>Houff, Sidney A</b>	3048104530	\$2.	\$0.	\$2.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Kasarskis, Edward J</b>	3048097600	\$0.	\$1,599.	\$1,599.
Columbia University Clinical Trial of High Dose COQ10 in ALS				
<b>Maragos, William F</b>		\$100,000.	\$0.	\$100,000.
American Heart Association Targeted Mitochondrial Uncoupling in Focal Cerebral Ischemia				
<b>Nelson, Kevin R</b>	3046886000	\$0.	\$7,458.	\$7,458.
Allergan Pharmaceuticals Inc Placebo Controlled Trial of BOTOX versus Zanaflex for the Treatment of Subjects with Post-Stroke Upper Limb Spasticity				
<b>Pettigrew, Luther C</b>	3046450600	\$0.	\$899.	\$899.
Mayo Foundation Siblings with Ischemic Stroke (SWISS)				
<b>Pettigrew, Luther C</b>	3046617600	\$0.	\$4,620.	\$4,620.
University of Medicine and Dentistry of NJ Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Study				
<b>Pettigrew, Luther C</b>	3046617600	\$0.	\$1,000.	\$1,000.
University of Medicine and Dentistry of NJ Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Study				
<b>Pettigrew, Luther C</b>	3046617600	\$0.	\$200.	\$200.
University of Medicine and Dentistry of NJ Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Study				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$100.	\$100.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$5,000.	\$5,000.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$1,000.	\$1,000.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$2,600.	\$2,600.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$200.	\$200.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Neurology</u></b>				
<b>Pettigrew, Luther C</b>	3046749700	\$0.	\$1,050.	\$1,050.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$2,820.	\$2,820.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$17,908.	\$17,908.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$2,367.	\$2,367.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$1,022.	\$1,022.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$6,699.	\$6,699.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$2,767.	\$2,767.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3046858700	\$0.	\$10,055.	\$10,055.
Yale University Insulin Intervention after Stroke (IRIS) Trial				
<b>Pettigrew, Luther C</b>	3048038100	\$0.	\$27,103.	\$27,103.
Miami University Albumin in Stroke (ALIAS) Trial				
<b>Pettigrew, Luther C</b>	3048038100	\$0.	\$24,905.	\$24,905.
Miami University Albumin in Stroke (ALIAS) Trial				
<b>Pettigrew, Luther C</b>	3048038100	\$0.	\$3,662.	\$3,662.
Miami University Albumin in Stroke (ALIAS) Trial				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$23,994.	\$23,994.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$7,000.	\$7,000.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$12,993.	\$12,993.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$12,997.	\$12,997.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Pettigrew, Luther C</b>	3048103228	\$0.	\$18,995.	\$18,995.
Parexel International Co NeuroThera Effectiveness and Safety Trial - 2 (NEST-2)				
<b>Pettigrew, Luther C</b>	3048103735	\$2.	\$0.	\$2.
Columbia University Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF).				
<b>Pettigrew, Luther C</b>	3048104020	\$89,874.	\$0.	\$89,874.
Medical College of Georgia Minocycline to Improve Neurologic Outcomes				
<b>Pettigrew, Luther C</b>	3048104660	\$110,035.	\$0.	\$110,035.
Medical College of Georgia Minocycline to Improve Neurologic Outcomes				
<b>Slevin, John T</b>	3046949900	\$0.	\$2,577.	\$2,577.
AMGen A Multi-Center, Observational Safety Registry of Subjects with Idiopathic Parkinson's Disease Previously Treated with Intraputaminial Infusion of Liaternin				
<b>Slevin, John T</b>	3046949900	\$0.	\$700.	\$700.
AMGen A Multi-Center, Observational Safety Registry of Subjects with Idiopathic Parkinson's Disease Previously Treated with Intraputaminial Infusion of Liaternin				
<b>Slevin, John T</b>	3046992500	\$0.	\$1,250.	\$1,250.
Boston University Genetic Linkage Study in Parkinson's Disease				
<b>Slevin, John T</b>	3048031200	\$0.	\$4,803.	\$4,803.
University of Rochester Study of Anti-Depressants in Parkinson's Disease (SAD PD)				
<b>Slevin, John T</b>	3048072800	\$0.	\$2,684.	\$2,684.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048072800	\$0.	\$740.	\$740.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048072800	\$0.	\$1,731.	\$1,731.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048072800	\$0.	\$3,152.	\$3,152.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Neurology</u></b>				
<b>Slevin, John T</b>	3048072800	\$0.	\$4,222.	\$4,222.
Quintiles Inc A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048103525	\$0.	\$2,402.	\$2,402.
University of Rochester Study of Anti-Depressants in Parkinson's Disease (SAD PD)				
<b>Slevin, John T</b>	3048103525	\$0.	\$1,199.	\$1,199.
University of Rochester Study of Anti-Depressants in Parkinson's Disease (SAD PD)				
<b>Slevin, John T</b>	3048103525	\$2.	\$0.	\$2.
University of Rochester Study of Anti-Depressants in Parkinson's Disease (SAD PD)				
<b>Slevin, John T</b>	3048103836	\$35,000.	\$0.	\$35,000.
American Parkinsons Disease Association American Parkinson Disease Association Information Center				
<b>Slevin, John T</b>	3048104006	\$0.	\$215.	\$215.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048104006	\$0.	\$14,531.	\$14,531.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
<b>Slevin, John T</b>	3048104006	\$2.	\$0.	\$2.
Quintiles Inc A Multi-Centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinsons' Disease Patients with Motor Fluctuations				
<b>Smith, Charles D</b>	3048104409	\$2.	\$0.	\$2.
Neuronetrix Inc Evaluation of Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$9,480.	\$9,480.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$-4,330.	\$-4,330.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$15,955.	\$15,955.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$3,410.	\$3,410.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$10,940.	\$10,940.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$4,240.	\$4,240.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$2,210.	\$2,210.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$11,670.	\$11,670.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$5,740.	\$5,740.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$3,060.	\$3,060.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$2,520.	\$2,520.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046746400	\$0.	\$5,880.	\$5,880.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$600.	\$600.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$1,465.	\$1,465.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$887.	\$887.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3046788400	\$0.	\$356.	\$356.
Boehringer Ingelheim Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo-Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis (PRoFESS)				
<b>Vaishnav, Anand G</b>	3046973900	\$0.	\$-1,276.	\$-1,276.
Novo Nordisk Pharmaceuticals Inc Trial of Activated Recombinant Factor VII (NovoSeven/Niastase) in Acute Intracerebral Haemorrhage				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Neurology</b>				
<b>Vaishnav, Anand G</b>	3048009000	\$0.	\$8,600.	\$8,600.
Forest Laboratories Inc Desmoteplase (INN) in Acute Ischemic Stroke (DIAS-2)				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$1,932.	\$1,932.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$100.	\$100.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Vaishnav, Anand G</b>	3048103205	\$0.	\$100.	\$100.
Merck and Company Inc A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke				
<b>Neurology</b>	<b>Totals:</b>	<b>\$472,407.</b>	<b>\$1,012,433.</b>	<b>\$1,484,840.</b>
<b>Ophthalmology</b>				
<b>Ambati, Jayakrishna</b>	3046814400	\$0.	\$185,345.	\$185,345.
Quark Biotech Inc Assessment of the Validity of RTP801 as a Target for Treatment of AMD in Laser-induced CNV				
<b>Ambati, Jayakrishna</b>	3048084100	\$0.	-\$65,559.	-\$65,559.
BioCryst Pharmaceuticals Inc Assessment of BCX 1470 in inhibiting complement generation, inflammation and angiogenesis in CNV				
<b>Ambati, Jayakrishna</b>	3048102202	\$150,000.	\$0.	\$150,000.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
<b>Ambati, Jayakrishna</b>	3048103629	\$362,763.	\$0.	\$362,763.
National Eye Institute Pro- and Anti-Angiogenic Effect of Vascular Endothelial Growth Factor-A				
<b>Ambati, Jayakrishna</b>	3048104229	\$0.	\$22,970.	\$22,970.
Taigen Biotechnology Co Ltd Taigen Antagonist: Prevention and Regression of Laser-Induced Choroidal Neovascularization.				
<b>Ambati, Jayakrishna</b>	3048104229	\$2.	\$0.	\$2.
Taigen Biotechnology Co Ltd Taigen Antagonist: Prevention and Regression of Laser-Induced Choroidal Neovascularization.				
<b>Ambati, Jayakrishna</b>	3048104317	\$60,000.	\$0.	\$60,000.
Research to Prevent Blindness Physician Scientist Award				
<b>Ambati, Jayakrishna</b>	3048104491	\$366,250.	\$0.	\$366,250.
National Eye Institute Intrinsic Anti-Angiogenic Activity of siRNA				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Ophthalmology</b>				
<b>Ambati, Jayakrishna</b>	3048104528	\$104,878.	\$0.	\$104,878.
Taligen Therapeutics Inc Taligen Antibody in laser-induced choroidal neovascularization				
<b>Blackburn, Peter</b>	3046948500	\$0.	\$59,285.	\$59,285.
Control Delivery Systems Inc A Randomized, Double-Masked, Parallel Group, Multi-Center Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 pg/day and				
<b>Capoor, Seema</b>	3048044500	\$0.	\$1,429.	\$1,429.
Bausch and Lomb A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis				
<b>Capoor, Seema</b>	3048044500	\$0.	\$6,789.	\$6,789.
Bausch and Lomb A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis				
<b>Fannon, Michael</b>	3048088600	\$0.	\$66,200.	\$66,200.
National Heart Lung and Blood Institute Computer Modeling of Perlecan as a Vascular Regulator				
<b>Fannon, Michael</b>	3048088600	\$0.	\$264,797.	\$264,797.
National Heart Lung and Blood Institute Computer Modeling of Perlecan as a Vascular Regulator				
<b>Mohan, Royce</b>	3048103665	\$366,250.	\$0.	\$366,250.
National Eye Institute Molecular Targets of Corneal Antianangiogenesis				
<b>Pearson, Paul A</b>	3046445300	\$0.	\$100.	\$100.
Bausch and Lomb A Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of Intravitreal Fluocinolone (0.6, 2.1 mg) Implant in Patients with Diabetic Macular Edema.				
<b>Pearson, Paul A</b>	3046860300	\$0.	\$55,000.	\$55,000.
Research to Prevent Blindness Research To Prevent Blindness Challenge Grant				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$1,392.	\$1,392.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$1,392.	\$1,392.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$20,586.	\$20,586.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				
<b>Pearson, Paul A</b>	3048050700	\$0.	\$4,410.	\$4,410.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion( SCORE) Study				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b>Ophthalmology</b>				
<b>Pearson, Paul A</b>	3048083400	\$0.	\$50.	\$50.
QLT Inc Registry of Visudyne AMD Therapy (RVT 001)				
<b>Pearson, Paul A</b>	3048104093	\$2.	\$0.	\$2.
University of Utah Genetics of Macular Degeneration				
<b>Raisler, Brian J</b>	3048081400	\$0.	\$50,000.	\$50,000.
Research to Prevent Blindness The Role of Cellular Immunity in Neovascular Ischemic Retinopathies				
<b>Ophthalmology</b>	<b>Totals:</b>	<b>\$1,410,145.</b>	<b>\$674,186.</b>	<b>\$2,084,331.</b>
<b>Orthopaedic Surgery</b>				
<b>Johnson, Darren L</b>	3048104608	\$20,000.	\$0.	\$20,000.
Smith and Nephew Richards Inc CT and Radiographic Evaluation of Hamstring ACL Reconstruction with Bioabsorbable Screw Fixation				
<b>Orthopaedic Surgery</b>	<b>Totals:</b>	<b>\$20,000.</b>	<b>\$0.</b>	<b>\$20,000.</b>
<b>Radiation Medicine</b>				
<b>Kudrimoti, Mahesh</b>	3046880600	\$0.	\$7,416.	\$7,416.
AMGen A Phase 3 Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy				
<b>Kudrimoti, Mahesh</b>	3048044300	\$0.	\$5,870.	\$5,870.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				
<b>Kudrimoti, Mahesh</b>	3048044300	\$0.	\$9,580.	\$9,580.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				
<b>Kudrimoti, Mahesh</b>	3048044300	\$0.	\$2,748.	\$2,748.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				
<b>Kudrimoti, Mahesh</b>	3048104578	\$2.	\$0.	\$2.
Endo Pharmaceutical Inc A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled study to assess the Efficacy and Safety of ENDO3285 for Prevention or Delay to Onset of Severe Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy				
<b>McGarry, Ronald</b>	3046594300	\$0.	\$3,000.	\$3,000.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
<b>McGarry, Ronald</b>	3046594300	\$0.	\$5,150.	\$5,150.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Medicine</u></b>				
<b><u>Radiation Medicine</u></b>				
<b>McGarry, Ronald</b>	3046594300	\$0.	\$27,550.	\$27,550.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
<b>Randall, Marcus</b>	3048104462	\$8,800.	\$0.	\$8,800.
Gynecologic Oncology Group Chair or Co-Chair of the Corpus Committee				
<b>Rangnekar, Vivek M</b>	3046761100	\$0.	\$57,264.	\$57,264.
National Cancer Institute Novel Mechanisms of PTEN Gene Regulation				
<b>Rangnekar, Vivek M</b>	3046761100	\$0.	\$229,055.	\$229,055.
National Cancer Institute Novel Mechanisms of PTEN Gene Regulation				
<b>Rangnekar, Vivek M</b>	3046936200	\$0.	\$246,909.	\$246,909.
National Cancer Institute Regulation of Cell Survival and Tumor Progression by AKT				
<b>Sellitti, Marguerite</b>	3046859800	\$0.	\$875.	\$875.
American Cancer Society Transportation Grant- Satellites				
<b>Sellitti, Marguerite</b>	3046859800	\$0.	\$875.	\$875.
American Cancer Society Transportation Grant- Satellites				
<b>Sellitti, Marguerite</b>	3046859800	\$0.	\$1,740.	\$1,740.
American Cancer Society Transportation Grant- Satellites				
<b>Sellitti, Marguerite</b>	3046859800	\$0.	\$830.	\$830.
American Cancer Society Transportation Grant- Satellites				
<b>Soleimani Meigooni, Ali</b>	3046742400	\$0.	\$-3,500.	\$-3,500.
IsoAid LLC Dosimetric Characterization of the isoAid Pd-103 Brachytherapy Source				
<b>Soleimani Meigooni, Ali</b>	3048001000	\$0.	\$13,829.	\$13,829.
RadioMed Domestic Characterization of the RadioCoil pd-103 Brachytherapy Wires				
<b>St Clair, William H</b>	3048103792	\$270,998.	\$0.	\$270,998.
National Cancer Institute Redox Modulation Of Prostate Cancer				
<b>Radiation Medicine</b>	<b>Totals:</b>	<b>\$279,800.</b>	<b>\$609,191.</b>	<b>\$888,991.</b>
<b><u>Physical Medicine and Rehabilitation</u></b>				
<b>Adams, Lumy Sawaki</b>	3048104590	\$65,000.	\$0.	\$65,000.
American Heart Association Enhancing Cortical Plasticity with Nerve Stimulation in Stroke Patients with Severe Motor Deficit				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Medicine</b>				
<b><u>Physical Medicine and Rehabilitation</u></b>				
<b>Adams, Lumy Sawaki</b>	3048104591	\$295,500.	\$0.	\$295,500.
National Institute of Child Health and Human Development Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients				
<b>Adams, Lumy Sawaki</b>	3048104592	\$11,340.	\$0.	\$11,340.
National Institute of Child Health and Human Development Driving Neuroplasticity with Nerve Stimulation and Modified CIT				
<b>McEwen, Melanie L</b>	3048104272	\$108,053.	\$0.	\$108,053.
Craig H Neilsen Foundation NIM811 Treatment for Pediatric Spinal Cord Injury				
<b>Springer, Joe E</b>	3048104366	\$98,588.	\$0.	\$98,588.
KY Spinal Cord and Head Injury Research Trust Therapeutic Potential of NEU2000, A Dual Acting Pharmacological Agent in the Treatment of Acute Spinal Cord Injury				
<b>Physical Medicine and Rehabilitation</b>	<b>Totals:</b>	<b>\$578,481.</b>	<b>\$0.</b>	<b>\$578,481.</b>
	<b>Medicine Totals:</b>	<b>\$54,732,592.</b>	<b>\$52,438,800.</b>	<b>\$107,171,392.</b>
<b>Pharmacy</b>				
<b><u>Pharmacy</u></b>				
<b>Loftin, Charles D</b>	3048002800	\$0.	\$21,000.	\$21,000.
American Heart Association Ohio Valley Affiliate Julie Oestreich Fellowship: The Effects of P2Y12 Polymorphism on Platelet Receptor Density and Activation				
<b>MUMPER, RUSSELL J</b>	3046879800	\$0.	\$-148,278.	\$-148,278.
National Institute of Allergy and Infectious Diseases Nanoparticle HIV Protein Vaccines for Cellular Responses				
<b>MUMPER, RUSSELL J</b>	3046988600	\$0.	\$-223,666.	\$-223,666.
National Cancer Institute EGF-Receptor Targeted nanoparticles to Overcome Paclitaxel Resistant Breast Cancer				
<b>STINCHCOMB, AUDRA L.</b>		\$16,255.	\$0.	\$16,255.
AllTranz Evaluation of Adjuvants for Microneedle Drug Delivery				
<b>STINCHCOMB, AUDRA L.</b>	3048103101	\$0.	\$282,831.	\$282,831.
National Institute on Drug Abuse Naltrexone Prodrugs for transdermal Delivery				
<b>Pharmacy</b>	<b>Totals:</b>	<b>\$16,255.</b>	<b>\$-68,113.</b>	<b>\$-51,858.</b>
<b><u>Pharmaceutical Tech</u></b>				
<b>Al-Ghananeem, Abeer</b>	3048103648	\$12,371.	\$0.	\$12,371.
Airmid Inc Formulation Development for Water Insoluble Novel Compound PAP-1				
<b>Al-Ghananeem, Abeer</b>	3048103759	\$8,815.	\$0.	\$8,815.
University of California Davis Formulation Development for Acid Labile Novel Compound TRAM-34				
<b>Al-Ghananeem, Abeer</b>	3048103825	\$0.	\$-49,839.	\$-49,839.
US Worldmeds LLC Formulation Development of Intravenous and Oral Dosage Forms				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Pharmacy</b>				
<b>Pharmaceutical Tech</b>				
<b>Al-Ghananeem, Abeer</b>	3048103825	\$121,551.	\$0.	\$121,551.
US Worldmeds LLC Formulation Development of Intravenous and Oral Dosage Forms				
<b>ANDERSON, BRADLEY D.</b>	3048081600	\$0.	\$117,112.	\$117,112.
Arno Therapeutics Inc Stability and Pharmacokinetic Studies of DB-67 and DB-67/SBE-CD Formulations				
<b>Black, Esther P</b>	3048103763	\$71,776.	\$0.	\$71,776.
KY Lung Cancer Research Fund Dusp4 Activity in Non-Small Cell Lung Cancers: An Opportunity for Intervention?				
<b>Bummer, Paul M</b>	3048103769	\$290,101.	\$0.	\$290,101.
National Cancer Institute Development of Dosage Forms and Delivery Systems for Anti-Tumor Agents				
<b>Crooks, Peter A</b>	3046581000	\$0.	\$98,950.	\$98,950.
US Worldmeds LLC KSTC R & D Voucher: Product development and formulation				
<b>Crooks, Peter A</b>	3046698800	\$0.	\$40,147.	\$40,147.
Yaupon Therapeutics Inc Post Doctoral Fellowship				
<b>Crooks, Peter A</b>	3046831000	\$0.	\$63,272.	\$63,272.
Washington University Radiosensitization by the Cellular Heat Shock Response				
<b>Crooks, Peter A</b>	3046989300	\$0.	\$7,350.	\$7,350.
Yaupon Therapeutics Inc Lobeline Epimer Ratio Determination Study				
<b>Crooks, Peter A</b>	3048104281	\$76,561.	\$0.	\$76,561.
Pradama Inc Novel Bone-Targeting Agents				
<b>Crooks, Peter A</b>	3048104361	\$76,788.	\$0.	\$76,788.
University of Rochester A Novel Thiadiazolidine-Dione Targets Human Leukemia Stem Cells				
<b>Crooks, Peter A</b>	3048104752	\$150,000.	\$0.	\$150,000.
Yaupon Therapeutics Inc Nornicotine For the Treatment of Addiction				
<b>Deluca, Patrick P</b>	3046058100	\$0.	\$156,870.	\$156,870.
Oakwood Laboratories Development of Sustained Drug Delivery Microspheres for Clinical Trials				
<b>Deluca, Patrick P</b>	3046750700	\$0.	\$120,000.	\$120,000.
US Army Research Office Development of a Sustained Antiplateau, Antimicrobial Delivery System for KSL Localized in the Oral Cavity				
<b>Deluca, Patrick P</b>	3046909100	\$0.	\$89,974.	\$89,974.
Swedish Match North America Inc Development of a Microencapsulated System for Food Flavors				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Pharmacy</b>				
<b>Pharmaceutical Tech</b>				
<b>Deluca, Patrick P</b>	3048102700	\$0.	\$-20,000.	\$-20,000.
NexGenex Pharmaceuticals LLC Doxycycline Formulation Strategy for the Treatment of Dermal Neurofibromas				
<b>Dwoskin, Linda P</b>	3046930400	\$0.	\$531,621.	\$531,621.
National Institute on Drug Abuse Development of Novel Therapies for Methamphetamine Abuse				
<b>Dwoskin, Linda P</b>	3048103421	\$21,000.	\$0.	\$21,000.
American Heart Association Ohio Valley Affiliate Fellowship for Vidya Narayanaswami: The Role of Angiotensin in Nicotine Reward and Nicotine Induced Hypertension				
<b>Dwoskin, Linda P</b>	3048103627	\$1,290,333.	\$0.	\$1,290,333.
National Institute on Drug Abuse Development of Novel Treatments for Nicotine Addiction - Admin Core				
<b>Graf, Gregory Allen</b>	3048104273	\$65,000.	\$0.	\$65,000.
American Heart Association Formation, Folding and Trafficking of the ABCG5 ABCG8 Sterol Transporter				
<b>Jay, Michael J</b>	3048104037	\$3,956,620.	\$0.	\$3,956,620.
National Institute of Allergy and Infectious Diseases Development of Improved DTPA for Radionuclide Chelation				
<b>Kim, Kyung Bo</b>	3048104323	\$12,532.	\$0.	\$12,532.
University of Louisville Mechanisms for Gender Differences in Lung Adenocarcinoma: Estrogen Action in Lung Adenocarcinoma				
<b>Kim, Kyung Bo</b>	3048104666	\$27,835.	\$0.	\$27,835.
Baylor University Medical Center To Degrade or Not To Degrade: Targeting the Androgen Receptor in AR Dependent Prostate Cancer				
<b>Leggas, Markos</b>	3048080300	\$0.	\$36,251.	\$36,251.
NanoMed Pharmaceuticals Inc Phase 2: Idarubicin Nanoparticle Formulation Development and Preclinical Evaluation				
<b>Leggas, Markos</b>	3048085400	\$0.	\$205,100.	\$205,100.
National Cancer Institute Phase I and Biological Studies of DB67-A Blood Stable Camptothecin				
<b>Leggas, Markos</b>	3048104567	\$182,887.	\$0.	\$182,887.
Arno Therapeutics Inc Pharmacokinetic Studies for Development and Optimization of an Oral Formulation of the Camptothecin Analog DB-67				
<b>Li, Tonglei</b>	3046864900	\$0.	\$113,360.	\$113,360.
National Science Foundation CAREER: Towards Fundamental Understanding and Rational Control of Crystal Growth				
<b>Li, Tonglei</b>	3048103700	\$20,000.	\$0.	\$20,000.
PhRMA Foundation Fellowship for Aubrey-Medendorp: Investigation of Surface Energy Using Atomic Force Microscopy				
<b>Lodder, Robert A</b>	3046708000	\$0.	\$176,760.	\$176,760.
Science and Engineering Services Inc A Non-invasive Near IR Integrated Alcohol Sensor System				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Pharmacy</b>				
<b>Pharmaceutical Tech</b>				
<b>Loftin, Charles D</b>	3048100300	\$0.	\$-291,047.	\$-291,047.
National Heart Lung and Blood Institute Prostanoid-dependent Abdominal Aortic Aneurysm Formation				
<b>Loftin, Charles D</b>	3048103234	\$0.	\$290,815.	\$290,815.
National Heart Lung and Blood Institute Prostanoid-dependent Abdominal Aortic Aneurysm Formation				
<b>Nixon, Kimberly</b>		\$60,065.	\$0.	\$60,065.
AllTranz STTR: Transdermal Cannabidiol Delivery for Alcohol-Induced Neurodegeneration				
<b>Nixon, Kimberly</b>	3048104311	\$285,614.	\$0.	\$285,614.
National Institute on Alcohol Abuse and Alcoholism Ethanol Alteration of the Neurogenic Niche				
<b>Nixon, Kimberly</b>	3048104493	\$202,005.	\$0.	\$202,005.
National Institute on Alcohol Abuse and Alcoholism Neurogenesis and neurodegeneration in adolescent binge alcohol exposure				
<b>Pauly, Jim</b>	3048062600	\$0.	\$202,089.	\$202,089.
National Institute on Drug Abuse Prenatal Nicotine, Behavioral Teratogenicity and Dopamine				
<b>Porter, Todd D</b>	3048099100	\$0.	\$175,635.	\$175,635.
National Center for Complementary & Alternative Med Inhibition of Cholesterol Synthesis by Policosanol				
<b>Rohr, Jurgen</b>	3046893000	\$0.	\$246,853.	\$246,853.
National Cancer Institute Biosynthetic Key Steps of Angucycline Antitumor Drugs				
<b>Yokel, Robert A</b>	3048103547	\$43,997.	\$0.	\$43,997.
KY Science and Technology Co Inc Develop an In-line Filter to Remove Aluminum from Intravenous Feeding Solutions Given to Premature Infants				
<b>Yokel, Robert A</b>	3048104222	\$500,000.	\$0.	\$500,000.
Environmental Protection Agency Safety/Toxicity Assessment of Ceria (A Model engineered NP) to the Brain				
<b>Zhan, Chang-Guo</b>	3048046400	\$0.	\$47,406.	\$47,406.
University of Michigan Development of Esterases for the Treatment of Cocaine Overdose and Abuse				
<b>Zhan, Chang-Guo</b>	3048104655	\$55,769.	\$0.	\$55,769.
MITRE Corporation Enzyme Analysis and Design				
<b>Zhan, Chang-Guo</b>	3048104755	\$43,550.	\$0.	\$43,550.
Alkymos Inc STTR: A Device Containing Immobilized Chelator to Remove Aluminum from TPN Solutions				
<b>Pharmaceutical Tech</b>	<b>Totals:</b>	<b>\$7,575,170.</b>	<b>\$2,358,679.</b>	<b>\$9,933,849.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Pharmacy</u></b>				
<b><u>Pharmacy Practice &amp; Science</u></b>				
<b>Adams, Val R</b>	3048104062	\$0.	\$35,030.	\$35,030.
University of North Carolina EGFR Targeted Nanoparticles to Overcome Paclitaxel resistant Breast Cancer				
<b>Adams, Val R</b>	3048104062	\$41,195.	\$0.	\$41,195.
University of North Carolina EGFR Targeted Nanoparticles to Overcome Paclitaxel resistant Breast Cancer				
<b>Botts, Sheila R</b>	3048104772	\$25,000.	\$0.	\$25,000.
ASHP Foundation Evaluation of Medication Non-Adherence and Associated Factors in Posttraumatic Stress Disorder				
<b>Feola, David J</b>	3048104239	\$20,000.	\$0.	\$20,000.
Society of Infectious Diseases Pharmacists In Vivo Impact of Azithromycin on Macrophage Phenotype in P. aeruginosa Infection				
<b>Fink, Joseph L</b>	3048104691	\$10,000.	\$0.	\$10,000.
American Association of Colleges of Pharmacy Language Access Provisions in State Pharmacy Practice Acts and Relevant Resources: Part 1 State Pharmacy Practice Act				
<b>Kirsh, Kenneth L</b>	3046982300	\$0.	\$60,994.	\$60,994.
Memorial Sloan Kettering Cancer Center Overcoming Barriers to Depression Recognition in Cancer				
<b>Kirsh, Kenneth L</b>	3048061400	\$0.	\$186,286.	\$186,286.
National Institute for Nursing Research Building Bridges to Hospice and Rural Appalachia				
<b>Steinke, Douglas Theodore</b>	3048104573	\$30,000.	\$0.	\$30,000.
PhRMA Foundation Gender Disparities in type 2 Diabetes Medication Utilization: A Population Based Study Using Medicaid Data				
<b>Talbert, Jeffery C</b>		\$250,000.	\$0.	\$250,000.
KY Health Services Cabinet Medicaid Study				
<b>Talbert, Jeffery C</b>	3048103678	\$0.	\$160,000.	\$160,000.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				
<b>Talbert, Jeffery C</b>	3048103678	\$0.	-\$374,249.	-\$374,249.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				
<b>Talbert, Jeffery C</b>	3048103678	\$0.	\$374,249.	\$374,249.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				
<b>Talbert, Jeffery C</b>	3048103678	\$809,287.	\$0.	\$809,287.
Department for Mental Health Mental Retardation Service Research Information Systems Management for KY Department for Mental Health/Mental Retardation				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Pharmacy</u></b>				
<b><u>Pharmacy Practice &amp; Science</u></b>				
<b>Wermeling, Daniel P</b>	3048103728	\$30,000.	\$0.	\$30,000.
American College of Clinical Pharmacy fMRI Imaged Neuroactivation & Craving in Alcoholics is Modulated by Ondansetron				
<b>Pharmacy Practice &amp; Science</b>	<b>Totals:</b>	<b>\$1,215,482.</b>	<b>\$442,310.</b>	<b>\$1,657,792.</b>
	<b>Pharmacy Totals:</b>	<b>\$8,806,907.</b>	<b>\$2,732,876.</b>	<b>\$11,539,783.</b>
<b><u>Health Sciences</u></b>				
<b><u>Rehabilitation Sciences</u></b>				
<b>Capilouto, Gilson J</b>	3048104021	\$104,716.	\$0.	\$104,716.
Arizona State University Discourse Processing in Healthy Aging				
<b>Kleinert, Jane</b>	3048103608	\$152,160.	\$0.	\$152,160.
KY Health Services Cabinet Kentucky Youth Advocacy Project				
<b>Uhl, Timothy</b>	3048103707	\$1,000.	\$0.	\$1,000.
NATA Research & Education Foundation Comparison of Early Hip Strengthening to Early Quadriceps Strengthening in the Treatment of Females with Patellofemoral Pain				
<b>Rehabilitation Sciences</b>	<b>Totals:</b>	<b>\$257,876.</b>	<b>\$0.</b>	<b>\$257,876.</b>
<b><u>Administrative Services</u></b>				
<b>Peterson, Charlotte A.</b>	3048032300	\$0.	\$170,164.	\$170,164.
National Institute Diabetes & Digestive & Kidney Mechanisms Underlying Metabolic Syndrome in Obesity				
<b>Peterson, Charlotte A.</b>	3048049700	\$0.	\$274,128.	\$274,128.
National Institute on Aging Changes in Myogenic Progenitor Potential with Age				
<b>Administrative Services</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$444,292.</b>	<b>\$444,292.</b>
<b><u>Clinical Sciences</u></b>				
<b>Chendil, Damodaran</b>	3048001200	\$0.	\$125,000.	\$125,000.
Susan G Komen Breast Cancer Foundation A Novel Herbal Medicine for the Treatment of Breast Cancer				
<b>Chendil, Damodaran</b>	3048097100	\$0.	\$355,097.	\$355,097.
National Center for Complementary & Alternative Med Novel Herbal Medicine for the Treatment of Prostate Cancer				
<b>Gurwell, Julie A</b>	3048104398	\$4,514.	\$0.	\$4,514.
Physicians Assistant Education Association Evidence-Based Medicine Resource Usage and Practice Among Physician Community-Based Faculty Members and Physician Assistant Students During Clerkships				
<b>Ko, Chemyong</b>	3046997400	\$0.	\$231,414.	\$231,414.
National Institute of Child Health and Human Develop Endothelin-2 in Ovarian Follicle Rupture				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Health Sciences</u></b>				
<b><u>Clinical Sciences</u></b>				
<b>Nickell, Debra F</b>	3048103422	\$101,266.	\$0.	\$101,266.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
<b>Clinical Sciences</b>	<b>Totals:</b>	<b>\$105,780.</b>	<b>\$711,511.</b>	<b>\$817,291.</b>
	<b>Health Sciences Totals:</b>	<b>\$363,656.</b>	<b>\$1,155,803.</b>	<b>\$1,519,459.</b>
<b><u>Public Health</u></b>				
<b><u>Preventive Med &amp; Environmental Health</u></b>				
<b>Brion, Gail</b>	3046936300	\$0.	\$150,120.	\$150,120.
University of Louisville Health Effects of Occupational Exposure in PGDP Workers				
<b>Figgs, Larry W</b>	3048085600	\$0.	\$63,000.	\$63,000.
Lexington Fayette County Health Department Manager, Environmental Health and Protection				
<b>Figgs, Larry W</b>	3048103886	\$100,000.	\$0.	\$100,000.
Environmental Protection Agency Kentucky Regional Lead Screening Consortium: A Multi-county Approach to Lead Poisoning Risk Reduction in Kentucky's Pediatric Medicaid Population				
<b>Figgs, Larry W</b>	3048104071	\$249,750.	\$0.	\$249,750.
Environmental Protection Agency Regional Consortium for Leadership, Outreach, and Training (Regional CLOUT)				
<b>Lee, Kiyong</b>	3048103870	\$0.	\$20,000.	\$20,000.
Center for Disease Control and Prevention Validation of appropriate wood dust sampling and analysis procedures				
<b>Lee, Kiyong</b>	3048103870	\$20,000.	\$0.	\$20,000.
Center for Disease Control and Prevention Validation of appropriate wood dust sampling and analysis procedures				
<b>Lee, Kiyong</b>	3048104041	\$99,745.	\$0.	\$99,745.
Environmental Protection Agency Partnership to Address Lead Exposure Risk to Children Living in Older Housing: Podcast Lead Education Aimed at Doctors (PLEAD)				
<b>Mannino, David M</b>	3048070400	\$0.	\$6,742.	\$6,742.
Novartis Prevalence, Incidence and Outcomes of Comorbid Diseases among Adults in the Atherosclerosis Risk in Communities study (ARIC) and the Cardiovascular Health Study (CHS)				
<b>Mannino, David M</b>	3048103623	\$45,000.	\$0.	\$45,000.
Center for Disease Control and Prevention IPA: Mannino Consulting Agreement with CDC				
<b>Mannino, David M</b>	3048104017	\$93,750.	\$0.	\$93,750.
Pfizer Inc Tobacco Use as a Chronic Illness				
<b>Mannino, David M</b>	3048104246	\$168,475.	\$0.	\$168,475.
GlaxoSmithKline Validation of Lung Function Questionnaire (LFQ) in a clinical population				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Preventive Med &amp; Environmental Health</u></b>				
<b>Mannino, David M</b>	3048104386	\$59,596.	\$0.	\$59,596.
Center for Disease Control and Prevention IPA: Mannino Consulting Agreement with CDC				
<b>Preventive Med &amp; Environmental Health</b>	<b>Totals:</b>	<b>\$836,316.</b>	<b>\$239,862.</b>	<b>\$1,076,178.</b>
<b><u>Health Behavior</u></b>				
<b>Cecil, James C</b>	3048103533	\$0.	\$44,645.	\$44,645.
KY Department for Public Health Development of Institute for Maternal and Child Health Education and Training				
<b>Cecil, James C</b>	3048103533	\$79,000.	\$0.	\$79,000.
KY Department for Public Health Development of Institute for Maternal and Child Health Education and Training				
<b>Crosby, Richard</b>	3046879400	\$0.	\$20,025.	\$20,025.
GlaxoSmithKline Partner Notification to Identify and Diagnose Asymptomatic Genital Herpes Infection				
<b>Crosby, Richard</b>	3048104313	\$125,809.	\$0.	\$125,809.
Merck and Company Inc Predictors of HPV Acceptance Among Young Women in Rural Areas				
<b>Crosby, Richard</b>	3048104588	\$52,000.	\$0.	\$52,000.
Indiana University Rural Center of AIDS and STD Prevention				
<b>Health Behavior</b>	<b>Totals:</b>	<b>\$256,809.</b>	<b>\$64,670.</b>	<b>\$321,479.</b>
<b><u>Health Services Management</u></b>				
<b>Costich, Julia F</b>	3048103615	\$94,000.	\$0.	\$94,000.
KY Department for Public Health Administration of Core Curriculum for Bioterrorism				
<b>Costich, Julia F</b>	3048103756	\$14,168.	\$0.	\$14,168.
University of Southern Mississippi Public Health Finance: Advancing a Field of Study				
<b>Costich, Julia F</b>	3048103874	\$30,250.	\$0.	\$30,250.
KY Health Services Cabinet Health Information Security and Privacy Regulatory Standardization Analysis (Deliverable 4)				
<b>Costich, Julia F</b>	3048104271	\$130,000.	\$0.	\$130,000.
KY Health Services Cabinet Statewide eHealth Study				
<b>Hill, Raymond E</b>	3048103616	\$30,000.	\$0.	\$30,000.
KY Department for Public Health SCBD Diabetes Education/Training				
<b>Scutchfield, F Douglas</b>	3048103316	\$10,000.	\$0.	\$10,000.
Eastern KY University Personal Consulting Contract between ECU and UKRF				
<b>Scutchfield, F Douglas</b>	3048103517	\$226,560.	\$0.	\$226,560.
KY Department for Public Health KY Public Health Leadership Institute				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Health Services Management</u></b>				
<b>Scutchfield, F Douglas</b>	3048103603	\$712,318.	\$0.	\$712,318.
Robert Wood Johnson Foundation Public Health Systems and Services Research Center				
<b>Scutchfield, F Douglas</b>	3048103849	\$23,616.	\$0.	\$23,616.
National Library of Medicine Increasing the Availability and Promoting the Use of the National Library of Medicine's Datasets for Public Health Systems Research				
<b>Scutchfield, F Douglas</b>	3048104506	\$30,000.	\$0.	\$30,000.
Kettering Foundation Kentucky Commonwealth Common Health Conversations for Health Action (CWCH)				
<b>Health Services Management</b>	<b>Totals:</b>	<b>\$1,300,912.</b>	<b>\$0.</b>	<b>\$1,300,912.</b>
<b><u>Epidemiology</u></b>				
<b>Hopenhayn, Claudia</b>		\$74,654.	\$0.	\$74,654.
Battelle Memorial Institute Monitoring the Impact of a Prophylactic HPV Vaccine on HPV types in Cervical Cancer using Tissues for KCR				
<b>Hopenhayn, Claudia</b>	3048104057	\$144,086.	\$0.	\$144,086.
KY Lung Cancer Research Fund Lung cancer survival in Kentucky: a multifactorial approach				
<b>Robl, Joyce M</b>	3048103518	\$0.	\$-36,737.	\$-36,737.
KY Department for Public Health SJBA UK Birth Surveillance Registry				
<b>Robl, Joyce M</b>	3048103518	\$89,210.	\$0.	\$89,210.
KY Department for Public Health SJBA UK Birth Surveillance Registry				
<b>Epidemiology</b>	<b>Totals:</b>	<b>\$307,950.</b>	<b>\$-36,737.</b>	<b>\$271,213.</b>
<b><u>Biostatistics</u></b>				
<b>Branscum, Adam</b>	3048104628	\$27,461.	\$0.	\$27,461.
University of Tennessee Optimization and Evaluation of Novel Absorbed Serum and Milk Enzyme-Linked Immunosorbent Assays for Johne's Disease				
<b>Charnigo, Richard J</b>	3048103739	\$249,999.	\$0.	\$249,999.
National Science Foundation Estimation of Analytic Surfaces with Applications to Nanoparticle Characterization via Surface Waves				
<b>Biostatistics</b>	<b>Totals:</b>	<b>\$277,460.</b>	<b>\$0.</b>	<b>\$277,460.</b>
<b><u>Gerontology</u></b>				
<b>Rowles, Graham D</b>	3048103689	\$11,470.	\$0.	\$11,470.
KY Health Services Cabinet Kentucky Elder Readiness Initiative (KERI)				
<b>Teaster, Pamela B</b>	3048103781	\$0.	\$25,000.	\$25,000.
Gerontological Society of America Fellowship for Katherina Nikzad: Hartford Geriatric Social Work Doctoral Fellowship				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Gerontology</u></b>				
<b>Teaster, Pamela B</b>	3048103781	\$25,000.	\$0.	\$25,000.
Gerontological Society of America Fellowship for Katherina Nikzad: Hartford Geriatric Social Work Doctoral Fellowship				
<b>Teaster, Pamela B</b>	3048104477	\$83,909.	\$0.	\$83,909.
American Bar Association A Multi-State Assessment of Court-Focused Elder Abuse Initiatives				
<b>Teaster, Pamela B</b>	3048104511	\$23,150.	\$0.	\$23,150.
National Committee Prevention of Elder Abuse Empowering Elder Abuse Organizations Through Local, State and National Efforts				
<b>Teaster, Pamela B</b>	3048104652	\$80,316.	\$0.	\$80,316.
KY Health Services Cabinet A Week in the Life of Adult Protective Services				
<b>Gerontology</b>	<b>Totals:</b>	<b>\$223,845.</b>	<b>\$25,000.</b>	<b>\$248,845.</b>
<b><u>Center for Prevention Research</u></b>				
<b>Clayton, R R</b>	3046975300	\$0.	\$-100,000.	\$-100,000.
Robert Wood Johnson Foundation Tobacco Etiology Research Network: Communication and Dissemination				
<b>Harris, Torrie</b>	3048104729	\$7,560.	\$0.	\$7,560.
KY River Community Care Inc Owsley County Youth Tobacco Accessibility Project				
<b>Jones, Jeffery A</b>	3048092800	\$0.	\$10,000.	\$10,000.
KY Department of Education Coordinated School Health Youth Risk Behavior Survey Project				
<b>Jones, Jeffery A</b>	3048103786	\$40,000.	\$0.	\$40,000.
KY Child Now Improving Access to and the Integration of Child and Adolescent Medical and Mental Health Care				
<b>Jones, Jeffery A</b>	3048103822	\$83,723.	\$0.	\$83,723.
Foundation for a Healthy KY Foundation for a Healthy Kentucky, Coordinated School Health Grants Evaluation				
<b>Jones, Jeffery A</b>	3048104330	\$3,000.	\$0.	\$3,000.
Lexington Fayette Urban County Government Evaluation of 21st Century Grant				
<b>Center for Prevention Research</b>	<b>Totals:</b>	<b>\$134,283.</b>	<b>\$-90,000.</b>	<b>\$44,283.</b>
<b><u>KY Injury Prevention &amp; Research Center</u></b>				
<b>Bunn, Terry L</b>	3048103532	\$0.	\$35,019.	\$35,019.
KY Department for Public Health Occupational Safety and Health				
<b>Bunn, Terry L</b>	3048103532	\$223,500.	\$0.	\$223,500.
KY Department for Public Health Occupational Safety and Health				
<b>Costich, Julia F</b>	3048103516	\$0.	\$43,199.	\$43,199.
KY Department for Public Health State Injury Prevention Program				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>KY Injury Prevention &amp; Research Center</u></b>				
<b>Costich, Julia F</b>	3048103516	\$311,687.	\$0.	\$311,687.
KY Department for Public Health State Injury Prevention Program				
<b>Costich, Julia F</b>	3048103664	\$131,700.	\$0.	\$131,700.
Center for Disease Control and Prevention Public Health Injury Surveillance and Prevention Program				
<b>Costich, Julia F</b>	3048104245	\$49,333.	\$0.	\$49,333.
KY Department for Public Health KIPRC Consumer Product Safety				
<b>Costich, Julia F</b>	3048104559	\$27,099.	\$0.	\$27,099.
KY Hospital Association KY Trauma Registry				
<b>McCool, Robert H</b>	3048104046	\$143,470.	\$0.	\$143,470.
Center for Disease Control and Prevention Kentucky Residential Fire Injury Prevention Project				
<b>Pollack, Susan H</b>	3048103626	\$179,300.	\$0.	\$179,300.
KY Department for Public Health Pediatric and Adolescent Injury Prevention Program				
<b>Singleton, Michael</b>	3046708800	\$0.	\$76,000.	\$76,000.
National Highway Traffic Safety Administration CODES Data Network				
<b>Walsh, Sabrina L</b>		\$211,130.	\$0.	\$211,130.
Center for Disease Control and Prevention Kentucky Violent Death Reporting System				
<b>KY Injury Prevention &amp; Research Center</b>	<b>Totals:</b>	<b>\$1,277,219.</b>	<b>\$154,218.</b>	<b>\$1,431,437.</b>
<b><u>Southeast Cntr for Ag Health &amp; Injury Pr</u></b>				
<b>Clayton, R R</b>	3048104080	\$0.	\$51,673.	\$51,673.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
<b>Donovan, Teresa</b>	3048104420	\$6,000.	\$0.	\$6,000.
Colorado State University Developing and Testing Interactive CD Health and Safety Curricula for 4-H Youth				
<b>McKnight, Robert H</b>	3046930100	\$0.	\$6,470.	\$6,470.
Center for Disease Control and Prevention Southeast Center for Agriculture Health and Injury Prevention				
<b>McKnight, Robert H</b>	3048103519	\$60,000.	\$0.	\$60,000.
KY Department for Medicaid Services Dept. of Medicaid Services KCHIP Migrant Outreach Project				
<b>McKnight, Robert H</b>	3048103609	\$60,148.	\$0.	\$60,148.
National Institute of Occupational Safety and Health Agricultural Safety and Health Training for Public Health Graduate Students				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Public Health</u></b>				
<b><u>Southeast Cntr for Ag Health &amp; Injury Pr</u></b>				
<b>McKnight, Robert H</b>	3048104080	\$0.	\$51,673.	\$51,673.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
<b>McKnight, Robert H</b>	3048104080	\$934,866.	\$0.	\$934,866.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
<b>Southeast Cntr for Ag Health &amp; Injury Pr</b>	<b>Totals:</b>	<b>\$1,061,014.</b>	<b>\$109,816.</b>	<b>\$1,170,830.</b>
<b><u>Council on Aging</u></b>				
<b>Johnson, Helen A</b>	3048103229	\$143,446.	\$0.	\$143,446.
KY Department for Public Health UK Emergency Preparedness for Aging Training				
<b>Johnson, Helen A</b>	3048103875	\$414,000.	\$0.	\$414,000.
Health Resources and Services Administration Geriatric Education Centers: OVAR GEC Care Transitions				
<b>Johnson, Helen A</b>	3048104216	\$16,830.	\$0.	\$16,830.
Department for Mental Health Mental Retardation Service 2007 PASRR Skills Training				
<b>Smith, Michael D</b>	3048104436	\$100,000.	\$0.	\$100,000.
Bernard Osher Foundation Osher Lifelong Learning Institute				
<b>Council on Aging</b>	<b>Totals:</b>	<b>\$674,276.</b>	<b>\$0.</b>	<b>\$674,276.</b>
<b><u>College of Public Health Systems Res</u></b>				
<b>Scutchfield, F Douglas</b>	3048104441	\$18,266.	\$0.	\$18,266.
Ohio State University Buckeye Bluegrass Regional Leadership Academy				
<b>College of Public Health Systems Res</b>	<b>Totals:</b>	<b>\$18,266.</b>	<b>\$0.</b>	<b>\$18,266.</b>
<b>Public Health Totals:</b>		<b>\$6,368,350.</b>	<b>\$466,829.</b>	<b>\$6,835,179.</b>
<b><u>Assoc Provost Undergrad Educati</u></b>				
<b><u>Undergraduate Studies</u></b>				
<b>Tannenbaum, Robert S</b>	3046842100	\$0.	\$453,430.	\$453,430.
National Science Foundation Recruiting, Retaining, and Graduating University of Kentucky Appalachian and Minority Science, Technology, Engineering, and Mathematics Majors \ (UK AMSTEMM)				
<b>Tannenbaum, Robert S</b>	3048104642	\$115,800.	\$0.	\$115,800.
Arnold and Mabel Beckman Foundation Beckman Scholarship Program				
<b>Undergraduate Studies</b>	<b>Totals:</b>	<b>\$115,800.</b>	<b>\$453,430.</b>	<b>\$569,230.</b>
<b>Assoc Provost Undergrad Education Totals:</b>		<b>\$115,800.</b>	<b>\$453,430.</b>	<b>\$569,230.</b>
<b><u>Agriculture</u></b>				
<b><u>International Programs</u></b>				
<b>Reed, Michael R</b>	3046900500	\$0.	\$15,950.	\$15,950.
Foreign Agricultural Service Technical Assistance to the Extension System in Serbia				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>International Programs</u></b>				
<b>Reed, Michael R</b>	3046947200	\$0.	\$-30,000.	\$-30,000.
Foreign Agricultural Service Technical Assistance to Romanian Agriculture				
<b>International Programs</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$-14,050.</b>	<b>\$-14,050.</b>
<b><u>Assoc Dean Research/Director AES</u></b>				
<b>Cox, Nancy Marguerite</b>	3048053300	\$0.	\$6,600.	\$6,600.
Agricultural Research Service Acquisition of Goods and Services				
<b>Cox, Nancy Marguerite</b>	3048087900	\$0.	\$38,349.	\$38,349.
Agricultural Research Service ARS/SCA Cooperative Agreement				
<b>Cox, Nancy Marguerite</b>	3048087900	\$0.	\$782,880.	\$782,880.
Agricultural Research Service ARS/SCA Cooperative Agreement				
<b>Cox, Nancy Marguerite</b>	3048087900	\$0.	\$10,615.	\$10,615.
Agricultural Research Service ARS/SCA Cooperative Agreement				
<b>Cox, Nancy Marguerite</b>	3048104031	\$39,500.	\$0.	\$39,500.
Agricultural Research Service Acquisition of Goods and Services 2007-2008 for Ag North				
<b>Cox, Nancy Marguerite</b>	3048104749	\$873,493.	\$0.	\$873,493.
Agricultural Research Service Improving Sustainability of Forage-Based Production				
<b>Assoc Dean Research/Director AES</b>	<b>Totals:</b>	<b>\$912,993.</b>	<b>\$838,444.</b>	<b>\$1,751,437.</b>
<b><u>Tracy Farmer Cntr for the Environment</u></b>				
<b>Hanley, Carol D</b>	3048073400	\$0.	\$17,000.	\$17,000.
KY Council on Postsecondary Education Community-Based Science for Teachers				
<b>Hanley, Carol D</b>	3048103426	\$24,898.	\$0.	\$24,898.
KY Office of Energy Policy Exploring Energy with Kentucky Teachers				
<b>Hanley, Carol D</b>	3048104081	\$28,000.	\$0.	\$28,000.
Boyle County Schools Exploring Elk in Eastern Kentucky				
<b>Hanley, Carol D</b>	3048104469	\$1,155,525.	\$0.	\$1,155,525.
National Science Foundation Information Technology through Community Based Natural Resources Program for Students and Teachers				
<b>Hanley, Carol D</b>	3048104502	\$102,468.	\$0.	\$102,468.
KY Department of Education Environmental Education at UK: Addendum				
<b>Tracy Farmer Cntr for the Environment</b>	<b>Totals:</b>	<b>\$1,310,891.</b>	<b>\$17,000.</b>	<b>\$1,327,891.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Agr Economics</u></b>				
<b>Burdine, Kenneth H</b>	3046989600	\$0.	\$154,560.	\$154,560.
KY Beef Network Advanced Master Cattleman				
<b>Dillon, Carl R</b>	3048103541	\$49,961.	\$0.	\$49,961.
Texas A&M University Retirement Portfolio Planning for farmers.				
<b>Infanger, Craig L</b>	3048102208	\$0.	\$74,760.	\$74,760.
KY Governor's Office of Agricultural Policy Program Evaluation of the Agricultural Development Board Investments, 2001-2006				
<b>Maynard, Leigh J</b>	3048103830	\$0.	\$-270.	\$-270.
University of Alberta Consumer Reaction to Health Messages About Fish Consumption				
<b>Maynard, Leigh J</b>	3048103830	\$6,602.	\$0.	\$6,602.
University of Alberta Consumer Reaction to Health Messages About Fish Consumption				
<b>Maynard, Leigh J</b>	3048104356	\$9,500.	\$0.	\$9,500.
International Council for Canadian Studies Food Safety vs. Allegiance to Ranchers: Canadian Consumer Response to Three BSE Events				
<b>Meyer, Alphonse L</b>	3048103504	\$0.	\$-9,981.	\$-9,981.
Texas A&M University Annie's Project: Risk Management Education for Kentucky Farm Women				
<b>Meyer, Alphonse L</b>	3048103504	\$59,981.	\$0.	\$59,981.
Texas A&M University Annie's Project: Risk Management Education for Kentucky Farm Women				
<b>Meyer, Alphonse L</b>	3048103638	\$53,317.	\$0.	\$53,317.
University of Georgia Implement Plan of Work for the Southern Region Sustainable Agriculture Research and education (SARE) Professional Development (PDP) Program				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$2,000.	\$2,000.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$500.	\$500.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$700.	\$700.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$900.	\$900.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Robbins, Lynn W</b>	3048103813	\$0.	\$499.	\$499.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Agr Economics</u></b>				
<b>Robbins, Lynn W</b>	3048103813	\$1.	\$0.	\$1.
KY Governor's Office of Agricultural Policy KADB: Pilot Farm Management Cost-Share Program				
<b>Snell, William M</b>	3048104372	\$75,964.	\$0.	\$75,964.
Tobacco Education and Research Council Inc Improving Competitiveness in the Tobacco Global Market Through Information Channels and Decision-Making Tools				
<b>Woods, Timothy A</b>	3046997000	\$0.	\$3,500.	\$3,500.
KY Center for Cooperative Development Cooperatives Intern Program				
<b>Woods, Timothy A</b>	3048104265	\$28,150.	\$0.	\$28,150.
Tapps Dairy and Creamery Feasibility Study for Tapps Dairy and Creamery				
<b>Agr Economics</b>	<b>Totals:</b>	<b>\$283,476.</b>	<b>\$227,168.</b>	<b>\$510,644.</b>
<b><u>Biosystems &amp; Ag Eng</u></b>				
<b>Agouridis, Carmen</b>	3048053600	\$0.	\$516,824.	\$516,824.
KY Department of Fish and Wildlife Stream Restoration in Guy Cove II				
<b>Colliver, Donald G</b>		\$100,000.	\$0.	\$100,000.
National Renewable Energy Laboratory Solar Decathlon - 2009				
<b>Colliver, Donald G</b>	3048103761	\$54,520.	\$0.	\$54,520.
KY Office of Energy Policy Renewable Energy/Energy Efficiency (REEE) Program Support (07-08)				
<b>Fehr, Robert L</b>	3048059100	\$0.	\$278,341.	\$278,341.
KY Office of Energy Policy Enhanced Building Energy Efficiency Technology Deployment				
<b>Fehr, Robert L</b>	3048103423	\$95,500.	\$0.	\$95,500.
KY Office of Energy Policy A Cooperative Extension Program for Kentucky's Building Systems Energy Needs 2007-2008				
<b>Fehr, Robert L</b>	3048103424	\$0.	\$-15,800.	\$-15,800.
KY Health Services Cabinet Cooperative Extension Radon and Indoor Air Quality Education				
<b>Fehr, Robert L</b>	3048103424	\$105,000.	\$0.	\$105,000.
KY Health Services Cabinet Cooperative Extension Radon and Indoor Air Quality Education				
<b>Gates, Richard S</b>	3048074500	\$0.	\$12,025.	\$12,025.
KY Office of Energy Policy Energy Seed Grant Technical Merit Review				
<b>Gates, Richard S</b>	3048104023	\$10,000.	\$0.	\$10,000.
Agricultural Research Service Development of Line-Scan Image Algorithms for Inspection of Poultry Carcasses				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Biosystems &amp; Ag Eng</u></b>				
<b>Gates, Richard S</b>	3048104397	\$24,065.	\$0.	\$24,065.
United Egg Producers Inc Feeding and Altering Diets for Egg Laying Hens				
<b>Higgins, Stephen F</b>	3048103515	\$42,677.	\$0.	\$42,677.
Natural Resources Conservation Service Programmable Controls for Solid-Liquid Settling Basins				
<b>Montross, Michael D</b>	3048103748	\$6,000.	\$0.	\$6,000.
Idaho National Energy and Environment Studying Ensilability of Corn Stover Harvested Fractions				
<b>Montross, Michael D</b>	3048104010	\$111,664.	\$0.	\$111,664.
KY Office of Energy Policy R&D Seed Grant: Feasibility of Ethanol Production from Sweet Sorghum in Kentucky				
<b>Nokes, Sue E</b>	3048104206	\$250,000.	\$0.	\$250,000.
University of Tennessee Bacterial adaptations for enhanced cellulose utilization: a systems approach				
<b>Overhults, Douglas G</b>	3048104069	\$395,566.	\$0.	\$395,566.
KY Poultry Federation Poultry House Evaluation Service				
<b>Payne, Frederick A</b>	3048104505	\$182,996.	\$0.	\$182,996.
Cooperative State Research Education and Extension Syneresis Sensor Technology Development for Curd Moisture Content Control				
<b>Shearer, Scott A</b>	3048103531	\$74,897.	\$0.	\$74,897.
Natural Resources Conservation Service Spray Nozzle Control for Preservation of Vegetated Conservation Features				
<b>Workman, Stephen R</b>	3046872100	\$0.	\$1,000.	\$1,000.
Texas A&M University Enhancing Water Quality Education in Kentucky				
<b>Workman, Stephen R</b>	3046872100	\$0.	\$60,000.	\$60,000.
Texas A&M University Enhancing Water Quality Education in Kentucky				
<b>Workman, Stephen R</b>	3048104283	\$666,564.	\$0.	\$666,564.
KY Natural Resources Environmental Protection Cabinet Cane Run and Royal Spring Watershed Based Plan Project				
<b>Biosystems &amp; Ag Eng</b>	<b>Totals:</b>	<b>\$2,119,449.</b>	<b>\$852,390.</b>	<b>\$2,971,839.</b>
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Bailey, William A</b>	3048104552	\$6,000.	\$0.	\$6,000.
Advanced Technologies Cambridge Ltd Pilot Study into Reduction of TSNA in Cured Burley Leaf				
<b>Bruening, William P</b>	3048103838	\$4,800.	\$0.	\$4,800.
KY Small Grain Promotion Council Evaluation of Wheat Varieties for Differences in Straw Yield and Forage Potential				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Bruening, William P</b>	3048104521	\$5,000.	\$0.	\$5,000.
KY Soybean Promotion Board Evaluation of Hullless Barley: Minimizing the Late-Planted Yield Penalty in Double-crop Soybeans				
<b>Chappell, Joseph</b>	3048103869	\$0.	\$168,532.	\$168,532.
National Science Foundation Unraveling the Catalytic Specificity of Terpene Hydroxylases and Engineering Sesquiterpene Hydroxylation into Plants				
<b>Chappell, Joseph</b>	3048103869	\$215,379.	\$0.	\$215,379.
National Science Foundation Unraveling the Catalytic Specificity of Terpene Hydroxylases and Engineering Sesquiterpene Hydroxylation into Plants				
<b>Grabau, Larry J</b>	3048104045	\$2,400.	\$0.	\$2,400.
KY Small Grain Promotion Council Managing No-till Wheat to Optimize Harvest Index and Grain Yield				
<b>Grove, J H</b>	3048104516	\$7,500.	\$0.	\$7,500.
KY Soybean Promotion Board Soybean Yield Response to Soil P and K Availability: Optimizing Fertilization Expenses				
<b>Herbek, James H</b>	3048104517	\$2,000.	\$0.	\$2,000.
KY Soybean Promotion Board Optimum Planting Date for Soybean				
<b>Herbek, James H</b>	3048104518	\$11,000.	\$0.	\$11,000.
KY Soybean Promotion Board Low Soybean Populations and Weed Control, Year 2				
<b>Hildebrand, David F</b>	3046958900	\$0.	\$52,000.	\$52,000.
United Soybean Board Novel Approaches for Development of Soybeans with Improved Oil, Higher Oil Contents & Enhanced Fungal Resistance				
<b>Hildebrand, David F</b>	3048104097	\$19,853.	\$0.	\$19,853.
KY Science and Technology Co Inc Cyclopropane fatty acid accumulation in plant oil				
<b>Hunt, Arthur G</b>	3048104083	\$19,970.	\$0.	\$19,970.
KY Science and Technology Co Inc KSEF R&D Excellence: Uncoupling the timing of flowering from stress in plants				
<b>Karathanasis, Anastasios D</b>	3048104011	\$45,000.	\$0.	\$45,000.
KY Health Services Cabinet Soil Morphology Training for On-site Sewage Disposal Systems				
<b>Lee, Chad D</b>	3048104520	\$84,367.	\$0.	\$84,367.
KY Soybean Promotion Board Soy MVP: Soybean Management Verification Program				
<b>Martin, James R</b>	3048103843	\$2,500.	\$0.	\$2,500.
KY Small Grain Growers Association Application Timing for Italian Ryegrass Control in Conventional and No-Till Wheat				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Martin, James R</b>	3048103845	\$2,800.	\$0.	\$2,800.
KY Small Grain Growers Association Influence of Timing of Topdressing Nitrogen Fertilizer Relative to Application of Osprey Herbicide				
<b>Matocha, Christopher J</b>	3048103676	\$286,000.	\$0.	\$286,000.
Cooperative State Research Education and Extension Inhibition of Fe(III) reduction by nitrate: Impact of anoxic chemical and biological Fe(II) oxidation.				
<b>McCulley, Rebecca L</b>	3048104653	\$151,532.	\$0.	\$151,532.
Duke University Effects of Warming and Altered Precipitation Regime on Managed Grassland Structure and Function				
<b>Miller, Robert D</b>	3046576400	\$0.	-\$600,000.	-\$600,000.
Philip Morris Inc Burley Tobacco Breeding and Genetics				
<b>Miller, Robert D</b>	3048104450	\$600,000.	\$0.	\$600,000.
Philip Morris International Management SA Burley Tobacco Breeding and Genetics				
<b>Murdock, Lloyd W</b>	3048103846	\$4,000.	\$0.	\$4,000.
KY Small Grain Growers Association Improving Nitrogen Application Technology Under Kentucky Conditions				
<b>Omielan, Joseph A</b>		\$25,000.	\$0.	\$25,000.
North Carolina State University Testing and Deployment of a Web-Based Yield Loss Prediction Tool for Risk Management of Soybean Rust				
<b>Pfeiffer, T W</b>	3048104613	\$25,000.	\$0.	\$25,000.
South Dakota State University Regional Biomass Feedstock Partnership - Herbaceous Bioenergy Crop Field Trials				
<b>Schwab, Gregory J</b>	3048103844	\$2,500.	\$0.	\$2,500.
KY Small Grain Growers Association Wheat Management on Wet Natured Soils				
<b>Schwab, Gregory J</b>	3048104310	\$35,483.	\$0.	\$35,483.
KY Small Grain Growers Association Kentucky Grain Crops Academy				
<b>Slack, Charles H</b>	3048104451	\$10,000.	\$0.	\$10,000.
Pioneer Hi Bred International Inc Optimum GAT Corn University				
<b>Slack, Charles H</b>	3048104539	\$6,000.	\$0.	\$6,000.
Monsanto Co Dicamba Tolerant Soybeans--Weed Control				
<b>Smith, Samuel Ray</b>	3048103657	\$455,658.	\$0.	\$455,658.
KY Forage & Grasslands Council Expanding Opportunities for Biomass and Hay Production in Northeastern Kentucky				
<b>Tang, Guiliang</b>	3048104238	\$67,002.	\$0.	\$67,002.
University of California The role of methylation and uridylation in microRNA metabolism in Arabidopsis				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant &amp; Soil Sciences</u></b>				
<b>Tang, Guiliang</b>	3048104598	\$150,000.	\$0.	\$150,000.
KY Science and Technology Co Inc KSEF Commercialization: microRNA Array Technology and microRNA Biomarkers for Various Human Diseases				
<b>Van Doren, Saratha Kumudini</b>	3048103892	\$45,650.	\$0.	\$45,650.
Risk Management Agency Yield Loss Prediction Tool for Asian Soybean Rust - Continuation for Model Validation				
<b>Van Doren, Saratha Kumudini</b>	3048104529	\$24,000.	\$0.	\$24,000.
KY Soybean Promotion Board Validation Trial for Yield Loss Prediction Model for Asian Soybean Rust				
<b>VanSanford, D A</b>	3046780300	\$0.	\$62,784.	\$62,784.
Department of Agriculture Accelerating the Development of FHB-Resistant Soft Red Winter Wheat Varieties				
<b>VanSanford, D A</b>	3048030900	\$0.	\$163,916.	\$163,916.
Agricultural Research Service US Wheat & Barley Scab Initiative's Networking and Facilitation Office and Website				
<b>VanSanford, D A</b>	3048103847	\$30,000.	\$0.	\$30,000.
KY Small Grain Growers Association Soft Red Winter Wheat Breeding and Variety Development for Kentucky				
<b>VanSanford, D A</b>	3048104461	\$3,036.	\$0.	\$3,036.
Virginia Polytechnic Institute and State University Wheat CAP Grant				
<b>Wagner, George J</b>	3048065400	\$0.	\$15,000.	\$15,000.
Philip Morris Inc Analysis of Cd in Field Samples				
<b>Wagner, George J</b>	3048104558	\$532,321.	\$0.	\$532,321.
Procter & Gamble Company Production of Abietic Acid and Other Potentially-Useful, Related Diterpenes in Tobacco Trichomes				
<b>Wendroth, Ole Otto</b>	3048103848	\$4,000.	\$0.	\$4,000.
KY Small Grain Growers Association In-Season Observation of Wheat Growth Status for Yield Prediction in a Farmer's Field: Continuous Change of Nitrogen Application Rate Across the Landscape as an Alternative to Small Plot Research				
<b>Williams, David W</b>	3048104694	\$15,000.	\$0.	\$15,000.
South Dakota State University Regional Biomass Feedstock Partnership				
<b>Witt, William W</b>	3046705900	\$0.	\$177,286.	\$177,286.
KY Transportation Cabinet Management of Troublesome Weeds in Highway Rights of Way				
<b>Zhu, Hongyan</b>	3048103109	\$320,000.	\$0.	\$320,000.
National Science Foundation Function of non-legume orthologs of legume genes required for nodulation and arbuscular mycorrhizal symbiosis				
<b>Plant &amp; Soil Sciences</b>	<b>Totals:</b>	<b>\$3,220,751.</b>	<b>\$39,518.</b>	<b>\$3,260,269.</b>

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Animal and Food Sciences</u></b>				
<b>Amaral-Phillips, Donna M</b>	3048104479	\$15,000.	\$0.	\$15,000.
University of Nebraska DAIReXNET: A National Dairy Information and Communications Resource				
<b>Amaral-Phillips, Donna M</b>	3048104561	\$177,791.	\$0.	\$177,791.
KY Beef Network Master Grazer Educational Program Part II				
<b>Anderson, Leslie Harold</b>	3046982200	\$0.	\$215,500.	\$215,500.
KY Beef Network Integrated Resource Management				
<b>Burris, Walter R</b>	3046556200	\$0.	\$252,138.	\$252,138.
KY Cattleman's Association Master Cattlemen Program				
<b>Cantor, Austin H</b>	3048104339	\$26,500.	\$0.	\$26,500.
Alltech Biotechnology Inc Student Sponsorship Agreement for Lizza Macalintal				
<b>Cromwell, Gary L</b>	3048104089	\$52,000.	\$0.	\$52,000.
National Pork Board Assessment of Distillers Dried Grains with Solubles (DDGS) from Ethanol Production on Performance and Carcass Quality of Growing-Finishing Swine				
<b>Cromwell, Gary L</b>	3048104637	\$46,161.	\$0.	\$46,161.
National Pork Board Characteristics and Eating Quality of Bacon, Sausage, and Boneless Chops from Finishing Pigs Fed Medium and High Levels of Distillers Dried Grains with Solubles (DDGS)				
<b>Harmon, David L</b>	3048104079	\$30,000.	\$0.	\$30,000.
Alltech Biotechnology Inc Student Sponsorship Agreement - Holder				
<b>Hennig, B</b>	3048031500	\$0.	\$21,000.	\$21,000.
American Heart Association Fellowship - Oesterling: Polycyclic Aromatic Hydrocarbon-Medicated STAT Signaling and Implications in Vascular Inflammation				
<b>Hennig, B</b>	3048104563	\$1,941,662.	\$0.	\$1,941,662.
National Institute of Environmental Health Sciences Nutrition and Superfund Chemical Toxicity				
<b>Hicks, Clair L</b>	3048102145	\$5,000.	\$0.	\$5,000.
Tribo Flow Separations LLC Microbial and Cell Assay				
<b>Lawrence, Laurie M</b>	3048104078	\$30,000.	\$0.	\$30,000.
Alltech Biotechnology Inc Sponsored Student Stipend - Brummer				
<b>Lawrence, Laurie M</b>	3048104546	\$41,400.	\$0.	\$41,400.
Cooperative Research Farms Interactive Effects of Concentrate Starch and Soluble Fiber Levels on the Glucose and Insulin Responses of Horses				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Animal and Food Sciences</u></b>				
<b>Pescatore, Anthony J</b>	3048104690	\$103,425.	\$0.	\$103,425.
Alltech Biotechnology Inc Post Doctoral Fellow Scholarship: Rossi				
<b>Rentfrow, Gregg K</b>	3048104566	\$14,446.	\$0.	\$14,446.
Mississippi State University Letter of Intent: Evaluation of Potential Alternatives to Methyl Bromide Fumigation in Dry Cured Ham and Aged Cheese Production				
<b>Suman, Surendranath P</b>	3048104545	\$20,000.	\$0.	\$20,000.
KY Beef Council Investigating the Use of Ginger Extract to Improve Tenderness of Beef Biceps Femoris				
<b>Xiong, Youling</b>	3048104336	\$293,654.	\$0.	\$293,654.
Cooperative State Research Education and Extension Role of protein oxidation in water-binding and hydration of meat				
<b>Animal and Food Sciences</b>	<b>Totals:</b>	<b>\$2,797,039.</b>	<b>\$488,638.</b>	<b>\$3,285,677.</b>
<b><u>Entomology</u></b>				
<b>Bessin, Ricardo T</b>	3048104473	\$6,750.	\$0.	\$6,750.
University of Florida Alternative Insecticides for Management of Stink Bugs on Bell Peppers & IR-4 State Liaison				
<b>Bessin, Ricardo T</b>	3048104638	\$7,200.	\$0.	\$7,200.
Monsanto Co SMARTSTAX and YieldGard VT PRO Evaluations				
<b>Dobson, Stephen Leonard</b>	3046961000	\$0.	\$9,150.	\$9,150.
University of Queensland Genetic Modification of Mosquito Populations to Make Them Incapable of Transmitting Dengue Virus				
<b>Dobson, Stephen Leonard</b>	3046961000	\$0.	\$184,730.	\$184,730.
University of Queensland Genetic Modification of Mosquito Populations to Make Them Incapable of Transmitting Dengue Virus				
<b>Dobson, Stephen Leonard</b>	3048035600	\$0.	\$316,682.	\$316,682.
National Institute of Allergy and Infectious Diseases Eradication of a Primary Filariasis Vector Population at an Endemic Field Site				
<b>Dobson, Stephen Leonard</b>	3048104232	\$5,376,395.	\$0.	\$5,376,395.
Bill and Melinda Gates Foundation Supplemental Vector Intervention Required to Eliminate Lymphatic Filariasis in the South Pacific				
<b>Johnson, Douglas W</b>	3048103839	\$2,388.	\$0.	\$2,388.
KY Small Grain Growers Association Migration Patterns for Aphid Pests of Small Grains as Indexed by Capture in an Aphid Suction Trap				
<b>Johnson, Douglas W</b>	3048104513	\$2,388.	\$0.	\$2,388.
KY Soybean Promotion Board Migration Patterns for Aphid Pests of Small Grains as Indexed by Capture in an Aphid Suction Trap - Resubmission for Year 2 (FY09)				
<b>Lucas, Patricia A</b>	3048095700	\$0.	\$1,039.	\$1,039.
Cooperative State Research Education and Extension Development of the Regional Multi-State Insect Trapping Network for Use in Issuing Scouting Alerts and Predicting Potential Field Crop Damage in the Heartland				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Entomology</u></b>				
<b>Lucas, Patricia A</b>	3048103636	\$25,000.	\$0.	\$25,000.
North Carolina State University Establishment of a Kentucky State Contract for the Southern Region IPM Center				
<b>Lucas, Patricia A</b>	3048104706	\$24,000.	\$0.	\$24,000.
North Carolina State University State Contact and IPM Documents for Kentucky				
<b>Obrycki, John J</b>	3048104086	\$7,500.	\$0.	\$7,500.
KY Natural Resources Environmental Protection Cabinet Hemlock Woolly Adelgid Sampling Surveys				
<b>Obrycki, John J</b>	3048104565	\$50,000.	\$0.	\$50,000.
Slow the Spread Foundation Monitor Gypsy Moth Populations for Slow the Spread Program				
<b>Obrycki, John J</b>	3048104614	\$499,995.	\$0.	\$499,995.
Animal and Plant Health Inspection Service Emerald Ash Borer Survey and Outreach in Kentucky				
<b>Obrycki, John J</b>	3048104616	\$214,140.	\$0.	\$214,140.
Animal and Plant Health Inspection Service Cooperative Agricultural Pest Survey				
<b>Palli, Subba R</b>	3046973400	\$0.	\$58,850.	\$58,850.
Naprogenix Novel Active Insecticidal Compounds from Kentucky Native Plants				
<b>Palli, Subba R</b>	3048036700	\$0.	\$25,000.	\$25,000.
Dow AgroSciences Development of tightly regulated ecdysone receptor-based gene switches				
<b>Palli, Subba R</b>	3048104259	\$567,945.	\$0.	\$567,945.
Cooperative State Research Education and Extension Functional genomics studies on nuclear receptors: Target sites for insecticide development and resistance management				
<b>Potter, Daniel A</b>	3048103320	\$60,000.	\$0.	\$60,000.
US Golf Association Natural enemies affecting abundance of native and invasive white grubs and compatibility of golf course management practices with biological controls				
<b>Potter, Daniel A</b>	3048103321	\$60,000.	\$0.	\$60,000.
US Golf Association Use of baculovirus for season long control of black cutworms on golf courses and compatibility with soil insecticides and resistant turfgrasses				
<b>Rieske-Kinney, Lynne K</b>	3048104082	\$19,997.	\$0.	\$19,997.
KY Science and Technology Co Inc KSEF R&D Excellence: An innovative approach for elucidating trophic relationships of an invasive forest pest				
<b>Rieske-Kinney, Lynne K</b>	3048104722	\$3,000.	\$0.	\$3,000.
BAT Conservation International Dodd Scholarship: Application of Molecular Techniques for Detection of Prey of Insectivorous Bats				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Entomology</u></b>				
<b>Sharkey, Michael Joseph</b>	3046955300	\$0.	\$15,005.	\$15,005.
Florida State University MorphBank: Web Image Database Technology for Comparative Morphology and Biodiversity Research				
<b>Sharkey, Michael Joseph</b>	3046978900	\$0.	\$199,999.	\$199,999.
National Science Foundation TIGER: Thailand Inventory Group for Entomological Research				
<b>Townsend, Lee H</b>	3048104219	\$55,000.	\$0.	\$55,000.
KY Department of Agriculture Private Pesticide Applicator				
<b>Webb, Bruce Allen</b>	3046976900	\$0.	\$0.	\$0.
ParaTechs Corp STTR Phace I Grant: Enhancement of the baculovirus expression vector system				
<b>Webb, Bruce Allen</b>	3048104390	\$133,623.	\$0.	\$133,623.
ParaTechs Corp Enhancement of the Baculovirus Expression Vector System				
<b>Entomology</b>	<b>Totals:</b>	<b>\$7,115,321.</b>	<b>\$810,455.</b>	<b>\$7,925,776.</b>
<b><u>Forestry</u></b>				
<b>Arthur, Mary A</b>	3048103828	\$16,000.	\$0.	\$16,000.
Forest Service Fire and New Oak Seedlings				
<b>Arthur, Mary A</b>	3048104013	\$34,789.	\$0.	\$34,789.
Institute of Ecosystems Studies Long-term Ecological Research at Hubbard Brook Experimental Forest				
<b>Arthur, Mary A</b>	3048104371	\$0.	\$96,910.	\$96,910.
Forest Service Fire in the Southern Appalachians: Fuels, Stand Structure and Oaks, Part II				
<b>Arthur, Mary A</b>	3048104371	\$11,090.	\$0.	\$11,090.
Forest Service Fire in the Southern Appalachians: Fuels, Stand Structure and Oaks, Part II				
<b>Barnes, Thomas G</b>	3046995000	\$0.	\$13,700.	\$13,700.
Department of the Interior Japanese Spirea Control With Herbicides in the Big South Fork NRRRA				
<b>Barnes, Thomas G</b>	3048103647	\$10,000.	\$0.	\$10,000.
KY Heritage Land Conservation Fund Heritage Land Conservation Fund Publication				
<b>Barton, Christopher D</b>	3048104044	\$174,166.	\$0.	\$174,166.
KY Office of Energy Policy R&D Seed Grant: Techniques for Establishing Woody Biomass Plantations on Surface Mines as Feedstocks for energy Production				
<b>Cox, John J</b>	3048104235	\$60,000.	\$0.	\$60,000.
KY Department of Fish and Wildlife The Common Raven in Cliff Habitat: Detectability and Occupancy				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Forestry</u></b>				
<b>Hill, Deborah B</b>	3048103710	\$8,152.	\$0.	\$8,152.
KY Natural Resources Environmental Protection Cabinet Planting appropriately sized trees under utility lines				
<b>Lacki, Michael J</b>	3046994500	\$0.	\$40,000.	\$40,000.
National Council for Air and Stream Improvement Inc Effects of silvicultural treatments on insect prey and activity levels of forest-dwelling bats in the central appalachians				
<b>Lacki, Michael J</b>	3048104009	\$50,715.	\$0.	\$50,715.
KY Department of Fish and Wildlife Status, Distribution, and Reproductive Characteristics of River Otters in Kentucky				
<b>Maehr, David S</b>	3048102000	\$0.	\$-13,264.	\$-13,264.
Fish and Wildlife Service Cerulean Warbler and Golden Winged Warbler Status and Distribution in Kentucky				
<b>Maehr, David S</b>	3048103736	\$128,000.	\$0.	\$128,000.
KY Department of Fish and Wildlife Calf Survival, Meningeal Worm Impacts Dispersal and Population Expansion in and Eastern Kentucky Elk Herd				
<b>Maehr, David S</b>	3048103798	\$90,500.	\$0.	\$90,500.
KY Department of Fish and Wildlife Dispersal and Population Expansion of the Black Bear in Eastern Kentucky				
<b>Stringer, Jeffrey W</b>		\$7,500.	\$0.	\$7,500.
Forest Service Silvicultural Prescriptions for Degraded Hardwood Stands				
<b>Stringer, Jeffrey W</b>	3048103805	\$10,000.	\$0.	\$10,000.
Appalachian Hardwood Manufacturers Inc Silvicultural Prescriptions for Degraded Hardwood Stands				
<b>Stringer, Jeffrey W</b>	3048104244	\$15,419.	\$0.	\$15,419.
KY Natural Resources Environmental Protection Cabinet Kentucky Woodlands Magazine Production II				
<b>Stringer, Jeffrey W</b>	3048104257	\$30,000.	\$0.	\$30,000.
KY Natural Resources Environmental Protection Cabinet Kentucky Woodlands Magazine Production I				
<b>Forestry</b>	<b>Totals:</b>	<b>\$646,331.</b>	<b>\$137,346.</b>	<b>\$783,677.</b>
<b><u>Family &amp; Consumer Sciences</u></b>				
<b>Murray, Deborah A</b>	3048104075	\$322,205.	\$0.	\$322,205.
Cooperative State Research Education and Extension Mental Healthiness Aging Initiative (MHAI)				
<b>Family &amp; Consumer Sciences</b>	<b>Totals:</b>	<b>\$322,205.</b>	<b>\$0.</b>	<b>\$322,205.</b>
<b><u>Horticulture</u></b>				
<b>Durham, Richard E</b>	3048104467	\$0.	\$-14,800.	\$-14,800.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				
<b>Durham, Richard E</b>	3048104467	\$14,800.	\$0.	\$14,800.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Horticulture</u></b>				
<b>Durham, Richard E</b>	3048104490	\$14,800.	\$0.	\$14,800.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				
<b>Fulcher, Amy F</b>	3048103771	\$3,000.	\$0.	\$3,000.
University of Florida IR-4 Efficacy of Plant Growth Regulators on Branch Architecture of Container-Grown Trees and Shrubs				
<b>Houtz, Robert L</b>	3048104100	\$19,976.	\$0.	\$19,976.
KY Science and Technology Co Inc Isolation and Identification of Plant-Specific Peptide Deformylase Inhibitors from Soil Microorganisms for Use as Broad-Spectrum Herbicides and Selectable Markers				
<b>Ingram, Dewayne L</b>	3048104696	\$521,333.	\$0.	\$521,333.
Cooperative State Research Education and Extension New Crop Opportunities, Phase IX				
<b>Strang, John G</b>	3048103307	\$290,000.	\$0.	\$290,000.
KY Department of Agriculture Infrastructure Support for Growth of Kentucky's Grape and Wine Industry				
<b>Horticulture</b>	<b>Totals:</b>	<b>\$863,909.</b>	<b>\$-14,800.</b>	<b>\$849,109.</b>
<b><u>Plant Pathology</u></b>				
<b>De Sa' Guimaraes, Patricia</b>	3048103640	\$24,000.	\$0.	\$24,000.
Forest Service 2007 National Phytophthora ramorum Early Detection Survey of Forests in Kentucky				
<b>Farman, Mark L</b>	3048093200	\$0.	\$12,000.	\$12,000.
National Science Foundation Telomere Hypervariability in the fungus, Magnaporthe oryzae - a model plant pathogen				
<b>Farman, Mark L</b>	3048093200	\$0.	\$104,138.	\$104,138.
National Science Foundation Telomere Hypervariability in the fungus, Magnaporthe oryzae - a model plant pathogen				
<b>Farman, Mark L</b>	3048104365	\$990,000.	\$0.	\$990,000.
Cooperative State Research Education and Extension Localization of secreted proteins during penetration and invasive growth of the rice blast fungus Magnaporthe oryzae				
<b>Ghabrial, Said A</b>	3048103225	\$0.	\$52,309.	\$52,309.
University of Illinois Towards developing rust-resistant soybeans: identifying genes for rust resistance				
<b>Ghabrial, Said A</b>	3048103680	\$9,373.	\$0.	\$9,373.
Iowa State University Mitigating the effects of soybean virus diseases in the North Central states				
<b>Ghabrial, Said A</b>	3048104515	\$15,000.	\$0.	\$15,000.
KY Soybean Promotion Board Epidemiology of Bean Pod Mottle Virus and Resistance to Major Pathogens of Soybean				
<b>Goodin, Michael M</b>	3048088700	\$0.	\$12,308.	\$12,308.
National Institute of Allergy and Infectious Diseases Rhabdovirus phosphoproteins: RNA silencing and complex formation				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant Pathology</u></b>				
<b>Goodin, Michael M</b>	3048088700	\$0.	\$54,400.	\$54,400.
National Institute of Allergy and Infectious Diseases Rhabdovirus phosphoproteins: RNA silencing and complex formation				
<b>Goodin, Michael M</b>	3048104575	\$200,000.	\$0.	\$200,000.
National Science Foundation A Host Protein Interaction and Localization Map for a Plant				
<b>Hershman, Donald E</b>	3048103103	\$0.	\$7,164.	\$7,164.
Agricultural Research Service Uniform Trial on Integrated management of FHB: Kentucky				
<b>Hershman, Donald E</b>	3048103605	\$39,598.	\$0.	\$39,598.
North Carolina State University Kentucky Continued Development of the IPM PIPE Risk Management Tool NCSU Cooperative				
<b>Hershman, Donald E</b>	3048104258	\$6,000.	\$0.	\$6,000.
University of Tennessee Determining Distribution of a Corn Cyst Nematode in the MidSouth				
<b>Hershman, Donald E</b>	3048104519	\$9,100.	\$0.	\$9,100.
KY Soybean Promotion Board Impact of Newly-Recognized HG-Type 2 Populations of Soybean Cyst Nematode (SCN and Enhanced Grower Awareness of new SCN Challenges for Kentucky				
<b>Hershman, Donald E</b>	3048104597	\$19,625.	\$0.	\$19,625.
North Central Soybean Research Program Sentinel Plots to Monitor the Spread of Soybean Rust in US Soybean Production Regions				
<b>Hershman, Donald E</b>	3048104661	\$48,050.	\$0.	\$48,050.
North Carolina State University ipmPIPE 2008: University of Kentucky Component				
<b>Kachroo, Aardra P</b>	3048104449	\$100,302.	\$0.	\$100,302.
United Soybean Board Enhancing Soybean Yield by Manipulating the Expression of Seed Trait-Determining Genes				
<b>Kachroo, Aardra P</b>	3048104514	\$22,443.	\$0.	\$22,443.
KY Soybean Promotion Board Developing Glycerol as a Protective Agent Against Soybean Diseases Prevalent in Kentucky				
<b>Kachroo, Pradeep</b>	3048103749	\$0.	\$83,669.	\$83,669.
Boyce Thompson Institute for Plant Research Genetic, molecular and biochemical basis of resistance to turnip crinkle virus in Arabidopsis				
<b>Kachroo, Pradeep</b>	3048103749	\$85,564.	\$0.	\$85,564.
Boyce Thompson Institute for Plant Research Genetic, molecular and biochemical basis of resistance to turnip crinkle virus in Arabidopsis				
<b>Kachroo, Pradeep</b>	3048104688	\$0.	\$6,050.	\$6,050.
National Science Foundation Glycerol Metabolism and Its Role in Biotrophy Versus Necrotrophy in an Arabidopsis/Fungal Hemibiotroph Model System				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Plant Pathology</u></b>				
<b>Kachroo, Pradeep</b>	3048104688	\$149,997.	\$0.	\$149,997.
National Science Foundation Glycerol Metabolism and Its Role in Biotrophy Versus Necrotrophy in an Arabidopsis/Fungal Hemibiotroph Model System				
<b>NAGY, PETER D.</b>	3048086400	\$0.	\$163,200.	\$163,200.
National Institute of Allergy and Infectious Diseases Roles of host RNA binding proteins in virus replication				
<b>Seebold, Kenneth W</b>	3048104474	\$5,000.	\$0.	\$5,000.
University of Florida IR-4 Fungicide Performance Trials				
<b>Seebold, Kenneth W</b>	3048104757	\$6,000.	\$0.	\$6,000.
North Carolina State University Expanding ipmPIPE for Cucurbit Downy Mildew Forecasting				
<b>Vincelli, Paul</b>	3048103894	\$13,000.	\$0.	\$13,000.
University of Florida Southern Plant Diagnostic Network, IPM PIPE 2007, KY Component				
<b>Vincelli, Paul</b>	3048104024	\$39,000.	\$0.	\$39,000.
University of Florida Southern Region Plant Diagnostic Network, IPM PIPE 2007, KY Component				
<b>Vincelli, Paul</b>	3048104300	\$10,800.	\$0.	\$10,800.
KY State University Biofumigation for Soil Health in Organic High Tunnel and Conventional Field Vegetable Production Systems				
<b>Plant Pathology</b>	<b>Totals:</b>	<b>\$1,792,852.</b>	<b>\$495,238.</b>	<b>\$2,288,090.</b>
<b><u>Community &amp; Leadership Devel</u></b>				
<b>Horstmeier, Robin L</b>	3048103814	\$8,250.	\$0.	\$8,250.
KY Department for Technical Education University of Kentucky as a Landgrant Leader: Improving Teacher Education in the Commonwealth, UK Perkins Leadership Project				
<b>Hustedde, Ronald J</b>	3048102146	\$883,545.	\$0.	\$883,545.
KY Governor's Office of Agricultural Policy Kentucky Entrepreneurial Coaches Institute: Expansion Into South-Central Kentucky				
<b>Jones, Kenneth R</b>	3046975700	\$0.	\$811.	\$811.
National Four H Council Engaging Youth, SErving Community (EYSC4) Initiative				
<b>Jones, Kenneth R</b>	3048095200	\$0.	\$355.	\$355.
National Four H Council Engaging Youth, Serving Community (EYSC5) Initiative				
<b>Jones, Kenneth R</b>	3048104612	\$25,000.	\$0.	\$25,000.
National Four H Council Engaging Youth, Serving Community 6 (EYSC6)				
<b>Community &amp; Leadership Devel</b>	<b>Totals:</b>	<b>\$916,795.</b>	<b>\$1,166.</b>	<b>\$917,961.</b>

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Veterinary Science</u></b>				
<b>Artiushin, Sergey C</b>		\$26,646.	\$0.	\$26,646.
Biohelix Corp SBIR: Lateral Flow Molecular Assay for Detecting Streptococcus Equi				
<b>Bailey, Ernest F</b>	3046966200	\$0.	\$100,000.	\$100,000.
Morris Animal Foundation Horse Genomics: Linear Mapping and Microarray Development				
<b>Bailey, Ernest F</b>	3048104576	\$27,000.	\$0.	\$27,000.
University of Minnesota Program in Equine Medical Genetics (subcontract)				
<b>Balasuriya, Udeni</b>	3048103833	\$24,407.	\$0.	\$24,407.
American Quarter Horse Association Development of Real-Time PCR-Based Diagnostic Assays for Detection of Virus Infections in Horses				
<b>Balasuriya, Udeni</b>	3048104500	\$211,000.	\$0.	\$211,000.
Fort Dodge Laboratories Development and Characterization of Equine Arteritis Virus-Vectored Chimeric Viruses as Vaccines against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)				
<b>Balasuriya, Udeni</b>	3048104651	\$31,967.	\$0.	\$31,967.
Grayson Jockey Club Research Foundation Inc Molecular Epidemiology of EVA: 2006 Occurrence in the US				
<b>Horohov, David W</b>	3048009400	\$0.	\$31,250.	\$31,250.
University of Massachusetts Analysis and testing of equine immunologic reagents				
<b>Horohov, David W</b>	3048093500	\$0.	\$86,755.	\$86,755.
Grayson Jockey Club Research Foundation Inc Enhancing interferon-gamma in foals				
<b>Horohov, David W</b>	3048104662	\$52,000.	\$0.	\$52,000.
Fort Dodge Laboratories Effect of Equiloid Innovator or Metastim on Interferon-Gamma Production in the Foal				
<b>Issel, Charles J</b>	3046693300	\$0.	\$-6,415.	\$-6,415.
University of Pittsburgh EIAV Envelope Variation and Vaccine Efficacy				
<b>MacLeod, James N</b>	3048068600	\$0.	\$35,000.	\$35,000.
Morris Animal Foundation Articular Cartilage Maturation and Repair (Postdoctoral Fellowship for Michael Mienaltowski)				
<b>Tobin, Thomas</b>	3048104599	\$146,585.	\$0.	\$146,585.
KY Science and Technology Co Inc KSEF Commercialization: Early Diagnosis of Fescue Toxicity				
<b>Veterinary Science</b>	<b>Totals:</b>	<b>\$519,605.</b>	<b>\$246,590.</b>	<b>\$766,195.</b>
<b><u>Landscape Architecture</u></b>				
<b>Lee, Brian D</b>	3048103507	\$100,000.	\$0.	\$100,000.
KY Transportation Cabinet A Land Use Modeling Study in the Lexington-Fayette Area of Central Kentucky				
<b>Landscape Architecture</b>	<b>Totals:</b>	<b>\$100,000.</b>	<b>\$0.</b>	<b>\$100,000.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Regulatory Services</u></b>				
<b>McMurry, Stephen W</b>	3048103201	\$0.	\$2,500.	\$2,500.
Food and Drug Administration Medicated Feed Mill and BSE Rule Inspections				
<b>McMurry, Stephen W</b>	3048103201	\$23,429.	\$0.	\$23,429.
Food and Drug Administration Medicated Feed Mill and BSE Rule Inspections				
<b>Regulatory Services</b>	<b>Totals:</b>	<b>\$23,429.</b>	<b>\$2,500.</b>	<b>\$25,929.</b>
<b><u>Livestock Diag Disease Center</u></b>				
<b>Carter, Craig N</b>	3046829500	\$0.	\$37,872.	\$37,872.
Cooperative State Research Education and Extension Animal Health and Grazing Systems				
<b>Carter, Craig N</b>	3048103684	\$478,500.	\$0.	\$478,500.
KY Department of Agriculture Diagnostic Laboratory Services for Farmers and Agribusinesses				
<b>Carter, Craig N</b>	3048104564	\$23,036.	\$0.	\$23,036.
KY Department of Agriculture Bovine Spongiform Encephalopathy (BSE) Testing and Related Services				
<b>Livestock Diag Disease Center</b>	<b>Totals:</b>	<b>\$501,536.</b>	<b>\$37,872.</b>	<b>\$539,408.</b>
<b><u>Area Extension Field Programs</u></b>				
<b>Rose, Michael Anthony</b>	3048103692	\$37,500.	\$0.	\$37,500.
National Four H Council Adair County 4-H After School Program				
<b>Area Extension Field Programs</b>	<b>Totals:</b>	<b>\$37,500.</b>	<b>\$0.</b>	<b>\$37,500.</b>
<b><u>Family &amp; Consumer Sciences</u></b>				
<b>Vail, Ann</b>	3048030600	\$0.	\$-202,123.	\$-202,123.
KY Families and Children Cabinet Kentucky Food Stamp Nutrition Program				
<b>Vail, Ann</b>	3048030600	\$0.	\$159,084.	\$159,084.
KY Families and Children Cabinet Kentucky Food Stamp Nutrition Program				
<b>Vail, Ann</b>	3048030600	\$0.	\$1,393,841.	\$1,393,841.
KY Families and Children Cabinet Kentucky Food Stamp Nutrition Program				
<b>Family &amp; Consumer Sciences</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$1,350,802.</b>	<b>\$1,350,802.</b>
<b><u>e-Extension</u></b>				
<b>Craycraft, Carla G</b>	3048104096	\$243,491.	\$0.	\$243,491.
University of Nebraska The Transformation of Cooperative Extension				
<b>Griffin, Ashley S</b>	3048104498	\$15,000.	\$0.	\$15,000.
University of Nebraska HorseQuest Community of Practice				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>e-Extension</u></b>				
<b>Wood, Craig H</b>	3046887200	\$0.	\$150,000.	\$150,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
<b>Wood, Craig H</b>	3046887200	\$0.	\$115,000.	\$115,000.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
<b>Wood, Craig H</b>	3048065200	\$0.	\$-25,000.	\$-25,000.
University of Nebraska eXtension - The Transformation of Cooperative Extension				
<b>e-Extension</b>	<b>Totals:</b>	<b>\$258,491.</b>	<b>\$240,000.</b>	<b>\$498,491.</b>
<b><u>4-H Central Operations</u></b>				
<b>Delahanty, Terence J</b>		\$220,000.	\$0.	\$220,000.
Administration for Children and Families Positive Youth Development Partnership				
<b>Reed, Deana K</b>	3048104088	\$50,000.	\$0.	\$50,000.
Kansas State University 2008 Operation Military Kids				
<b>4-H Central Operations</b>	<b>Totals:</b>	<b>\$270,000.</b>	<b>\$0.</b>	<b>\$270,000.</b>
<b><u>Agr Programs</u></b>				
<b>Henning, Jimmy C</b>	3048020200	\$0.	\$23,701.	\$23,701.
KY Natural Resources Environmental Protection Cabinet University of Kentucky Cooperative Extension Service Liaison				
<b>Henning, Jimmy C</b>	3048103610	\$90,000.	\$0.	\$90,000.
University of Georgia Kentucky Sheep and Goat Herder Curriculum - Phase I				
<b>Henning, Jimmy C</b>	3048103612	\$10,000.	\$0.	\$10,000.
University of Georgia Training Program - Southern Region Sustainable Agriculture Research and Education (SARE) Professional Development Program (PDP) Model State Plan				
<b>Henning, Jimmy C</b>	3048104373	\$74,000.	\$0.	\$74,000.
Tobacco Education and Research Council Inc Developing Online Web Courses for Distance Education on Tobacco				
<b>Henning, Jimmy C</b>	3048104374	\$10,000.	\$0.	\$10,000.
Tobacco Education and Research Council Inc Kentucky Agriculture Agent Professional Development - Attending the 2008 Tobacco Workers Conference				
<b>Husband, Andrea L</b>	3048104569	\$38,500.	\$0.	\$38,500.
New Mexico State University Strengthening Community Agrosecurity Planning				
<b>Agr Programs</b>	<b>Totals:</b>	<b>\$222,500.</b>	<b>\$23,701.</b>	<b>\$246,201.</b>
<b><u>Nutrition and Food Science</u></b>				
<b>Forsythe, Hazel W</b>	3048104395	\$0.	\$29,886.	\$29,886.
Lexington Fayette Urban County Government Bluegrass/Aspendale HOPE VI Revitalization				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Agriculture</u></b>				
<b><u>Nutrition and Food Science</u></b>				
<b>Forsythe, Hazel W</b>	3048104395	\$27,498.	\$0.	\$27,498.
Lexington Fayette Urban County Government Bluegrass/Aspendale HOPE VI Revitalization				
<b>Kurzynske, Janet S</b>	3046768200	\$0.	\$182,000.	\$182,000.
Cooperative State Research Education and Extension CYFERnet-Program				
<b>Kurzynske, Janet S</b>	3048102104	\$0.	\$134,000.	\$134,000.
Cooperative State Research Education and Extension Promoting Life Skills in Middle School Youth				
<b>Kurzynske, Janet S</b>	3048103651	\$0.	\$27,447.	\$27,447.
University of Connecticut Innovative Food Safety Education for Low Literacy Food Service Employees Using Enhanced and Interactive Distance Learning				
<b>Kurzynske, Janet S</b>	3048103651	\$6,413.	\$0.	\$6,413.
University of Connecticut Innovative Food Safety Education for Low Literacy Food Service Employees Using Enhanced and Interactive Distance Learning				
<b>Kurzynske, Janet S</b>	3048104261	\$46,000.	\$0.	\$46,000.
Cooperative State Research Education and Extension CYFARnet Liaison				
<b>Nutrition and Food Science</b>	<b>Totals:</b>	<b>\$79,911.</b>	<b>\$373,333.</b>	<b>\$453,244.</b>
<b><u>Family Studies</u></b>				
<b>Mimbs, Cheryl A.</b>	3048104061	\$5,500.	\$0.	\$5,500.
KY Department for Technical Education Professional Development for Family and Consumer Sciences Teacher Educators				
<b>Vail, Ann</b>	3048014400	\$0.	\$333,334.	\$333,334.
KY Health Services Cabinet The UK/BHMP Cooperative Relationship to Establish a Pro-Marriage/Pro-Family Initiative among Central Kentucky's Communities and Institutions				
<b>Family Studies</b>	<b>Totals:</b>	<b>\$5,500.</b>	<b>\$333,334.</b>	<b>\$338,834.</b>
<b><u>Merchandising, Apparel &amp; Textiles</u></b>				
<b>Easter, Elizabeth P</b>	3046898300	\$0.	\$34,293.	\$34,293.
National Association of Institutional Linen Management Quality Control Laboratory For NAILM				
<b>Merchandising, Apparel &amp; Textiles</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$34,293.</b>	<b>\$34,293.</b>
<b><u>Ky Tobacco Research &amp; Dev Center</u></b>				
<b>Littleton, John M</b>	3048104656	\$54,400.	\$0.	\$54,400.
Naprogenix STTR: Hypericum Extracts as Potential Anti-Relapse Medications in Alcoholism				
<b>Littleton, John M</b>	3048104657	\$76,180.	\$0.	\$76,180.
Naprogenix STTR: Transgenic Plant Cells as a Source of Hepatoprotective Drugs				
<b>Ky Tobacco Research &amp; Dev Center</b>	<b>Totals:</b>	<b>\$130,580.</b>	<b>\$0.</b>	<b>\$130,580.</b>
<b>Agriculture Totals:</b>		<b>\$24,451,064.</b>	<b>\$6,520,938.</b>	<b>\$30,972,002.</b>

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Minority Affairs</u></b>				
<b><u>Minority Affairs</u></b>				
Turner, William H	3048004100	\$0.	\$13,967.	\$13,967.
KY Council on Postsecondary Education Governor's Minority Student College Preparation Program				
Turner, William H	3048004100	\$0.	\$80,506.	\$80,506.
KY Council on Postsecondary Education Governor's Minority Student College Preparation Program				
<b>Minority Affairs</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$94,473.</b>	<b>\$94,473.</b>
<b><u>Student Support Services</u></b>				
Wims, Lydia E	3046933700	\$0.	\$270,030.	\$270,030.
Department of Education Student Support Services				
<b>Student Support Services</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$270,030.</b>	<b>\$270,030.</b>
	<b>Minority Affairs Totals:</b>	<b>\$0.</b>	<b>\$364,503.</b>	<b>\$364,503.</b>
<b><u>Student Affairs</u></b>				
<b><u>Student Affairs</u></b>				
Edwards, Dorothy Jo		\$138,624.	\$0.	\$138,624.
Department of Education Grant Proposal to Prevent Violence Behavior Among College Students				
Edwards, Dorothy Jo	3046843700	\$0.	\$-1,576.	\$-1,576.
Department of Justice Violence Against Women on Campus				
Edwards, Dorothy Jo	3048102109	\$0.	\$1,576.	\$1,576.
Department of Justice Grants to Reduce Violent Crimes Against Women on Campus--Supplemental				
Edwards, Dorothy Jo	3048103552	\$0.	\$144,203.	\$144,203.
Department of Education Grant Proposal to Prevent Violence Behavior Among College Students				
Edwards, Dorothy Jo	3048103888	\$10,000.	\$0.	\$10,000.
Toyota Motor Manufacturing USA Inc Students Educating and Empowering to Develop Safety				
<b>Student Affairs</b>	<b>Totals:</b>	<b>\$148,624.</b>	<b>\$144,203.</b>	<b>\$292,827.</b>
	<b>Student Affairs Totals:</b>	<b>\$148,624.</b>	<b>\$144,203.</b>	<b>\$292,827.</b>
<b><u>Library Administration</u></b>				
<b><u>Library Administration</u></b>				
Greider, Antoinette	3048090900	\$0.	\$109,880.	\$109,880.
Lexmark International Inc Lexmark International, Inc. Information Center				
Kennedy, Gail A	3048103666	\$2,500.	\$0.	\$2,500.
Lexarts Looking at Jazz, America's Art Form				
Molinaro, Mary H	3046894500	\$0.	\$399,886.	\$399,886.
National Endowment for the Humanities National Digital Newspaper Program Phase One: The Kentucky Test Bed, or KNP Redux				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Library Administration</u></b>				
<b><u>Library Administration</u></b>				
<b>Weig, Eric C</b>	3048063800	\$0.	\$107,921.	\$107,921.
KY Council on Postsecondary Education Kentuckiana Digital Library Program				
<b>Library Administration</b>	<b>Totals:</b>	<b>\$2,500.</b>	<b>\$617,687.</b>	<b>\$620,187.</b>
<b><u>Medical Center Library</u></b>				
<b>Stith, Janet B</b>	3046555600	\$0.	\$10,182.	\$10,182.
Frontier School Midwifery Family Nursing Consulting Agreement UKCMC Library & Frontier School Midwifery and Family Nursing				
<b>Medical Center Library</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$10,182.</b>	<b>\$10,182.</b>
	<b>Library Administration Totals:</b>	<b>\$2,500.</b>	<b>\$627,869.</b>	<b>\$630,369.</b>
<b><u>Office of the Provost</u></b>				
<b><u>Office of the Provost</u></b>				
<b>Stewart, Sharon R</b>	3048104067	\$61,432.	\$0.	\$61,432.
Jumpstart For Young Children Inc Higher Education Affiliate Partnership				
<b>Office of the Provost</b>	<b>Totals:</b>	<b>\$61,432.</b>	<b>\$0.</b>	<b>\$61,432.</b>
<b><u>Art Museum</u></b>				
<b>Borrowdale-Cox, Deborah</b>		\$7,500.	\$0.	\$7,500.
Lexarts School and Teacher Outreach				
<b>Nelson, Amy</b>	3048104333	\$1,000.	\$0.	\$1,000.
KY Historical Society Kentucky: The Master Paintings From the Frontier Era to the Great Depression				
<b>Walsh-Piper, Kathleen A</b>	3048104709	\$10,000.	\$0.	\$10,000.
Central Indiana Community Foundation El Anatsui Sculpture Installation and Lecture				
<b>Welker, Janie</b>		\$25,000.	\$0.	\$25,000.
National Endowment for the Arts Art Museum Photography Catalogue				
<b>Art Museum</b>	<b>Totals:</b>	<b>\$43,500.</b>	<b>\$0.</b>	<b>\$43,500.</b>
<b><u>Partnership Inst. for Math and Science</u></b>				
<b>Eakin, Paul M</b>	3048103548	\$67,700.	\$0.	\$67,700.
Northern KY University Technical Support for Kentucky Mathematics Center Coaching Teaching				
<b>Eakin, Paul M</b>	3048103696	\$15,505.	\$0.	\$15,505.
Northern KY University Technical Support for Kentucky Center for Mathematics				
<b>Mohr, Margaret J.</b>	3048104043	\$748,625.	\$0.	\$748,625.
National Science Foundation University of Kentucky NOYCE Fellows Program: New Opportunities Yielding Classroom Excellence				
<b>Zeidler, Kimberly J</b>	3048104328	\$200,000.	\$0.	\$200,000.
KY Department of Education 2007-08 Mathematics & Science Partnership (Science)				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Office of the Provost</u></b>				
<b><u>Partnership Inst. for Math and Science</u></b>				
<b>Zeidler, Kimberly J</b>	3048104329	\$200,000.	\$0.	\$200,000.
KY Department of Education 2007-08 Mathematics & Science Partnership				
<b>Zeidler, Kimberly J</b>	3048104368	\$131,456.	\$0.	\$131,456.
KY Department of Education 2007-2008 MLSN/SLSN; UK Leadership Networks				
<b>Zeidler, Kimberly J</b>	3048104424	\$140,000.	\$0.	\$140,000.
KY Council on Postsecondary Education Putting All Students on Track: A Partnership to Ensure Success in College Level Mathematics				
<b>Partnership Inst. for Math and Science</b>	<b>Totals:</b>	<b>\$1,503,286.</b>	<b>\$0.</b>	<b>\$1,503,286.</b>
<b><u>International Affairs</u></b>				
<b>Bettez, David J</b>	3048103682	\$0.	\$80,848.	\$80,848.
Department of Education Strengthening Asian Studies and Languages Across the Curriculum				
<b>Bettez, David J</b>	3048103682	\$76,912.	\$0.	\$76,912.
Department of Education Strengthening Asian Studies and Languages Across the Curriculum				
<b>Bettez, David J</b>	3048104101	\$0.	\$-31,097.	\$-31,097.
Georgetown University NESA Program				
<b>Bettez, David J</b>	3048104101	\$229,976.	\$0.	\$229,976.
Georgetown University NESA Program				
<b>Goldstein, Beth L</b>	3048018900	\$0.	\$44,000.	\$44,000.
Freeman Foundation National Consortium for teaching About Asia- Year IX				
<b>Slaymaker, Douglas N</b>		\$1,200.	\$0.	\$1,200.
KY Humanities Council Asia Center Symposium on Social and Environmental Justice in Asia				
<b>Wang, Cecilia</b>	3048103679	\$15,000.	\$0.	\$15,000.
National Endowment for the Arts Asian Folk Music Outreach Program				
<b>International Affairs</b>	<b>Totals:</b>	<b>\$323,088.</b>	<b>\$93,751.</b>	<b>\$416,839.</b>
	<b>Office of the Provost Totals:</b>	<b>\$1,931,306.</b>	<b>\$93,751.</b>	<b>\$2,025,057.</b>
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Anthropology</u></b>				
<b>Ahler, Steven R</b>	3048089300	\$0.	\$5,700.	\$5,700.
American Consulting Engineers Phase 2 Srch. Investigations at 3 Sites along KY 922 (Newtown Pike) Fayette County, Kentucky- State Item No. 7-261.00				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$20,000.	\$20,000.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b>Anthropology</b>				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$115,000.	\$115,000.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$3,751.	\$3,751.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$23,857.	\$23,857.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$4,171.	\$4,171.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$95,776.	\$95,776.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$5,243.	\$5,243.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$85,728.	\$85,728.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$3,066.	\$3,066.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$37,812.	\$37,812.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$60,000.	\$60,000.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$20,235.	\$20,235.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$37,500.	\$37,500.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$34,334.	\$34,334.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
<b>Ahler, Steven R</b>	3048103305	\$0.	\$9,756.	\$9,756.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b>Anthropology</b>				
<b>Ahler, Steven R</b>	3048103653	\$9,076.	\$0.	\$9,076.
HMB Professional Engineers Inc				
A Proposal to Conduct Follow-up Investigations of Three Anomalies Found During Side-scanning Sonar (Underwater) Survey of Sections 2 and 5 of the Louisville-Southern Indiana Ohio River Bridgects Project in Jefferson County, Kentucky State Item #5-118.00				
<b>Ahler, Steven R</b>	3048104008	\$0.	\$3,144.	\$3,144.
National Park Service				
Testing and Monitoring and Paleontological Assessment of Selected Cave Trail Segments in Mammoth Cave				
<b>Ahler, Steven R</b>	3048104008	\$259,529.	\$0.	\$259,529.
National Park Service				
Testing and Monitoring and Paleontological Assessment of Selected Cave Trail Segments in Mammoth Cave				
<b>Ahler, Steven R</b>	3048104208	\$7,931.	\$0.	\$7,931.
Bernardin Lochmueller and Associates				
Phase I Archaeological Survey of Selected Borrow Tracks Associated With US Highway 68, Trigg County, Kentucky				
<b>Ahler, Steven R</b>	3048104221	\$81,256.	\$0.	\$81,256.
Illinois State Museum Society				
National Register Eligibility of the POW Camp and Five Archaelogical sites, Ft Leonard Wood, Missouri, FY07				
<b>Ahler, Steven R</b>	3048104435	\$38,068.	\$0.	\$38,068.
QK4				
Phase 2 National Register Evacuation of Three Sites (15TR409, 15TR410, 15TR411) Located within Little River Flowage Easement Mitigation Tract, Trigg County, KY				
<b>Anglin, Mary Kivas</b>	3048104605	\$2,900.	\$0.	\$2,900.
National Science Foundation				
Women's Health and Illness in a Migrant-Sending Community in Southern Mexico				
<b>Cliggett, Lisa C</b>	3046669200	\$0.	\$4,500.	\$4,500.
National Science Foundation				
Migration and Environmental Change: Tenure Insecurity in a Zambian Frontier				
<b>Cliggett, Lisa C</b>	3048104701	\$25,000.	\$0.	\$25,000.
National Science Foundation				
Semiar: Tonga Timeline-Appraising 60 years of multidisciplinary research in Southern Province, Zambia				
<b>Jefferies, Richard</b>	3048104230	\$1,150.	\$0.	\$1,150.
Virginia Academy of Science				
Ceramic Analysis of Late Prehistoric Groups in Southwestern Virginia				
<b>Little, Peter Deal</b>	3048103644	\$0.	\$7,300.	\$7,300.
National Science Foundation				
Doctoral Dissertation Improvement Grant for Daniel Murphy: Absentee Herd-Ownership and Common Property Resource Management in Rural Mongolia				
<b>Little, Peter Deal</b>	3048103644	\$0.	\$-7,300.	\$-7,300.
National Science Foundation				
Doctoral Dissertation Improvement Grant for Daniel Murphy: Absentee Herd-Ownership and Common Property Resource Management in Rural Mongolia				
<b>Little, Peter Deal</b>	3048103644	\$7,800.	\$0.	\$7,800.
National Science Foundation				
Doctoral Dissertation Improvement Grant for Daniel Murphy: Absentee Herd-Ownership and Common Property Resource Management in Rural Mongolia				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Anthropology</u></b>				
<b>Pollack, David</b>	3048104445	\$15,000.	\$0.	\$15,000.
KY Department of Environmental Protection Memorandum of Agreement for the Arch. Reconnaissance Survey & Site Identification of the Heritage Land Conservation Found Tract (the Reynolds Tract), Laurel County, KY				
<b>Anthropology</b>	<b>Totals:</b>	<b>\$447,710.</b>	<b>\$569,573.</b>	<b>\$1,017,283.</b>
<b><u>Ky Archaeoloigcal Survey</u></b>				
<b>Henderson, A G</b>	3048104475	\$52,750.	\$0.	\$52,750.
AMEC Earth and Environmental Inc Analyze Mississippian Ceramics from 15JF702/ McAlpine Artifact				
<b>McBride, Kim A</b>	3048000800	\$0.	\$35,000.	\$35,000.
KY Heritage Council Historic Preservation Initiative				
<b>Pollack, David</b>	3048104250	\$30,000.	\$0.	\$30,000.
KY Heritage Council Urban Archaeology				
<b>Pollack, David</b>	3048104267	\$10,000.	\$0.	\$10,000.
KY Department of Environmental Protection Adkins Property Archaeological Survey				
<b>Pollack, David</b>	3048104307	\$30,000.	\$0.	\$30,000.
KY Department of Environmental Protection Knobs State Forest Archaeological Survey				
<b>Pollack, David</b>	3048104426	\$22,000.	\$0.	\$22,000.
KY Heritage Council Central Kentucky Survey				
<b>Pollack, David</b>	3048104685	\$301,600.	\$0.	\$301,600.
Louisville Metro Government Updating Jefferson County, Kentucky Inventory and Survey of Historic Sites				
<b>Stottman, Michael Jay</b>	3048103670	\$40,177.	\$0.	\$40,177.
Riverside the Farnsley Moremen Landing Farnsley-Moremen Landing, Building Blocks of History Education				
<b>Ky Archaeoloigcal Survey</b>	<b>Totals:</b>	<b>\$486,527.</b>	<b>\$35,000.</b>	<b>\$521,527.</b>
<b><u>Chemistry</u></b>				
<b>Anthony, John Edward</b>	3046842200	\$0.	\$107,000.	\$107,000.
US Office of Naval Research Photovoltaic Devices from Self-Assembled Organic Semiconductors				
<b>Anthony, John Edward</b>	3048103690	\$25,012.	\$0.	\$25,012.
Oregon State University Oregon nanoscience and Microtechnologies Institute, Nanometrology and Nanoelectronics Iniative				
<b>Anthony, John Edward</b>	3048104220	\$36,493.	\$0.	\$36,493.
Merck and Company Inc Development of a New Synthetic Route to Fluorinated TES ADT				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b>Chemistry</b>				
<b>Anthony, John Edward</b>	3048104433	\$115,000.	\$0.	\$115,000.
National Science Foundation A Exploration of Higher Acenes				
<b>Atwood, David A</b>	3046933600	\$0.	\$41,466.	\$41,466.
Merloc LLC Chemical Solutions to Metal Waste Problems				
<b>Atwood, David A</b>	3046933600	\$0.	\$59,472.	\$59,472.
Merloc LLC Chemical Solutions to Metal Waste Problems				
<b>Atwood, David A</b>	3048104268	\$19,971.	\$0.	\$19,971.
KY Science and Technology Co Inc R&D Excellence: Gas Phase Phosphate Ester Binding				
<b>Bachas, Leonidas G</b>	3048104452	\$38,050.	\$0.	\$38,050.
Western KY University Integrated Biomarker Diagnostic Systems for Monitoring Astronaut Health				
<b>Butterfield, David A</b>	3048104686	\$122,124.	\$0.	\$122,124.
St Louis University Oxidative Dysfunction of Lrp at the Blood-Brain Barrier in Alzheimer's Disease				
<b>Clouthier, Dennis J</b>	3046984200	\$0.	\$79,467.	\$79,467.
National Science Foundation REU Site: Undergraduate Research for Appalachian Students at the Department of Chemistry, University of Kentucky				
<b>Clouthier, Dennis J</b>	3048075500	\$0.	\$50,000.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Laser Spectroscopic Detection and Characterization of Molecular Ions				
<b>Daunert, Sylvia</b>	3046791700	\$0.	\$23,862.	\$23,862.
National Institute of General Medical Sciences Modified Photoproteins as Labels and Molecular Switches in Bioanalysis				
<b>Daunert, Sylvia</b>	3048103862	\$405,000.	\$0.	\$405,000.
National Science Foundation Spore-Based Biosensing Systems: A Stabilized Dormant-Active Approach to Whole-Cell Biosensors				
<b>Daunert, Sylvia</b>	3048104224	\$96,431.	\$0.	\$96,431.
University of California Irvine C-MEMS/C-NEMS for Miniature Biofuels Cells				
<b>Holmes, Stephen M</b>	3048074800	\$0.	\$49,999.	\$49,999.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecule-Based Magnetic Clusters Constructed from Poly(pyrazolyl) borate Acetylide and Butadiynylide Building Blocks				
<b>Holmes, Stephen M</b>	3048080800	\$0.	\$185,000.	\$185,000.
National Science Foundation CAREER: Construction of Magnetic Cyanide-, Acetylide-, and Butadiynylide-Based Clusters				
<b>JI, TAE H</b>	3046875900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Intermolecular Activation of GPCR				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Chemistry</u></b>				
<b>Lynn, Bert C</b>	3046839000	\$0.	\$168,291.	\$168,291.
National Institute on Aging Mitochondrial Proteome Changes in Alzheimer's Disease				
<b>Watson, Mark Deas</b>	3048020300	\$0.	\$116,000.	\$116,000.
National Science Foundation Organic Conjugated Polymers composed of Alternating Non-Fluorinated and Fluorinated Units: Novel Syntheses and Structure-Property Studies				
<b>Watson, Mark Deas</b>	3048020300	\$0.	\$116,000.	\$116,000.
National Science Foundation Organic Conjugated Polymers composed of Alternating Non-Fluorinated and Fluorinated Units: Novel Syntheses and Structure-Property Studies				
<b>Yang, Dong-Sheng</b>	3048075600	\$0.	\$50,000.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Probing Metal Binding to NDA and RNA Nucleobases with High-Resolution Photoelectron Spectroscopy				
<b>Yang, Dong-Sheng</b>	3048103656	\$406,516.	\$0.	\$406,516.
National Science Foundation Photoelectron and Photoionization Spectroscopy of Metal-Organic Complexes				
<b>Yates, S W</b>	3048103226	\$0.	\$260,000.	\$260,000.
National Science Foundation Using fast Neutrons to Explore Nuclear Structure				
<b>Yates, S W</b>	3048103226	\$260,000.	\$0.	\$260,000.
National Science Foundation Using fast Neutrons to Explore Nuclear Structure				
<b>Chemistry</b>	<b>Totals:</b>	<b>\$1,524,597.</b>	<b>\$1,591,321.</b>	<b>\$3,115,918.</b>
<b><u>Geography</u></b>				
<b>Grossardt, Theodore H</b>	3048104391	\$119,916.	\$0.	\$119,916.
Department of Transportation Deploying Structured Public Involvement for Transit Agency Planning				
<b>Leinbach, Thomas R</b>	3048103721	\$110,023.	\$0.	\$110,023.
National Science Foundation Towards a Knowledge Economy: Firm Competitiveness, Institutional Thickness, Localized Learning and Value Added Supply Chain Networks in Penang, Malaysia				
<b>Roberts, Susan</b>	3048104620	\$9,000.	\$0.	\$9,000.
National Science Foundation Fellowship for Chris Blackden: Doctoral Dissertation Research: Transnational Policy Articulations: India, Agriculture, and the WTO				
<b>Secor, Anna J</b>	3048103720	\$0.	\$41,444.	\$41,444.
National Science Foundation The Veiling-Fashion Industry: Transnational Geographies of Islamism, Capitalism, and Identity				
<b>Secor, Anna J</b>	3048103720	\$56,884.	\$0.	\$56,884.
National Science Foundation The Veiling-Fashion Industry: Transnational Geographies of Islamism, Capitalism, and Identity				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b>Geography</b>				
<b>Sherriff, Rosemary Lynne</b>	3048104015	\$29,794.	\$0.	\$29,794.
National Park Service				
Tree-ring Reconstruction of Insect Outbreaks in Lake Clark and Katmai National Park and Preserve				
<b>Sherriff, Rosemary Lynne</b>	3048104249	\$0.	\$9,632.	\$9,632.
National Science Foundation				
Collaborative Research: Fire Risk and Ecological Integrity in the Wildland Urban Interface of Colorado Front Range				
<b>Sherriff, Rosemary Lynne</b>	3048104249	\$63.	\$0.	\$63.
National Science Foundation				
Collaborative Research: Fire Risk and Ecological Integrity in the Wildland Urban Interface of Colorado Front Range				
<b>Wood, Andrew M.</b>	3048104200	\$3,730.	\$0.	\$3,730.
National Science Foundation				
Collaborative Research: Mapping Globalization: Geographies of Knowledge in the Oil Exploration and Production Industry				
<b>Geography</b>	<b>Totals:</b>	<b>\$329,410.</b>	<b>\$51,076.</b>	<b>\$380,486.</b>
<b>Geology</b>				
<b>Moecher, David P</b>	3048068900	\$0.	\$55,471.	\$55,471.
National Science Foundation				
Identifying the Limitations and Expanding the Utility of Detrital Mineral U-Pb Geochronology to Tectonic Studies				
<b>Moecher, David P</b>	3048104554	\$13,933.	\$0.	\$13,933.
US Geological Survey				
Bedrock Geology of the Southern Winchendon 7.5 Minute Quadrangle, North-central Massachusetts				
<b>Ravat, Dhananjay</b>	3048103864	\$30,000.	\$0.	\$30,000.
National Science Foundation				
Spectral Analysis of Aeromagnetic Data for Geothermal Reconnaissance of West of the Red Sea Region in Egypt				
<b>Ravat, Dhananjay</b>	3048104004	\$25,000.	\$0.	\$25,000.
US Geological Survey				
Magnetic Anomalies of the Continental US from NURE Data Using Comprehensive Model				
<b>Rimmer, S M</b>	3048103715	\$0.	\$95,372.	\$95,372.
National Science Foundation				
Collaborative Research: The Permian-Triassic Transition in Antarctica: Evaluating the Rates and Variability of Carbon Isotope Fluctuations in Terrestrial Organic Matter				
<b>Rimmer, S M</b>	3048103715	\$9,266.	\$0.	\$9,266.
National Science Foundation				
Collaborative Research: The Permian-Triassic Transition in Antarctica: Evaluating the Rates and Variability of Carbon Isotope Fluctuations in Terrestrial Organic Matter				
<b>Thomas, William A</b>	3048103732	\$10,000.	\$0.	\$10,000.
Weyerhaeuser Company				
Stratigraphy of Floyd Shale and Related Units in the Black Warror Basin				
<b>Woolery, Edward W</b>	3048104676	\$58,617.	\$0.	\$58,617.
US Geological Survey				
Towards Construction of the Central United States Seismic Observatory and Calibration Site: Defining the Geologic Site Model				
<b>Geology</b>	<b>Totals:</b>	<b>\$146,816.</b>	<b>\$150,843.</b>	<b>\$297,659.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Mathematics</u></b>				
<b>DEMLOW, ALAN</b>	3048103110	\$0.	\$49,280.	\$49,280.
National Science Foundation Adaptive FEM for Controlling Pointwise Errors and Level Sets				
<b>Eakin, Paul M</b>	3046635800	\$0.	\$17,628.	\$17,628.
National Science Foundation Appalachian Mathematics and Science Partnership				
<b>Eakin, Paul M</b>	3046635800	\$0.	\$10,461.	\$10,461.
National Science Foundation Appalachian Mathematics and Science Partnership				
<b>Kang, Sung</b>	3048103694	\$106,201.	\$0.	\$106,201.
National Science Foundation Image Deblurring and Decomposition: Texture and Color Image Analysis				
<b>Lee, C W</b>	3046540100	\$0.	\$6,000.	\$6,000.
University of Tennessee Appalachian Collaborative Center for Learning, Assessment, and Instruction in Mathematics (ACCLAIM)				
<b>Man, Chi-Sing</b>	3046808600	\$0.	\$12,423.	\$12,423.
National Science Foundation Microstructures and Residual Stress in Polycrystalline Materials: Their Nondestructive Characterization and Effects on Mechanical Properties				
<b>Millman, Richard S</b>	3046990400	\$0.	\$612,280.	\$612,280.
National Science Foundation Algebra Cubed: Algebraic Concepts In Middle and High School in Two Appalachian Counties-Track 1				
<b>Nagel, Uwe R</b>	3048077400	\$0.	\$29,160.	\$29,160.
National Security Agency Hilbert Functions and Multiplicity				
<b>Mathematics</b>	<b>Totals:</b>	<b>\$106,201.</b>	<b>\$737,232.</b>	<b>\$843,433.</b>
<b><u>Physics and Astronomy</u></b>				
<b>Das, Sumit Ranjan</b>	3046999400	\$0.	\$160,000.	\$160,000.
National Science Foundation Research on Gauge Theories, Gravity and Strings				
<b>Delong, L E</b>	3046114000	\$0.	\$120,000.	\$120,000.
Department of Energy Dynamic Flux Line Response in Layered Superconductors with Tailored Defect Structures				
<b>Delong, L E</b>	3048104201	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc R&D Excellence: Investigation of a new Class of High-Temperature Ferromagnetic Semiconductors				
<b>Eides, Michael</b>	3048104663	\$60,000.	\$0.	\$60,000.
National Science Foundation Theory of Light Hydrogenlike Bound States: High Order Corrections to Lamb Shift, Hyperfine Splitting, and g-Factors				
<b>Elitzur, Moshe</b>	3048103887	\$90,870.	\$0.	\$90,870.
Jet Propulsion Laboratory The AGN Obscuring Torus				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Physics and Astronomy</u></b>				
<b>Elitzur, Moshe</b>	3048104353	\$9,090.	\$0.	\$9,090.
Jet Propulsion Laboratory Water ice and warm CO in extremely obscured ULIRGs at z-2				
<b>Ferland, Gary</b>	3046895100	\$0.	\$74,148.	\$74,148.
Goddard Space Flight Center Unraveling the Message of the Light - Spectral Diagnostics of AGN and Starbursts				
<b>Ferland, Gary</b>	3048104595	\$118,155.	\$0.	\$118,155.
National Aeronautics and Space Administration Unraveling the Message of the Light; Spectral Diagnostics of AGN, Starbursts, and Star-forming Regions				
<b>Gardner, Susan V</b>	3046921600	\$0.	\$95,000.	\$95,000.
Department of Energy Tests of Fundamental Symmetries				
<b>Gorringe, Tim P</b>	3046998400	\$0.	\$187,476.	\$187,476.
National Science Foundation Studies of Basic Symmetries and Fundamental Constants with Muons and Pions				
<b>Korsch, Wolfgang</b>	3046251300	\$0.	\$150,000.	\$150,000.
Energy Research Studies of Hadronic Structure Using Electromagnetic Probes				
<b>Korsch, Wolfgang</b>	3048103893	\$11,438.	\$0.	\$11,438.
Southeastern Universities Research Association Inc SURA Graduate Student Fellowship				
<b>Liu, Kehfei</b>	3046169100	\$0.	\$169,490.	\$169,490.
Energy Research Research in Theoretical Nuclear Physics				
<b>Liu, Kehfei</b>	3046169100	\$0.	\$20,510.	\$20,510.
Energy Research Research in Theoretical Nuclear Physics				
<b>Murthy, Ganpathy</b>	3048104379	\$100,000.	\$0.	\$100,000.
National Science Foundation Mesoscopic Quantum Critical Regimes and Disorder-Driven Deconfinement				
<b>Shlosman, Isaac</b>	3046992700	\$0.	\$58,031.	\$58,031.
University of Texas at Austin Structure and Dynamics of Local and Intermediate Redshift Disks				
<b>Shlosman, Isaac</b>	3048039000	\$0.	\$99,485.	\$99,485.
Goddard Space Flight Center Study of Galactic Disk Evolution in Realistic Dark Matter Halos				
<b>Shlosman, Isaac</b>	3048039000	\$0.	\$82,595.	\$82,595.
Goddard Space Flight Center Study of Galactic Disk Evolution in Realistic Dark Matter Halos				
<b>SUSHKO, YURIY V.</b>	3046898700	\$0.	\$49,055.	\$49,055.
Columbia University Probing Quantum Phase Transitions by MuSR and Complementary Methods in Applied Pressure				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Physics and Astronomy</u></b>				
<b>Troland, Thomas H</b>	3048103691	\$18,000.	\$0.	\$18,000.
Western KY University				
Fellowship for Matthew Lykins: The Origins of Stars & Planets - A Study of the Role of Magnetic Fields in Star Formation in the W3 Region of the Galaxy				
<b>Physics and Astronomy</b>	<b>Totals:</b>	<b>\$427,553.</b>	<b>\$1,265,790.</b>	<b>\$1,693,343.</b>
<b><u>Political Science</u></b>				
<b>Randazzo, Kirk</b>	3048103812	\$68,795.	\$0.	\$68,795.
National Science Foundation				
Legislatures and the Judiciary: The Effects of Statutory Constraint				
<b>Political Science</b>	<b>Totals:</b>	<b>\$68,795.</b>	<b>\$0.</b>	<b>\$68,795.</b>
<b><u>Psychology</u></b>				
<b>Akins, Chana</b>	3048099700	\$0.	\$179,463.	\$179,463.
National Institute on Drug Abuse				
Prenatal Cocaine Effects on Sexual Motivation				
<b>Bardo, Michael T</b>	3046741300	\$0.	\$279,334.	\$279,334.
National Institute on Drug Abuse				
Novelty, Dopamine and Response to Amphetamine				
<b>Bardo, Michael T</b>	3048104308	\$9,700.	\$0.	\$9,700.
US Worldmeds LLC				
Effect of Lofexidine on Norepinephrine levels				
<b>Bardo, Michael T</b>	3048104309	\$1,427,367.	\$0.	\$1,427,367.
National Institute on Drug Abuse				
CDART - Center for Drug Abuse Research Translation				
<b>Bardo, Michael T</b>	3048104314	\$150,000.	\$0.	\$150,000.
Targacept				
Targacept Contract				
<b>Bardo, Michael T</b>	3048104466	\$29,304.	\$0.	\$29,304.
National Institute on Drug Abuse				
Fellowship for Thomas Wooters: Reinforcing and Neurochemical Effects of Cocaine in a Rodent Model of ADHD				
<b>Bardo, Michael T</b>	3048104600	\$150,000.	\$0.	\$150,000.
Targacept				
Targacept Contract #2				
<b>Carlson, Charles R</b>	3048103868	\$56,000.	\$0.	\$56,000.
Eastern State Hospital				
Clinical Training Agreement with Eastern State Hospital				
<b>Fillmore, Mark</b>	3046950400	\$0.	\$305,644.	\$305,644.
National Institute on Drug Abuse				
Neurocognitive Consequences of Adolescent Drug Use				
<b>Fillmore, Mark</b>	3048052100	\$0.	\$192,040.	\$192,040.
National Institute on Alcohol Abuse and Alcoholism				
Mechanisms Of Alcohol Tolerance And Priming In Humans				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Psychology</u></b>				
<b>GIANCOLA, PETER</b>	3046840800	\$0.	\$272,965.	\$272,965.
National Institute on Alcohol Abuse and Alcoholism Individual Differences in Alcohol-Related Aggression				
<b>Gottlob, Lawrence R</b>	3048104358	\$56,361.	\$0.	\$56,361.
National Science Foundation DHB Collaborative: Lifespan Dynamics of Cognition and Action				
<b>Prendergast, Mark A</b>	3046760800	\$0.	\$48,196.	\$48,196.
National Institute on Alcohol Abuse and Alcoholism Ethanol Withdrawal and HIV-1 Neurotoxicity				
<b>Prendergast, Mark A</b>	3046760800	\$0.	\$192,786.	\$192,786.
National Institute on Alcohol Abuse and Alcoholism Ethanol Withdrawal and HIV-1 Neurotoxicity				
<b>Samuel, Doug</b>	3048102150	\$33,943.	\$0.	\$33,943.
National Institute of Mental Health Comparing Personality Disorder Models: FFM				
<b>Segerstrom, Suzanne</b>	3048019200	\$0.	\$334,878.	\$334,878.
National Institute on Aging Repetitive Thought, Stress and Immunity in Older Adults				
<b>Smith, Gregory T</b>	3048103235	\$30,239.	\$0.	\$30,239.
National Institute on Alcohol Abuse and Alcoholism Fellowship for Melissa Cyders: Longitudinal & Experimental Analysis of Positive Urgency				
<b>Smith, Gregory T</b>	3048104634	\$471,780.	\$0.	\$471,780.
National Institute on Alcohol Abuse and Alcoholism Developmental Transitions and Risk for Alcohol Use				
<b>Zentall, Thomas R</b>	3046923100	\$0.	\$-19,514.	\$-19,514.
National Institute of Mental Health NRSA to Digian: Determinants of Stimulus Preference				
<b>Zentall, Thomas R</b>	3048103770	\$32,590.	\$0.	\$32,590.
National Institute of Mental Health NRSA Fellowship for Singer: Value of Rewards after Relatively Aversive Events				
<b>Psychology</b>	<b>Totals:</b>	<b>\$2,447,284.</b>	<b>\$1,785,792.</b>	<b>\$4,233,076.</b>
<b><u>Statistics</u></b>				
<b>Zhou, Mai</b>	3046995500	\$0.	\$69,612.	\$69,612.
National Science Foundation Empirical Likelihood and Censored Quantile Regression				
<b>Statistics</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$69,612.</b>	<b>\$69,612.</b>
<b><u>Sociology</u></b>				
<b>Hougland, James G</b>	3048046600	\$0.	\$30,000.	\$30,000.
KY Community & Technical College System/University of Evaluation Subasard for Evaluation of KITCenter Initiatives				
<b>Oser, Carrie</b>	3048103624	\$140,779.	\$0.	\$140,779.
National Institute on Drug Abuse Rural Drug Abuse Treatment: Organizations, Counselors, and Client Outcomes				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Arts &amp; Sciences</u></b>				
<b><u>Sociology</u></b>				
<b>Oser, Carrie</b>	3048104523	\$574,039.	\$0.	\$574,039.
National Institute on Drug Abuse African American Female Drug Users: HIV, Health Disparities, & Criminality				
<b>Sociology</b>	<b>Totals:</b>	<b>\$714,818.</b>	<b>\$30,000.</b>	<b>\$744,818.</b>
<b><u>Biological Sciences</u></b>				
<b>Birge, Wesley J</b>	3048012200	\$0.	\$15,000.	\$15,000.
KY Department of Environmental Protection Whole Effluent Toxicity Analysis of Discharge Samples Taken from Kentucky Pollution Discharge Elimination				
<b>Crowley, P H</b>	3048103405	\$0.	\$-300.	\$-300.
KY Heritage Land Conservation Fund Bluegrass Savanna-Woodland Restoration				
<b>Crowley, P H</b>	3048103405	\$0.	\$26,800.	\$26,800.
KY Heritage Land Conservation Fund Bluegrass Savanna-Woodland Restoration				
<b>Jones, Grace M</b>	3046941900	\$0.	\$284,764.	\$284,764.
National Institute of General Medical Sciences Role of USP Ligand Binding Pocket During Development				
<b>O'Hara, Bruce</b>	3046887000	\$0.	\$15,000.	\$15,000.
Stanford University Non-circadian Role for Clock-Genes in Sleep Homoestasis				
<b>O'Hara, Bruce</b>	3046887000	\$0.	\$-23,650.	\$-23,650.
Stanford University Non-circadian Role for Clock-Genes in Sleep Homoestasis				
<b>O'Hara, Bruce</b>	3046887000	\$0.	\$73,650.	\$73,650.
Stanford University Non-circadian Role for Clock-Genes in Sleep Homoestasis				
<b>Osborn, Jeffrey</b>	3046858000	\$0.	\$239,999.	\$239,999.
KY Science and Technology Co Inc Noyce Loan/Scholarship Program				
<b>Price, David J</b>	3048102151	\$182,452.	\$0.	\$182,452.
KY Department of Environmental Protection Division of Waste Management Soil / Sediment / Water / Fish Sample Study				
<b>Staben, Charles A</b>	3048104756	\$171,991.	\$0.	\$171,991.
University of Louisville Subcontract, Kentucky Biomedical Research Infrastructure Network				
<b>Voss, Stephen Randal</b>	3046896000	\$0.	\$207,302.	\$207,302.
National Science Foundation Operational Support for the Ambystoma Genetic Stock Center				
<b>Voss, Stephen Randal</b>	3046942800	\$0.	\$25,000.	\$25,000.
National Science Foundation Collaborative Reserach: Gauging Introgression: Variation across the Genome in Mode and Tempo of Natural Selection in a Tiger Salamander Hybrid Zone				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Arts &amp; Sciences</b>				
<b><u>Biological Sciences</u></b>				
<b>Voss, Stephen Randal</b>	3048070900	\$0.	\$100,000.	\$100,000.
KY Spinal Cord and Head Injury Research Trust Functional Analysis of Candidate Genes Identified from Naturally Regenerating Spinal Cords of the Salamanser (Ambystoma)				
<b>Voss, Stephen Randal</b>	3048093100	\$0.	\$234,400.	\$234,400.
National Center for Research Resources Genome Resources for Model Amphibians				
<b>Westneat, David F</b>	3048034800	\$0.	\$6,000.	\$6,000.
National Science Foundation Development of Signaler and Receiver Phenotypes				
<b>Westneat, David F</b>	3048104429	\$1,000.	\$0.	\$1,000.
Sigma XI Scientific Research Society Inc Causes and Consequences of Individual Variation in Parental Care in the Eastern World				
<b>Westneat, David F</b>	3048104438	\$1,700.	\$0.	\$1,700.
American Ornithologists Union The Role of Habit Structure in Extraterritorial Movements of Two Hybridizing Warblers				
<b>Westneat, David F</b>	3048104708	\$1,000.	\$0.	\$1,000.
KY Ornithological Society Avian Research Fund Causes and Correlates of Individual Variation in Parental Care				
<b>Biological Sciences</b>	<b>Totals:</b>	<b>\$358,143.</b>	<b>\$1,203,965.</b>	<b>\$1,562,108.</b>
<b><u>Modern &amp; Classical Languages</u></b>				
<b>Jiang, Wei</b>	3048104275	\$13,789.	\$0.	\$13,789.
KY Department of Education Chinese Course Development				
<b>Leontseva, Dorothy Porter</b>	3048104758	\$17,500.	\$0.	\$17,500.
University of Notre Dame Digital Edition of Cambridge, Pembroke 25: A New Electronic Edition				
<b>Modern &amp; Classical Languages</b>	<b>Totals:</b>	<b>\$31,289.</b>	<b>\$0.</b>	<b>\$31,289.</b>
<b><u>Russian and Eastern Studies</u></b>				
<b>Fiedler, Theodore</b>	3046345400	\$0.	\$25,450.	\$25,450.
Omar Ibn Al Khattab Foundation Lectureship in Islamic Studies				
<b>Russian and Eastern Studies</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$25,450.</b>	<b>\$25,450.</b>
	<b>Arts &amp; Sciences Totals:</b>	<b>\$7,089,143.</b>	<b>\$7,515,654.</b>	<b>\$14,604,797.</b>
<b><u>Business &amp; Economics</u></b>				
<b><u>Management</u></b>				
<b>Borgatti, Stephen</b>	3048104312	\$393,781.	\$0.	\$393,781.
Defense Threat Reduction Agency Combating Weapons of Mass Destruction Basic Research Program				
<b>Holsapple, Clyde W</b>	3048104090	\$63,080.	\$0.	\$63,080.
US Navy Facilitating Agility in Knowledge-Intensive Network Organizations				
<b>Management</b>	<b>Totals:</b>	<b>\$456,861.</b>	<b>\$0.</b>	<b>\$456,861.</b>

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Business &amp; Economics</u></b>				
<b><u>Economics</u></b>				
<b>Troske, Kenneth R</b>	3048104640	\$45,000.	\$0.	\$45,000.
Eastern KY University Review of Kentucky's Child Support Schedule				
<b>Economics</b>	<b>Totals:</b>	<b>\$45,000.</b>	<b>\$0.</b>	<b>\$45,000.</b>
<b><u>Center for Business &amp; Econ Res</u></b>				
<b>Troske, Kenneth R</b>	3048030500	\$0.	\$61,000.	\$61,000.
KY Economic Development Cab Effectiveness of Incentive Programs in Attracting New Business and Promoting Economic Growth				
<b>Troske, Kenneth R</b>	3048104570	\$19,648.	\$0.	\$19,648.
KY Council on Postsecondary Education The Effects of KCTCS Tuition Freeze on Enrollment and Revenue: CBER Research Project 2008				
<b>Troske, Kenneth R</b>	3048104703	\$34,250.	\$0.	\$34,250.
University of Baltimore Administrative Data Research and Evaluation (ADARE)				
<b>Center for Business &amp; Econ Res</b>	<b>Totals:</b>	<b>\$53,898.</b>	<b>\$61,000.</b>	<b>\$114,898.</b>
<b><u>B&amp;E Poverty Center</u></b>				
<b>Ziliak, James P</b>	3048103841	\$202,375.	\$0.	\$202,375.
Meals on Wheels Association of American Foundation The Causes, Consequences, and Future of Senior Hunger in America				
<b>Ziliak, James P</b>	3048104033	\$600,000.	\$0.	\$600,000.
National Institute of Allergy and Infectious Diseases UK Center for Poverty Research				
<b>Ziliak, James P</b>	3048104649	\$21,600.	\$0.	\$21,600.
Eastern KY University Implications of Child Care Subsidies on the Economic Well-Being of Recipient Families				
<b>B&amp;E Poverty Center</b>	<b>Totals:</b>	<b>\$823,975.</b>	<b>\$0.</b>	<b>\$823,975.</b>
<b><u>Center for Entrepreneurship</u></b>				
<b>Harvey, Dean E</b>	3048062000	\$0.	\$170,359.	\$170,359.
KY Science and Technology Co Inc KSTC ICC Project				
<b>Naugle, Lottie Becky</b>	3046356600	\$0.	\$29,700.	\$29,700.
Small Business Administration OnGoing SBDC PROGRAM INCOME ACCOUNT				
<b>Naugle, Lottie Becky</b>	3046356600	\$0.	\$2,000.	\$2,000.
Small Business Administration OnGoing SBDC PROGRAM INCOME ACCOUNT				
<b>Naugle, Lottie Becky</b>	3048051900	\$0.	\$24,447.	\$24,447.
Small Business Administration Kentucky Small Business Development Center				
<b>Naugle, Lottie Becky</b>	3048051900	\$0.	\$14,697.	\$14,697.
Small Business Administration Kentucky Small Business Development Center				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Business &amp; Economics</u></b>				
<b><u>Center for Entrepreneurship</u></b>				
<b>Naugle, Lottie Becky</b>	3048104236	\$0.	\$112,100.	\$112,100.
Small Business Administration Kentucky Small Business Development Center				
<b>Naugle, Lottie Becky</b>	3048104236	\$1,127,564.	\$0.	\$1,127,564.
Small Business Administration Kentucky Small Business Development Center				
<b>Center for Entrepreneurship</b>	<b>Totals:</b>	<b>\$1,127,564.</b>	<b>\$353,303.</b>	<b>\$1,480,867.</b>
	<b>Business &amp; Economics Totals:</b>	<b>\$2,507,298.</b>	<b>\$414,303.</b>	<b>\$2,921,601.</b>
<b><u>Education</u></b>				
<b><u>Education</u></b>				
<b>Cibulka, James G</b>	3046950600	\$0.	\$148,900.	\$148,900.
Knight Foundation Community Partners Program Grant Proposal				
<b>Cibulka, James G</b>	3046950600	\$0.	\$200,000.	\$200,000.
Knight Foundation Community Partners Program Grant Proposal				
<b>Education</b>	<b>Totals:</b>	<b>\$0.</b>	<b>\$348,900.</b>	<b>\$348,900.</b>
<b><u>Educational Leadership Studies</u></b>				
<b>Bjork, Lars</b>	3046993400	\$0.	\$20,000.	\$20,000.
Fayette County Public Schools Evaluation of the High School Math Alliance				
<b>Bjork, Lars</b>	3048104264	\$0.	\$23,344.	\$23,344.
KY Department of Education UK/KSU Joint Tuition Program				
<b>Browne-Ferrigno, Patricia</b>	3048102152	\$68,752.	\$0.	\$68,752.
Education Development Center Inc How school districts influence the Quality of University-based principal leader preparations programs: an evaluation study				
<b>Rinehart, James S</b>	3048103810	\$117,612.	\$0.	\$117,612.
KY Department of Education CEO Superintendent Network				
<b>Rinehart, James S</b>	3048104225	\$15,822.	\$0.	\$15,822.
KY Department of Education New Superintendents Training and Assessment Program 2007-2008				
<b>Rinehart, James S</b>	3048104264	\$20,000.	\$0.	\$20,000.
KY Department of Education UK/KSU Joint Tuition Program				
<b>Rinehart, James S</b>	3048104580	\$53,959.	\$0.	\$53,959.
University of Louisville Kentucky Principals Academy				
<b>Educational Leadership Studies</b>	<b>Totals:</b>	<b>\$276,145.</b>	<b>\$43,344.</b>	<b>\$319,489.</b>

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Curriculum &amp; Instruction</u></b>				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$1,537.	\$1,537.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$400.	\$400.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$325.	\$325.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$-325.	\$-325.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$325.	\$325.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$1,125.	\$1,125.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$575.	\$575.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$575.	\$575.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$900.	\$900.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$1,400.	\$1,400.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$675.	\$675.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046791200	\$0.	\$1,795.	\$1,795.
University of California Berkeley				
Bluegrass Writing Project - Program Income				
<b>Burns, Leslie David</b>	3046898600	\$0.	\$43,000.	\$43,000.
University of California Berkeley				
Bluegrass Writing Project				
<b>Burns, Leslie David</b>	3046898600	\$0.	\$45,000.	\$45,000.
University of California Berkeley				
Bluegrass Writing Project				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Curriculum &amp; Instruction</u></b>				
<b>Burns, Leslie David</b>	3048104019	\$65,000.	\$0.	\$65,000.
KY Department of Education Bluegrass Writing Project 0708				
<b>Sandidge, Rosetta F</b>	3048104636	\$25,000.	\$0.	\$25,000.
KY Department of Education University of Kentucky 2008 FEA Summer Camp				
<b>Smith, Douglas C</b>	3048103867	\$2,750.	\$0.	\$2,750.
KY Department for Technical Education UK Perkins 08 TE01 Professional Development				
<b>Curriculum &amp; Instruction</b>	<b>Totals:</b>	<b>\$92,750.</b>	<b>\$97,307.</b>	<b>\$190,057.</b>
<b><u>Education Psych &amp; Counsel</u></b>				
<b>Ruble, Lisa A.</b>	3048103745	\$0.	\$119,114.	\$119,114.
National Institute of Mental Health Outcomes of Teacher Training on Autism				
<b>Ruble, Lisa A.</b>	3048103745	\$208,363.	\$0.	\$208,363.
National Institute of Mental Health Outcomes of Teacher Training on Autism				
<b>Education Psych &amp; Counsel</b>	<b>Totals:</b>	<b>\$208,363.</b>	<b>\$119,114.</b>	<b>\$327,477.</b>
<b><u>Kinesiology and Health Promoti</u></b>				
<b>Beighle, Aaron</b>	3048104007	\$0.	\$-3,000.	\$-3,000.
KY Health Services Cabinet Get Healthy Kentucky Schools				
<b>Beighle, Aaron</b>	3048104007	\$6,000.	\$0.	\$6,000.
KY Health Services Cabinet Get Healthy Kentucky Schools				
<b>Clasey, Jody L</b>	3048103746	\$0.	\$11,200.	\$11,200.
Shriners Hospital for Crippled Children Scoliosis and Testing of Exercise Parameters Study (STEPS)				
<b>Clasey, Jody L</b>	3048103746	\$10,500.	\$0.	\$10,500.
Shriners Hospital for Crippled Children Scoliosis and Testing of Exercise Parameters Study (STEPS)				
<b>Clasey, Jody L</b>	3048104577	\$15,087.	\$0.	\$15,087.
Shriners Hospital for Crippled Children Validation of Two Different Methods to Assess Body Composition in Ambulatory Children with CP				
<b>Erwin, Heather E.</b>	3048104604	\$0.	\$-5.	\$-5.
American Alliance for Health Physical Education Recreati Relation of Children's Perception of their Social and Physical Environments to Physical Activity Levels: A Mixed Methodology Approach				
<b>Erwin, Heather E.</b>	3048104604	\$9,555.	\$0.	\$9,555.
American Alliance for Health Physical Education Recreati Relation of Children's Perception of their Social and Physical Environments to Physical Activity Levels: A Mixed Methodology Approach				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Kinesiology and Health Promoti</u></b>				
<b>Shapiro, Robert</b>	3046974000	\$0.	\$4,414.	\$4,414.
Drayer Physical Therapy Institute Research Assistantship to Study Biomechanical and Gender Issues in Sport				
<b>Kinesiology and Health Promoti</b>	<b>Totals:</b>	<b>\$41,142.</b>	<b>\$12,609.</b>	<b>\$53,751.</b>
<b><u>Ed Policy Studies &amp; Evaluation</u></b>				
<b>Clements, Stephen K</b>	3048104303	\$135,000.	\$0.	\$135,000.
KY Council on Postsecondary Education Embedded Teacher Learning Through Online Modules: Leveraging Professional Development Resources in Kentucky				
<b>Goldstein, Beth L</b>	3046997100	\$0.	\$-9,559.	\$-9,559.
Japan Foundation Extending Lessons on Japan: Kentucky Teachers Training Teachers				
<b>Ed Policy Studies &amp; Evaluation</b>	<b>Totals:</b>	<b>\$135,000.</b>	<b>\$-9,559.</b>	<b>\$125,441.</b>
<b><u>Special Ed. &amp; Rehab Counseling</u></b>				
<b>Bausch, Margaret</b>	3046935500	\$0.	\$99,996.	\$99,996.
Department of Education Kentucky Assistive and Rehabilitation Technology Training (KARTT)				
<b>Bishop, Malachy L</b>	3048103865	\$44,000.	\$0.	\$44,000.
National Multiple Sclerosis Society Adherence to Disease Modifying Therapy in Multiple Sclerosis				
<b>Crystal, Ralph M</b>	3046721100	\$0.	\$149,937.	\$149,937.
Rehabilitation Services Administration Partnership for Preparing Rehabilitation Counselors for Public Rehabilitation Employment: A Long Term Training Program				
<b>Crystal, Ralph M</b>	3046933100	\$0.	\$198,662.	\$198,662.
Department of Education University of Kentucky Accelerated Distance Education Program in Rehabilitation Counseling				
<b>Crystal, Ralph M</b>	3046933100	\$0.	\$198,665.	\$198,665.
Department of Education University of Kentucky Accelerated Distance Education Program in Rehabilitation Counseling				
<b>Feist-Price, Sonja</b>	3048103854	\$29,736.	\$0.	\$29,736.
Pacific Institute for Research and Evaluation School-Based Alcohol and HIV Prevention in South Africa				
<b>Grisham-Brown, Jennifer L</b>	3046971800	\$0.	\$76,048.	\$76,048.
Kent State University Preparing Tomorrow's Early Childhood Intervention Leaders				
<b>Grisham-Brown, Jennifer L</b>	3048103206	\$250,000.	\$0.	\$250,000.
KY Department of Education KIDS NOW Evaluation Project				
<b>Grisham-Brown, Jennifer L</b>	3048103729	\$228,133.	\$0.	\$228,133.
KY Department of Education Deaf/Blind Project Supplemental Grant				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Special Ed. &amp; Rehab Counseling</u></b>				
<b>Grisham-Brown, Jennifer L</b>	3048104036	\$0.	\$1,889.	\$1,889.
KY Department of Education Kentucky Deaf Blind Project (Main Grant)				
<b>Grisham-Brown, Jennifer L</b>	3048104036	\$165,145.	\$0.	\$165,145.
KY Department of Education Kentucky Deaf Blind Project (Main Grant)				
<b>Jung, Lee Ann</b>	3046963700	\$0.	\$199,981.	\$199,981.
Department of Education Project Increasing the Number, Competence, and Resources of Early Interventions in Areas of Shortage (INCREAS) - (Alternate Name = "Combined Priority for Personnel Preparation")				
<b>Jung, Lee Ann</b>	3048102807	\$96,000.	\$0.	\$96,000.
KY Department for Public Health UK First Steps Part C Coordinator				
<b>McCormick, Katherine</b>	3048103807	\$0.	\$10,996.	\$10,996.
KY Health Services Cabinet University of Kentucky First Step Technical Assistance Team				
<b>McCormick, Katherine</b>	3048103807	\$0.	\$10,411.	\$10,411.
KY Health Services Cabinet University of Kentucky First Step Technical Assistance Team				
<b>McCormick, Katherine</b>	3048103807	\$217,903.	\$0.	\$217,903.
KY Health Services Cabinet University of Kentucky First Step Technical Assistance Team				
<b>Sampers, Jackie L</b>	3048103726	\$104,760.	\$0.	\$104,760.
KY Department for Public Health UK First Steps Evaluation Coordinator				
<b>Slaton, Deborah B</b>	3048103418	\$130,464.	\$0.	\$130,464.
KY Department of Education Reading First Coach 2007-2008				
<b>Stenhoff, Donald M</b>	3048102805	\$0.	\$1.	\$1.
KY Department of Education Behavior Web Home Page				
<b>Stenhoff, Donald M</b>	3048102805	\$29,344.	\$0.	\$29,344.
KY Department of Education Behavior Web Home Page				
<b>Special Ed. &amp; Rehab Counseling</b>	<b>Totals:</b>	<b>\$1,295,485.</b>	<b>\$946,586.</b>	<b>\$2,242,071.</b>
<b><u>Collaborative Center for Literacy Develo</u></b>				
<b>Cantrell, Susan Chambers</b>	3048103835	\$150,000.	\$0.	\$150,000.
KY Department of Education Early Childhood Teacher Academy-Undergraduate Project UK Collaborative Center for Literacy Development				
<b>Cantrell, Susan Chambers</b>	3048103852	\$250,761.	\$0.	\$250,761.
KY Department of Education Kentucky Reading First Evaluation Project				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Education</u></b>				
<b><u>Collaborative Center for Literacy Develo</u></b>				
<b>Cantrell, Susan Chambers</b>	3048104601	\$0.	\$5,260.	\$5,260.
Danville Schools Kentucky Content Literacy Consortium: Striving Readers Grant				
<b>Cantrell, Susan Chambers</b>	3048104601	\$550,151.	\$0.	\$550,151.
Danville Schools Kentucky Content Literacy Consortium: Striving Readers Grant				
<b>Smith, Felicia C</b>	3048103637	\$1,539,322.	\$0.	\$1,539,322.
KY Department of Education Adolescent Literacy Project 0708				
<b>Smith, Felicia C</b>	3048103851	\$312,151.	\$0.	\$312,151.
KY Council on Postsecondary Education Kentucky Adult Education Literacy Institute-KAELI				
<b>Collaborative Center for Literacy Develo</b>	<b>Totals:</b>	<b>\$2,802,385.</b>	<b>\$5,260.</b>	<b>\$2,807,645.</b>
	<b>Education Totals:</b>	<b>\$4,851,270.</b>	<b>\$1,563,561.</b>	<b>\$6,414,831.</b>
<b><u>Engineering</u></b>				
<b><u>Visualization Center</u></b>				
<b>Carswell, Catherine M</b>	3048103806	\$348,947.	\$0.	\$348,947.
University of Maryland The Smart Image Pipeline - Year 4				
<b>Donohue, Kevin D</b>	3048104025	\$94,740.	\$0.	\$94,740.
Federal Bureau of Investigation Assessment of Statistical Array Geometries for Covert Surveillance				
<b>Hassebrook, Laurence G</b>	3046838400	\$0.	\$-20.	\$-20.
Stevrin and Partners Axial 3-D Imaging of Ear Canal				
<b>Hassebrook, Laurence G</b>	3048104039	\$21,000.	\$0.	\$21,000.
Michigan Aerospace Corp UUV Surface-based Capture and Deployment System (U-SCADS)				
<b>Hassebrook, Laurence G</b>	3048104568	\$83,881.	\$0.	\$83,881.
Flashscan 3D Single 3D Fingerprint Biometric Sensor				
<b>Hassebrook, Laurence G</b>	3048104629	\$48,746.	\$0.	\$48,746.
KY Science and Technology Co Inc COMMFUND: 3-Dimensional Surround Scanning and Surface Feature Tracking				
<b>Seales, William B</b>	3048053000	\$0.	\$925,000.	\$925,000.
US Army Surgical Technology Integration With Tools For Cognitive Human Factors (STITCH)				
<b>Yang, Ruigang</b>	3046875100	\$0.	\$12,000.	\$12,000.
National Science Foundation CAREER: The Light Portal: 3D Reconstruction and Visualization over Space and Time				
<b>Yang, Ruigang</b>	3046875100	\$0.	\$100,000.	\$100,000.
National Science Foundation CAREER: The Light Portal: 3D Reconstruction and Visualization over Space and Time				

Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b><u>Visualization Center</u></b>				
<b>Yang, Ruigang</b>	3048104632	\$140,090.	\$0.	\$140,090.
KY Science and Technology Co Inc Flexible Pixel Compositor for Scalable Visual Computing				
<b>Visualization Center</b>	<b>Totals:</b>	<b>\$737,404.</b>	<b>\$1,036,980.</b>	<b>\$1,774,384.</b>
<b><u>Computer Science</u></b>				
<b>CALVERT, KENNETH L.</b>	3046836500	\$0.	\$100,821.	\$100,821.
National Science Foundation NeTS-NR: Generalizing the Network Layer				
<b>CALVERT, KENNETH L.</b>	3048051100	\$0.	\$62,029.	\$62,029.
National Science Foundation NeTS-NBD: Collaborative Research: Human-Centered Networking for the Home				
<b>Douglas, Craig</b>	3048103779	\$100,000.	\$0.	\$100,000.
National Science Foundation CSR-CSI: Collaborative Research: Dynamic Sensor/Computation Network for Wildfire Management				
<b>Liu, Jinze</b>	3048104736	\$19,002.	\$0.	\$19,002.
KY Science and Technology Co Inc KY EPSCoR: The Development of a Model of Molecular Events Leading to Seed Germination				
<b>Seales, William B</b>	3048047200	\$0.	\$28,421.	\$28,421.
National Science Foundation EDUCE: Enhanced Digital Unwrapping for Conservation and Exploration				
<b>Seales, William B</b>	3048103776	\$29,356.	\$0.	\$29,356.
National Science Foundation Changing the Center of Gravity: Transforming Classical Studies Through Cyberinfrastructure				
<b>Singhal, Mukesh</b>	3046721300	\$0.	\$79,634.	\$79,634.
National Science Foundation ITR Collaborative Research: Pervasively Secure Infrastructures \ (PSI): Integrating Smart Sensing, Data Mining, Pervasive Networking, and Community Computing				
<b>Zhang, Jun</b>	3048027000	\$0.	\$51,247.	\$51,247.
Alzheimers Association Diffusion Tensor MRI Analysis for Early Detection of AD				
<b>Zhang, Jun</b>	3048074900	\$0.	\$46,028.	\$46,028.
KY Science and Technology Co Inc KSEF R&D Excellence: Generalized Diffusion Simulation-Based Tractography for Mapping Human Brain				
<b>Zhang, Jun</b>	3048104073	\$190,000.	\$0.	\$190,000.
National Science Foundation A Unified Framework for Large Scale Scientific Computing				
<b>Computer Science</b>	<b>Totals:</b>	<b>\$338,358.</b>	<b>\$368,180.</b>	<b>\$706,538.</b>
<b><u>Kentucky Transportation Center</u></b>				
<b>Agent, Kenneth R</b>	3048104527	\$55,000.	\$0.	\$55,000.
KY Transportation Cabinet Identification and Analysis of Crash Locations RS-08-01				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Agent, Kenneth R</b>	3048104553	\$150,000.	\$0.	\$150,000.
KY Transportation Cabinet Safety Belt and Child Safety Seat Survey - OP-08-05				
<b>Anderson, Patsy P</b>	3048104345	\$150,000.	\$0.	\$150,000.
KY Transportation Cabinet LTAP Safety Circuit Rider Program				
<b>Anderson, Patsy P</b>	3048104437	\$140,000.	\$0.	\$140,000.
KY Transportation Cabinet FHWA/LTAP Technology Transfer to Local Agencies				
<b>Crabtree, Joseph D</b>		\$550,000.	\$0.	\$550,000.
KY Transportation Cabinet Southeast Regional Research Initiative (SERRI) Integrated Threat Tracking and Information System, Research Study-Federal no. 22				
<b>Crabtree, Joseph D</b>	3046531300	\$0.	\$908,839.	\$908,839.
KY Transportation Cabinet Development, Deployment, and Testing of an Integrated Commercial Motor Vehicle Safety System				
<b>Crabtree, Joseph D</b>	3048043200	\$0.	\$237,500.	\$237,500.
KY Transportation Cabinet Support of Kentucky's PRISM and CVISN Programs, Research Study-Federal no. 20				
<b>Crabtree, Joseph D</b>	3048043200	\$0.	\$200,000.	\$200,000.
KY Transportation Cabinet Support of Kentucky's PRISM and CVISN Programs, Research Study-Federal no. 20				
<b>Crabtree, Joseph D</b>	3048104761	\$15,718.	\$0.	\$15,718.
KY Transportation Cabinet KVE Staff Training, Research Study-Federal No. 23				
<b>Crabtree, Joseph D</b>	3048104767	\$27,470.	\$0.	\$27,470.
KY Transportation Cabinet Targeted Commercial Vehicle Enforcement, Research Study-Federal No. 24				
<b>Graves, Ronnie C</b>	3048104051	\$18,000.	\$0.	\$18,000.
KY Transportation Cabinet Monitoring Installation of HDPE Storm Sewer Pipe KY 70, Edmonson County, item 3--141.00 - Federal Aid Research Task no. 166				
<b>Graves, Ronnie C</b>	3048104052	\$18,000.	\$0.	\$18,000.
KY Transportation Cabinet Monitoring Installation of HDPE Storm Sewer Pipe KY 84, Hardin County - Federal Aid Research Task no. 167				
<b>Graves, Ronnie C</b>	3048104053	\$22,000.	\$0.	\$22,000.
KY Transportation Cabinet Monitoring Installation of HDPE Storm Sewer Pipe US 42 Carroll County- Federal Aid Research Task no. 168				
<b>Graves, Ronnie C</b>	3048104055	\$50,000.	\$0.	\$50,000.
KY Transportation Cabinet Annual Update of Data for Estimating ESALs - Planning Study no.13				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Green, Eric R</b>	3048103551	\$150,000.	\$0.	\$150,000.
KY Transportation Cabinet Evaluation Plan for the Ticketing Aggressive Cars and Trucks (TACT) Program in Kentucky				
<b>Grossardt, Theodore H</b>	3046337100	\$0.	\$80,000.	\$80,000.
KY Transportation Cabinet Information Technology Technical Assistance Project -- Federal Aid Research Task No. 88				
<b>Grossardt, Theodore H</b>	3048104480	\$13,000.	\$0.	\$13,000.
University of Tennessee Southeastern Transportation Center Transportation Systems Management Program				
<b>Grossardt, Theodore H</b>	3048104674	\$23,707.	\$0.	\$23,707.
KY Transportation Cabinet US 27 to I-75 Corridor Scoping Study, Federal Aid Research Task No.170				
<b>Hartman, Donald G</b>	3048104453	\$118,820.	\$0.	\$118,820.
KY Transportation Cabinet EPA MS4 Communities Survey Specifications--Kentucky Highway Investigative Task No. 63				
<b>Hopkins, Tommy C</b>	3048103722	\$19,587.	\$0.	\$19,587.
KY Transportation Cabinet Monitoring culvert Load with Shallow Filling Under Geofoam Areas - Federal Aid Research Task no. 165				
<b>Hopwood, Theodore</b>	3048095600	\$0.	\$60,956.	\$60,956.
KY Transportation Cabinet Follow-on Investigation of Anchor Bolts/Bearings on the I-64 Ohio River Bridge at Louisville, KY--Kentucky Highway Investigative Task No. 57				
<b>Hopwood, Theodore</b>	3048103697	\$24,300.	\$0.	\$24,300.
KY Transportation Cabinet Experimental Painting of the I-64 Riverside parkway in Louisville, KY--Kentucky Highway Investigative Task No. 59				
<b>Hopwood, Theodore</b>	3048103723	\$56,650.	\$0.	\$56,650.
KY Transportation Cabinet Investigation of Voids/Cracking on the I-25 Twin Bridges over the Ohio River in Kenton County, KY--Kentucky Highway Investigative Task No. 60				
<b>Hopwood, Theodore</b>	3048103785	\$22,600.	\$0.	\$22,600.
KY Transportation Cabinet Accelerated Performance Testing of Category 2 Two-Coat Bridge Coating Systems--Kentucky Highway Investigative Task No. 61				
<b>Hopwood, Theodore</b>	3048104617	\$106,456.	\$0.	\$106,456.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
<b>Hunsucker, David Q</b>	3046553100	\$0.	\$62,000.	\$62,000.
NORPASS Inc NORPASS Program Support				
<b>Kreis, Steven D</b>	3048104485	\$21,888.	\$0.	\$21,888.
KY Transportation Cabinet Local Highway Finance Report FHWA 536 - Planning Study No 16				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Palle, Sudhir</b>	3048104359	\$18,505.	\$0.	\$18,505.
KY Transportation Cabinet Monitoring of Calloway County Seeding Operation - KHIT #62				
<b>Pigman, Jerry G</b>	3048104207	\$25,000.	\$0.	\$25,000.
KY Transportation Cabinet Update of Traffic Forecasting Report - Planning Study No 14				
<b>Pigman, Jerry G</b>	3048104360	\$60,195.	\$0.	\$60,195.
KY Transportation Cabinet Growth Trends for Towns in Kentucky - Planning Study No 15				
<b>Rister, Bradley W</b>	3048104486	\$9,500.	\$0.	\$9,500.
KY Transportation Cabinet Wolfe County Mountain parkway Pipe Inspection - Kentucky Highway Investigative Task No. 64				
<b>Toussaint, Paul</b>	3048102101	\$220,000.	\$0.	\$220,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 08-28 (Part III)				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$27,000.	\$27,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$46,362.	\$46,362.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$25,000.	\$25,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$83,500.	\$83,500.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$8,250.	\$8,250.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$418,581.	\$418,581.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$0.	\$419.	\$419.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048102102	\$2,365,314.	\$0.	\$2,365,314.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 08-28				
<b>Toussaint, Paul</b>	3048103783	\$0.	\$15,000.	\$15,000.
KY Transportation Cabinet Right of Way Co-Op Intern Program - Federal Aid Research Task no. 163				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Kentucky Transportation Center</u></b>				
<b>Toussaint, Paul</b>	3048103783	\$166,709.	\$0.	\$166,709.
KY Transportation Cabinet Right of Way Co-Op Intern Program - Federal Aid Research Task no. 163				
<b>Walton, Jennifer R</b>	3046592300	\$0.	\$35,000.	\$35,000.
KY Transportation Cabinet Highway Crash Site Management--Kentucky Highway Investigative Task No. 43				
<b>Kentucky Transportation Center</b>	<b>Totals:</b>	<b>\$4,618,419.</b>	<b>\$2,208,407.</b>	<b>\$6,826,826.</b>
<b><u>OISTL/Engineering Distance Learning</u></b>				
<b>Lu, Y. Charles</b>	3048104734	\$20,000.	\$0.	\$20,000.
Spartan Light Metal Products Development of Magnesium Engine Components for Elevated Temperature Applications				
<b>OISTL/Engineering Distance Learning</b>	<b>Totals:</b>	<b>\$20,000.</b>	<b>\$0.</b>	<b>\$20,000.</b>
<b><u>Chemical and Materials Engin.</u></b>				
<b>Anderson, Kimberly Ward</b>	3048081500	\$0.	\$49,993.	\$49,993.
KY Science and Technology Co Inc KSEF R&D Excellence: Characterization of Hydrogel Magnetic Nanocomposites and Analysis of an In Vitro Biocompatibility				
<b>Anderson, Kimberly Ward</b>	3048103212	\$0.	\$103,000.	\$103,000.
National Science Foundation Adsorption of Treponema Pallidum Protein to Functionalized Alkanethiol Self-Assembled Monolayers for Improving Biocompatibility				
<b>Anderson, Kimberly Ward</b>	3048103212	\$103,000.	\$0.	\$103,000.
National Science Foundation Adsorption of Treponema Pallidum Protein to Functionalized Alkanethiol Self-Assembled Monolayers for Improving Biocompatibility				
<b>Anderson, Kimberly Ward</b>	3048103842	\$599,811.	\$0.	\$599,811.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				
<b>Balk, Thomas John</b>	3048060700	\$0.	\$5,000.	\$5,000.
American Iron and Steel Institute Developing Ferrous Matallurgy Course Material For An Updated Materials Engineering Curriculum at the University Of Kentucky				
<b>Balk, Thomas John</b>	3048104210	\$19,999.	\$0.	\$19,999.
KY Science and Technology Co Inc KSEF R&D Excellence: Microstructure-Property Relations in Osmium-Ruthenium Coatings for Porous Tungsten Dispenser Cathodes				
<b>Bhattacharyya, Dibakar</b>	3046984300	\$0.	\$25,000.	\$25,000.
J M Huber Corp Functionalization and Characterization of Silica Materials for High Value Applications				
<b>Gulke, Eric A</b>	3046945600	\$0.	\$18,000.	\$18,000.
US Air Force Office of Scientific Research Self-Assembled Coatings for Military Optical Applications				

## Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b><u>Chemical and Materials Engin.</u></b>				
<b>Gulke, Eric A</b>	3046945600	\$0.	\$72,000.	\$72,000.
US Air Force Office of Scientific Research Self-Assembled Coatings for Military Optical Applications				
<b>Gulke, Eric A</b>	3048102205	\$0.	\$25,000.	\$25,000.
Innovative Productivity Inc Development of Design Tools for Blast Mitigation by Layered Aluminum Mesh				
<b>Gulke, Eric A</b>	3048102205	\$0.	\$42,707.	\$42,707.
Innovative Productivity Inc Development of Design Tools for Blast Mitigation by Layered Aluminum Mesh				
<b>Gulke, Eric A</b>	3048103782	\$150,213.	\$0.	\$150,213.
Ashland Inc Nanofluids for Advanced Military Mobility Systems - Coolants, Fuels and Lubricants				
<b>Gulke, Eric A</b>	3048103802	\$500,001.	\$0.	\$500,001.
Department of Energy DOE EPSCoR: Nanoscale Materials and Architecture for Energy Conversion				
<b>Gulke, Eric A</b>	3048103803	\$250,000.	\$0.	\$250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
<b>Gulke, Eric A</b>	3048104282	\$19,999.	\$0.	\$19,999.
KY Science and Technology Co Inc KSEF R&D for Excellence: Scale-up of DNA Encapsulatation Processes				
<b>Gulke, Eric A</b>	3048104376	\$28,618.	\$0.	\$28,618.
Optical Dynamics Co Len-forming Nanocomposite for High-strength, Clear Ophthalmic Lenses				
<b>Gulke, Eric A</b>	3048104399	\$20,000.	\$0.	\$20,000.
Inhibitrol Inc Robust Non-Toxic Corrosion Inhibitory Systems				
<b>Hinds, Bruce J</b>	3048057100	\$0.	\$294,650.	\$294,650.
National Institute on Drug Abuse Gated Carbon Nanotube Membrane Transdermal Drug Delivery				
<b>Kalika, Douglass S</b>	3048029000	\$0.	\$5,000.	\$5,000.
Petroleum Research Fund Investigation of Structure and Dynamics in Novel Nanocomposite Membranes				
<b>Knutson, Barbara</b>	3048104744	\$999,964.	\$0.	\$999,964.
Department of Agriculture Separation and recovery of high value pentose derivatives from cellulosic biomass using molecular imprinting				
<b>RANKIN, STEPHEN</b>	3046767000	\$0.	\$5,700.	\$5,700.
National Science Foundation CAREER: Kinetics and Engineering of Functional Nanoscale Organic-Inorganic Hybrids				
<b>RANKIN, STEPHEN</b>	3048074100	\$0.	\$50,000.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Interfacially Controlled Incorporation of Transition Metal Oxides within Ordered Mesoporous Ceramics				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b><u>Chemical and Materials Engin.</u></b>				
<b>Ray, Asit K</b>	3048034700	\$0.	\$101,911.	\$101,911.
Duke University Radiative and Hygroscopic Properties of Aerosols Containing Black Carbon at Various Mixing States				
<b>Ray, Asit K</b>	3048102200	\$0.	\$59,512.	\$59,512.
National Science Foundation Hygroscopic Properties of Microstructured Aerosols				
<b>Yang, Fuqian</b>	3048073700	\$0.	\$44,540.	\$44,540.
KY Science and Technology Co Inc KSEF R&D Excellence: Nano-Electromechanical Interaction in NanoSemiconducting Structures				
<b>Yang, Fuqian</b>	3048076500	\$0.	\$49,884.	\$49,884.
KY Science and Technology Co Inc KSEF R&D Excellence: Characterization of Metallic Tin Whiskers in Lead-Free Solders				
<b>ZHAI, TONGGUANG</b>		\$160,000.	\$0.	\$160,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
<b>ZHAI, TONGGUANG</b>	3048103774	\$0.	\$60,000.	\$60,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
<b>Chemical and Materials Engin.</b>	<b>Totals:</b>	<b>\$2,851,605.</b>	<b>\$1,011,897.</b>	<b>\$3,863,502.</b>
<b><u>CFFLS</u></b>				
<b>Huffman, Gerald P</b>	3046900100	\$0.	\$400,000.	\$400,000.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
<b>Huffman, Gerald P</b>	3046900100	\$0.	\$110,000.	\$110,000.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
<b>Huffman, Gerald P</b>	3048103876	\$819,999.	\$0.	\$819,999.
US Army Production of Military Fuels by C1 Chemistry				
<b>Shah, Naresh</b>	3048103725	\$0.	\$7,000.	\$7,000.
Chevron Research and Technology Company Evaluation of the pyrolysis of post consumer waste plastics containing PVC to generate feedstock for lube oil				
<b>Shah, Naresh</b>	3048103725	\$22,000.	\$0.	\$22,000.
Chevron Research and Technology Company Evaluation of the pyrolysis of post consumer waste plastics containing PVC to generate feedstock for lube oil				
<b>CFFLS</b>	<b>Totals:</b>	<b>\$841,999.</b>	<b>\$517,000.</b>	<b>\$1,358,999.</b>
<b><u>Civil Engineering</u></b>				
<b>Bryson, Lindsey Sebastian</b>	3048051400	\$0.	\$38,501.	\$38,501.
National Science Foundation Deformation based design methodology for excavation support systems				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Civil Engineering</u></b>				
<b>Bryson, Lindsey Sebastian</b>	3048104252	\$19,963.	\$0.	\$19,963.
KY Science and Technology Co Inc KSEF R & D Excellence:Dynamic, Distributed Real-Time System for Geosystem Health Monitoring				
<b>Goodrum, Paul</b>	3048104203	\$320,665.	\$0.	\$320,665.
Construction Industry Institution/University of Texas Craft Productivity Research Program				
<b>Goodrum, Paul</b>	3048104470	\$17,290.	\$0.	\$17,290.
National Center for Construction Education and Research National Craft Assessment and Certification Program (NCACP) Analysis and Reporting Project				
<b>Harik, Issam E</b>	3048104028	\$240,000.	\$0.	\$240,000.
KY Transportation Cabinet GFRP stay-in-Place Forms and Reinforced Concrete Overlay for Bridge Deck Replacement for Galloway Road Bridge over North Elkhorn Creek - Federal Aid Research Task no. 159				
<b>Harik, Issam E</b>	3048104029	\$260,000.	\$0.	\$260,000.
KY Transportation Cabinet High Strength and High Modulus CFRP Laminates Strengthening of Steel Girders on I-65 in Louisville- Federal Aid Research Task no. 160				
<b>Harik, Issam E</b>	3048104054	\$95,000.	\$0.	\$95,000.
KY Transportation Cabinet Stainless Steel Reinforcement for a Concrete Bridge Deck - Federal Aid Research Task no. 161				
<b>Harik, Issam E</b>	3048104056	\$150,000.	\$0.	\$150,000.
KY Transportation Cabinet Carbon Fiber Reinforced Polymer Strengthening of the KY 714 Bridge over Jephtha Creek in Shelby County - Federal Aid Research Task no. 158				
<b>Harik, Issam E</b>	3048104204	\$7,000.	\$0.	\$7,000.
KY Transportation Cabinet Evaluation of Type 9T Barrier Wall - Federal Aid Research Task no. 169				
<b>Stamatiadis, Nikiforos</b>	3048103755	\$25,000.	\$0.	\$25,000.
University of Tennessee Transportation Center Effects of Gender and Passengers on the Crash Patterns of Older Drivers				
<b>Stamatiadis, Nikiforos</b>	3048104251	\$17,640.	\$0.	\$17,640.
University of Vermont Measuring the effect of Passengers on the Safety of Older Drivers				
<b>Civil Engineering</b>	<b>Totals:</b>	<b>\$1,152,558.</b>	<b>\$38,501.</b>	<b>\$1,191,059.</b>
<b><u>Mining Engineering</u></b>				
<b>Honaker, Rick</b>	3048104697	\$100,000.	\$0.	\$100,000.
Virginia Polytechnic Institute and State University Dry Beneficiation of Thermal Coals in India				
<b>Lusk, Braden Trex</b>	3048103880	\$100,000.	\$0.	\$100,000.
Department of the Interior Acoustic Response of Structures to Blast Vibration Analyzed Against Comfort Levels of Residents Near Surface Coal Operations				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Mining Engineering</u></b>				
<b>Sottile, Joseph</b>	3048104434	\$94,023.	\$0.	\$94,023.
KY Office of Energy Policy Development of Autonomous Machine Navigation Concepts for Mining Thin-Seam Coal Reserves				
<b>Sweigard, Richard J</b>		\$13,500.	\$0.	\$13,500.
KY Science and Technology Co Inc Technology Roadmap for Future Terrestrial & Extraterrestrial Mining Systems Phase I				
<b>Sweigard, Richard J</b>	3048104733	\$199,927.	\$0.	\$199,927.
Surface Mining Reclamation and Enforcement Field Investigation of Best Practices for Steep-Slope Mine Reclamation Employing the Forestry Reclamation Approach				
<b>Tao, Dongping</b>	3048102804	\$0.	\$25,030.	\$25,030.
Florida Institute of Phosphate Research Development and Pilot Scale Demonstration of Deep Cone Past Thickening Process for Phosphatic Clay Disposal				
<b>Tao, Dongping</b>	3048104209	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc R & D Excellence: Selective Clay Agglomerant to Enhance Fine Coal Cleaning Efficiency and Recovery				
<b>Tao, Dongping</b>	3048104234	\$67,498.	\$0.	\$67,498.
Virginia Polytechnic Institute and State University Improving Coal Flotation Recovery Using Cavitation Concepts				
<b>Tao, Dongping</b>	3048104334	\$249,632.	\$0.	\$249,632.
Canadian Natural Resources Ltd Development and Performance Evaluation of Innovative Clay Binders for Simultaneously Enhanced Bitumen Recovery and Tailing Dewatering				
<b>Mining Engineering</b>	<b>Totals:</b>	<b>\$844,580.</b>	<b>\$25,030.</b>	<b>\$869,610.</b>
<b><u>Electrical and Computer Engineering</u></b>				
<b>Adams, Robert J</b>	3046777800	\$0.	\$142,491.	\$142,491.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
<b>Adams, Robert J</b>	3046777800	\$0.	\$102,158.	\$102,158.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
<b>Adams, Robert J</b>	3048104022	\$375,000.	\$0.	\$375,000.
NanoSonic Inc Modular Fast Direct Library for ESA Design on Large Platforms				
<b>Adams, Robert J</b>	3048104710	\$70,000.	\$0.	\$70,000.
Lyndon B Johnson Space Center Parallel LOGOS-based Solvers and Preconditioners for EIGER				
<b>Gedney, Stephen D</b>	3048087600	\$0.	\$12,000.	\$12,000.
Aerospace Corp The Discontinuous Galerkin Finite-Element Time-Domain Method				
<b>Gedney, Stephen D</b>	3048104278	\$85,575.	\$0.	\$85,575.
Aerospace Corp The Discontinuous Galerkin Finite-Element Time-Domain Method				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b>Electrical and Computer Engineering</b>				
<b>Hastings, Jeffrey T</b>	3046993700	\$0.	\$6,000.	\$6,000.
National Science Foundation Self-referenced SPR Sensing Using Multiple Surface-Plasmon Modes				
<b>Hastings, Jeffrey T</b>	3048104534	\$74,370.	\$0.	\$74,370.
National Science Foundation CAREER: Reference Compensation for Localized Surface-Plasmon Resonance Sensors				
<b>Hastings, Jeffrey T</b>	3048104543	\$500,000.	\$0.	\$500,000.
National Science Foundation Tip Directed-Assembly of Nanoparticles via Surface Plasmon Excitation				
<b>Heath, J R</b>	3046947100	\$0.	\$20,000.	\$20,000.
Lexmark International Inc Systemic Approach to SOC Evaluation and Verification				
<b>Holloway, Lawrence E</b>	3048104627	\$7,340.	\$0.	\$7,340.
Department of Commerce NIST-SURG- Gaithersburg				
<b>Holloway, Lawrence E</b>	3048104730	\$15,000.	\$0.	\$15,000.
Adaptive Intelligent Systems LLC SBIR Phase 1: A Modified GMAW System for Distortion Reduction and Travel Speed Increase through Separate Heat Input and Deposition Rate Control				
<b>Lau, Daniel L</b>	3048082200	\$0.	\$721,472.	\$721,472.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
<b>Lau, Daniel L</b>	3048082200	\$0.	\$75,000.	\$75,000.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
<b>Li, Jingshan</b>	3048104016	\$241,116.	\$0.	\$241,116.
National Science Foundation GOALI: Quality Analysis in Flexible Manufacturing Systems: A Systems Approach				
<b>Li, Jingshan</b>	3048104471	\$30,000.	\$0.	\$30,000.
General Motors Research Bottleneck-based Scheduling of Workforce with Real Time Information				
<b>Liao, Yuan</b>	3048103900	\$15,000.	\$0.	\$15,000.
EON US Stability Study of EON Power System				
<b>Liao, Yuan</b>	3048104270	\$60,000.	\$0.	\$60,000.
EPRI Fault Type Classification and Utilizing Voltage and Current Waveforms: Next Generation Monitoring System Requirement Specification				
<b>Liao, Yuan</b>	3048104510	\$15,000.	\$0.	\$15,000.
EON US Impact of Adding New Generators on Power Supply Stability				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Engineering</u></b>				
<b><u>Electrical and Computer Engineering</u></b>				
<b>Lu, Caicheng</b>	3048104456	\$20,000.	\$0.	\$20,000.
Buswell Energy LLC Scalability for Stranded Core Transformer Analysis and Testing				
<b>Lumpp, James E</b>	3048104695	\$15,000.	\$0.	\$15,000.
KY Science and Technology Co Inc Site Preparation for Space Systems Laboratory Spacecraft Assembly & Test Facility				
<b>Lumpp, James E</b>	3048104732	\$265,000.	\$0.	\$265,000.
KY Science and Technology Co Inc KySAT-1 Launch Readiness				
<b>St Omer, Ingrid</b>	3046977900	\$0.	\$139,538.	\$139,538.
National Science Foundation REU Site: Electrical & Computer Engineering at the University of Kentucky				
<b>Todd, Lee T</b>	3048032200	\$0.	\$486,042.	\$486,042.
National Science Foundation LSAMP: Kentucky-West Virginia Alliance for Minority Participation				
<b>Walcott, Bruce L</b>	3046647600	\$0.	\$3,099.	\$3,099.
KY Economic Development Cab Visualization Center/21st Century Manufacturing Initiative				
<b>Walcott, Bruce L</b>	3046647600	\$0.	\$3,111.	\$3,111.
KY Economic Development Cab Visualization Center/21st Century Manufacturing Initiative				
<b>Walcott, Bruce L</b>	3046647600	\$0.	\$338,735.	\$338,735.
KY Economic Development Cab Visualization Center/21st Century Manufacturing Initiative				
<b>Zhang, Yuming</b>	3046931000	\$0.	\$12,000.	\$12,000.
National Science Foundation Sensors: Measurement of Dynamic Weld Pool Surface				
<b>Electrical and Computer Engineering</b>	<b>Totals:</b>	<b>\$1,788,401.</b>	<b>\$2,061,646.</b>	<b>\$3,850,047.</b>
<b><u>UK Center for Manufacturing</u></b>				
<b>Holloway, Lawrence E</b>	3048104587	\$55,464.	\$0.	\$55,464.
Adaptive Intelligent Systems LLC Sensor Torch Based Adaptive Intelligent Control for Circumferential Welding of Pipes: SBIR Phase II				
<b>Zhang, Yuming</b>	3048103775	\$352,365.	\$0.	\$352,365.
National Science Foundation Measurement and Control of Dynamic Weld Pool Surface in Gas Metal Arc Welding				
<b>UK Center for Manufacturing</b>	<b>Totals:</b>	<b>\$407,829.</b>	<b>\$0.</b>	<b>\$407,829.</b>
<b><u>Mechanical Engineering</u></b>				
<b>Herrin, David W</b>	3048104446	\$75,000.	\$0.	\$75,000.
John Deere Dubuque Works of Deere and Company Development of a Noise Prediction/Assessment Process Map				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b>Engineering</b>				
<b>Mechanical Engineering</b>				
<b>Jawahir, Ibrahim S</b>	3048104277	\$0.	\$111,608.	\$111,608.
Advanced Technology Institute Next Generation Manufacturing Technology Initiative Program (NGMTI) Phase III Program: SIP Support and MBE Tools Development				
<b>Jawahir, Ibrahim S</b>	3048104277	\$338,392.	\$0.	\$338,392.
Advanced Technology Institute Next Generation Manufacturing Technology Initiative Program (NGMTI) Phase III Program: SIP Support and MBE Tools Development				
<b>Lebeau, Raymond P</b>	3048104555	\$6,808.	\$0.	\$6,808.
Western KY University Development of an Improved General Circulation Model for Uranus				
<b>Menguc, M P</b>	3048091300	\$0.	\$50,000.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Fundamental Multiscale Modeling of Nanomachining Process via Molecular Dynamics and Electron Hydrodynamic Equation Simulations				
<b>Saito, Koza</b>	3048103549	\$109,803.	\$0.	\$109,803.
KY Office of Energy Policy Vortecone Modification for Emission Control at Coal Fired Power Plants				
<b>Seigler, Thomas M.</b>	3048079400	\$0.	\$12,500.	\$12,500.
Virginia Polytechnic Institute and State University Scalable Approaches to Integrated Flight and Planform Control of Morphing Air Vehicles				
<b>Seigler, Thomas M.</b>	3048104327	\$102,942.	\$0.	\$102,942.
US Air Force Office of Scientific Research Flight Mechanics of Reversible Attachment Landing for Micro-Aerial Vehicles with Self-Decontaminating Surfaces				
<b>Sekulic, Dusan P</b>	3048104237	\$19,602.	\$0.	\$19,602.
KY Science and Technology Co Inc R&D Excellence: Metallic and Carbon Foam Bonding				
<b>Sheng, Jian</b>	3048104213	\$20,000.	\$0.	\$20,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Development of Micro-Actuated Artificial Mucus Layer for Drag Management and Flow Control for Unmanned Micro Vehicles				
<b>Smith, Suzanne W</b>	3048104340	\$20,000.	\$0.	\$20,000.
Mevicon Inc Deployment Measurement of Stowed Thin Film Shells				
<b>Mechanical Engineering</b>	<b>Totals:</b>	<b>\$692,547.</b>	<b>\$174,108.</b>	<b>\$866,655.</b>
<b>IR4TD</b>				
<b>Saito, Koza</b>	3048104364	\$49,810.	\$0.	\$49,810.
Toyota Motor Manufacturing USA Inc Accurate Temperature Measurement 2008				
<b>Saito, Koza</b>	3048104440	\$156,000.	\$0.	\$156,000.
Toyota Motor Co Material Characterization of New Paint Stomizers				
<b>IR4TD</b>	<b>Totals:</b>	<b>\$205,810.</b>	<b>\$0.</b>	<b>\$205,810.</b>
	<b>Engineering Totals:</b>	<b>\$14,499,510.</b>	<b>\$7,441,749.</b>	<b>\$21,941,259.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Law</u></b>				
<b><u>Law</u></b>				
<b>Bratt, Carolyn S</b>	3048103856	\$18,000.	\$0.	\$18,000.
Bureau of Prisons Legal Assistance to Inmates				
<b>Bratt, Carolyn S</b>	3048104306	\$18,000.	\$0.	\$18,000.
Bureau of Prisons Legal Assistance to Inmates				
<b>Law</b>	<b>Totals:</b>	<b>\$36,000.</b>	<b>\$0.</b>	<b>\$36,000.</b>
	<b>Law Totals:</b>	<b>\$36,000.</b>	<b>\$0.</b>	<b>\$36,000.</b>
<b><u>Communication</u></b>				
<b><u>Communication</u></b>				
<b>Cupp, Pamela</b>	3046625300	\$0.	\$-31,960.	\$-31,960.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Cupp, Pamela</b>	3046625300	\$0.	\$5,360.	\$5,360.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Cupp, Pamela</b>	3046625300	\$0.	\$-114,384.	\$-114,384.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Cupp, Pamela</b>	3048103861	\$0.	\$31,960.	\$31,960.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Cupp, Pamela</b>	3048103861	\$0.	\$-5,360.	\$-5,360.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Cupp, Pamela</b>	3048103861	\$114,384.	\$0.	\$114,384.
National Institute for Nursing Research Improving School Learning Environments in HIV Prevention				
<b>Noar, Seth Michael</b>	3048104503	\$207,475.	\$0.	\$207,475.
National Institute of Mental Health Enhancing Message Design in Tailored, Computerized HIV/STI Interventions				
<b>Sellnow, Timothy L</b>	3048104430	\$0.	\$-41,020.	\$-41,020.
University of Minnesota National Center for Food Protection and Defense: Robust Case Study Analysis of Media				
<b>Sellnow, Timothy L</b>	3048104430	\$156,205.	\$0.	\$156,205.
University of Minnesota National Center for Food Protection and Defense: Robust Case Study Analysis of Media				
<b>Zimmerman, Rick S</b>	3046965300	\$0.	\$143,280.	\$143,280.
National Institute of Mental Health Targeting Mass Media Campaigns for HIV, STD and Pregnancy Prevention				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Communication</u></b>				
<b><u>Communication</u></b>				
<b>Zimmerman, Rick S</b>	3046965300	\$0.	\$653,478.	\$653,478.
National Institute of Mental Health Targeting Mass Media Campaigns for HIV, STD and Pregnancy Prevention				
<b>Communication</b>	<b>Totals:</b>	<b>\$478,064.</b>	<b>\$641,354.</b>	<b>\$1,119,418.</b>
<b><u>School of Library &amp; Information Science</u></b>				
<b>O'Connor, Lisa G</b>	3048104572	\$5,000.	\$0.	\$5,000.
American Library Association Information Seeking Behaviors of Amateur Investors				
<b>Sineath, Timothy W</b>		\$10,000.	\$0.	\$10,000.
KY Department for Libraries and Archives KDLA LSTA Kentucky Guide Program '08				
<b>School of Library &amp; Information Science</b>	<b>Totals:</b>	<b>\$15,000.</b>	<b>\$0.</b>	<b>\$15,000.</b>
	<b>Communication Totals:</b>	<b>\$493,064.</b>	<b>\$641,354.</b>	<b>\$1,134,418.</b>
<b><u>Design</u></b>				
<b><u>Design</u></b>				
<b>Mohney, David</b>	3048104065	\$50,000.	\$0.	\$50,000.
Louisville Metro Government Urban Design Studio FY07-08				
<b>Design</b>	<b>Totals:</b>	<b>\$50,000.</b>	<b>\$0.</b>	<b>\$50,000.</b>
<b><u>School of Interior Design</u></b>				
<b>McNabb, Sarah</b>	3048104012	\$2,000.	\$0.	\$2,000.
KY Arts Council Kentucky Craft Award in Interior Design				
<b>School of Interior Design</b>	<b>Totals:</b>	<b>\$2,000.</b>	<b>\$0.</b>	<b>\$2,000.</b>
	<b>Design Totals:</b>	<b>\$52,000.</b>	<b>\$0.</b>	<b>\$52,000.</b>
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Badger, Karen</b>	3048103662	\$13,000.	\$0.	\$13,000.
Abington Foundation Examination of the Role of Peer Support and Social Comfort on Community Reintegration and Quality of Life of Burn Survivors				
<b>Cerel, Julie A</b>		\$65,550.	\$0.	\$65,550.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - Project Evaluation				
<b>Cerel, Julie A</b>	3048103712	\$7,992.	\$0.	\$7,992.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - Project Evaluation				
<b>Clark, James J</b>	3048103428	\$322,755.	\$0.	\$322,755.
KY Health Services Cabinet Comprehensive Assessment and Training Services Project: Adoption Support Services				
<b>Collins-Camargo, Crystal</b>	3048103711	\$900,000.	\$0.	\$900,000.
Administration for Children and Families National Quality Improvement Center on the Privatization of Child Welfare Services				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Collins-Camargo, Crystal</b>	3048103718	\$50,000.	\$0.	\$50,000.
KY Administrative Office of the Courts Children's Summit Evaluation				
<b>Collins-Camargo, Crystal</b>	3048104085	\$83,401.	\$0.	\$83,401.
KY Health Services Cabinet Citizens Review Panel				
<b>Cook-Craig, Patricia G</b>	3048103704	\$70,844.	\$0.	\$70,844.
Eastern KY University START Network Evaluation				
<b>Cook-Craig, Patricia G</b>	3048104389	\$37,000.	\$0.	\$37,000.
KY Association of Sexual Assault Programs EMPOWER Project				
<b>Godlaski, Theodore M</b>	3048104240	\$57,000.	\$0.	\$57,000.
KY River Community Care Inc Assertive Community Living for Appalachian Dually Diagnosed Adults Grant (ACLADDA)				
<b>HOFFMAN, KAY DORIS</b>	3048097500	\$0.	\$21,433.	\$21,433.
University of Louisville Strengthening Marital Relationships and Post-Adoption Services Through Community of Care Teams				
<b>HOFFMAN, KAY DORIS</b>	3048103613	\$371,270.	\$0.	\$371,270.
Eastern KY University Office of Technology and Outcome Support				
<b>HOFFMAN, KAY DORIS</b>	3048103614	\$810,344.	\$0.	\$810,344.
Eastern KY University Training Resource Center: Resource Parent Training and Mentoring Programs				
<b>HOFFMAN, KAY DORIS</b>	3048103625	\$0.	\$-127,832.	\$-127,832.
Eastern KY University Training Resource Center: Credit for Learning Program				
<b>HOFFMAN, KAY DORIS</b>	3048103625	\$617,163.	\$0.	\$617,163.
Eastern KY University Training Resource Center: Credit for Learning Program				
<b>HOFFMAN, KAY DORIS</b>	3048103630	\$300,000.	\$0.	\$300,000.
KY Health Services Cabinet Chafee Independent Living Statewide Mentoring (KYNEX)				
<b>HOFFMAN, KAY DORIS</b>	3048103675	\$215,428.	\$0.	\$215,428.
KY Health Services Cabinet Post Secondary - Successful Transitions Program				
<b>HOFFMAN, KAY DORIS</b>	3048104402	\$3,790.	\$0.	\$3,790.
Eastern KY University Cultural Diversity Program				
<b>Rompf, Elizabeth L</b>	3048103308	\$8,584.	\$0.	\$8,584.
Eastern KY University Public Child Welfare Certification Program				

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Social Work</u></b>				
<b><u>Social Work</u></b>				
<b>Sprang, Mary</b>	3048103502	\$200,000.	\$0.	\$200,000.
KY Health Services Cabinet Comprehensive Assessment and Training Services Project: Title IV-B				
<b>Sprang, Mary</b>	3048104035	\$400,000.	\$0.	\$400,000.
Substance Abuse & Mental Health Services Administr Child and Adolescent Trauma Treatment Institute				
<b>Swanberg, Jennifer E</b>	3048104404	\$30,000.	\$0.	\$30,000.
Bluegrass Business Development Partnership Bluegrass Region High-Tech Entrepreneurial Environment Project				
<b>Swanberg, Jennifer E</b>	3048104497	\$10,000.	\$0.	\$10,000.
Families and Work Institute When Work Works				
<b>Tindall, Michele Staton</b>	3048104072	\$91,800.	\$0.	\$91,800.
Chrysalis Inc Post-partum, and Parenting Women Project				
<b>Social Work</b>	<b>Totals:</b>	<b>\$4,665,921.</b>	<b>-\$106,399.</b>	<b>\$4,559,522.</b>
	<b>Social Work Totals:</b>	<b>\$4,665,921.</b>	<b>-\$106,399.</b>	<b>\$4,559,522.</b>
<b><u>Graduate School</u></b>				
<b><u>Martin School of Public Policy</u></b>				
<b>Berger, Philip K</b>	3048104050	\$144,090.	\$0.	\$144,090.
University of Cincinnati Worker Health and Safety Training Cooperative Agreement				
<b>Jennings, Edward T</b>	3048045000	\$0.	\$75,151.	\$75,151.
KY Department of Military Affairs Hazard Mitigation Grants Program				
<b>Jennings, Edward T</b>	3048103655	\$0.	\$29,023.	\$29,023.
KY Health Services Cabinet Policy Analysis for the Kentucky Council for Developmental Disabilities				
<b>Jennings, Edward T</b>	3048103655	\$76,407.	\$0.	\$76,407.
KY Health Services Cabinet Policy Analysis for the Kentucky Council for Developmental Disabilities				
<b>Jennings, Edward T</b>	3048103890	\$44,805.	\$0.	\$44,805.
Georgetown University East Central European Scholarship Program				
<b>Toma, E F</b>	3048104594	\$2,500.	\$0.	\$2,500.
KY Council on Postsecondary Education Martin School Graduate Student 2008				
<b>Martin School of Public Policy</b>	<b>Totals:</b>	<b>\$267,802.</b>	<b>\$104,174.</b>	<b>\$371,976.</b>
<b><u>Graduate School Dean</u></b>				
<b>Blackwell, J L</b>	3048104269	\$81,000.	\$0.	\$81,000.
National Science Foundation National Science Foundation Graduate Fellowship Program				
<b>Graduate School Dean</b>	<b>Totals:</b>	<b>\$81,000.</b>	<b>\$0.</b>	<b>\$81,000.</b>

**Sponsored Project Awards Received Through UKRF Year 2008 as of 6/30/2008**

		New Accounts	Adjustments to Existing Accounts	Total
<b><u>Graduate School</u></b>				
<b><u>Center for Biomedical Engineering</u></b>				
<b>Bruce, Eugene N</b>	3048022300	\$0.	\$64,565.	\$64,565.
National Institute of Occupational Safety and Health A Model-Based Estimate of Carbon Monoxide Uptake by Heart Muscle During Exercise				
<b>Knapp, Charles F</b>	3046541200	\$0.	\$91,000.	\$91,000.
Western KY University Monitoring and Assessment of Human Health and Responses to Countermeasures During Space Deconditioning				
<b>Knapp, Charles F</b>	3048104489	\$166,666.	\$0.	\$166,666.
Western KY University NASA EPSCoR: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
<b>Patwardhan, Abhijit</b>	3048103227	\$60,500.	\$0.	\$60,500.
American Heart Association Ohio Valley Affiliate Restitution of Repolarization Duration: Hysteresis, Alternans and Spatial Heterogeneity				
<b>Patwardhan, Abhijit</b>	3048104316	\$269,994.	\$0.	\$269,994.
National Science Foundation Dynamics of Period Doubling Bifurcation in Myocytes				
<b>Puleo, David A</b>	3048072600	\$0.	\$16,934.	\$16,934.
Shriners Hospital for Crippled Children Recapitulation of a Growth Plate in a Rabbit Model				
<b>Puleo, David A</b>	3048074400	\$0.	\$49,716.	\$49,716.
KY Science and Technology Co Inc KSEF R&D Excellence: Improved Machining of Metal-on-Metal Hip Implants				
<b>Yu, Guoqiang</b>		\$52,184.	\$0.	\$52,184.
American Heart Association Great Rivers Affiliate Diffuse Optical Mapping of Blood Flow, Oxygenation, and Metabolism in Ischemic Skeletal Muscle				
<b>Yu, Guoqiang</b>	3048104645	\$136,362.	\$0.	\$136,362.
National Heart Lung and Blood Institute Assessment of Muscle Vascular Disease With Diffuse Light				
<b>Center for Biomedical Engineering</b>	<b>Totals:</b>	<b>\$685,706.</b>	<b>\$222,215.</b>	<b>\$907,921.</b>
	<b>Graduate School Totals:</b>	<b>\$1,034,508.</b>	<b>\$326,389.</b>	<b>\$1,360,897.</b>
<b><u>Fine Arts</u></b>				
<b><u>Art</u></b>				
<b>Christ, Alice T</b>	3048104338	\$20,000.	\$0.	\$20,000.
International Catacomb Society Ways of Religious Seeing In Late Antique Material Culture Conference				
<b>Art</b>	<b>Totals:</b>	<b>\$20,000.</b>	<b>\$0.</b>	<b>\$20,000.</b>
	<b>Fine Arts Totals:</b>	<b>\$20,000.</b>	<b>\$0.</b>	<b>\$20,000.</b>
	<b>University Totals:</b>	<b>\$156,054,177.</b>	<b>\$91,168,289.</b>	<b>\$247,222,466.</b>